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Résumé 
 
L’existence d’effets secondaires dans les traitements de la médecine moderne constitue 
actuellement l’une des principales préoccupations du grand public. La mise au point de 
thérapies ciblant spécifiquement les cellules malades représente l’un des challenges de la 
lutte contre le cancer. Mis à part quelques exceptions, la plupart des thérapies 
anticancéreuses ne permettent pas d’éradiquer véritablement la maladie, on parle plutôt 
de période de rémission qui ne font qu’allonger la durée de vie des patients. 
         
 La thérapie photodynamique (PDT) ciblant l’acide-δ-aminolevulinic (ALA) représente 
une méthode pour le traitement du cancer. ALA est une molécule naturellement présente 
dans nos cellules, elle est à l’origine de la biosynthèse de l’hème, un constituant des 
globules rouges. Dans le cas des cellules cancéreuses, ce mécanisme est perturbé et 
conduit à l’accumulation d’un composé intermédiaire Protoporphyrine (PpIX) qui a la 
particularité d’être photosensible et fluorescent. Par conséquent l’utilisation d’ALA 
comme ‘prodrogue’ conduit à une surproduction de ce composé photosensible au sein des 
cellules malades et permet leurs détection ainsi que leurs traitement. 
H 2N OH
O
O
5-aminolevulinic acid (ALA)
N
H
HOH O
O
O
H2N
porphobilinogen (PBG)  
De nouvelles ‘prodrogues’ plus sélectives que ALA sont cependant nécessaires. Nous 
avons donc synthétisé des dérivés où une molécule d’ALA est connectée à différentes 
biomolécules, comme des glucides, des acides aminés, des glycérols ou encore des 
vitamines. 
H2N OR
O
O
5-aminolevulinic acid derivatives
R= sugars (glucose, mannose and galactose)
or
R= vitamins
or
R= natural alcohol
or
R= nucleosides
O
HO
HO
OH
OH
O
HO
HO
OH
OH
O
HO
HO
OH
OH
OH
OH
OH
Glucose
Mannose
Galactose  
Tous les produits synthétisés ont été testés sur différents types de cellules cancéreuses, les 
dérivés ALA-glucide  se sont révélés particulièrement efficaces et non cytotoxiques. En 
effet certains d’entre eux induisent une production plus importante de composés 
photosensibles  que ALA et de plus ils s’avèrent très sélectifs envers certains types de 
cellules cancéreuses. 
Ce travail de thèse a finalement permis la synthèse d’une nouvelle variété de prodrogues 
plus efficaces que celle disponible sur le marché (ALA), contribuant à la détection des 
cellules cancéreuses et dans certains cas à leur élimination. 
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Summary 
 
One of the concerns of the general public about modern day medicine is ‘side effects’. 
Therapies targeting only the diseased cells are the solution for this. The targeted delivery 
of drugs is one of the main challenges that all cancer therapies are dealing with. With 
very few exceptions, almost all the therapies for cancer today are only extending the life 
of patients by few months instead of really targeting cancer cells and cure patients.  
           
Delta aminolevulinic acid (or 5-aminolevulinic acid or shortly ALA) based photodynamic 
therapy (PDT) is one among the therapies for cancer. ALA is a natural product which is 
synthesized in the body of all human beings which transforms in series of steps to heme. 
One of the intermediates in heme pathway is Protoporphyrin IX (PpIX) which is a 
photosensitizer. ALA, when administered externally induces preferentially higher PpIX 
production in cancer cells. The fluorescent nature of PpIX is used for detection of cancer 
cells besides therapy. 
H 2N OH
O
O
5-aminolevulinic acid (ALA)
N
H
HOH O
O
O
H2N
porphobilinogen (PBG)  
Novel prodrugs for inducing higher PpIX generation than ALA and having more 
selectivity towards cancer cells are required. We synthesized novel derivatives of ALA 
where ALA is conjugated with monosaccharides (sugars), natural alcohols, vitamins and 
aminoacids. Also derivatives of porphobilinogen (PBG) which is an advanced 
intermediate in heme pathway were synthesized. We synthesized different ALA-sugar 
derivatives where not only different sugars were utilized for conjugation, but also, ALA 
was substituted in different hydroxyl groups of sugars. 
H2N OR
O
O
5-aminolevulinic acid derivatives
R= sugars (glucose, mannose and galactose)
or
R= vitamins
or
R= natural alcohol
or
R= nucleosides
O
HO
HO
OH
OH
O
HO
HO
OH
OH
O
HO
HO
OH
OH
OH
OH
OH
Glucose
Mannose
Galactose  
All the novel prodrugs were evaluated for PpIX induction using various cancer cell lines. 
We found that all these novel prodrugs are not cytotoxic; some of them induce higher 
generation of PpIX than ALA. But the selectivity towards cancer cells is not better than 
ALA. 
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 1. Introduction 
 
One of the most fruitful concepts applied with increasing success in recent years in 
bioorganic chemistry may be the synthesis and study of natural product hybrids. A 
natural product hybrid is a synthetic compound having two or more natural products 
derived fragments joined at least by one carbon-carbon bond. Using the enormous 
number of natural products known and available, an unlimited number of natural-product 
hybrids as combination of different natural products can be synthesized. This new 
synthetic approach has proven to be very promising in the development of leads for 
medicinal applications, as the biological activity of several new hybrids exceeds that of 
the parent compounds. An example is geldanamycin- estradiol hybrid 117. Geldanamycin 
115, a natural antibiotic binds and causes the degradation of several important signalling 
proteins. Estradiol 116 is a natural hormone and novel estradiol-geldanamycin hybrids 
have been synthesized and evaluated in cancer cells for their ability to induce the 
selective degradation of tumor-relevant proteins in breast (estrogen receptor (ER)). The 
hybrid compounds are not only active but also more selective than the parent causing 
degradation of ER (estrogen receptor), but not other targets [1].  
OH
H
H H
HO
N
H
OMe
OOH
MeO
MeO
O
O
O
H2N
O
 
115 116              
 
OH
H
H H
HO
N
H
OMe
OOH
MeO
O
O
O
H2N
O
Linker
H
N
Linker=
Linker=
 
                                                               117 
Scheme 1: Example of a natural product hybrid 
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 The advantage of this natural product hybrid concept over a combinatorial chemistry 
approach is the high diversity and the inherent biological activity of the hybrids [2, 3]. 
Actually, from a general view, the approach is not quite new, since even Nature employs 
such a strategy; Nature makes natural products of diversity and complexity and these are 
generally derived through specific biosynthetic pathways like shikimate, polyketide or 
mevalonate, leading to a particular class of compounds. Many biologically active natural 
products are also derived through mixed biosynthesis [4, 5]. An example of naturally 
occurring natural product hybrid can be the indole alkaloid vincristine 118b which is a 
famous drug for lymphatic leukemia. This is a dimeric indole alkaloid consisting of 
vindoline—an alkaloid of the Aspidosperma subgroup—and catharanthine—a member of 
the Iboga subgroup of indole alkaloids. It is of special interest that both monomeric 
alkaloids do not express any pronounced or useful biological activity. Artificial natural 
product hybrids have not yet been used as drugs, as this idea is quite new, but several 
novel compounds of this type developed in the last years show promising biological 
activity. 
 
N
H
N
N
R
N
MeO2C
OH
H
HO
OAcMeO
CO2Me
H
118a; R=Me Vinblastine
118b; R=CHO Vincristine  
Scheme 2: A natural product hybrid synthesized by Nature 
                                                                                  
The starting point of our work is the use of natural product hybrids in photodynamic 
therapy (here after referred as PDT). All the compounds synthesized in this thesis can be 
classified as natural-product hybrids. Each compound is derived from two natural 
products, namely a sugar or vitamin or nuceloside and an aminolevulinic acid 119 (here 
after referred as ALA) moiety. How this natural product hybrid is synthesized and how 
its biological activity exceeds the efficiency of the natural product (aminolevulinic acid) 
alone in the field of photodynamic therapy (PDT) of cancer is the main focus of the work 
reported here. 
H2N OH
O
O
119
 
Scheme 3: 5-aminolevulinic acid (ALA) 
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 Cancer is one of the dreaded diseases which affect the human population. Almost 7 
million people died of cancer in the year 2005 alone as per the World Cancer Report, 
done by the World Health Organization [6]. The report states also that 11 million new 
cases were diagnosed during the same period. Cancer claims twice as many lives 
worldwide as AIDS. In fact, more than 12% of all deaths (60 million cases of deaths due 
to all causes) every year is caused by cancer (7 million cases of cancer) [7]. This figure is 
more than AIDS, tuberculosis, and malaria put together which are 6.8 million cases [8]. 
In industrialized countries, cancer is the leading cause of premature mortality, and the 
same trend is emerging in developing countries. Cancer rates could further increase by 
50% to 15 million new cases in the year 2020, according to the World Cancer Report, the 
most comprehensive global examination of the disease to date [6]. 
 
Chemotherapy, surgery, radiotherapy, hormone therapy and many other therapies are 
used today to treat cancer patients. Most of these treatments help to relieve the symptoms 
to prolong the life expectancy sometimes only by months in the better cases by years, but 
most of the actual treatment do not lead to a real cure (for exceptions see the use of 
Gleevec® 120) [9, 10]. Many of the cancer therapies used lead to severe side-effects, 
which would be unacceptable in any other modern treatment. Photodynamic therapy 
(PDT) is one of the especially mild treatments of cancer, which thereby has the potential 
to lead to a real cure.  
                                          
N
N
N
H
N
HN
O
N
N
120  
Scheme 4: Structure of Gleevec® 
 
1.1. History of Photodynamic therapy  
 
Light has been used as therapy for more than three thousand years. Ancient Egyptian, 
Indian and Chinese civilization used light to treat various diseases including psoriasis, 
rickets, vitiligo and skin cancer [11]. In one of India’s sacred books Atharva-veda (1400 
BC) the use of seeds of the plant Psoralea corylifolia for the treatment of vitiligo is 
described. Psoralens are the photoactive components of these seeds, just as in the extracts 
of the plant Ammi majus, which grows on the banks of the Nile. The Egyptians used 
Ammi majus to treat vitiligo.  
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 In 1898, O. Raab showed the cytotoxic effects of the combination of acridine 121 and 
light on infusoria  (Paramecium caudatum) [12]. 
 
                                                 
N
121  
Scheme 5: Acridine 
 
 ‘Phototherapy’ or the use of light to treat disease was developed systematically during 
1900s by a scientist from Denmark named N. Finsen. He was awarded a Nobel Prize in 
1903 for his work in phototherapy [13, 14]. He invented the red light treatment for small 
pox [15] and also used ultraviolet light to treat tuberculosis. The term ‘photodynamic 
action’ was introduced by A. Jesionek  and H.v.Tappeiner (Professor of O.Raab) and who 
had treated skin tumors with topically applied eosin 122 and white light in 1903 [16].  
 
                                 
O
COO
BrBr
Br
O O
Br
Na
Na
122  
Scheme 6: Eosin 
 
F. Meyer-Betz investigated as early as 1913 porphyrins, the class of compounds most 
often used today, for their application in photodynamic therapy (PDT). He studied the 
accumulation of hematoporphyrin (HP) and its derivatives in rat tumors and PDT effects 
following systemic administration [17]. The fluorescence from these compounds was 
further investigated for diagnostic and tumor margin delineation in the late 1940s and 
1950s by F.H.J. Figge and colleagues [18]. Modern photodynamic therapy (PDT) was 
initiated by R.L. Lipson and E.J. Blades. They established that an impurity in HP was the 
tumor-localizing agent, and not the parent compound. This led to the “synthesis” of 
hematoporphyrin derivative (HPD; 123), a mixture of porphyrins produced by the acid 
treatment of HP [19]. The exact chemical composition and structure of this mixture 
remains unclear, although there is general consensus that the active portions consist of 
porphyrin oligomers with ether and/or ester linkages along with monomeric porphyrins. 
HPD was further developed for laboratory and clinical investigations through the efforts 
of T. J. Dougherty and colleagues in 1970s and 1980s [20]. The history of photodynamic 
therapy can be depicted as shown in the table1. 
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 Table 1:  History of Photodynamic therapy – Time line 
 
HISTORY OF 
PHOTODYNAMIC 
THERAPY: PERIOD 
1900 – present 
Year of 
discovery 
Scientist (University or company) Discovery, commercial 
application or important event 
1900 O. Raab (Zeitschrift fuer Biologie, 
Munich, Germany) 
 
The cytotoxic effects of the combination 
of acridine and light on infusoria 
(Paramecium caudatum). 
1901 N. Finsen (University of Copenhagen, 
Denmark) 
Light treatment of smallpox and cutaneous 
tuberculosis 
H. von Tappeiner and A. Jesionek 
(Zeitschrift für Biologie, Munich, 
Germany) 
Topical eosin application and white light 
treatment of malignant melanomas 
 
1903 
N. Finsen (University of Copenhagen, 
Denmark) 
Nobel Prize for his work on phototherapy. 
1907 H. vonTappeiner (Director, 
Pharmacological institute of the Ludwig-
Maximilian University, Munich) and 
A.Jodlbauer  
Introduction of the term ‘photodynamic’ 
1911 W. Hausmann (Physiol. Inst.,  Hochschule 
für Bodenkultur,  Vienna, Austria) 
Phototoxic effects of haematoporphyrin 
on the skin of mice 
1913 F. Meyer–Betz (Chief Physician in 
Königesberg, 
Germany) 
First human tests. PDT using porphyrins. 
Self-experiment using his own hands 
1955 S. Schwartz (University of Minnesota,  
Minneapolis, USA) 
Development of haematoporphyrin 
derivative (HPD) by acetylation and 
reduction of haematoporphyrin. 
1960 R. L. Lipson and E. J. Baldes (Mayo clinic 
/ University of Vermont College of 
Medicine, U.S.A) 
Accumulation of HPD in tumors and its 
use in the photodetection of tumors 
1972 I. Diamond (University of California, 
U.S.A) 
Demonstration of the phototoxicity of 
haematoporphyrin against gliomas in vivo 
and in vitro 
T.J. Dougherty (Photodynamic Therapy 
Center, Roswell Park Cancer Institute, 
New York, U.S.A) 
Successful treatment of skin cancer in 
patients 
1975 
J. F. Kelly (St. Mary's Hospital Medical 
School, London, United Kingdom) 
Treatment of bladder cancer in humans ; 
using HPD tumor regression is observed 
1978 T.J. Dougherty (Photodynamic Therapy 
Center, Roswell Park Cancer Institute, 
New York, U.S.A) 
First controlled clinical study in humans 
of PDT for the treatement of skin tumor 
1999 QLT Phototherapeutics, Vancouver, 
Canada and American Cyanamid Co. Pearl 
River, New York, 
Approval of the first PDT drug in Canada 
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 Tumors in virtually every anatomic site have been treated with PDT, and most are 
responsive to this therapy to some extent. Although, to date, several thousand patients 
have been treated with PDT for a variety of neoplasms, randomized clinical trials of this 
mode of cancer treatement were initiated only in 1987, using a purified form of HPD, 
called porfirmer sodium (Brand name-Photofrin®) [21]. These first randomized trials, 
were sponsored by Quadra Logic Technologies, Inc. (now QLT Phototherapeutics, 
Vancouver, Canada) and American Cyanamid Co. (Pearl River, New York), and 
compared the efficacy of PDT with that of other forms of therapy for bladder, 
oesophagal, and lung cancers. Within the past 5 years significant progress has been made 
worldwide in obtaining regulatory approval for a variety of indications. Currently, PDT 
with Photofrin® 124 is approved in 10 countries. 
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Scheme 7: First generation photosensitizers 
 
The understanding of the biology of PDT has advanced, and efficient, convenient, and 
inexpensive systems of light delivery are now available. Moreover, encouraging results 
from randomized phase III trials are becoming published, and improved photosensitizing 
drugs are under development. Besides, Porfirmer sodium (Photofrin®), temoporfin (also 
called meso-tetra (hydroxyphenyl) porphyrin (m -THPP) (brand name - Foscan®) has 
now been approved for systemic administration, and aminolevulinic acid and methyl 
aminolevulinate have been approved for topical use. PDT has several potential 
advantages over surgery and radiotherapy: it is less invasive, it can be targeted 
accurately, repeated doses can be given without the total-dose limitations associated with 
radiotherapy, and the healing process results in little or no scarring. PDT can usually be 
done in an outpatient or day-care setting and has few side effects, improving patient 
convenience. 
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 1.2. Mechanism of Photodynamic therapy  
 
PDT is the result of combination of three non-toxic elements namely light, oxygen and 
photosensitizer. In the following paragraphs, the essentials of each of these components 
will be described. 
1.2.1. Light 
 
Light is a form of electromagnetic radiation that covers a wide range of wavelengths, λ, 
between radio wavelengths in the meter (m) range to gamma rays with wavelengths 
around 10-11 m. Visible light, most relevant to PDT, covers the limited range of 4 to 7 × 
10-7 m (400–700 nm). The energy content (E) of light is related to the wavelength of 
absorption by E = hγ = hc/ λ, where h is Planck’s constant (6.63 x 10-34Js), γ is  
frequency, c is the speed of light in vacuum (3.0 x 106 m/s), and λ is a single wavelength.  
 
Conventional gas discharge lamps were initially used for the photosensitization process. 
The introduction of lasers equipped with optical fibers revolutionized photosensitization 
and expanded its applicability in medicine, enabling the endoscopic delivery of light to 
almost every site of the human body. Photodynamic treatment in dermatology is 
simplified by the accessibility of the skin to light application and allows using any light 
source with the appropriate spectrum e.g.: metal halogen lamps, which emit 600 to 800 
nm radiation at high power density, short-arc xenon lamps, tunable over a bandwidth 
between 400 and 1200 nm. The broad light beam produced by incoherent lamps is useful 
for the treatment of large lesions. In contrast to traditional incandescent lamps, lasers 
permit to select the exact wavelengths and to apply the light beam with high precision. 
Pulsed lasers, such as the gold vapor laser (GVL) and the copper vapor laser or pumped 
dye lasers (GVDL), produce brief light pulses of millisecond to nanosecond duration 
[22]. The comparison of the efficacy of PDT using continuous-wave light sources and 
pulsed lasers has shown no difference. Tunable solid-state lasers, such as the neodymium 
doped YAG laser, are particularly useful for PDT. The above-listed laser systems are 
expensive, relatively immobile, and require frequent repair. The development of 
semiconductor diode lasers is a novel approach to circumvent these disadvantages. 
Portable diode lasers, such as the gallium-aluminium-arsenide laser, produce light in the 
range from 770 to 850 nm, which corresponds to the absorption peaks of many new 
photosensitizers [23]. 
1.2.2. Oxygen and photochemistry 
 
Numerous investigations supported the idea that the efficacy of photosensitization is 
directly related to the yield of singlet oxygen (1O2) created in the tumor environment and 
the yield of singlet oxygen (1O2) depends on the concentration of ground state oxygen 
(which is the triplet state) in the tissue [24]. Hypoxic cells are very resistant to 
photosensitization and the photodynamic reaction mechanism itself may consume oxygen 
at a rate sufficient to inhibit further photosensitization effects. It has been suggested, that 
hyperbaric oxygen might enhance the photosensitization effect. 
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When light is absorbed, the energy of the absorbed photons causes the absorbing 
molecule to be electronically excited. This excitation energy may be converted into heat 
(kinetic energy) by the collision of the excited molecule with surrounding molecules by 
radiationless decay. Alternatively, it may be re-emitted as fluorescence. The electronic 
energy levels between which transitions occur by absorption of ultraviolet-visible light 
(λ = 200–700 nm) may be represented by the simplified energy level diagram presented 
in Fig 1. 
 
                     Figure 1: Jablonski energy level diagram for photodynamic therapy 
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The electronic states of the photosensitizer are the singlet states S0 to Sn and the triplet 
states T1 and Tn. The ground state of the photosensitizer S0 can only be a singlet state, all 
electron spins are paired. In the excited states the electron spin of the two unpaired 
electrons can either be antiparallel Sn, singlet states, or parallel Tn, triplet states. With 
conventional light sources, a photosensitizer molecule will typically absorb a single 
photon exciting the molecule to the first excited singlet state S1. From this excited state 
the molecule may directly initiate photochemistry (depending on the chemical structure) 
or undergo intersystem crossing to an electronically different excited state, the first triplet 
state T1. From S1, the excited molecule may also relax back to S0 by radiationless decay 
and generate heat or may re-emit radiation as fluorescence, which may be used for 
diagnostic purposes. In general, T1 is longer lived and chemically more reactive so that 
the biologically relevant photochemistry is often mediated by this state. T1 can initiate 
photochemical reactions directly, giving rise to reactive free radicals, or transfer its 
energy to the ground state oxygen molecules (3O2) to give rise to excited singlet state 
oxygen molecules 1O2. This excitation responsible for the production of 1O2 requires 
excitation energy of at least 20 kcal/mole, which places limits on the wavelength of 
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 absorption of the photosensitizer. If the energy of T1 is appropriate, photo-oxidative 
reactions may occur mediated by the formation of 1O2 (see Fig.1 and 3).  
 
Figure 2: Molecular orbital diagram of oxygen showing the electron distribution of 
singlet and triplet oxygen 
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The excited triplet of the photosensitzer can undergo two kinds of reactions (Fig.2). The 
photoinduced oxidation processes have been classified by Macdonald et al  as [25] : Type 
I reaction is a radical or redox reaction. The excited triplet can react directly with 
substrates, such as molecules forming the cell membrane or other molecules (A) of the 
cell content, and abstract an electron to form radical cations of the molecules contained in 
the cells. These radical cations interact with oxygen to produce oxygenated products 
(eqn1).  
 
Equation 1 
                          
3S + A S.- + A.+
A.+ + 3O2 Aox  
 
Alternatively, the radical anion of excited photosensitizer can transfer their electron to 
oxygen to produce superoxide radical anions which in turn can react with the substrate 
such as molecules contained in the cell membrane to give oxygenated products. There 
exists another possibility of forming superoxide radical anions from oxygen. Triplet 
oxygen can react directly with excited triplet state of a photosensitizer to give superoxide 
radical anions and a radical cation of the photosensitizer. Those two reactive species can 
 9
 react with substrate molecules e.g. contained in the cell membrane to produce oxygenated 
products and at the end of this process the photosensitizer is back in the ground state (eqn 
2). 
Equation 2 
                        
S.- + 3O2 S0 + O2.
-
O2.- + A Aox  
  Or  
                       
3S + 3O2 S+ + O2.-
+ AS+ A.+S0 +  
                  
The second kind of reaction called type II reaction is an energy transfer process. Here, 
the excited triplet can transfer its energy directly to oxygen, to form singlet oxygen — a 
highly reactive oxygen species (ROS) as shown in eqn 3.  
Equation 3 
                         
3S + 3O2 + 1O2
A + 1O2 Aox
S0
 
 
Independent of the sort of photosensitizer used for PDT, the efficiency of the treatment is 
oxygen dependent. Photosensitization typically does not occur in anoxic areas of tissue. 
In vivo studies showed that induction of tissue hypoxia, by blood vessel clamping, 
abolished the PDT effects of porphyrins [26]. Both type I and type II reactions occur 
simultaneously, and the ratio between these processes depends on the type of sensitizer 
used, the concentrations of substrate and oxygen, as well as the binding affinity of the 
sensitizer for the substrate. Because of the high reactivity and short half-life of the ROS, 
only cells that are proximal to the area of the ROS production (areas of photosensitizer 
localization) are directly affected by PDT [27]. The half-life of singlet oxygen in 
biological systems is <0.04 μs, and the radius of the action of singlet oxygen is <0.02 μm. 
The extent of photodamage and cytotoxicity is multifactorial and depends on: the type of 
sensitizer, the extracellular and/or intracellular localization, the total dose administered, 
the total time of light exposure, the light flux, the availability of oxygen and the time 
between the administration of the drug and light exposure. All of these factors are 
interdependent [28] and need to be carefully optimized. 
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 Figure 3: Reactions of Photosensitizer on Exposure to Light [28]. 
Type I 
reaction 
Type II 
 reaction 
Radicals 
Radical ions 
Activated 
Photosensitizer 
1O2 
1O2 
Products  of 
Oxidation 
Light 
Substrate Substrate O2 
Photosensitizer 
Products  of 
Oxidation 
 
1.2.3. Mechanism of tumor destruction by PDT 
 
There are three main mechanisms by which PDT mediates tumor destruction [29]. In the 
first case, the ROS that is generated by PDT can kill tumor cells directly. PDT also 
damages the tumor-associated vasculature, leading to tumor infarction. Finally, PDT can 
activate an immune response against tumor cells. These three mechanisms can also 
influence each other. The relative importance of each one of them for the overall tumor 
response has yet to be defined. It is clear, however, that the combination of all these three 
processes is required for long-term tumor control. 
1.2.3.1. Direct killing of tumor cells 
 
In vivo exposure of tumors to PDT has been shown to reduce the number of clonogenic 
tumor cells, through direct photodamage [30]. However, complete tumor eradication is 
not always fully realized by this mechanism alone. One reason is the non-homogenous 
distribution of the photosensitizer within the tumor. Furthermore, in 1995, Mladen 
Korbelik et al showed that both intravenously administered photosensitizer accumulation 
and the level of tumor cell killing decrease with the distance of tumor cells from the 
vascular supply [31]. Another parameter that can limit direct tumor-cell destruction is the 
availability of oxygen within the tissue that is targeted by PDT. Oxygen shortage can 
arise as a result of the photochemical consumption of oxygen during the photodynamic 
process, as well as from the immediate effects of PDT on the tissue microvasculature. 
Rapid and substantial reduction in the tissue oxygen tension during and after illumination 
of photosensitized tissue have been reported [32, 33]. Depending on the localization of 
 11
 the photosensitizer at the time of illumination, oxygen tension can increase transiently 
[34]. Although the developments of microvascular damage and hypoxia after PDT have 
been shown to contribute to the long-term tumor response, the reductions in oxygen that 
occur during PDT can limit the response. There are two ways to overcome this problem. 
One is to lower the light flux to reduce the oxygen consumption rate, and the other is to 
fractionate the PDT light delivery to allow re-oxygenization of the tissue [35, 36]. The 
extent of modulation by light intensity is dependent on the localization of the 
photosensitizer [37]. 
1.2.3.2. Vascular damage 
 
The viability of tumor cells also depends on the amount of nutrients supplied by the 
blood vessels. In turn, formation and maintenance of blood vessels depend on growth 
factors produced by tumor or host cells [38, 39]. Targeting the tumor vasculature is 
therefore one promising approach to cancer treatment. In the past 15 years, there have 
been a number of reports of PDT causing microvascular collapse [40-42], leading to 
severe tissue hypoxia and anoxia. As early as 1989, Barbara Henderson et al showed in a 
fibrosarcoma mouse model that Photofrin-based PDT (Photofrin is a photosensitizer 
produced by Axcan Pharma, Montreal, Canada) induced vascular shutdown, limiting the 
oxygen supply to the tumor [43]. Pre-clinical in vivo studies, performed last year with the 
photosensitizer MV6401 — a pyropheophorbide derivative (Miravant Medical 
Technologies, Santa Barbara, California) —, showed a biphasic vascular response 
following PDT. The first, immediate response was vasoconstriction. After three hours, a 
second, long-term response, characterized by thrombus formation, occurred [40]. This 
response could be inhibited with heparin. These vascular effects were associated with a 
delay in tumor growth. Previous studies with other photosensitizers, such as a 
benzoporphyrin derivative (BPD) [41] , HPD [42] and Photofrin [41] also reported 
vascular constriction, thrombus formation and inhibition of tumor growth. On the other 
hand, expression of vascular endothelial growth factor (VEGF) and cycloxygenase 
(COX)-2 — both potent angiogenic factors — were upregulated during PDT [44]. These 
effects were presumably due to the ROS formation and hypoxia that was induced by 
PDT. Further studies are required to determine the long-term effects of PDT on tumor 
vasculature. 
1.2.3.3. Immune response 
 
 Studies in the late 1980s and early 1990s also reported infiltration of lymphocytes, 
leukocytes and macrophages into PDT-treated tissue, indicating activation of the immune 
response [45, 46]. Differences in the nature and intensity of the inflammatory reaction 
between normal and cancerous tissues could contribute to the selectivity of PDT-induced 
tissue damage. The inflammatory process is mediated by factors such as vasoactive 
substances, components of the complement and clotting cascades, acute phase proteins, 
proteinases, peroxidases, ROS, leukocyte chemoattractants, cytokines, growth factors and 
other immunoregulators. The inflammatory cytokines interleukin (IL)-6 and IL-1, but not 
tumor necrosis factor- α (TNF-α), have been shown to be upregulated in response to PDT 
[47]. In 1996, Wil de Vree and colleagues also reported that PDT activated neutrophil 
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 accumulation, which slowed tumor growth [48]. Depletion of neutrophils in tumor-
bearing mice decreased the PDT-mediated effect on tumor growth. 
 
In 1996, Mladen Korbelik et al compared the long-term effects of PDT on tumor growth 
in normal Balb/C and immunodeficient mice. Whereas short-term tumor responses to 
Photofrin PDT were similar, long-term effects were quite different, as tumor recurrence 
occurred frequently. These results indicate that, whereas the direct effects of PDT can 
destroy the bulk of the tumor, the immune response is required to eliminate the surviving 
cells [49]. In 1999, Korbelik et al reported that PDT generated tumor-sensitized immune 
cells that could be recovered from lymphoid sites distant to the treated tumor at different 
time intervals after PDT [50]. An interesting observation was also made by Barbara 
Henderson et al, who reported that a tumor-cell lysate that was isolated following PDT 
with Photofrin could be used to vaccinate mice against the development of further 
tumors, indicating the induction of tumor-specific immunity [51]. This vaccination 
approach has been shown to be more effective at activating an immune response than 
lysates made from tumors that were exposed to ultraviolet or ionizing irradiation. These 
PDT vaccines seem to induce a cytotoxic T-cell response that involves induction of IL-12 
expression. Studies with PDT and tumor-cell lysates indicate that PDT could have 
potential as a systemic immune therapy [51]. Further experiments are required to 
determine whether similar results can be obtained in patients who receive PDT. 
1.3. Photosensitizers 
1.3.1. First Generation Photosensitizers 
 
Hematoporhyrin and its derivatives comprise the first generation of photosensitizers. The 
first generation photosensitizers starts in the 1960s, when R. Lipson et al initiated the 
modern era of PDT at the Mayo Clinic [19]. These studies involved a compound that was 
developed by S. Schwartz called ‘haematoporphyrin derivative’ (HPD) [52]. To prepare 
this derivative, crude haematoporphyrin was treated with acetic and sulphuric acids, 
filtered and then neutralized with sodium acetate. The precipitate was then purified to 
produce HPD. R.L. Lipson and E.J. Baldes then showed that HPD localized to tumors, 
where it emitted fluorescence. Because this derivative could also be administered at much 
smaller doses than crude haematoporphyrin, it held promise as a diagnostic tool. The 
mechanisms by which photosensitizers such as HPD selectively accumulate in tumors are 
complex and not fully understood. It is presumably because of the high vascular 
permeability of the agents, as well as their affinity for proliferating endothelium and the 
lack of lymphatic drainage in tumors [21]. HPD has been partially purified to remove the 
less-active porphyrin monomers, to form Photofrin® (also called porphymer sodium) [20], 
a very widely used photosensitizer in clinical PDT. Photofrin® is the first photosensitizer 
for which marketing clearance was obtained. It was first approved for prophylaxis of 
bladder cancer in Canada on April 16, 1993. Since then, it has been approved in several 
countries for the treatment of not only bladder but also oesophageal, gastric, cervical, and 
lung cancers [20, 53] . The suitability of Photofrin® for the treatment of several other 
cancerous diseases is being studied in phase I, II, or III clinical trials. For example, 
Photofrin® has been studied to treat head and neck cancers and, in a phase I clinical trial, 
 13
 to treat chest-wall recurrences of breast cancer. In addition, Photofrin® PDT was 
performed after surgery in the treatment of intraperitoneal cancer in a phase I clinical trial 
and colorectal cancer in a phase III clinical trial. Photofrin fits some of the criteria for 
ideal photosensitizers but suffers from several drawbacks. First, it is a complex mixture 
of porphyrins with various monomeric and oligomeric forms, so poorly characterized 
chemically. Secondly, its long wavelength falls at 630 nm, which lies well below the 
wavelength necessary for maximum tissue penetration. Finally, it induces prolonged 
cutaneous photosensitivity, and patients are advised to keep away from direct sunlight (at 
least for a month or so) after treatment. These drawbacks stimulated the research for the 
synthesis and testing of new and efficient photosensitizers which forms the class of 
second generation photosensitizers. 
1.3.2. Second Generation Photosensitizers 
 
During the last 10 years, various new porphyrin based long wavelength absorbing 
photosensitizers related to chlorins, bacteriochlorins and phthalocyanines (Table 2) have 
been reported. The basic structure of these classes are shown in scheme 8. These, second 
generation photosensitizers are pure synthetic compounds, which can absorb light of 
longer wavelengths and exhibit a strong absorption band in the red wavelength region. 
Like HpD, they are composed of an aromatic macrocycle such as porphyrins and 
benzoporphyrins, chlorins, bacteriochlorins or phtalocyanins. The properties that were 
aimed for in the development of these sensitizers were improved selectivity, longer 
wavelengths of light absorption, and increased extinction coefficient (molar absorptivity) 
at these wavelengths. Many second-generation photosensitizers have been studied in 
phase I, II, or III clinical trials for various indications. Among the new photosensitizers, 
marketing clearance has been obtained for the BPD-MA (Benzoporphyrin derivative-
monoacid ring A), the m-THPC (meta-tetrahydroxyphenyl chlorine) chlorin and the Tin 
etiopurpurin (SnET2 ) metallochlorin. PDT treatments with BPD-MA and m-THPC have 
also been approved in Europe, Canada and in the USA  [21, 53]. Besides the porphyrin 
based photosensitizers, a precursor for endogenous photosensitizer (Protoporphyrin – 
shortly referred as PpIX) called δ- aminolevulinic acid (ALA) was also developed as a 
second generation photosensitizer. These second generation photosensitizers can be 
classified in three categories: anionic lipophilic photosensitizers, cationic 
photonsensitizers and 5-aminolevulinic acid based PDT. 
 
Scheme 8 Chemical structures of Porphyrin, Chlorin, Bacteriochlorin and Phthalocyanine      
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 Scheme 9 Photosensitizers under clinical and preclinical trials 
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 Table 2: Porphyrin, chlorin, Phthalocyanine based Photosensitizers  
 
 Modified from [54] Allison R.R. et al, Photosensitizers in clinical PDT, Photodiagnosis 
and Photodynamic Therapy, 2004, Vol 1, issue 1, p27-42 and  [28] Dolmans D.E.J.G.J et 
al, Photodynamic therapy for cancer, Nature Reviews Cancer. Vol 3, issue 5, p 380-387.  
 
 
Drug 
(Brand 
name) 
Active 
ingredient 
Manufacturer Diseases treated Activation 
wavelength
Photofrin® HpD Axcan Pharma Cervical, 
endobronchial, 
Oesophagal , bladder 
and gastric cancer 
and brain tumors 
630 nm 
 
Visudyne® Vertiporfin 
(Benzoporphyrin 
derivative 
monoacid A) 
Novartis 
Pharmaceuticals 
Age-related macular 
degeneration, 
NMSC 
690 nm 
Foscan® Temoporfin 
(m-THPC) 
Biolitec Pharma 
Ltd 
NMSC of head and 
neck 
652 nm 
Antrin®, 
Lutex® 
Lutexaphyrin Pharmacylics Cervical, prostate and 
brain tumors 
732 nm 
Purlytin® SnET2 Miravant 
Medical 
Technologies 
Cutaneous metastatic 
breast cancer, basal-
cell carcinoma, 
kaposi’s sarcoma, 
prostate cancer 
664 nm 
LS11 Talaporfin 
(Taporfin 
sodium) 
Light Science Solid tumors from 
diverse origins 
664 nm 
Photochlor HPPH RPCI Basal-cell carcinoma 665 nm 
Photosens® mixture of 
sulphonated Al-
phthalocyanines 
General Physics 
Institute 
Cutaneous / 
subcutaneous lesions 
from diverse solid 
tumor origins 
670 nm 
Pc 4® Silicon 
phthalocyanine 
--- Solid tumors from 
diverse origins 
670 nm 
 
 
 
NMSC-Non-melonama skin cancer 
HPPH- Hexyl Ether Derivative of Pyropheophorbide 
RPCI-Roswell Park Cancer Institute 
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1.3.2.1. Anionic lipophilic photosensitizers 
 
These compounds all of which are tetrapyrrole compounds are lipophilic due to 
tetrapyrrole core and also are anionic. These newer compounds show somewhat 
improved selectivity for tumor over normal tissue compared to photofrin and 
consequently have reduced cutaneous phototoxicity. For some, the pharmacokinetics is 
reasonably rapid with plasma half-lives that are often biphasic, with values ranging from 
a few hours to up to a few days. They also have superior photochemical properties in 
terms of the absorption at longer wavelengths and corresponding extinction coefficients. 
For example, the chlorins have red-shifted absorption spectra (λmax 650–670 nm, 
compared with 630 nm for photofrin [55] and extinction coefficients in the 3 to 5 x 104 
M-1cm-1 range compared with the estimated values of 1.5 x 103 M-1cm-1 for photofrin. 
Some of the most important anionic lipophilic photosensitizers are listed in Scheme 9. 
 
1.3.2.1.1. Benzoporphyrin Derivative Monoacid (BPD-MA, Verteporfin, 
Visudyne® ) 
 
Of the newer photosensitizers, the most advanced as far as clinical application is 
concerned is benzoporphyrin derivative monoacid A 129 (BPD-MA) [56-59]. The BPD 
chromophores have absorption maxima around 690 nm. This chlorin-type compound 
which is a mixture of two diasteroisomers (ring A Diels–Alder adduct as monocarboxylic 
acid) with essentially equivalent photosensitizing properties is formulated in liposomes. 
The drug is currently in phase I/II trials for treatment of skin cancer and in a phase I/II 
clinical trial for treatment of basal cell carcinoma and metastatic skin lesions. Patients 
with basal cell carcinoma were found to respond better than those with metastatic skin 
lesions. However, due to its effectiveness in the obliteration of neovessels, this compound 
is being aggressively developed by QLT Phototherapeutics and Ciba-Vision as a first-line 
treatment for age related macular degeneration (AMD) of the eye [60] . This direction 
was stimulated by a series of preclinical studies, [61] where intraocular tumors implanted 
in rabbit eyes were used as a model for neovasculature. These studies showed that the 
very efficient destruction of these tumors could be achieved.  
The filings have been made in Europe, Canada, and the United States for the approval of 
BPD-MA in the treatment of AMD, approval was granted in Switzerland and a panel of 
the FDA recommended approval in the USA.  
Advantages:  (i) Long-wavelength absorption; (ii) No skin phototoxicity. 
Disadvantages:  (i) Difficult to separate the A and B ring Diels–Alder products from the 
mixture, and only the ring A isomer is effective; (b) Clears rapidly 
 
1.3.2.1.2. Tetra (m-hydroxyphenyl)chlorin (m-THPC, Foscan®) 
 
meta-tetrahydroxyphenyl chlorin 130 (m-THPC), tradenamed Foscan®, is the most active 
photosensitizer in a series of tetrahydroxyphenyl analogues. This photosensitizer has a 
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 singlet-oxygen quantum yield comparable to other chlorines [57, 62, 63] and appears to 
be the most active, requiring in some cases only a dose as low as 0.1 mg kg-1 and a light 
dose of 10 J cm-2. In a preliminary trial, patients have been treated for early stage 
squamous cell carcinoma of the aerodigestive tract, Barrett’s esophageous with 
superficial adenocarcinoma, and bronchial and oesophagal tumors [64]. In patients with 
early stage tumors, no recurrence was seen during follow-up of 3–35 months. This drug is 
also in phase II/III clinical trials for head and neck cancers in Europe and the United 
States. 
Advantages: (i) Easy to synthesize; (ii) Long–wavelength absorption at 650 nm; (iii) 
Effective photosensitizer. 
Disadvantages: (i) Skin phototoxicity which lasts for several weeks; (b) For optimal 
activity, light treatment is required 7–9 days after injection of the drug. 
 
1.3.2.1.3. Tin Etiopurpurin (SnEt2, Purlytin®)  
 
Tin etiopurpurin 131 (SnEt2), tradenamed Purlytin®, is a chlorin photosensitizer being 
investigated for use in PDT [57]. Purlytin® has a tin atom in the center of the macrocycle 
and has an absorption maximum near 650 nm. It has been reported that Purlytin1 
localizes into the skin and can produce a photoreaction for 7 to 14 days after 
administration [65, 66]. This compound is currently in phase II clinical trials for age 
related macular degeneration and prostate cancer. In preliminary trials for basal cell 
carcinoma and metastatic breast cancer, patients were treated with 1.2 mg kg-1 of drug, 
then 24 h post-injection with 200 J cm-2 of light at 660 nm. Photosensitivity reactions 
were seen in patients 1–2 months post-treatment. 
Advantages: (i) Slightly deeper light penetration into tissue compared to Photofrin; (ii) 
Availability of diode lasers at 660–665 nm. 
Disadvantages: (i) Insoluble in water, hence formulated in lipids, which causes some 
dark toxicity and (ii) Delayed phototoxicity—a major drawback. 
 
1.3.2.1.4. Lutetium Texaphyrin (Lutex ®) 
 
Lutetium texaphyrin 132, tradenamed Lutex®, is a non-porphyrin photosensitizer 
currently in Phase-II clinical trials for the treatment of cancer [67]. Lutex® has been used 
to treat malignant melanoma [68] because it is highly selective for tumor tissue and it can 
be activated with 732 nm light that penetrates more deeply into pigmented lesions than 
the light needed to excite Photofrin®, Verteporfin® or Foscan®. Lutex® is also being used 
to prevent re-stenosis of vessels after cardiac angioplasty [69] by photo-inactivating foam 
cells that accumulate within arteriolar plaques. For this indication Lutex® has been given 
the tradename Antrin®. A phase II/III trial using Lutex® for treating certain cancers is 
under way.  
Advantages:  (i) Strong absorption at 732 nm; (ii) Limited skin phototoxicity; (c) 
Effective photosensitizer. 
Disadvantages:  (i) Severe pain during light treatment; (ii) Multi-step synthesis. 
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 1.3.2.1.5. Hexyl Ether Derivative of Pyropheophorbide-a (HPPH, Photoclor®) 
 
Among the chlorophyll derivatives prepared so far, the alkyl ether analogs of methyl 
pyropheophorbide  [64] have attracted the most attention. In this series of compounds it 
was observed that the biological activity increased by increasing the length of the alkyl 
ether carbon chain, being maximum in compounds with n-hexyl 133 and n-heptyl chains. 
It possesses a strong absorption at 660 nm with a high singlet oxygen quantum yield. It is 
highly selective and has reduced phototoxicity compared to Photofrin. HPPH has been 
approved by the United States Food and Drug Administration for phase I/II clinical trials 
at Roswell Park Cancer Institute, Buffalo. Five patients with oesophagal cancer have 
already been treated with excellent results and no skin phototoxicity was observed. 
Advantages: (i) Easy to synthesize; (ii) Long-wavelength absorption near 665 nm; (iii) 
Excellent efficacy at very low doses; (iv) No skin phototoxicity. 
Disadvantages: (i) Poor solubility in physiological medium (ii) Pain during treatment 
 
1.3.2.2. Cationic photonsensitizers  
 
                              
N
S NH(C2H 5)(C2H 5)2N
134  
Scheme 10: A benzophenothiaze based sensitizer 
 
A different group of photosensitizers that merits a brief mention are the cationic 
photosensitizers. In contrast to the porphyrins, which derive their PDT effect in large part 
via destruction of the tumor vasculature, cationic photosensitizers are suggested to be 
cellularly localized molecules and to act at the tumor cell level. It is believed that the 
basis for their preferential accumulation in tumor tissue is that the electrical potential 
across the mitochondrial membrane in tumor cells is much steeper than in normal cells 
[70]. This steep gradient leads to a high accumulation in tumor cells of compounds with a 
delocalized positive charge. The best developed of the series are the 
benzophenothiazinium dyes [71, 72]. In systematic investigations of these dyes, Cincotta 
and colleagues showed high cure rates in two animal models of sarcoma, using the 
cationic photosensitizer 5-ethylamino-9-diethylaminobenzo (a) phenothiazinium chloride 
134  (EtNBS) activated with 652 nm irradiation [71]. Cellular uptake of these compounds 
appears to occur rapidly, within seconds. In an attempt to combine vascular and cellular 
effects, a benzophenothiazinium sensitizer and BPD-MA were used in PDT of EMT-6 
tumors in Balb/c mice. The treatment produced a synergistic effect, compared with the 
single treatments [73]. Using the iodinated form of the cationic photosensitizer, it was 
shown that the antitumor effect was mediated by both T cells and NK cells, indicating 
that PDT can elicit antitumor protective immunity [74]. These preclinical studies may be 
useful in various clinical settings and are currently under development. 
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 1.4. 5-Aminolevulinic acid based PDT (ALA-PDT) 
 
A new approach to PDT based on the use of endogenous photosensitizer protoporphyrin 
IX (fig. 4), a precursor in the biosynthesis of heme was introduced in 1990. It made use 
of 5-Aminolevulinic acid 119 (5-ALA, also called δ-ALA or simply ALA), the first 
intermediate for the biosynthesis of heme. 
H3N OH
O
O
Cl
 
 
                                                                 119 
1.4.1. Heme Biosynthesis 
  
Almost all cells in the body have a requirement for heme. Heme forms the reactive centre 
of a number of enzymes and proteins including proteins which are widely present such as 
cytochrome P450 and the respiratory chain cytochromes. These cells must maintain a 
capacity for heme biosynthesis and this process occurs by the now-classical porphyrin 
biosynthetic pathway which is shown in Figure 4. Although the starting components are 
the common metabolites succinate and glycine, the first dedicated intermediate in the 
porphyrin biosynthetic pathway is 5-aminolevulinic acid (ALA), an unusual amino acid 
119. The details of this pathway have been well studied over many years, partly because 
of its relevance in the porphyria. The pathway is very tightly regulated by a number of 
control points, with feedback inhibition by heme being an important component of this 
regulation. The process is not only under strict enzymatic control but it is also regulated 
through the fact that different subcellular compartments are responsible for different parts 
of the biosynthesis. The synthesis of ALA occurs in the mitochondria by the 
condensation of glycine and succinyl CoA, catalyzed by ALA-synthase. Once 
synthesized ALA is exported into the cytosol, where it undergoes a series of synthetic 
steps forming porphobilinogen (PBG), then porphyrinogens (the colourless precursors of 
porphyrins), protoporphyrin IX and finally heme. Eight molecules of ALA form four 
molecules of PBG using the enzyme porphobilinogen synthase .These four molecules of 
PBG in turn form one molecule of Uro III which is shown in Fig 4. These precursors of 
porphyrin intermediates are colourless because they have a reduced chromophor system 
compared to the porphyrins and lack thereby the delocalized electron system seen in the 
porphyrin macrocyclic ring. In the final stages of heme biosynthesis the intermediate 
coproporphyrinogen is transported from the cytosol into the mitocondria and converted to 
the first true porphyrin, protoporphyrin IX (PpIX). The last step requires the insertion of 
iron into PpIX to produce haem. PpIX is a very powerful photosensitizer. It does not 
normally cause significant photodynamic damage (except in certain examples of the 
porphyrias), since it does not accumulate but is simply used as an intermediate in low 
concentrations in the pathway to heme. 
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 Figure 4: Heme Biosynthesis: Endogenous ALA is synthesized by ALA Synthase. 
Exogenous ALA comes from outside the cell and/or from ALA-prodrugs and allows 
bypassing the negative feedback of Heme on ALA synthase. Gly: glycine, Succ-CoA: 
succinyl-coenzyme A, PBG: porphobilinogen and URO III: uroporphyrinogen III. 
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1.4.2. Mechanism of ALA-PDT 
 
The slowest and thereby rate limiting step in heme biosynthesis is the formation of 5-
aminolevulinic acid (ALA) from succinyl-coenzyme A and glycine catalyzed by the 
enzyme ALA synthase. Under physiologic conditions, cellular heme synthesis is 
regulated in a negative feedback control of the enzyme ALA synthase by free heme.  
 
The ALA-PDT depends on the generation of the only photosensitizing intermediate of 
heme biosynthesis, which is protoporphyrin (PpIX). Under normal conditions PpIX is an 
intermediate and does not accumulate in the pathway. The only way to generate larger 
quantities of PpIX is by administering ALA exogenously (Fig 4). So, when exogenous 
ALA is given to cells with an active heme biosynthetic pathway, the pathway becomes 
temporarily overloaded, the control mechanism is bypassed, and downstream metabolites 
are synthesized in excess. Under these conditions, ferrochelatase, which catalyzes iron 
insertion into PpIX, becomes the rate-limiting enzyme. Following the addition of 
exogenous ALA, the low physiologic rate of iron insertion by ferrochelatase is unable to 
compensate for the excess PpIX that is formed. PpIX, therefore, accumulates in cells and 
renders them photosensitive. The build-up of porphyrins on addition of ALA to cells has 
been known for many years,  but it is only in the last decade that this has been developed 
as an effective form of PDT [75]. Following 5-ALA-induced synthesis in mitochondria, 
PpIX selectively accumulates in mitochondria. Some investigators have indicated that the 
primary cause of cell death after PDT is mitochondrial phototoxicity (47–49). Some 
investigators have shown that ALA induced PpIX formation induced an apoptotic 
responses [76]. It has been established that ALA uses the intestinal and renal apical 
peptide transporters for entering into epithelial cells [77] and in certain type of cells ALA 
is transported by system BETA transporters [78]. This explains the excellent intestinal 
absorption of ALA when it is adminstered by oral route. The production rate of PpIX 
increased with cell size and with increasing ALA concentration [79]. 
 
At present, our knowledge of the mechanisms involved in ALA-based PDT is limited. 
One of the important open questions is the following: the reason for preferential ALA 
uptake and conversion by tumors and dysplastic tissue is not clear. Various theories have 
been put forward to account for the selectivity of PpIX formation in tumors and other 
lesions: 
• It has been suggested that tumors contain lower levels of ferrochelatase (the 
enzyme responsible for the insertion of iron into PpIX) than the surrounding 
normal tissue, resulting in less effcient conversion of PpIX into heme within 
tumor cells and hence the build-up of PpIX. 
• Tumors may have less readily accessible iron than surrounding normal tissue 
which would result in poorer conversion of PpIX into heme. 
• It is well established that tumors have a lower pH than normal cells and this may 
result in more PpIX retention in the tumor cells due to the various protonated               
species which may be formed from PpIX. 
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 • Selective accumulation of PpIX may be related to selective uptake of ALA since 
the skin or epithelium overlying the tumor or lesion has greater permeability              
than non-tumoral tissue. 
• There is some indication that porphobilinogen deaminase the enzyme that 
converts four porphobilinogen molecules into the protoporphyrin precursor, 
uroporphyrinogen III, may have a regulatory role in the 5-ALA induced increase 
of PpIX.  
• Porphyrin biosynthesis capacity is 20 fold enhanced in cancer cells at least from 
the stages of porphobilinogen (PBG) formation up to that of coporphyrinogen, 
when compared with its original normal tissue [80].  
 
The reason why ALA administration results in the build-up of PpIX rather than other 
porphyrin intermediates is also not well understood. Simple arguments such as the 
supposed rate-limiting effects of ferrochelatase have been advanced, but it is now clear 
that this represents an oversimplification of the true picture. For example, it is known that 
other intermediates in the pathway do indeed accumulate [81] but that these intermediates 
may be more readily excreted from cells than PpIX. Another possibility is that the 
immediate precursor of PpIX, known as protoporphyrinogen IX, may also accumulate 
and be converted non-enzymatically into PpIX. Finally, the subcellular compartmentation 
of the heme biosynthetic pathway may be important, since excess PpIX may escape from 
the mitochondria and therefore might not be available for the iron insertion step to make 
heme. The effects of exogenous ALA cannot be imitated by administration of pre 
synthesized PpIX.[82] Along with deficiencies in the metabolic pathway of heme, other 
factors including increased ALA uptake, limited availability of ferrous iron, cell cycle 
activation, proliferative activity, mitochondrial density, increased temperature and lower 
pH values have been suggested to be responsible for the alteration in the biosynthesis of 
heme in neoplastic cells. 
1.4.3. Advantages of ALA 
 
9 5-ALA in contrast to porphyrins is a small, soluble molecule able to penetrate the 
abnormal stratum corneum overlying skin tumors. So it can be applied topically 
unlike other photosensitizers. 
9 In contrast to most tetrapyrrole photosensitizers, ALA-PpIX localizes in cells 
(where it is incorporated into the biosynthesis) rather than in the tumor 
vasculature. 
9 ALA and ALA-PpIX are rapidly cleared from the system, which results in an 
acceptably short period (1-2 days compared to 1-1.5 months with HpD and 
Photofrin®) of cutaneous photosensitivity or skin phototoxicity. This is viewed as 
an advantage over some of the other photosensitizers where light protection may 
be required for several weeks. This allows multiple treatment regims and thereby 
increases the efficacy of PpIX. 
9 ALA can be easily synthesized unlike other porphyrin based photosensitizers. 
9 ALA-PDT is noninvasive, can be used to treat multiple lesions by short treatment 
sessions, produces excellent cosmetic results by not causing damage to 
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 surrounding tissue, has no side effects beyond slight pain during irradiation, and is 
well accepted by patients  [83]. 
9 ALA can be easily formulated. So ALA can be topically applied which gave 
promising results in the treatment of superficial cutaneous malignancies. 
1.4.4. Disadvantages of ALA 
o A significant shortcoming of ALA is its limited ability to cross certain biological 
barriers (e.g. cellular membranes) due to its low lipid solubility [84]. 
o PpIX is active at 630 nm, which should give adequate depth penetration; when 
topically administered, ALA does not penetrate to great depth; it has limited depth 
penetration (up to about 1 mm). 
o No matter how good the delivery of ALA may be, the formation of PpIX requires 
the activity of several enzymes (Figure 4)  
o Pain associated with PDT; when administered systemically: transient liver 
abnormalities have been observed and patients have reported mild nausea after 
ALA administration [85]. 
o Though multiple treatment regimens are possible, the efficacy of  PpIX generation 
is decreased in the subsequent regimen if taken within 24 hours [86]. 
o ALA is stable at acidic pH as low as 2-2.5. In aqueous solutions buffered to a 
physiological pH (pH=7), ALA dimerises to give pyrazine derivatives 135 while 
at higher pH pseudo-porphobilinogen 136 may be formed [87-91] and conversion 
to ester derivatives appears to worsen these problems. Esters are known to 
increase the potential for formation of lactam type derivatives 137 (See Scheme 
11). 
 
Scheme 11: ALA degradation products 
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 1.4.5. ALA derivatives 
 
In order to overcome the shortcomings of ALA and improve its bioavailability, ALA can 
be derivatized. ALA has two principal functional groups, a carboxylic acid and an amino 
moiety which are both easily accessible for derivatization. The simplest way to alter the 
lipophilicity of ALA is via esterification of acid moiety. The use of ALA derivatives as 
good candidates for the treatment of skin cancer has been extensively reviewed [92, 93] 
1.4.5.1. ALA esters  
 
ALA esters were originally studied as potential PDT drugs on the basis that they may 
have improved pharmacological properties compared with ALA itself. For example, since 
they are more hydrophobic / lipophilic than ALA, it was believed that they might be 
taken up into cells by different mechanisms, which might improve the efficiency of the 
therapy. The rationale was, that once inside cells ALA esters may be hydrolysed to ALA, 
which could then enter the heme biosynthetic pathway. ALA esters were first developed 
by Peng et al [94, 95] and Kloek et al [84, 96]. Esters with various chain lengths were 
prepared by these investigators (Table 3). They concluded that esters with chain length of 
C5- C7 (pentyl, hexl and heptyl) generate very high PpIX formation; esters longer than 
C7 length produce less efficient PpIX formation. Also, 2-(hydroxy methyl) 
tetrahydrofuranyl, 2-(hydroxy methyl) tetrahydropyranyl esters and benzyl esters of ALA 
were found to generate higher amount of PpIX. The esters have indeed proved to be 
effective in both phototherapy and photodetection [97, 98]. However, the mechanisms 
involved in the production of PpIX from ALA esters may not be as simple as first 
thought. Certainly the uptake is different from that of ALA itself [78]. Increased cellular 
uptake of lipophilic ALA esters resulting in enhanced PpIX concentrations has been 
demonstrated in a number of in vitro and in vivo systems [94, 96, 99] . Though these 
esters are incorporated into the cells at higher rate than ALA, studies conducted show that 
they also efflux at an increased rate mediated by passive diffusion [100].  
 
The octanol-water partition coefficients of ALA esters (log P) have been determined to 
obtain a parameter related to lipophilicity. The influence of this parameter lipophilicity 
along with concentration, time and pH dependence on PpIX formation was studied. But 
no direct relationship between lipophilicity and total PpIX build-up has been found, 
indicating that two different processes, uptake and ester cleavage are necessary for 
efficient PpIX formation [101]. These long chain ALA esters require 30-150 fold lower 
concentration than ALA for comparable amounts of PpIX production. However, the use 
of these esters resulted in a non-specific distribution of ALA in all cell types, with a 
certain preference for tumor cells [84, 99, 101]. Berger et al synthesized and tested 
various ethylene glycol esters of ALA 141 (Scheme 13) with varying chain length. They 
found that these esters are designed to target cellular esterases. They induce high levels of 
PpIX, but they are also less toxic than 5-ALA hexyl esters over a wide range of 
concentrations [102]. Brunner et al synthesized and tested a series of ALA esters carrying 
electron withdrawing groups to enhance PpIX generation. These electron withdrawing 
groups enhance the ester hydrolysis and should so help to generate higher intracellular 
PpIX. They found that ALA nonafluorohexylester hydrochloride, ALA thiohexylester 
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 hydrochloride and ALA dibenzyldiester dihydrochloride 142 (Scheme 13) produced 
higher levels of PpIX than that produced by ALA, ALA hexyl ester and ALA benzyl 
esters  [103]. The data indicates that the altered properties further improve the diagnostic 
and therapeutic potential significantly beyond what is achieved with ALA-based PDT 
[104, 105].  
 
Scheme 12: ALA esters under clinical trials and / or approved drugs 
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Scheme 13: ALA esters efficient in PpIX induction 
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Table 3: Other ALA derivatives (selected) 
 
Adapted from Lopez, R.F.V., et al., Photodynamic therapy of skin cancer: controlled  
drug delivery of 5-ALA and its esters. Advanced Drug Delivery Reviews, 2004. 56(1): p.  
77-94.                                      
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 Molecule R1 R2 
ALA-Ethyl -H -C2H5 
ALA-Propyl -H -C3H7 
ALA-Butyl -H -C4H9 
ALA-Pentyl -H -C5H11 
ALA-Octyl -H -C8H17 
R,S- ALA-2-
(hydroxymethyl) 
tetra- hydrofuranyl 
-H 
O
 
R,S- ALA-2-
(hydroxymethyl) 
tetra- hydropyranyl 
-H 
O
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N-acetyl- ALA-ethyl CH3CO -C2H5 
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N-butanoyl-ALA CH3(CH2)2CO- -H 
N-pentyl-ALA CH3(CH2)3CO- -H 
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N-heptanoyl-ALA CH3(CH2)5CO- -H 
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 1.4.5.2. ALA – pseudo peptide derivatives  
   
ALA with N-terminal blocked by acetyl, butanoyl, pentyl, hexanoyl groups were 
synthesized. All these N-terminal blocked ALA failed to induce high quantities of PpIX 
in vitro [84, 106] though a carbobenzyloxy phenylalanyl ALA ethyl ester has been shown 
to induce considerable amounts of PpIX in human and rat skin explants [106]. 
 
ALA-amino acid pseudo peptide derivatives were also synthesized and tested on various 
cancer cell lines by different research groups [102, 106-108] . These can be potential 
substrates for cytoplasmic amino peptidases (acidic or neutral or basic) and/ or peptide 
and amino acid transporters. It was observed by Berger et al that the compounds blocked 
at the N-terminal of amino acid were no good precursors measured by the amount of 
PpIX formed. Also the pseudo peptides containing acidic or basic amino acid moiety 
were not active. Only ALA pseudo peptides containing neutral amino acids like Alanine, 
Phenylalanine with the acid moiety of ALA either free or protected as esters generate 
comparable amount of PpIX than that ALA. Later it was found that N-blocked or N-free 
dipeptides-ALA-ethyl esters 143 (Scheme 14), but not tripeptides–ALA-ethyl esters were 
substrates for cellular peptidases and were metabolized to ALA. The precursors were 
hydrolyzed intracellularly involving serine-proteases and metalloproteases. Cell 
selectivity for human endothelial or carcinoma cells was observed for some of this 
dipeptides-ALA. 
In general ALA-pseudo peptide derivatives do not induce high PpIX quantities unlike 
that of the simpler ALA ester derivatives. This difference might be due to low cellular 
peptidase activity. 
 
Scheme 14: ALA -peptides efficient in PpIX induction 
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1.4.5.3. ALA dendrimers 
 
Recent advances in polymer chemistry now allow the synthesis of structurally defined, 
hyperbranched polymers (or dendrimers) which can be conjugated with drug molecules 
[109]. The drug can either be bound to a preformed dendrimer, in which case the exact 
loading of the drug cannot easily be controlled, or the drug can be incorporated into the 
structure of the dendrimer during synthesis. With this approach, Battah et al synthesized 
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 dendrimers bearing 6 or 9 ALA residues by attaching a tris (Boc-protected ALA)- 
containing wedge to a di- or tripodent aromatic, or tripodent aliphatic core 144  and 145 
(Scheme 15). Two second generation 18-ALA-containing dendrimers were also 
synthesized using a 3, 3’-iminodipropionic acid spacer unit between the wedge and the 
aromatic core. These compounds differed only in the distance between the core and the 
linker unit. The results show that the ALA-containing dendrimers are clearly able to pass 
through the cell membrane, release ALA intracellularly and generate comparable 
quantities of PpIX as that of ALA; however, there is no direct correlation between the 
number of ALA molecules attached to the dendrimer and PpIX accumulation [110]. Rhe 
same group recently evaluated in vivo and in vitro the efficacy of the dendron, 
aminomethane tris-methyl ALA (containing 3 ALA residues) in PpIX generation. 
Although this dendron is capable of being taken up by cells and liberate the active ALA 
thereby induce PpIX, in vivo it was not possible to improve the efficacy of ALA-induced 
PpIX formation [111].  
 
Scheme 15:  ALA dendrimers efficient in PpIX induction 
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1.4.6. ALA formulations 
 
The major obstacle of ALA is its limited penetration depth and consequently low 
induction of PpIX. The simplest approach is to introduce so-called penetration enhancers, 
such as DMSO, oleic acid, azacycloalkane derivatives, and ethanol into the formulation. 
Malik et al found that ALA with 2% DMSO enhances PpIX production significantly 
[112]. 
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 Also, glycerol monooleate, a lipid permeation enhancer, increased in vitro permeation 
and retention of ALA [113]. Another approach is to introduce additives that act on heme 
biosynthesis, e.g. by removing ferrous iron. This can be achieved by adding iron 
chelating substances such as ethylene diamine tetracetic acid (EDTA), desferrioxamine 
(DFO), and 3-hydroxypyridin-4-ones (HPOs). In vitro, the iron specific DFO is superior 
to EDTA [114] at equal concentration with respect to PpIX formation. 
 
1.4.7. Clinical and Pre-clinical Aspects of ALA-PDT for 
Diagnosis and Therapy 
 
Besides therapeutic indications which are expanding, the use of ALA-induced PpIX 
(ALA-PpIX) has gained much interest in diagnostics. (table 4). PpIX fluorescence is 
being used for the detection of early malignancies, carcinomas in situ, and cancer 
precursor lesions. By minimally invasive diagnostic procedures, accessible organs, such 
as the bladder [115], oral cavity [116], lungs [117], upper and lower gastrointestinal tract 
[118], and cervix [119], to name a few, are being viewed with optical devices, and ALA-
PpIX fluorescence is used to detect suspicious areas for guided biopsy and therapy. In 
urology, ALA-PpIX is used for the early diagnosis of urothelial dysplasia and carcinoma. 
In this case, the ALA is administered locally by instillation and remains for about 2 h in 
the bladder. Subsequently, the bladder wall is examined by using a modified cystoscope 
that allows regular illumination and blue-light excitation for observation of porphyrin 
fluorescence. With white light, the lesion can be barely distinguished, while blue light-
induced ALA-PpIX fluorescence clearly demonstrates the outline of the neoplasia. In 
larger patient groups, this use of ALA significantly enhanced the cystoscopic detection of 
malignant and dysplastic lesions, and in the application of imaging following surgical 
resection it has been shown to be a useful “second-look” tool to find remaining dysplastic 
tissues, thereby significantly reducing the local recurrence rate following surgery. ALA-
PpIX fluorescence is also useful for determining tumor margins. In a similar manner, 
during brain surgery ALA-PpIX fluorescence-guided resection of malignant gliomas 
reportedly results in prolonged patient survival [120]. 
 
Patients with Barrett’s esophagus, precancerous dysplasia and early oesophagal 
carcinomas are being efficiently treated with oral ALA-based PDT [121]. An ingenious 
and highly successful blue light system employing ALA for actinic keratosis with 
outpatient treatment as devised by DUSA Pharmaceuticals Inc has FDA approval. Given 
the excellent cosmetic outcome, one might predict this system will become widespread in 
cosmetic and plastic surgery circles. ALA also has had success for head and neck tumors, 
though invasive lesions do not achieve complete response. Given its limited penetration, 
ALA would more likely to show higher efficiency for dysplastic and in situ lesions, 
which are rather common in the oralcavity. PhotoCure ASA, a Norwegian company has 
employed methylated ALA (Metvix®) for a wide variety of lesions. The drug is topically 
applied and then about 3 h later red light illumination is employed. The drug/light therapy 
is approved in many European countries for treatment of actinic keratosis. The same 
company produces Hexvix® for photodiagnosis and likely photodynamic therapy. 
Currently this drug is infused in the bladder and 30-60 min later blue light is employed to 
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 induce fluorescence abnormal tissues. Benzvix® is the drug Photocure ASA believes will 
allow for diagnosis and treatment of early oesophagal and GI tract lesions. ALA has been 
successful for oesophagal treatment and with an oral form of drug available this is 
convenient treatment.  
 
 
Table 4: ALA esters as Prodrugs- Disease treated and/or under clinical trials 
 
Drug 
(Brand 
name) 
Active 
ingredient 
Manufacturer Diseases treated Activation 
wavelength
Levulan® ALA DUSA 
Pharmaceuticals 
Actinic keratosis, 
Basal cell carcinoma, 
Bowen’s disease, 
psoriasis, hair 
removal, acne, 
bladder cancer 
detection 
632 nm 
 
Metvix® ALA-Methyl 
ester 
Photocure ASA 
Galderma 
Actinic keratosis, 
Basal cell carcinoma 
632 nm 
Hexvix® ALA Hexyl 
ester 
Photocure ASA Bladder cancer 
detection 
632 nm 
Benzvix® ALA Benzyl 
ester 
Photocure ASA Bladder cancer 
detection 
632 nm 
 
 
1.5. Third Generation Photosensitizers or Targeted 
Photodynamic therapy  
 
Most therapeutic drugs distribute through the whole body, which results in general 
toxicity and poor acceptance of the treatments by patients. The targeted delivery of 
chemotherapeutics to defined cancer cells is one of the main challenges and a very active 
field of research in the development of treatment strategies to minimize side-effects of 
drugs. Disease-associated cells express molecules, including proteases, receptors, or 
adhesion molecules, that are different or differently expressed than their normal 
counterparts. Therefore one goal in the field of targeted therapies is to develop 
chemically derivatized drugs or drug vectors able to target defined cells via specific 
recognition mechanisms [122-124]. This approach should also be able to overcome 
biological barriers.  
 
Four different strategies of improving selectivity (targeting) in PDT have been practiced 
so far [125]. First strategy for selective photosensitizer (PS) delivery utilizes targeting 
moieties, such as monoclonal antibodies (MAbs), directed against antigens or ligands that 
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 are specifically overexpressed on cancer cells. An important determinant of successful 
PDT is the localization of the PS at the time of irradiation. More precise drug targeting is 
therefore desirable in order to ensure success but also to reduce toxicity to uninvolved 
tissues and organs in complex sites, such as in the abdominal cavity. It is important to 
note that contrary to conventional targeted chemotherapy where the drug has to be 
released from the carrier moiety to elicit a response; this is not a prerequisite when carrier 
molecules are used for delivery of PS in PDT if PS is not ALA. Antibodies raised against 
epitopes of cancer cells have also been coupled to photosensitizers (photoimmunotherapy 
= PIT). Hp, Ce6 or phthalocyanins have been bound to monoclonal antibodies 
recognizing cancer cells and PIT was found to be active against cancer cells [126]. 
 
A second strategy which is commonly used, to improve the delivery of PS to target tissue 
involves their encapsulation in colloidal carriers, such as liposomes, oil-dispersions, 
polymeric particles, and polymers to facilitate drug delivery [127, 128].  
 
Third strategy is to conjugate photosensitizer (PS) with specific receptors which are over 
expressed in cancer cells. This helps in receptor mediated endocytosis. The expression of 
low density lipoproteins (LDL) receptors is increased in many cancer cells. Hydrophobic 
photosensitizers were incorporated into LDL and targeted to their receptors [129]. 
Chlorin e6 (Ce6) was also conjugated to LDL. The cellular uptake of the conjugate and 
efficiency of PDT were increased in retinoblastoma and fibroblasts compared to free Ce6 
assuming that the conjugate will be carried by LDL and internalized by an LDL-receptor 
dependant mechanism.  
 
Nuclear targeting was also investigated by coupling a porphyrin to the nuclear 
localization sequence (NLS) [130]. Several types of cancer cells exhibit increased 
expression of transferin receptors and therefore, hematoporphyrin (Hp) was conjugated to 
transferin. The uptake of the Hp-transferin in human colon carcinoma HT29 cells was 
shown to be receptors mediated. Another receptor overexpressed on cancer cells is 
epidermal growth factor (EGF) receptors. EGF has been coupled to various 
photosensitizers to target specially cancer cells. Metal-disulfonated phtalocyanins bound 
to EGF were 10 times more active than free phtalocyanins in human breast carcinoma 
MCF7 cells [131]. Estradiol, a steroid hormone, has also been evaluated to target 
estrogen receptors (ER). The hormone has been conjugated to Tetraphenylporphyrin 
(TPP) and it has been shown that the molecule has still a strong affinity for ER [132]. 
 
The main problem of these protein-based conjugations may reside in their potential 
immunogenicity. Therefore, non-proteic ligands have also been evaluated such as folic 
acid which is vitamin B9. Tetraphenylporphyrin (TPP) has been conjugated to folic acid 
146 (Scheme 16) to target tumor cells overexpressing its receptors [133]. Cellular uptake 
and photodynamic activity of the conjugate on human nasopharyngeal cell line were 
greatly increased compared to free TPP and competitive assays using free folic acid 
demonstrated folate-receptor dependent uptake of the conjugate.  
 
 32
 N HN
NNH
NH
O
O
O
HN
OH
O
N
H
N
N N
N
H 2N
OH
N
H
146
 
Scheme 16: Tetraphenylporphyrin (TPP) has been conjugated to folic acid 
 
Fourth strategy to selectively enhance PS levels in a disease site is to facilitate PS uptake 
more in the target tissue than the surrounding normal areas. For example in the case of 
ALA- based PDT, there are various formulations of ALA designed to increase its uptake 
as discussed in chapter 1.4.6.  
 
Alternative ways of targeting PS to a specific cell population need to take advantage of 
certain properties of these cells, which either distinguish them from other cell or tissue 
types, or differentiate, malignant from normal cells. An approach that was used by Zhang 
et al., [134] is based on the altered sugar metabolism of cancer cells. Rapidly growing 
tumors are able to maintain high glucose catabolic rate by upregulation of the enzyme 
hexokinase. This enzyme phosphorylates glucose to glucose-6-phosphate, which is then 
retained in the cell. Photosensitizers have been also functionalized with a large quantity 
of different sugars. Saccharides-porphyrin or –chlorin conjugates are probably the most 
active field of research in the targeting of photosensitizers [135]. The efficiency of the 
saccharide composition has been evaluated using xylosyl, arabinosyl, glucosyl, galactosyl 
or 2-aminoglucosamide groups [134]. When linked to a photosensitizer, uptake and 
accumulation in the endoplasmic reticulum and photoxicity were increased in cancer 
cells. The length of the oligosaccharide is also an important factor for the membrane 
penetration [136].  
 
1.6. ALA - Other applications 
 
ALA has a variety of agricultural applications not only as an herbicide, insecticide and 
growth promoting factor, but also based on its ability to confer salt and cold temperature 
tolerance in plants [137].  
 
1.6.1. Agricultural applications 
1.6.1.1. Biodegradable herbicide 
The practical application of ALA as a biodegradable herbicide was demonstrated by 
Rebeiz et al. [138]. This was quite significant because ALA is a selective, not harmful 
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 and biodegradable material. The mechanism of ALAs function as “photodynamic 
herbicide,” as proposed by Rebeiz et al. is as follows: Plants which are treated with a 
high concentration of ALA accumulate an excess amount of protoporphyrin IX (PpIX) at 
the stage preceding chlorophyll biosynthesis. When such plants are exposed to light, the 
excess PpIX produces active oxygen, which oxidizes unsaturated fatty acids on the cell 
surface thereby damaging the plant. ALA can be used as a safe substitute for highly toxic 
herbicides such as paraquat. However, the herbicide effects of ALA were not as great as 
those of chemical herbicides. Therefore, ALA was applied as a herbicide accelerator for 
diphenyl-ether-type herbicides such as NIP (2,4-dichlorophenyl-4-nitrophenyl ether), 
which act by a mechanism similar to the photodynamic herbicide effect of ALA [137, 
139] 
 
1.6.1.2. Growth promoting factor for plants 
ALA application in a low concentration increased chlorophyll content and accelerated the 
growth of plant tissue and rice seedling [140]. Foliage, soil and root treatment with ALA 
was considered to be effective for increasing the yield of crops [137, 139]. The effects 
were particularly strong for root crops, such as potatoes, and garlic [141]. It was observed 
that ALA application enhanced photosynthetic activity and CO2 uptake in radishes. The 
ability of ALA to enhance photosynthesis (photosystems I and II) has also been observed 
in Spirulina platensis [142]. 
 
1.6.1.3. Increased salt and cold temperature tolerance 
All over the world, large areas of farmland are being lost due to salt accumulation in the 
soil. ALA was found to increase salt tolerance in cotton [143]. Cotton seedlings treated 
with ALA (30–100 mg/l) were able to grow in soil containing 1.5% (w/w) NaCl, and Na+ 
uptake by the plants was suppressed by ALA application. In addition, when applied at 
0.1–1.0 mg/l, ALA increased the survival of rice plants at 5 °C by 40–50% compared to 
the control (without ALA application). In the cells, polysaccharide-like compounds were 
accumulated and seemed to protect the plants by enhancing photosynthesis.  
 
Further agricultural applications of ALA, such as color-intensifying effects for apples, 
quality improvement of vegetables (nitrate content reduction) and green-color 
maintenance for grass, are summarized in Table 5. 
 
1.6.2. Medical (other than PDT) applications 
Diagnosis of heavy-metal poisoning & other medical applications 
It has long been known that ALA accumulates in the urine of patients with heavy-metal 
poisoning, and the ALA concentration in the urine is frequently measured for detection 
and screening [144, 145]. ALA dehydratase is inhibited by heavy metals, therefore, 
accumulation of ALA is observed. Accurate ALA detection is important for the early 
diagnosis of heavy-metal poisoning. The quantity of ALA in the urine gives an indication  
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 for diagnosing porphyria [146, 147]. The application of ALA for treating rheumatoid 
arthritis has been reported [148]. A method for hair removal from a skin area 
(photodynamic depilation) consisting of selective photoinactivation and using derivatives 
of aminolevulinic acid (ALA) with lipophilic chains has been reported [149], although 
the mechanism is not known, heme compounds are assumed to play a role. Study of ALA 
mediated PDT for killing bacteria which are capable of synthesizing porphyrins 
(Haemophilus parainfluenzae) has been evaluated [150]. Other medical applications, 
such as treatment of mycosis and cosmetic and dermatological applications (prevents skin 
penetration of UV), are summarized in Table 5. 
 
1.6.3. Biotechnology application 
 
ALA applications in the biotechnology fields such as heme containing enzyme 
production [151], vitamin B12 production  [152] and bacterial culture [153] are also 
summarized in Table 5. 
 
Table 5 Applications of ALA in agriculture, medicine (other than cancer) and 
biotechnology 
 
Field Application Reference
Agriculture Biodegradable herbicide 
Biodegradable insecticide 
Herbicide accelerator 
Growth promoting factor and yield enhancement 
Salt tolerance 
Cold temperature tolerance 
Quality improvement of vegetables, Color intensifying 
effects 
Growth and green –color maintenance of grass 
 
[138] 
[154] 
[137, 139] 
[141] 
[143] 
[141] 
[141] 
 
[141] 
Medicine Diagnosis of heavy – metal poisoning 
Diagnosis of porphyria 
Treatment of rheumatoid arthritis 
Photodynamic depilation 
Photodynamic destruction of bacteria 
Treatment for mycosis 
Cosmetic and dermatological applications 
 
[144, 145] 
[146, 147] 
[148] 
[149] 
[150] 
[155] 
[156] 
Biotechnology Heme-containing enzyme production 
Vitamin  B12 production 
Genetically treated bacteria culture 
  
[151] 
[152] 
[153] 
 
 35
 2. Biological background behind prodrugs’ design 
    -A review of literature knowledge 
 
2.1. Sugars in targeted PDT 
 
Carbohydrates are an essential part of cell surface molecules and are crucial in cell 
surface recognition and information transfer. Oligosaccharides are attached to proteins or 
lipids to form glycoproteins or glycolipids that comprise part of the lipid bilayer as shown 
in the schematic view below (Figure 1) adapted from Seeberger, P.H. and D.B. Werz, 
Automated synthesis of oligosaccharides as a basis for drug discovery. Nature Reviews 
Drug Discovery, 2005. 4(9);vp. 751-763 [157]. However, the lack of carbohydrate-based 
drugs is not surprising considering that our understanding of fundamental glycobiology is 
a recent development. With the advent of automated solid-phase synthesis of 
oligosaccharides as a basis for drug discovery, the days of carbohydrate-based 
pharmaceuticals are not very far [158, 159]. 
 
 
 
 
Figure 5: Schematic view of a cell membrane with glycoproteins, glycolipids and  
glycosylphosphatidylinositol (GPI)-anchored proteins.  
Adapted from Seeberger, P.H. and D.B. Werz, Automated synthesis of oligosaccharides 
as a basis for drug discovery. Nature Reviews Drug Discovery, 2005. 4(9): p. 751-763. 
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 2.1.1. Altered glycosylation in cancer cells- Potential target  
  
Glycans, which decorate all eukaryotic cell surfaces, undergo changes in structure with 
the onset of diseases such as cancer and inflammation. The term glycan refers to 
polysaccharides or oligosaccharides. Glycans may also be used to refer to the 
carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid etc. Glycans 
usually consist of monosaccharides linked to each other via O-linkages or N-linkage. As 
the bioconjugates synthesized in our research are of the type O-glycosidic 
monosaccharides we will concentrate our discussion on this type of glycans.  
 
Aberrant glycosylation is a hallmark of cancer cells. Altered glycosylation patterns in 
cancer cells result in modified expression of glycans. These altered glycans are very 
typical and provides an indication of cancer. Glycosidases and glycosyltransferases in 
these glycosylation pathways represent potential innovative targets for drug development 
in cancer therapies [160].  Functionalized pyrrolidine derivatives like 4-bromobenzoyl 
derivative of pyrrolidine 147 have been found to inhibit α-mannosidases more effectively 
than the conventional ones like swainsonine 148 (Figue 2). Pyrrolidine derivative 147 
was found to show a promising inhibition of glioblastoma and melanoma cells whereas it 
was less effective on healthy human fibroblasts [161]. 
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   Scheme 17: α-mannosidase inhibitors 
   
Glycoproteins act as critical cell surface communication markers [162, 163] and therefore 
it does not come as a surprise that change in glycosylation pattern occurs in cancer cells. 
The induced change in glycan pattern can be detected in certain motifs such as the 
Thomsen-Friedenreich (Tf) antigen, which are associated with various cancer cell lines 
[164]. Glycosyltransferases (for example sialyltransferases) involved in linking 
terminating residues on glycans tend to be overexpressed in tumour tissue. The increase 
in activity of these glycosyltransferases in turn leads to the overexpression or altered 
pattern of certain terminal glycans. Examples of terminal glycan epitopes commonly 
found on cancer associated cells include Tn 149, sialyl Tn (sTn) 150, sialyl Lewis a (sLe 
a)151 (Tn is a precursor of tumour associated antigen called T antigen or Thomsen-
Friedenreich antigen) etc [165] (Figure 3).  
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Scheme 18: Cancer- associated glycans 
 
With the ability to engineer the cell surface oligosaccharides by replacing the N-acetyl 
group by an N-levulinamide group a ketone group was introduced on the cell surface. 
This unnatural sialic acid with ketone group allowed to fix biotin via hydrazone 
formation with the keto function. Selective drug delivery (indirectly) utilizing this biotin 
has been achieved through biotin-avidin complex formation where the drug is conjugated 
to avidin. This work was reported by Bertozzi et al [166]. 
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 2.1.2. Enhanced glycolysis in cancer cells- a target for 
transporting glycoconjugates?   
 
Many tumor cells have a very distinctive metabolism, characterized by a high rate of 
aerobic glycolysis. Significantly, the glycolytic capacity of a given tumor is characteristic 
of its state of differentiation [167]. One of the biochemical “hallmarks” of malignancy is 
enhanced tumor glycolysis, which is primarily due to the overexpression of glucose 
transporters (GLUTs) and the increased activity of mitochondria-bound hexokinase in 
tumors [168]. This hexokinase enzyme is responsible for catalyzing glucose to glucose 6-
phosphate which in a further series of reaction breaks down to pyruvic acid and high 
energy molecules. 
 
The ability to sustain an enhanced glycolytic rate represents one of the most consistent 
and profound biochemical phenotypes of many cancer cells. This high rate of glycolysis 
is important for rapidly growing tumors, as they may obtain as much as 50% of their 
energy from this process [169]. Enhanced rates of glucose intake and turnover and 
alterations of cellular levels and kinetic properties of key glycolytic enzymes have been 
suggested to account, at least in part, for the enhanced glycolysis of many tumors. For 
example, in comparison to normal cells, the activity of hexokinase is markedly elevated 
in rapidly growing tumors that exhibit the high glycolytic phenotype   [167, 170]. 
2.1.2.1. Glucose transporters 
 
Glucose is a basic source of energy for mammalian cells whose metabolism provides 
ATP under both anaerobic and aerobic conditions. The maintenance of a relatively 
constant blood glucose concentration to sustain cerebral metabolism and the delivery of 
glucose to peripheral tissues for storage and utilization are key metabolic processes and, 
in many situations, transport of D-glucose across cell membranes plays a key role in their 
regulation and control. Cell membranes are effectively impermeable to D-glucose, so 
movement of glucose across cell membranes must be mediated by protein transporters. 
The transport of glucose across the plasma membrane is carried out by members of two 
distinct transporters. 
 
There are two types of sugar transporters. One is energy-independent facilitated diffusion 
transporter. E.g. the family of hexose transporters, mainly GLUT (glucose transporters) 
those are present on the surface of cells. They have Km values for glucose uptake in the 
2-20mM range. A second type of transporter is an energy-dependent variety such as 
sodium-glucose transporters (SGLT). These are typically found in epithelial cells of 
intestine and in kidney tubules where they absorb monosaccharide derived from the diet 
or retrieve glucose from the kidney filtrates, respectively. They are more efficient than 
GLUT transporters and have Km values of less than 1mM. 
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 2.1.2.1.1. Sodium-dependent glucose co-transporters 
 
The sodium-dependent glucose transporters, also known as co-transporters or symporters, 
are integral membrane proteins that mediate the transport of glucose and galactose across 
the plasma membrane by an active transport mechanism [171]. This transport process is a 
co-transport of glucose molecules and sodium ions. The SGLT1 protein is a high-affinity, 
low-capacity sodium-glucose symporter with sodium to glucose coupling ratio of 2:1. 
The SGLT2 protein is in contrast to SGLT1 protein a low-affinity, high-capacity sodium-
glucose symporter with a sodium-to-glucose coupling ratio of 1:1. Deficiencies of these 
transporters can result in glucose/galactose malabsorption [172]. 
 
2.1.2.1.2. The GLUT family 
 
Glucose transport by glucose transporters facilitators (GLUT) follows its gradient. The 
human genome contains 14 members of the GLUT family [171]. The different 
characteristics of the members allow a complex and specific regulation of glucose uptake 
according to the cellular requirements and the physiologic conditions of substrate supply. 
For the basic supply of glucose, GLUT1 is expressed ubiquitously in all cells but at very 
high expression levels in erythrocytes and endothelial cells of the brain. GLUT2 is a low-
affinity glucose transporter with predominant expression in pancreatic cells, liver, kidney, 
and small intestine. In all these tissues, the uptake of glucose is not dependent on the 
number and activity of the glucose transporters but on the blood glucose concentration. 
Thus, transport activity of GLUT cannot be saturated by physiologic blood glucose 
concentrations [171]. GLUT3 is a high-affinity glucose transporter with predominant 
expression in tissues with a high glucose requirement (e.g., brain). GLUT4 is a high-
affinity glucose transporter expressed in insulin-sensitive tissues (heart, skeletal muscle, 
adipose tissue). GLUT7 is a high-affinity transporter for glucose and fructose and it can 
be detected in small intestine, colon, testis, and prostate. GLUT8 is a high-affinity 
glucose transporter which also transports D-fructose and D-galactose. GLUT8 is 
predominantly expressed in testis. GLUT9 exhibits highest expression levels in kidney 
and liver; lower levels were detected in small intestine, placenta, lung, and leukocytes. 
GLUT10 is predominantly expressed in the liver and pancreas. GLUT12 is 
predominantly expressed in heart and prostate and it can also transport D-galactose and to 
a lesser extent by D-fructose. In addition, GLUT12 seems to sustain the increased glucose 
consumption in prostate carcinoma and breast cancer. Defects in primary glucose 
transport appear to be extremely rare. One has to admit that not all possible deficiencies 
have been identified so far [171]. 
 
2.1.2.2. Mannose Transport 
 
In humans part of mannose transport is using the glucose transporters. High-affinity 
glucose transporters GLUT1, GLUT2, GLUT3 and GLUT4 proteins can also mediate the 
mannose transport with relatively good affinities [173]. Because mannose is not 
commonly found as terminal residues in mammalian glycoproteins but is frequently 
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 found on the glycoprotein that decorate the surface of many microorganisms, mannose 
receptors are generally a recognition element for the immune response. There are two C-
type lectins of the mannose receptor family that recognize mannose derivatives. They are 
called the mannose receptor (MR) and the M-type Endo180 protein [174]. The MR (also 
called CD206) plays a role in the innate and adaptive immune system and is found on 
macrophages. Endo180 is a recycling endocytic receptor involved in remodelling of the 
extracellular matrix and is generally found in stromal cells, endothelial cells and also in 
macrophages. There is another C-type lectin, the mannan- (or mannose-) -binding lectin 
(MBL), which can also bind mannose saccharides [175]. However, this protein is 
secreted by the liver into the bloodstream and its role is to bind sugar arrays found on 
many microbial surfaces and activate the complement via associated serine proteases. 
[176]. 
2.1.2.3. Galactose Transporters 
 
In humans part of galactose transport appears to use the glucose transporters in an 
arrangement similar to the one already described for the mannonse transport. The 
sodium-dependent glucose transporters SGLT1 and SGLT2 are active transporters that 
can also mediate the galactose transport [171]. GLUT8 and GLUT12 proteins which are 
both high affinity glucose transporters, can also mediate the galactose transport [171]. 
Galectin proteins can also recognize extracellular β-galactosides with their carbohydrate 
recognition domain (CRD) [177]. This family of proteins is composed of 14 different 
galectins both intracellular and extracellular proteins. Galectins can have various 
functions; they can modulate cell-cell and cell-matrix interactions and cell adhesion. 
They can act on cell division, apoptosis, pre-mRNA splicing, metastasis, cell maturation 
and differentiation [177]. Their expression varies among different adult tissues, changes 
during development and is dramatically altered upon neoplastic transformation [178].  
 
Some extracellular C-type (Calcium ion-dependant) lectins different of galectins can 
internalize β-galactosides via a receptor-mediated endocytosis mechanism. The hepatic 
asialoglycoprotein receptor (ASGP-R) was the first described and is one of the best 
characterized proteins responsible for receptor-mediated endocytosis [179]. The ASGP-R 
mediates the endocytosis and degradation of a wide variety of desialylated glycoproteins 
and neoglycoproteins that contain terminal galactose (Gal) or N-acetylgalactosamine 
(GalNAc) residues on their N-linked carbohydrate chains. The ASGP-R has been used 
for targeted gene delivery [180]. Other Gal/GalNAc binding proteins sharing extensive 
amino acid sequence homology to the hepatic ASGP-R are found in various tissues or 
cell types, such as macrophages, intestinal epithelial cells, testis and thyroid glands [179]. 
They could also be used as target for controlled delivery as the testis galactose binding 
protein in the delivery of antioxidant compounds [181].  
 
The cumulated literature evidence shows that cancer cells possess a modified metabolism 
of sugar molecules. The observed differences in sugar metabolism between cancer and 
normal cells are significantly large that the hope to use these differences in the detection 
and recognition of cancer cells has a good foundation. 
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 2.1.3. Glycoconjugates 
 
Glycoconjugation can be a potentially effective strategy for targeting and transporting 
photosensitizers towards tumor cells. Glycosylation provides the possibility for specific 
interaction of the resulting conjugate with lectin type receptors which are overexpressed 
in certain malignant cells  [182, 183]. Lectins are typically sugar-binding proteins which 
show a remarkable specificity in their binding of multivalent complex carbohydrate 
structures. Hydrogen bonding between lectin and carbohydrate, protein-bound calcium 
ions which can coordinate with vicinal carbohydrate groups and van der Waals’ 
interactions between typically aromatic side chains of protein and hydrophobic ‘patches’ 
on carbohydrates (Figure 4) are responsible for the specific binding of lectins. [184] . 
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Figure 6: Hydrophobic and ‘polar’ patches on carbohydrates 
 
Glycoconjugate compounds exhibit a number of useful properties due to their 
amphiphilicity and multiple functionalities. In particular, their high solubility in water 
and other polar solvents makes them suitable for intravenous administration and widens 
the possibilities of their use in medicine. There are many examples of proteins and 
peptides whose biological activity is enhanced by conjugation to carbohydrates. For 
example, the activity of the anti-diuretic nonapeptide arginine-Vasopressin 152 is almost 
doubled through glycosylation or galactosylation 153 [185] (Scheme 19). Carbohydrate 
moieties can interact with specific receptors on the cell surface membrane [186] which 
may help internalize such conjugates by the cell due to the receptor-mediated endocytosis 
and enhance the selectivity of their accumulation in tumor tissues. Griegel and co-
workers [187] established that human retinoblastoma cells express sugar receptors that 
exhibit a preferential affinity for galactose and mannose residues 
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Scheme 19:  Arginine-Vasopressin 152 and glucosylated Arginine-Vasopressin 153 
 
In PDT, glycoconjugated porphyrins where m-tetraphenyl porphyrins (TPPs) conjugated 
with galactose or mannose via ethylene glycol linker had been synthesized (Eg. TPP(p-
Meg-O-R-ManOH)3 154 in Scheme 20) and their preferential cellular uptake had been 
demonstrated [188]. Nowadays, the interest in the use of glycoporphyrins as efficient 
sensitizers for PDT is growing [189] and synthesis of glycoporphyrins has been reviewed 
[190] . The unsubstituted porphyrins are not soluble in water and only sparingly soluble 
in organic solvents. In contrast to the normal prophyrins the glycoporphyrins can be 
easily disolved in water. The water solubility allows intravenous administration of these 
amphiphilic glycoporphyrins and thereby considerably widens their use in medicine. 
Photosensitizers targeted at glucose transporters (GLUTs) like pyropheophorbide 2-
deoxyglucosamide 155 (Pyro-2DG) (Scheme 20) had been synthesized and their 
efficiency of the intracellular trappings by tumor cells has been evaluated [134]. 
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Scheme 20: Glycoconjugated m-tetraphenyl porphyrins (TPPs) 154   and 
Pyropheophorbide 2-deoxyglucosamide (Pyro-2DG) 155. 
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 The reasons cited above justify the recent interest in the synthesis and use of 
glycoporphyrins as efficient sensitizers for the photodynamic cancer therapy [134, 188, 
190].  Using glycoconjugates of ALA instead of porphyrins for targeting tumour cells has 
not been attempted so far. This is all the more surprising because besides specifically 
targeting cancer cells through the sugar part of the bioconjugate, the various sugar 
transporters often overexpressed in cancer cells can also be used for the effective 
internalization of glycoconjugate of ALA.  
2.1.4. Glycosidase activities 
For a successful application of glycoconjugates in PDT the following biological 
processes must occur in sequence and with high efficiency: specific recognition of the 
glycoconjugate (= prodrug) by the cancer cells, transport of the glycoconjugate through 
the cell membrane, cleavage of the glycoconjugate and transformation of the biological 
precursor to the active chromophore. In view of this complex sequence each step has to 
be understood and if possible to be optimized. Therefore the understanding of 
glycosidase activities is essential for the design glycoconjugates of ALA which can target 
specifically tumour cells. 
 
Studies with the goal to characterize the glycosidase activities were carried out by the 
group of Dr.L. Juillerat-Jeanneret and her PhD student F.Schmitt, University Institute of 
Pathology, CHUV (Centre Hospitalier Universitaire Vaudois), Lausanne, Switzerland.  
[191] . 
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Scheme 21: Glycosidase activities on cancer cells using 4-methylumbelliferyl glycoside 
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Glycosidase activities of various cancer cell lines were studied using 4-
methylumbelliferyl glycoside derivatives 156. Glycosidase activities in the cell 
supernatants were negligible. α-glucosidase, α-mannosidase and β-galactosidase activities 
in cellular extracts were studied. Kinetic studies were performed for all cell lines and in 
all cell lines, fluorescence due to 4-methylumbelliferone 157 was strong for α-
glucosidase activity, medium for α-mannosidase and weak for β-galactosidase. 
Commercially available inhibitors of these activities were also tested: Miglitol 158 as an 
inhibitor of α-glucosidase, swainsonin 148 of α-mannosidase, phenylethyl-β-galactoside 
159 and phenylethyl-β-thiogalactoside 160 of β-galactosidase. Miglitol and swainsonin 
were strong inhibitors of α-glucosidase and α-mannosidase respectively, whereas 
phenylethyl-β-galactoside and phenylethyl-β-thiogalactoside did not inhibit β-
galactosidase. α-glucosidase, α-mannosidase and β-galactosidase activities of HT29 cells. 
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 The tests showed a higher fluorescence for α-glucosidase activity than for α-mannosidase 
and β-galactosidase. 
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Scheme 22: Structures of glycosidase inhibitors : Miglitol 158,  Swainsonin 148, 
phenylethyl β-galactoside 160 and phenylethyl β-thiogalactoside 161.   
 
These results indicate that α-glucosidase, α-mannosidase and β-galactosidase are 
potential targets for the treatment of cancer cell lines as they have increased activities 
compared to normal cells.  ALA glycoconjugate derivatives connecting ALA as an ester 
to the C1 or C6 hydroxyl group of the carbohydrates have the potential to be a totally 
novel approach to photodynamic therapy. These novel prodrugs should be designed 
taking into account α-glucosidase, α-mannosidase and β-galactosidase as receptors or 
targets which will then release ALA as biological precursor to generate PpIX. 
2.2. Vitamins in targeted PDT 
 
Dietary habit is instrumental in about 40-60% of human colon cancer. Fruit and vegetable 
consumption is associated with decreased risk of several types of cancer, including 
colonic malignancy. Fruits and vegetables contain many non-nutritive as well as nutritive 
compounds such as carotenoids, dithiolthiones, flavonoids, glucosinolates, indoles, 
isothiocyanates, monoterpenes, polyphenols and vitamins (including vitamin C, vitamin 
E, and folate). These non-nutritive compounds are known as 'chemopreventive agents'. 
Many of them are anti-oxidants and might suppress carcinogenesis [192].   
 
Retinoic acid 162 (Figure 9) metabolized from Vitamin A has been shown to inhibit the 
growth of a variety of tumor cells [193]. Retinoic acid 162 is being used clinically to treat 
promyelocytic leukemia, head and neck tumors as well as cervical dysplasia [193]. Also, 
1, 25-dihydroxy vitamin D3, the metabolized form of vitamin D3 71 (also called 
cholcalciferol, figure 9) has been recently shown to inhibit tumor cell replication and 
stimulate differentiation of selected tumor types. 1, 25-Dihydroxy vitamin D3 exerts its 
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 effects via the vitamin D receptor (VDR). The antiproliferative action makes 1,25-
dihydroxyvitamin D3 and its analogs a possible therapeutic tool to treat hyperproliferative 
disorders [194]. Also, Vitamin D enhances ALA-induced protoporphyrin IX production 
and photodynamic cell death in the cultures of keratinocytes [195] .  
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Scheme 23: Structures of retinoic acid 162, vitamin D3 (cholcalciferol) 71 and Folic acid 
163 
Vitamin B9 called pteroylglutamic acid 163 or more commonly folic acid are daily 
required for many biosynthetic processes. Traditionally, the folate leucovorin (folinic 
acid), for instance, is used to reduce antifolate toxicity in leukemia or to enhance the 
effect of the fluoropyrimidine 5-fluorouracil in some solid tumors. More recently, it has 
also been noted that folic acid has the ability to increase antitumor activity of several 
structurally unrelated regimens, such as alimta/pemetrexed and cis-platin. It has been 
demonstrated that the folates could modulate the expression and the activity of multidrug 
resistance (MDR) transporters (MRP1/ABCC1) and the breast cancer resistance protein 
BCRP/ABCG2. [196]. These crucial and specific cell membrane-associated transporters 
mediate drug resistance by increasing the rate of excretion of a wide spectrum of toxic 
agents. Thus, folate supplementation may have differential effects on chemotherapy: (1) 
reduction of toxicity, (2) increase of antitumor activity, and (3) modulation of MRP1 and 
BCRP associated cellular drug resistance. It is well known that folate receptors present in 
the cells has the ability to transport folic acid and folate derivatives. 
            
Folate receptors (FRs) exhibit limited expression on healthy cells, but are often present in 
large numbers on cancer cells. For example, FRs are overexpressed on cancers of the 
ovary, uterus, cervix, mammary gland, colon, lung, prostate, nose, throat, and brain. 
Targeted photodynamic therapy (PDT) using a photosensitizer covalently bound with 
folic acid via a small linker had been described. Selective recognition of the conjugate by 
the human nasopharyngeal cells (KB) which overexpress FR, was revealed [133]. 
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 Scheme 24: Structures of vitamin E (tocopherol) 62 and Biotin 67 
 
Conjugation of vitamins with photosensitizer or precursors of photosensitzers has not yet 
been tried to the best of our knowledge (searched in Scifinder programme in chemical 
abstract database by (1) structure search and (2) key words search containing “vitamins” 
and “photosensitizer”, then looking the hits for synthetic molecule combining vitamin 
and photosensitizer). Hydroxyl functions of vitamins like vitamin E (tocopherol) 62 and 
vitamin D3 (cholecalciferol) 71 can be conjugated with ALA as ester and acid moiety of 
vitamins like folic acid 163 and biotin 67 can be coupled with ALA as a pseudo peptide. 
Considering the vitamin based receptors as target and considering ALA part of the 
bioconjugate as being effective photodynamic detection and therapy agent, the 
conjugation of ALA with various vitamins can provide not only an innovative approach 
but also a synergistic approach towards target oriented ALA-photodynamic therapy. 
2.3. Nucleosides in targeted PDT 
 
Though the application of nucleoside analogs has been in use for chemotherapy, the 
conjugation of nucleoside with any photosensitizer has not yet been reported so far 
(searched in Scifinder programme in chemical abstract database by (1) structure search 
and (2) key words search containing “nucleosies” and “photosensitizer”, then looking the 
hits for synthetic molecule combining nucleoside and photosensitizer). Adenosine 164 
one of the four nucleosides is found to be released from a variety of cells throughout the 
body, as the result of increased metabolic rates, in concentrations that can have a 
profound impact on the vasculature, immunoescaping, and growth of tumor masses. 
Adenosine acts as a regulatory molecule by binding to specific G-protein-coupled A1, 
A2A, A2B, and A3 cell surface receptors. It is recognized that the concentrations of this 
nucleoside are increased in cancer tissues [197]. It has been recently demonstrated that 
adenosine induces a differential effect on tumor and normal cells [198]. Adenosine 164 
acts as a potent regulator of normal and tumor cell growth. While inhibiting in vitro 
tumor cell growth, adenosine stimulates bone marrow cell proliferation. Studies have 
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 shown that A3 adenosine receptor agonist, exhibits systemic anticancer, antimetastatic, 
and myeloprotective effects in colon carcinoma [199]. 
 
As measured by receptor binding assays, the density of A3 receptor was higher in colon 
carcinomas as compared with normal mucosa originating from the same individuals 
[200]. A3 receptor plays a role in colon tumorgenesis and, more importantly, can 
potentially be used as a diagnostic marker or a therapeutic target for colon cancer. 
Nucleosides play an essential role in intermediary metabolic and biosynthesis, as well as 
signal transduction through interaction with purinergic receptors [201]. Inhibitors of the 
active site of thymidine kinase 1 (TK1) enzyme have a high potential as therapy for 
cancer [202]. 
 
These studies indicate that adenosine receptors like A3 receptors and thymidine kinase 
(TK1) can be a potential substrate for targeting tumour cells. The occurence of thymidine 
receptors and thymidine transporters suggests that ALA can be conjugated with 
thymidine 165 besides adenosine 164 by coupling with the hydroxyl group of ribose 
sugar in nuceloside could pave a new way for targeted ALA-PDT. 
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Scheme 25: Structures of adenosine 164 and thymidine 165. 
2.4. Novel ALA esters and peptides of natural products 
 
An important limiting factor for topical delivery of 5-ALA to the targeted cancer tissue is 
the skin. One strategy to enhance the transport through the skin of charged drugs like 5-
ALA, can be the alteration of the dipole potential over the skin membranes due to 
incorporation of molecules with inherent dipole moments into the membrane double 
layer. In studies of model membranes addition of 6-ketocholestanol increased the dipole 
potential of the membrane bilayers  6-Ketocholestanol increased the crossing rate of 
anions and reduced the rate of cations in these model phospholipids membranes [203]. 
The ability of 6-ketocholestanol 166 to increase the skin permeation of the prodrug 
aminolevulinic acid (5-ALA) was investigated already [204]. Another possibility could 
be to couple 6-ketocholestanol 166 with ALA so that the bioconjugate ester penetrates 
more easily than ALA. The bioconjugate could then be cleaved by esterases to release the 
prodrug ALA. It is well documented that glycerol or long chain glycerides are widely 
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 used in drug formulations to enhance its permeability [205]. From this emerge the idea of 
coupling all the three hydroxyl of glycerol with ALA. The ALA glycerides should be 
able to cross the plasma membrane much more easily. In this approach not only crossing 
the lipid bilayer should be enhanced but a single ALA glyceride is able to generate three 
ALA molecules.  
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 Scheme 26: Structures of 6-Ketocholestanol 166, 2,4-Diacetyl Phloroglucinol 167 and 
GABA 76 
        
It has been reported that 2,4-diacetyl phloroglucinol (2,4-DAPG) 167 is an antibiotic with 
broad-spectrum antibacterial and antifungal activities. 2,4-DAPG 167 is a major 
determinant in the biological control of several plant diseases [206]. 2,4-DAPG is a 
polyphenol (three hydroxyl groups) which can act as antioxidant essential for 
chemoprevention of cancer besides being an antibiotic. Esterifying all the phenolic 
groups of 2,4-DAPG with the acid group of three ALA molecules which might have 
synergistic approach for the destruction of tumor cells. The unsubstituted phloroglucinol 
has also been studied for its cytoprotective effects against oxidative stress induced cell 
damage in Chinese hamster lung fibroblast (V79-4) cells [207].   
 
Gamma-aminobutyric acid (GABA) 76 is the inhibitory neurotransmitter in the brain, 
also playing a role in diseases like epilepsy. Due to its structural similarity with GABA, 
ALA is incorporated into the cells by a carrier protein which is a GABA transporter [208, 
209]. GABA receptors have been detected on epithelial colon cancer cells. The presence 
of GABA receptors on colon cancer cell lines (KM12SM, HT29) has been demonstrated 
[210]. GABA can also reduce migratory activity in SW 480 colon carcinoma cells [211] . 
ALA can be coupled with GABA through an amide bond. The ALA-GABA pseudo 
peptide should be easily transported by GABA transporters and should also be recognized 
by GABA receptors. Besides ALA- GABA, ALA pseudo peptides with tyrosine, ALA 
coupled with ALA itself to give oligo ALA peptides (dimmer, hexamer, octamer etc) 
would be attractive goals to be studied for their potential in PDT. 
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2.5. PBG as precursor for PpIX generation in PDT 
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Scheme 27: Heme biosynthesis: ALA–starting material; PBG–advanced intermediate  
 
In heme biosynthesis, four molecules of porphobilinogen (PBG) 168 are formed from 
eight molecules of ALA 119 catalysed by the enzyme called ALA dehydratase or 
porphobilinogen synthase [212, 213]. Porphyrin biosynthesis capacity is twenty fold 
enhanced at least from the porphobilinogen (PBG) formation up to that of 
coporphyrinogen, when compared with the original biosynthetic capacity of normal tissue 
[80]. ALA-dehydratase regulates PpIX synthesis and thereby impact the effectiveness of 
ALA-mediated photosensitization [214]. This suggests that if ALA is replaced by a more 
advanced intermediate of heme biosynthesis the rate limits imposed by ALA-dehydratase 
could be surpassed. Such an approach should generate considerably higher amounts of 
PpIX than that generated from exogenous ALA. Enhancing the PpIX production might be 
achieved by giving exogenously PBG instead of ALA. The major obstacle to test this 
approach is the difficulty of synthesizing PBG in useful quantities and also the instability 
of PBG [215]. 
 
To the best of our knowledge, there has not been a single publication with PBG as 
precursor of photosensitizer PpIX  (searched in Scifinder programme in chemical abstract 
database by (1) structure search and (2) key words search containing “porphobilinogen” 
and “photosensitizer”, then looking the hits for synthetic molecule composed of PBG 
structure). This makes a strong case to develop stable PBG lipophilic derivatives which 
should be easy to be internalized into cancer cells. Once inside the cancer cell, the 
bioconjugate might release PBG which in turn should induce an efficient PpIX 
production. The reported synthesis of PBG yields the natural compound without any 
protecting group [215-218]. In order to couple PBG with an amino acid the acid of PBG 
have to be protected e.g. as methyl esters so that the amino group of the side chain can be 
coupled with a judiciously protected amino acid. In this approach one obtains a PBG 
bioconjugate in the form of a stable and easily releasable derivative. The only uncertainty 
in this strategy might be the transport of the bioconjugate through the membrane.  
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 3. Goal 
 
Nowadays in cancer, a therapy with total destruction of the cancer tissue together with 
some of the healthy tissue surrounding the cancer is still an acceptable treatment despite 
the heavy side effects inflicted on the patients. In view of the progress made in molecular 
biology, a more selective approach to cancer treatment must be possible. 
 
PDT has the potential to become a more selective treatment of cancer, because visible 
light is much less aggressive than X-ray radiation used for radiotherapy. Guiding visible 
light precisely onto cancer tissue is possible using modern laser technologies.  Systemic 
injection of the clinically used photosensitizer leads to relatively higher retention of the 
compounds in tumors than in the surrounding normal tissue, resulting in increased 
accumulation of the photosensitizer in tumors. However, this accumulation in tumor is 
not discriminating enough and results in false positive detection and damage to the 
surrounding tissue in PDT protocols. Thus improvement in the targeting of 
photosensitizers is needed. So the major challenge for progress is to develop 
photosensitizer or precursors of photosensitizer which possess sufficient specificity for 
cancer cells. 
 
In this context it was our task to design, synthesize and test novel bioconjugates of ALA 
and their application in targeted PDT. To be effective, the novel ALA- bioconjugates 
should be designed keeping in mind the following criteria: 
 
1. Transport: The bioconjugates should allow modulating the physico chemical and 
physiological properties of these novel ALA- bioconjugates which could be 
transported intracellularly.  
 
2. Target: These ALA-bioconjugates should be able to make use of the specific 
cellular pathways or metabolisms related to cancer to target specifically cancer 
cells. The specificity of these bioconjugates for cancer cells, their metabolism in 
cancer cells etc in comparison to normal cells is discussed in chapter “Biological 
background for Prodrugs’ design- A review of literature knowledge”. 
 
3. Release active ingredient: The enzymes found in the cells should be able to 
release the active ingredient ALA from the ALA-bioconjugates.  
 
A major advantage of the approach chosen is the opportunity to use the specific 
recognition sites of the partner conjugated with ALA as a means to increase the 
specificity for cancer cells.  
 
In view of this reflection, the goal of this thesis was to synthesize different classes of 
ALA/PBG-bioconjugates, then evaluate them for ALA-PDT. To be more efficient than 
the standard ALA, the bioconjugates of ALA should satisfy the following requirements: 
 
 
a) Conjugates should be stable and easy to synthesize. 
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b) Increase the efficiency of Protoporphyrin (PpIX) generated from ALA-
bioconjugates compared to that of ALA as precursor for the application in PDT 
(measure PpIX fluorescence). 
 
c) Selectively target cancer cells - compare PpIX fluorescence due to cancer cells 
and normal cells (fibroblast cells). 
 
d) Should not be cytotoxic (measured by MTT or alamar blue assay) in the absence 
of exposure to light. 
 
 
We planned, synthesized and tested (all the conjugates are not yet tested) the following 
bioconjugates: 
 
1. Sugar-ALA derivatives 
 
2. Vitamin-ALA derivatives 
 
3. Nucleoside - ALA  derivatives 
 
4. ALA ester/pseudopeptide derivatives 
 
5. PBG peptide derivatives 
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 4. Chemistry of ALA 
 
δ-aminolevulinic acid (ALA) is a natural amino acid, but not a common amino acid. The 
most common amino acids are α-amino acids which forms the building block of all 
proteins. As shown in the structure of α-amino acid here, the R represents a side chain 
specific to each amino acid. The central carbon atom called Cα is a chiral atom (except 
glycine). δ-aminolevulinic acid (ALA) is an amino acid where the amino group is at the 
delta or 4 carbons away from the acid moiety. ALA can be classified in the class of δ-
amino acids as well as in the class of α-amino ketones. 
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                 Alanine (α-amino acid)               δ-aminolevulinic acid (ALA)        
Scheme 28: Structure of a α-amino acid and δ-Aminolevulinic acid (ALA) 
                            
4.1. Similarities and dissimilarities between ALA and α- 
amino acids  
Similarities 
1. Like α-amino acids, ALA is white crystalline solid and water soluble 
2. ALA has the properties of ionic salts. 
3. ALA is a natural amino acid and is a product of biosynthesis in living organisms. 
4. The aqueous solution of ALA can conduct electric current like α-amino acids. 
5. Similar to α-amino acids, the COOH groups and NH2 groups in ALA are 
ionizable. As in the case of α-amino acid, when ALA is at physiological pH 
(pH=7.4), the carboxyl groups are unprotonated and amino groups of ALA are 
protonated and exists in the electrically neutral form called zwitter ion. 
6.  Like α-amino acids, the amino group of ALA can react with an acid moiety to 
form peptide bond and the carboxyl groups of ALA can react with an amino 
group of any molecule to form amide or peptide bond. Also the carboxyl group of 
ALA similar to α-amino acids can form esters.  
Dissimilarities 
1. There is no chiral carbon in ALA where as α-amino acids due to the presence of 
chiral carbon rotate linearly polarized light (optical rotation). 
2. ALA lacks any side chain compared to α-amino acids. Depending on the polarity 
of the side chain, α-amino acids vary in their hydrophilic or hydrophobic 
character. This character determines the tertiary structure of protein.  
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 3. ALA is not used in the protein biosynthesis and it is synthesized from glycine, a 
α-amino acid. 
4. The amino group in ALA is 4 carbons far away from the acid group which makes 
the ALA (with free amine) prone to intramolecular condensation [108] to form 
stable six membered lactam 137 as shown in scheme 29. 
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               Scheme 29: Intramolecular condensation of ALA ester to form lactam 
     
5. ALA belongs to the class of α-amino ketones. α-amino ketones readily dimerize 
to dihydropyrazines and are never isolated although the ammonium salts such as 
the hydrochlorides of these compounds are stable [219]. The dihydropyrazines 
thus formed from α-amino ketones are easily oxidized even by air to form 
pyrazine. ALA being an α-amino ketone, gets dimerized (inter molecular 
condensation/cyclization) to form dihydropyrazines as per scheme 34. The NMR 
and kinetic studies [88] suggest that under physiologic conditions, ALA rapidly 
equilibrates between the ketone, the hydrate at C4 and two enol forms (C3-C4 and 
C4-C5) as shown in scheme 30.  
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             Scheme 30: Equilibrium of ALA between hydrated form and enol forms   
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6.  The acidity constant (pKa) values of ALA and α-alanine are different. The first 
pKa value of ALA is 4.05 and the second pKa value is 8.90. In the case of 
alanine, the first pKa value is 2.35 and the second pKa values is 9.87. The first 
pKa value of α-amino acids ranges from 1.80 (histidine) to 2.46 (Tryptophan). 
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           Scheme 31: pKa comparison between ALA and alanine.  
             
4.2. Similarities and dissimilarities between ALA and 
other δ- amino acids  
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                 δ-amino acid (D-Ala-L-Ala isostere)   δ-aminolevulinic acid (ALA) 
Scheme 32: Structure of a simple δ-amino acid and δ-aminolevulinic acid (ALA) 
 
Similarities 
1. Similar to δ-amino acids, ALA when protonated exists in the electrically neutral 
form called zwitter ion. 
2. ALA is white crystalline solid and water soluble. 
3. Like δ-amino acids, the amino group can react with an acid moiety to form 
peptide bond and the carboxyl groups of ALA can react with an amino group of 
any molecule to form amide or peptide bond. Also the carboxyl group of ALA 
similar to α-amino acids can form esters.  
4. At pH=7, both exists as zwitterions. 
Dissimilarities 
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 1. ALA is a natural product and the starting intermediate of heme biosynthesis. It is   
biosynthesized in living organisms where as δ-amino acids are synthetic. 
2. δ- Peptides with well defined and stable secondary and tertiary structures are 
known. These synthetic δ- amino acids which are isosteric replacement of α-
dipeptide unit, attracted considerable interest nowadays in the design of 
peptidomimetics [220, 221]. Furthermore, δ-amino acids have gained importance 
as building blocks for backbone generation of peptide nucleic acid (PNA) 
structures as well as for foldamers, since the six-atom length of these amino acid 
homologues corresponds to the optimal distance to mimic the ribose unit found in 
RNA and DNA [222-225].                                                                                                                        
Similar long chain peptides having repetitive ALA monomer unit has not yet been 
synthesized using ALA which might be due to two reasons: A) Many of the δ- 
Peptide libraries have been synthesized using the methodology of Merrifield’s 
solid phase synthesis which was well established for peptides based on α-amino 
acids . But the same methodology of solid phase synthesis was not successful for 
the construction of peptide libraries based on ALA which is also a δ-amino acid 
[226]. The Fmoc strategy required for the standard solid phase synthesis was 
impossible for ALA due to the stability problems associated with ALA in the 
presence of nucleophilic and / or basic moieties [102, 226]. Fmoc-ALA on Fmoc 
deprotection/coupling step of solid phase synthesis, got cylized (intra-molecular 
cyclization) to form stable six-membered 2,5-dioxo piperidine. Similar 
observation was made for Fmoc δ- amino valeric acid also, which got cyclized to 
form valerolactam while deprotecting Fmoc from wang linker [226] as shown in 
scheme33. B) Another reason of difficulty with ALA is dimerisation of two 
molecules of ALA leading to intermolecular cyclization in the presence of base to 
give various products like dihydro pyrazine, pyrazine, pseudo porphobilinogen etc 
as shown in scheme 34. This difference of reactivity in ALA compared to other δ-
amino acids is due to its unique keto group. 
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     Scheme 33: Valerolactam formation from aminovaleric acid joined to Wang linker 
 
3.  The synthesis of amino group protected ALA- acid chloride was not achieved 
whereas similar acid chlorides have been reported for various synthetic δ- amino 
acids except for δ- amino valeric acid. The synthesis of acid chlorides from  Fmoc 
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 δ- amino valeric acid and benzoyl δ- amino valeric acid were either impossible or 
very difficult [227-229].  
4.3. Stability of ALA and ALA derivatives 
Several studies indicated that ALA reacts in aqueous solutions to yield several 
condensation products [87-91, 230-233]. A 1% solution of ALA at pH 7.53 can be 
predicted to have a shelf-life (t90%, the time it takes for the substance to degrade 10%) of 
1.9 h at 200C. The shelf-life (t90%) of 10% ALA at pH 7.53 can be predicted to be as short 
as 10 min at 200C [91]. Even in freezers at -200C breakdown of ALA occurs [89]. 
Conversion to ester derivatives does not eliminate the problems of instability, introducing 
the potential formation of lactam type derivatives as shown in scheme 2 [108].  In 
aqueous solutions buffered to a physiological pH (pH=7), ALA dimerises to give 
pyrazine derivatives while at higher pH pseudo-porphobilinogen may be formed. 
Analytical methods like reverse-phase chromatography, capillary electrophoresis etc 
were developed to quantify ALA and other degradation products [90, 234]. 
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Scheme 34: Condensation products of ALA on dimerisation 
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 4.4. ALA functionalization   
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                Scheme 35: Numbering of carbons in δ-aminolevulinic acid (ALA) 
 
1. C1 (Acid moiety): The C1 carbon is sp2 hybridized. The acid moiety can be 
derivatized as ester by reacting with an alcohol. Also it can be coupled with an 
amino group to form peptide. Though, the acid moiety can be converted to thiol 
acid or dithio acid or thiol ester or phosphonate or unsaturated alkyl ester, there 
are very few literature reported on these derivatives [103, 235, 236] . Majority of 
the reported literature on ALA deals with esterification of the acid moiety of 
ALA. This is because of the presence of cellular esterases enzymes which can 
release ALA from ALA derivative prodrug. 
2. C2, C3 and C5 (methylene moiety): Though transformations on these sp3 
hybridized carbons are possible, they are not performed as the compounds have to 
be stable and need a mechanism to release ALA molecule inside the cells for 
photodynamic activity. 
3. C4 (keto moiety): Ketone group can be either transformed into alcohol or thio 
ketone. But as the keto group in ALA is essential for the formation of PBG, the 
next intermediate in heme biosynthesis, there is not a single report in the literature 
(searched Scifinder Scholar with structure mode) where these derivatives are used 
for ALA-PDT. 
4. Amino moiety: The peptidic coupling of the amino group is the useful 
transformation for ALA-PDT as the peptidases enzymes in cells can cleave this 
and release ALA. When the amino group is not protected, it is always synthesized 
in salt form. All the literature reported so far in ALA-PDT keeps the free amine 
either as hydrochloride salt or trifluoroacetate salt except one where a p-toluene 
sulfonate salt was made [237]. The salt formation of the free amine is done to 
prevent any intramolecular cyclization due to free amino group as shown in 
scheme 34. 
 We followed the carbon mumbering of ALA as mentioned here in scheme 35, for all our 
ALA derivatives. 
 
4.5. Synthesis of ALA-based starting material 
 
In the synthesis of ALA derivatives as prodrugs for ALA-PDT, most of the reported 
literature utilized aminolevulinic acid hydrochloride (ALA-HCl) as starting material with 
the exception of two reports [103, 110] where they utilized Boc-aminolevulinic acid 
(Boc-ALA).  
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 4.5.1. ALA-HCl as starting material 
In the literature, synthesis of ALA-HCl has been carried out by various methods as 
shown in scheme 36.  
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Scheme 36: Synthesis of ALA by various routes- An overview  
 
ALA can be synthesized (scheme 36) from the following starting materials: (A) furfuryl 
amine 194 (B) tetrahydrofurfuryl amine 190 (C) succinic acid (D) 2-hydroxy pyridine (E) 
levulinic acid 1. One of the first and relatively simple routes was conversion of N-
benzoylfurfurylamine to ALA [238]. This route starts with the formation of 
dihydrodimethoxyfuran 192 by an electrochemical variant of the Clauson-Kass oxidation. 
Catalytic hydrogenation of this hemiacetal led to a tetrahydrofuran that after oxidation 
and hydrolysis resulted in the formation of ALA.  A similar pathway is the oxidation of 
5-acetamido-methylfurfural  [239-241]. This generates a butenolide 193 which after 
selective reduction of the hydroxyl group followed by ring opening gives acetyl protected 
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 ALA. Also ring opening of the phthalimide of tetrahydrofurfurylamine  190  by oxidation 
led to ALA [242]. Another precursor for ALA is succinoyl chloride monomethyl ester 
188 which can be transformed to ALA via acyl cyanide [243-245] . A strategy involving 
hydrolytic ring opening of lactam which was obtained by hydrogenation of 5-hydroxy-3-
pyridone 187 has been reported [246]. This 5-hydroxy-3-pyridone can be synthesized 
from 2-hydroxy pyridine. Starting from levulinic acid 1, activation of C5-position has 
been made by direct bromination. From 5-bromolevulinate 2, there are three ways to 
synthesize ALA: via azide derivative 3 [247], via phthalimide derivative 186 [248] and 
via diformylamide derivative 185 [249].  
The synthesis of ALA-HCl was performed in our group [250] in 3 steps (overall 
yield=25%) as per the method of Benedikt et al [248]. The first step was bromination of 
levulinic acid in methanol solvent to give major product 5-bromo methyl levulinate 
which was then converted to 5-(phthalimido) methyl leulinate. This on acidic hydrolysis 
afforded ALA-HCl. 
4.5.2. Disadvantages of ALA-HCl  
 
With our group’s experience in the field of ALA prodrug synthesis, we found that ALA-
HCl as starting material has following disadvantages for synthesizing ALA derivatives: 
1. ALA-HCl is a highly polar compound, which makes the common purification 
techniques like column chromatography, crystallization etc very difficult once it is 
derivatized as ester. 
2. ALA-HCl being highly hygroscopic has difficulty in handling. It has to be stored in 
freezer. 
3.  It is less stable even at neutral pH conditions and tends to form side products like 
pyrazine, pseudo porphobilinogen etc [87, 89-91, 108].  
4. Besides the above mentioned problems, ALA-HCl has reactivity problem e.g.: For the 
efficient synthesis of esters, one requires activated form of acids which can be stable and 
be storable as well. 
ALA acid chlorides though active, are not stable and could not be either isolated or stored 
as it could form lactam-type impurities[108]. Our trials to synthesize activated ester 
(pentafluoro phenyl ester) of ALA-HCl were futile.  
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 5. Results and Discussion 
5.1. Boc-ALA and activated esters as starting material 
 
As ALA-HCl has above mentioned disadvantages, we wanted to synthesize stable, easy 
to handle and also reactive species of ALA-HCl which could be used for synthesizing 
ALA based derivatives. A solution for this is to synthesize amino protected ALA. As 
mentioned in chapter 4.1.2, Fmoc protected ALA is not an attractive solution because 
ALA gets cyclized when Fmoc group is deprotected. A solution for this can be a 
protecting group which is stable, easy to synthesize and stable during transformations of 
the acid moiety of ALA. Also the protecting group should be easy to cleave without 
affecting esters /amides functionalities since ALA is derivatized usually as esters or 
amides. ‘Boc’ protecting group is the best choice in this case. The ‘Boc’ group protection 
of ALA renders it stable, easy to handle and helps in purification techniques. The ‘Boc’ 
group is also easy to cleave under acidic conditions which transform the free as well very 
reactive amine of ALA to stable ammonium salt. Besides this, Boc-ALA can be 
converted to stable ‘Boc’ protected activated ester of ALA which can be efficient in 
coupling with wide variety of alcohols. So we decided to synthesize Boc-ALA 
 
We synthesized Boc-ALA in four steps (scheme 37) starting from levulinic acid (overall 
yield = 33% to 30%) which is efficient and also different from the reported ones. The 
reported literatures synthesized Boc-ALA from ALA-HCl in 60% yield, but the best yield 
available in literature to synthesize ALA-HCl from levulinic acid is 40%. Therefore, with 
the reported literatures, an overall yield of 24% can be achieved for synthesizing Boc-
ALA from levulinic acid where as our scheme achieved 30 to 33% overall yield. 
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O
O
BocHN
1 3 5  
Reagents and conditions: (i) Br2, MeOH, reflux, 1.5 h, 57%; (ii) NaN3, rt, 1 h, 95%; (iii) 
H2/Pd, Boc2O, 12 h, rt, 74%; (iv) Pig liver esterase (PLE), phosphate buffer, pH=8, rt, 7 
h, 85%;  
Scheme 37: Synthesis of Boc-ALA and Azidolevulinic acid 
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 5.1.1. 5-Bromo methyl levulinate 
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Reagents and conditions: (i) Br2, MeOH, reflux, 1.5 h, 57%. 
Scheme 38: Bromination of levulinic acid 
 
Levulinic acid 1 was brominated with MeOH as solvent (scheme 38). In a typical 
reaction, levulinc acid was dissolved in MeOH, cooled and then bromine was added drop 
wise. After, the reaction mass was refluxed for 1.5h. [247, 249, 251-253]. The 
bromination is induced by traces of acid (HBr) that catalyze enolization of keto group 
(scheme 39), the 5-bromo ester 2 is probably formed first (kinetic product), whereafter it 
slowly isomerizes to the 3-bromo isomer 195 under the influence of the dissolved HBr.  
Other by-products from this reaction are 3,5-dibromo ester 196 and methyl levulinate 
197. All the products are obtained as methyl esters as a result of HBr catalyzed 
esterification. There are reports which found that the selectivity of bromination is 
controlled by an equilibrium (scheme 40) that is supported by the presence of HBr in 
solution [254-256].   
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Scheme 39: Enolization of levulinic acid 
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Scheme 40: Equilibrium of brominated products of levulinic acid 
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 Besides, the problem of erratic fluctuations of boiling points which we experienced 
(experienced by other researchers also [249] which they attribute due to traces of HBr), 
we also found that some of the fractions collected at the end contained methyl levulinate 
along with our desired 5-bromo ester. This is bizarre as the difference between the 
boiling point of methyl levulinate and 5-bromo ester was approximately 300C at 
0.05mbar and it normally gets collected during the initial fractions. This can be explained 
from the study carried out by Rappe [254] on rearrangement of 3-bromo levulinic acid to 
5-bromo levulinic acid. The first step of this rearrangement is replacement of a halogen 
atom by a hydrogen atom, a reduction performed by HBr. Thus, one can say that the 
presence of methyl levulinate along with the 5-bromo ester factions was due to the 
reduction occurring at high temperature by traces of the dissolved HBr.  
 The kinetically favorable product 5-bromo methyl levulinate 2 was isolated by a 
fractional distillation using a widmer column as the difference between the boiling points 
of 5-bromo methyl levulinate and 3-bromo methyl levulinate was approximately 100C at 
0.05mbar. We also tried to avoid this very critical fractional distillation by attempting 
crystallization at low temperatures (-10 to -300C), which were not successful. The ratio of 
methyl levulinate: 5-bromo methyl levulinate: 3-bromo methyl levulinate: 3, 5-dibromo 
methyl levulinate after the reaction was 5: 26: 65: 4. We followed the procedure of 
Manny et al [253] who studied this bromination using various solvents and reaction 
conditions. The authors concluded that ratio of 5-bromo methyl levulinate: 3-bromo 
methyl levulinate was highest with MeOH as solvent, using 1 molar equivalent Br2 and 
refluxing the reaction for 1.5 h. Though there are other reported methods [256-259] of 
synthesizing 5-bromo methyl levulinate some of which are efficient, they were not 
favored because they either use starting material which is not commercially available 
[257] or use diazomethane [256, 258, 259] whose handling requires special apparatus. 
The bromination using NBS instead of Br2 is not efficient [260]. Recently, there was a 
report where unsymmetrical ketones were non selectively di brominated and then 
selectively debrominated to give terminally brominated compound [261]. This method 
might be able to give selectively 5-bromo methyl levulinate.  
5.1.2. 5-Azido methyl levulinate 
There are many ways of introducing amino group to the halogen group like via nitro, via 
azide etc. The requirement of a nitrogen nucleophile is such that the alkylation of amino 
group stops with the first alkylation as amines are prone to polyalkylation. The azide ion 
N3 - ion is a good nucleophile in this respect and also stabilized by resonance forms. This 
azide anion is a weak base (pKa (HN3) = 4.68) and is a good nucleophile and could react 
with halogen easily by a SN2 attack. 
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Scheme 41: Resonance forms of azide ion 
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Reagents and conditions: (i) NaN3, rt, 1 h, 95%. 
Scheme 42: Synthesis of 5-azido methyl levulinate 
 
Then, 5-bromo methyl levulinate was converted to 5-azido methyl levulinate 3 by a SN2 
attack of azido on the carbon bearing bromine with an excellent yield of 95% (scheme 
42). The excess NaN3 used in this reaction need to be destructed whose protocol is 
available in the experimental section. 
 
5.1.3. 5-(Boc) amino methyl levulinate 
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Reagents and conditions: (i) H2/Pd, Boc2O, 12 h, rt, 74%. 
Scheme 43: Hydrogenation and Boc protection of 5-azido methyl levulinate 
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Scheme 44: Other reagents for Boc protection 
 
There are many reports of converting azido to Boc amino compound in one pot reactions 
[262-265]. The method of staudinger reaction [264] using triphenly phosphine had been 
tried before in our group [250] which gave very poor yield (47%). We  followed the 
method of Saito et al [265] where azide is reduced by hydrogenolysis using H2 and Pd 
over carbon in the presence of di-t-butyl dicarbonate (Boc2O). This method (scheme 43) 
was very clean and efficient to afford 5-(Boc) amino methyl levulinate 4 in 70% yield.  
We also tried other reagents(scheme 44) such as Boc-ON 200, t-butyl aminocarbonate 
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 201 [266] instead of Boc2O and also Boc2O in the presence of DMAP in order to achieve 
higher yield, but were not successful. 
5.1.4. 5-(Boc) aminolevulinic acid (Boc-ALA) 
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Reagents and conditions: (i) Pig liver esterase (PLE), phosphate buffer, pH=8, rt, 7 h, 
85%. 
Scheme 45: Hydrolysis of Boc-ALA-OMe 
The hydrolysis of 5-(Boc) amino methyl levulinate (scheme 45) was performed in the 
presence of enzyme Pig liver esterase (PLE). 5-(Boc) amino methyl levulinate was 
treated with PLE in phosphate buffer (containing 0.6 g NaH2PO4 + 13.5 g Na2HPO4 in 1 
litre deionised water). The liberation of acid was neutralized using 0.1N NaOH solution 
by means of a pH-stat (pH=8). The reaction was connected with pH-stat was stirred at 
ambient temperature till the disappearance of starting material by TLC. The crude on 
purification by column chromatography led to 5-(Boc) aminolevulinic acid (Boc-ALA) 5 
in 63% yield. 
5.1.5. Azidolevulinic acid as starting material 
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Reagents and conditions: (i) Pig liver esterase (PLE), phosphate buffer, pH=8, rt, 7 h, 
87%.  
Scheme 46: Azidolevulinic acid from azido methyl levulinate 
 
One of the intermediates in synthesizing Boc ALA is 5-azido methyl levulinate which 
can be utilized for making efficient peptide bond with any activated ester when subjected 
to catalytic hydrogenation. The hydrolysis product of this ester (scheme 46), 
azidolevulinic acid 6 can also be used in esterification reactions because azido group is a 
masked functionality of amine so that the amine group could be obtained by catalytic 
hydrogenation. The hydrolysis of 5-azido methyl levulinate was performed in the 
presence of enzyme Pig liver esterase (PLE). 5-azido methyl levulinate was treated with 
PLE in phosphate buffer. The liberation of acid was neutralized using 0.1N NaOH 
solution by means of a pH-stat (pH=8). The crude upon purification by column 
chromatography, led to 5 in 83 % yield. 
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 5.1.6. Activated esters 
 
We synthesized activated ester of azidolevulinic acid, pentafluorophenyl ester of 
azidolevulinic acid 10b (scheme 47). The azidolevulinic acid was easily converted to the 
more reactive  acid chloride 10a [267]. This can be used for coupling reactions though 
this acid chloride could not be isolated because of its thermal instability. Our attempts to 
synthesize Boc-ALA-acid chloride 202 (scheme 48) were not successful even though 
acid chlorides of many Boc protected α-amino acids are very common and reported [268-
270]. Boc-ALA-acid chloride is not stable and it could get cyclized to form 1-Boc-2,5-
dioxopiperidine 203 (lactam) as similar cyclization were reported to be occurred when 
Fmoc-aminovaleric acid  and Benzoyl aminovaleric acid were subjected for their 
transformation to acid chlorides [227-229]. 
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Reagents and conditions: (i) DCC, rt, 2 h, C6F5OH; (ii) SOCl2, reflux, 1 h. 
Scheme 47: Activated ester and acid chloride of azido levulinic acid 
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Reagents and conditions: (i) SOCl2, reflux, 1 h. 
Scheme 48: Failed reaction of Boc-ALA acid chloride 
 
We synthesized three activated esters from Boc-ALA 5 (Scheme 49): Boc-ALA-
trichloroethyl ester 9 (Boc-ALA-TCE ester), Boc-ALA-pentafluorophenyl ester 7 (Boc-
ALA-PFP ester) and Boc-ALA-oxime ester 12. Boc-ALA-PFP ester was synthesized by 
DCC mediated coupling of Boc-ALA 5 with pentafluorophenol 68. Boc-ALA-TCE ester 
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 and Boc-ALA-oxime ester were synthesized by EDCI /DMAP mediated coupling of Boc-
ALA with trichloro ethanol 8 and acetone oxime 11 respectively. All these activated 
esters which were synthesized for the first time were utilized for various esterification 
reactions below to obtain various ALA-glycoconjugates, Vitamin-ALA conjugates, 
nucleoside-ALA conjugates, ALA esters, ALA-pseudo peptides etc. 
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Reagents and conditions: (i) DCC, rt, 2 h; (ii) EDCI, DMAP, rt, 6 h. 
Scheme 49: Activated esters of Boc-ALA synthesis 
 
5.1.6.1. Mechanism of DCC coupling: 
¨ 
By DCC 204 (dicyclohexyl carbodimide) mediated coupling, the acid is converted to a 
better leaving group. The mechanism (scheme 50) is similar to nucleophilic catalysis 
mechanism. DCC is converted to DHU 205 (dicyclohexyl urea). Evidence for this 
mechanism is the O-acyl ureas synthesized gave esters when they reacted with alcohols 
catalyzed by acids. 
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Scheme 50: DCC coupling mechanism 
 
5.1.6.2. Mechanism of EDCI/ DMAP coupling: 
 
This mechanism using EDCI 206 (scheme 51) is similar to DCC except that instead of 
the direct nucleophilic attack of alcohol on acid-urea complex, here the attack comes 
from DMAP 207. This reactive amide of DMAP is later attacked by alcohol to form 
ester. 
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Scheme 51: EDCI / DMAP coupling mechanism. 
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 5.2. Biological Procedures and tests 
The biological tests for the evaluation of PpIX induction by all the precursors we 
synthesized were performed by the group of Dr.L.Juillerat-Jeanneret and her PhD student 
Mr.F.Schmitt, University Institute of Pathology, CHUV (Centre Hospitalier Universitaire 
Vaudois), Lausanne, Switzerland. 
5.2.1. Cell lines and Culture Conditions 
Human colon adenocarcinoma HT29 and SW480, breast carcinoma T47D and MCF7, 
lung carcinoma A549, glioblastoma LN18, human microvascular endothelial HCEC cell 
lines and human primary fibroblasts were used for testing all ALA-conjugates.Cells were 
grown in DMEM medium (Gibco BRL) with phenol red containing 10 % FCS (Gibco 
BRL) and penicillin/streptomycin, at 37 °C and 6 % CO2. They were routinely 
maintained every week in 25 cm² flasks using trypsinization for plate detachment. All the 
handling with cell plates was performed in sterile hood. 
5.2.2. PpIX Fluorescence Measurements 
Cells were cultured in 48 (8 × 6) well plate (Corning, NY, USA) 48 h prior to 
experiments in complete culture medium. The cell plates were taken out from the 
incubator and the growth medium above the cells from each well of the plate were 
removed by sterile pipette. Confluent cell layers in 48-well plates were then exposed to 
the indicated concentrations (3 wells per concentration) of the different PpIX precursors 
in 250 μL/well DMEM medium without phenol red and free of FCS. Increase of 
fluorescence was measured in a fluorescent multi-well reader CytoFluor Series 4000 
(PerSeptive Biosystems, MA, USA) at 37 °C using excitation filter at λ = 409 nm and 
emission filter at λ = 640 nm.  
     
5.2.3. Determination of Cell Viability 
Cell viability was determined after 24 h exposure to ALA derivatives using the Alamar 
Blue (AB) assay or the MTT assay.  
5.2.3.1. Alamar Blue assay 
Alamar Blue (Serotec) assay is the most simple and rapid test, whereby 10% of the 
commercially available solution is added to the cell medium and measured either by 
colourimetry or fluorimetry. Alamar Blue is nontoxic to cells. The oxidized form 208 
which is nonfluorescent, is reduced to a pink fluorescent dye 209 in the medium by cell 
activity (likely to be by oxygen consumption through metabolism).There is a direct 
correlation between the reduction of Alamar Blue 208 (or resazurin) in the growth media 
and the quantity/proliferation of living organisms. Unlike MTT assay, no cell lysis is 
necessary for alamar blue assay. 
The basic assay steps in a fluorescent multi-well reader CytoFluor Series 4000 
(PerSeptive Biosystems, MA, USA) are as follows: (A) 25 µL/well of resazurin solution 
were added on cells in culture medium in 48-well plates. (B) Incubation for 2 h at 37°C. 
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 (C) Measurement of the fluorescence using excitation filter at λ = 530 nm and emission 
filter at λ = 580 nm. 
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Scheme 52: Structures of resazurin and resorufin (alamar blue assay) 
5.2.3.2. MTT assay 
MTT assay evaluates the mitochondrial succinate dehydrogenase activity by the 
reduction of 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyltetrazolium bromide 210 (MTT) to 
formazan 211, an insoluble compound which absorbs at 540 nm (scheme 53). MTT was 
added to each well at 250 μg/mL and incubation was continued at 37 °C for 2 h. The 
supernatant was removed, the cell layer was dissolved in iso-propanol/HCl 0.04 N and 
absorbance at 540 nm was quantified in a multiwell plate reader iEMS Reader MF 
(Labsystems, Bioconcepts, Switzerland). 
. 
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Scheme 53: Structures of MTT and Formazan (reduced form)  
5.2.4. Microscopy 
SW480 cells were grown on histological slides in complete medium until 25% of 
confluence and then, 1-α-Glc-ALA (2mM) was added for further 24h. Slides were 
washed with PBS, mounted and analyzed on a fluorescent microscope Axioplan2 (Carl 
Zeiss AG, Feldbach, Switzerland) using 535 ± 25 nm excitation light (BP 510-560, FT 
580, LP 590). 
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 5.3. Synthesis of ALA-Glycoside Derivatives (Sugar-
ALA derivatives) 
 
For the substitution of ALA in sugars, we chose three simple sugars namely glucose; 
mannose and galactose because various transporters of these sugars are available in cells 
(refer chapter 2 “Biological background behind Prodrugs’ design-A review of literature 
knowledge”). These transporters can help for the effective internalization of ALA - 
glycoconjugates. Three types of ALA glycoside derivatives were synthesized. First, the 
acid moiety of ALA was esterified with C6 hydroxyl group of the three sugars mentioned 
above. Second, ALA was esterified with C1 hydroxyl group of sugars to obtain α-
glucoside, α-mannoside and β-galactoside derivatives. Finally, ALA was esterified with 
C1 hydroxyl group of sugars via an ethylene glycol linker to obtain α-glucoside, α-
mannoside and β-galactoside derivatives. 
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Scheme 54: Monosaccharides chosen for ALA substitution 
5.3.1. Synthesis of 6´-O-(ALA) sugars (First generation ALA-
glycoconjugates) 
 
We decided to synthesize our first generation ALA- glycoconjugates where ALA is 
linked as an ester with C6 hydroxyl group of the three monosaccharides namely glucose, 
mannose and galactose (scheme 55).  
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Scheme 55:  6´-O-(ALA) sugars (first generation ALA-glycoconjugates)  
 
Regioselective acylation of sugars is a fundamental and difficult task in organic 
chemistry [271]. Even preferential acylation of primary (C6) over secondary hydroxyl 
groups can only rarely be efficiently carried out with free sugars [271, 272]. Although  
many reports are available in literature for the synthesis of ester-carbohydrate linkages 
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 over C6 hydroxyl group by either chemical or enzymatic ways [273-317], there are very 
few reports of synthesis of amino acid esters of carbohydrates [318-323].  This is more 
surprising given the fact that several biofunctional molecules, such as enkephalin-
carbohydrate conjugates 213 (scheme 56) that influence opioid activity [275, 308-310, 
324], exhibit antiviral activity against HIV-1 [325] and also modulate fibroblast and 
melanoma growth [326], are α-amino acid esters of carbohydrates. Enkephalins 212 are 
pentapeptides containing either Tyr-Gly-Gly-Phe-Leu or Tyr-Gly-Gly-Phe-Met sequence. 
They are found in the thalamus of the brain and in some parts of the spinal cord that 
transmit pain impulses. They act as analgesics and sedatives in the body and appear to 
affect mood and motivation. Carbohydrate–peptide conjugates connected by potentially 
metabolisable, sacrificial linkages, such as esters, have high potential utility as prodrugs 
in which the glycan moiety affords both protection and specific transport properties 
[324]. 
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Scheme 56: Structure of enkephalin 212 and enkephalin-carbohydrate conjugates 213 
 
There are four main ways of carrying out the synthesis of ester-carbohydrate linkages 
over C6 hydroxyl group:  A) condensing an unprotected sugar with an acid by DCC 
coupling [312] or using tributylstannyloxide [284-286] or via cobalt chelates [282, 283] 
or via mitsunobu reaction [279-281] B) condensing an unprotected sugar with an 
activated ester  using imidazole [274, 275, 307-311] or using base catalysis [304-306, 
327] C) Following stepwise protection methodology with protecting groups [313, 314] 
such as benzyl [302, 303], boronate [297-300], isopropylidine [273, 294-296], 
benzylidine [293] etc. keeping the C6 hydroxyl group free for coupling with an acid 
moiety. D) Enzymatic regioselective acylation on C6 hydroxyl group by an activated 
ester [276-278, 287-292, 301, 316] and more specifically by an activated ester of an 
amino acid [318, 320, 321]. 
5.3.1.1. Synthesis of 6´-O-(ALA) glucose 
 
We planned to synthesize the substitution of Boc-ALA on the primary hydroxyl (C6) of 
glucose and then deprotect the ‘Boc’ group to obtain the required 6´-O-(ALA) glucose as 
the ‘Boc’ group facilitates not only the ease of purifying the product by column 
chromatography but also in handling the product. 
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 5.3.1.1.1. Preliminary attempts for 6´-O-(ALA) glucose (Imidazole catalyzed) 
 
In the first attempt to synthesize 6´-O- (Boc-ALA) glucose 14, Boc-ALA-PFP ester 7 was 
coupled with D-glucose 13 promoted by imidazole, an approach termed “accelerated 
activated ester” method [307-310]. In this method, 3 equivalents of sugar and 5 
equivalents of imidazole were taken for each equivalent of activated ester. By this 
method, the attempts to isolate the pure product 6´-O- (Boc-ALA) glucose from the 
excess imidazole which had the same retention factor in TLC, have been failed. This was 
despite the various trials like crystallization, column chromatography, aqueous work-up, 
ion-exchange complexation etc which were either unsuccessful or hydrolyzes the 
product.
O
O
BocHN F
F
O
F
F
F
7
O
HO
HO
OH
OH
OH
O
HO
HO
OH OH
O
O
O
NHBoc
13 14
(i)
 
Reagents and conditions: (i) catalytic imidazole, rt, 12 h, 70%. 
Scheme 57: Imidazole catalyzed synthesis of 6´-O-(ALA) glucose 
 
Later, as a modified attempt of the first, Boc-ALA-PFP ester was coupled successfully 
with D-glucose in the presence of imidazole which was added in a catalytic quantity 
instead of excess (scheme 57). This coupling also works well with catalytic DMAP. 
Though this attempt of using either catalytic imidazole or DMAP takes longer reaction 
time (~12h), it was easy to isolate the product 6´-O- (Boc-ALA) glucose 14 unlike the 
former attempt. But this method gave the product 6´-O- (Boc-ALA) glucose 
approximately of 75% purity, rest of which contained other regioisomers Though this 
method did not give the pure regioselective product, it provided a quick manner to 
conduct preliminary biological tests in various cancer cell lines which was necessary to 
demonstrate if our fundamental concept of ALA –sugar conjugation (‘proof of principle’) 
can generate PpIX, so that we could proceed in this direction. 6´-O- (Boc-ALA) glucose 
14 synthesized by the above method was deprotected for the removal of Boc group by 
TFA (scheme 58), to give 6´-O- (ALA) glucose 15. This product, 6´-O- (ALA) glucose 
was tested in various cancer cell lines for the induction of PpIX generation and also cell 
survival (MTT evaluation) after 24 h exposure. 6´-O- (ALA) glucose 15 was able to 
generate higher levels of PpIX than that generated from ALA.  
           
O
HO
HO
OH OH
O
O
O
NH3
15
(i)O
HO
HO
OH OH
O
O
O
NHBoc
14
CF3COO
 
Reagents and conditions: (i) TFA, rt, 1h, 98%. 
Scheme 58: ‘Boc’ deprotection 
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 5.3.1.1.2. Preliminary evaluation of PpIX induction by 6´-O- (ALA) glucose 
 
PpIX production was evaluated for 6´-O- (ALA) glucose 15 by measuring increase in 
fluorescence intensity in living cells at different times by incubating cells in medium 
containing ALA conjugate at concentrations from 0.1mM to 3 mM. Cells used for 
experiments were Human colon carcinoma HT-29 and SW 480, human breast T47D and 
MCF7 carcinoma, A549 lung carcinoma, LN18 glioblastoma cell lines and HCEC human 
immortalized brain endothelial cells  
 
 6´-O- (ALA) glucose induced strong PpIX production in all cell lines. The PpIX 
produced after 24h (figure7) show that all the concentrations of 6´-O- (ALA) glucose 
except 0.1mM induced higher level of PpIX than that induced by 3mM ALA. Also, the 
increase in PpIX level for 3 h (figure8) shows that 6´-O- (ALA) glucose with 
concentrations 3mM, 2mM and 1mM produce higher level of PpIX than that induced by 
standard ALA at any point of time. 
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Figure 7: Comparison of PpIX induction between 6´-O-(ALA)-glucose and ALA after 
24h 
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     Figure 8: Increase in PpIX level between 6´-O-(ALA)-glucose and ALA during 3h 
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 5.3.1.1.3. Attempts for pure regio isomer 6´-O-(ALA) glucose (Protection 
method 1) 
Once this concept of ALA-sugar conjugation was demonstrated for PpIX generation, 
attempts to synthesize pure regioisomer 6´-O- (Boc-ALA) glucose 14 without any other 
regio isomer were tried using protection-deprotection methdology. As a first trial of this 
approach, easily soluble α-D-glucofuranose 1,2:3,5-bis phenyl boronate 23 was 
synthesized (scheme 59) [297-300]. This boronate protected glucose was attempted for 
condensing with Boc-ALA-PFP ester using either enzyme Porcine pancreatic lipase 
[301, 317] or DMAP which were not successful (scheme 59).  
OHO
HO
OH
OH
OH
13
2PhB(OH)2
O
O
O
OHO O
B
BPh
Ph22 23
(i) (ii) or (iii)
O
HO
HO
OH OH
O
O
O
NHBoc
14
10b
Reagents and conditions: (i) toluene, reflux, 2 h; 45% (ii) enzyme Porcine pancreatic 
lipase (PPL), rt, 7 h (iii) catalytic DMAP, rt, 7 h. 
 
Scheme 59: ‘Boronate’ protection of glucose 
5.3.1.1.4. Attempts for pure regio isomer 6´-O-(ALA) glucose (Protection 
method 2) 
As a second approach of this protection-deprotection methodology, glucose 13 was 
protected in a stepwise manner (scheme 60) via Benzyl glucose 17, Benzyl 6´-O-TBDMS 
-D-glucose 18, Benzyl 6´-O-TBDMS -2´,3´,4´-tri-O-benzyl-D-glucose 19, Benzyl 
2´,3´,4´-tri-O-benzyl-D-glucose 20 etc [303]. Although by this benzyl protection-
deprotection method, it was possible to condense Boc-ALA  with benzyl 2, 3, 4-tri benzyl 
glucose 20 to obtain pure benzyl 6´-O-(Boc-ALA)- 2´,3´,4´-tri-O-benzyl-D-glucose 21 
(scheme 32), we felt that this approach is time-consuming and less efficient if we try to 
follow this procedure for other sugars as well. So this approach was laid back in our goal 
of synthesizing pure regioisomer 6´-O- (Boc-ALA) glucose 14.  
OHO
HO
OH
OH
OH
13
(i) OHO
HO
OH
OTBDPS
OBn
O
BnO
BnO
OBn
OH
OBn
OBnO
BnO
OBn OBn
O
O
O
NHBoc
2118 20
(ii)
(iii)
(iv)
(v)
Reagents and conditions: (i) BnOH, dry HCl, 1000C, 3 h, 58%; (ii) TBDPSCl, imidazole, 
-300C to rt, 3.5 h, 90%; (iii) NaH, BnBr, TBAI, rt, 7 h, 67%; (iv) TBAF, 00C to rt, 9 h, 
74% (v) 5, EDCI, DMAP, rt, 4 h, 74%. 
 
Scheme 60: ‘Benzyl’ protection of glucose 
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 5.3.1.1.5. Enzyme catalyzed method for pure region isomer 6´-O-(ALA) 
glucose  
 
Enzymes possess a unique place as selective catalysts in organic chemistry. They can 
function not only in aqueous solutions but also in dry organic solvents. For example, 
lipases, the most widely used group of enzymes have been used in anhydrous organic 
solvents for a wide range of stereoselective and regioselective transformations.  
 
Carbohydrates molecules with multiple hydroxyl groups represent a challenge for 
regioselecetive modifications. Sugars are soluble in only a few, very hydrophilic organic 
solvents such as pyridine, DMF etc. Although there are reports of pancreatic porcine 
lipase regioselectively acylating the primary hydroxyl group of monosaccharides, 
unfortunately, there are only very few commercially available enzymes which are 
catalytically active in hydrophilic organic solvents such as pyridine, DMF etc [328]. 
 
Regioselective enzyme catalyzed acylation (or trasnesterification) of sugars is well 
documented in the literature [276-278, 287-292, 301, 329]. Besides the activity of the 
enzyme, the regioselectivity of enzyme catalyzed acylation depends on many factors: 1) 
substrate solubility 2) length of acyl group 3) nature of activated ester and others such as 
temperature of reaction etc.  
1) Substrate solubility : Although enzyme as a catalyst controls the regioselectivity of a 
reaction, with poorly soluble substrates such as glucose, the relative solubility of the 
product compared to substrate also contributes to the regioselectivity [278]. Glucose has 
poor solubility compared to alkyl glucosides, which explains the fact that higher 
regioselectivity by enzyme is always obtained for glucosides compared to free glucose 
when they are used as substrates. In glucosides, the product 6-O-acyl glucoside and the 
substrate has similar solubility and do not affect regioselectivity which is not the case for 
glucose [278]. This might be one of the reason that many reports are available for 
acylating glucosides but not for glucose [316, 321, 330-333]. Glucose remains suspended 
solid and the initial 6-O-acylation yields a more soluble compound, which then 
undergoes further acylation to the 3,6-diacyl derivative [278]. 
 
2) Length of acyl group: This factor influences the above mentioned factor ie solubility 
of the product. Acylation with shorter chains (e.g C2 to C6) gives a mixture of 
regioisomers because the initially formed 6-O-acyl derivative is soluble and undergoes 
further acylation. Pig pancreatic lipase (PPL) catalyzed acylation of glucose in pyridine 
with activated acetyl esters gave 5.6:1 ratio of 6-substituted : other mixture of 
regioisomers  [288] whereas acylation with lauryl esters (C12) gave a 20:1 ratio of 6-
substituted : other mixture of regioisomers  [288]. 
 
3) Nature of activated ester: Due to the reversible nature of the reaction 
(transesterification) when catalyzed by an enzyme, the activated ester should render 
transesterification essentially irreversible. An example for such ester is enol esters [334]. 
The enol freed on transesterification rapidly tautomerizes to the corresponding volatile 
aldehyde or ketone preventing back reactions.  Also oxime esters are well known as 
irreversible acyl transfer for enzyme catalyzed transesterifications [335-337]. Activated 
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 esters of pentafluorophenol are stable and provide a tool to monitor the reaction by 19F 
NMR spectroscopy. 
 
This approach of regioselective enzyme catalyzed acylation was tried to obtain pure 6´-
O- (Boc-ALA) glucose 14 without any other regio isomers. In the case of glucose, the 
method of Therisod et al [288] using the enzyme Porcine pancreatic lipase (PPL) 
(scheme 34) and the method of Gotor et al [287, 291] using the enzyme Candida 
antarctica lipase (Novozyme 435) alongwith Boc-ALA-oxime ester (scheme 61) were 
successful but still did not give high regioselectivity. We had problems to quantify the 
other regiosiomers which will be described below. Although the 1H-NMR of products of 
these above methods did not show any significant impurities, the 13C-NMR (espically 
DEPT) showed minor extra peaks due to regioisomers.  
(i) or (ii)O
HO
HO
OH
OH
OH
O
HO
HO
OH
OH
O
O
O
NHBoc
13 14
regioisomers
O
O
BocHN O
R1
7 ; R1 =
12; R1 =
F
F
F
F
F
N
Reagents and conditions: (i) 10a, Porcine pancreatic lipase, 500C, 48 h (ii) 10b, Candida 
antarctica lipase (Novozyme 435), 500C, 48 h. 
Scheme 61: Enzymatic acylation of glucose with poor regioselectivity 
 
We tried to estimate the composition of regioisomers of the reaction by GLC (Gas-liquid 
chromatography). There are reports of derivatizing carbohydrates into volatile trimethyl 
silyl (TMS) derivatives which can be easily analyzed by GLC [316, 338, 339]. We 
derivatized our compound 6´-O- (Boc-ALA) glucose by heating with hexamethyl 
disilazane and trimethysilyl chloride (scheme 62). When this derivatized sample was 
injected, the chromatogram showed major peak corresponding to the derivative of 
glucose. Even after repeated trials like derivatizing at room temperature etc, changing 
columns, changing temperature gradient etc showed the same peak as that of glucose in 
GLC whereas the same sample by NMR proved it to be 6´-O- (Boc-ALA) glucose. The 
reason could be either our columns were not able to give separation between glucose and 
6´-O- (Boc-ALA) glucose or the product 6´-O- (Boc-ALA) glucose is getting cleaved 
while making the derivative.  So we abandoned this GLC method.  
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Reagents and conditions: (i) HMDS, TMS-Cl, reflux, 5min 
Scheme 62: Silyl derivatization of glucose and 6´-O-(Boc-ALA) glucose 
 
The method of Riva et al [320] using the enzyme subtilisin proteinase (scheme 63) gave 
exclusive regioselectivity for 6´-O- (Boc-ALA) glucose with a reasonable yield (50%). 
Bacillus subtilis proteinase is stable and active in organic solvents such as pyridine, DMF 
etc. The product of this method showed only peaks corresponding to 6-regioisomer (not 
even traces of any other regioisomer) in 1H-NMR, 13C-NMR and DEPT. 
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CF 3COO
 
 
Reagents and conditions: (i) subtilisin proteinase, 500C, 24 h, 48%; (ii) TFA, rt, 0.5 h, 
92%. 
Scheme 63: Successful enzymatic regioselective acylation of glucose 
 
The position of acylation at C6-hydroxyl group was confirmed by 13C NMR, taking the 
cue from Yoshimoto at al who had described the additivity of shift parameters in 13C 
NMR for O-acyl glucoses (see table 6) [340]. Yoshimo et al studied 13C NMR of all 
positional isomers of various acyl glucoses dissolving in various NMR solvents. He 
found that the acylation shift parameters are independent of the solvent and the kind of 
acyl group. So these shift values proposed by him could be regarded as universal set of 
additive values for any acyl glucoses. We found that the chemical shift of 6´-O-(Boc-
ALA) glucose also matched this universal set of additive values with a change of ±0.2 
ppm. We also confirmed the position of acylation using COSY techniques. 
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 Carbon number Compound 
C-1 C-2 C-3 C-4 C-5 C-6 
1-O-Acyl α 
1-O-Acyl β 
2-O-Acyl α 
2-O-Acyl β 
3-O-Acyl α 
3-O-Acyl β 
4-O-Acyl α 
4-O-Acyl β 
6-O-Acyl α 
6-O-Acyl β 
-0.4 
-2.9 
-2.9 
-2.1 
0 
+0.1 
-0.1 
+0.2 
+0.1 
+0.1 
-2.0 
-2.6 
+1.6 
+0.3 
-1.7 
-1.8 
+0.3 
+0.3 
0 
+0.1 
0 
-0.1 
-3.0 
-2.1 
+2.3 
+1.0 
-2.5 
-2.5 
0 
-0.2 
-1.1 
-0.9 
+0.3 
+0.4 
-2.3 
-2.0 
+1.0 
+1.0 
-0.1 
-0.2 
+3.3 
+1.0 
0 
+0.4 
+0.1 
+0.1 
-2.0 
-2.0 
-2.7 
-3.1 
-0.7 
-0.8 
-0.1 
-0.1 
-0.5 
-0.4 
-0.4 
-0.4 
+2.0 
+2.2 
Table 6: Acylation shift parameters for D-glucopyranoses 
 
In the enzymatic regioselective acylation, for the activated ester we used pentafluoro 
phenyl ester (Boc-ALA-PFP ester) instead of trichloroethyl ester which was mentioned in 
the literature [320]. Our method employed 0.5 g (approximately 2.5 eq. per eq. of 
glucose) of subtilisin proteinase (activity = 5units per mg of protein) and 3 eq.of Boc-
ALA-PFP ester per eq. of glucose (Scheme 63). The suspension (as subtilisin proteinase 
was not soluble in pyridine) was stirred at 500C. After 20h, no free glucose was left. Then 
the enzyme was removed by filtration over celite, the product was purified by silica gel 
flash chromatography followed by crystallisation.  
6´-O- (Boc-ALA) glucose 14, thus prepared by enzymatic regioselective 
transesterification was deprotected by TFA to give pure regioisomer 6´-O- (ALA) 
glucose 15 (Scheme 58). This pure 6´-O- (ALA) glucose was further tested in various 
cancer cell lines for the induction of PpIX. 
5.3.1.2. Synthesis of 6´-O-(ALA) mannose 
 
In the case of mannose also, regioselective enzyme catalyzed acylation (or 
trasnesterification) was employed for the selective substitution of ALA on C6 hydroxyl 
group. A good regioselectivity on C6 hydroxyl group and a reasonable yield (68%) were 
obtained by the method of Therisod et al using the enzyme porcine pancreatic lipase 
(PPL) [288]. For the activated ester, we used pentafluoro phenyl ester (Boc-ALA-PFP 
ester) instead of trichloroethyl ester as mentioned in the literature. Our method (scheme 
64) employed 0.325 g (approximately 8eq. per eq. of mannose) of porcine pancreatic 
lipase (activity = 24 units per mg of protein) and 2 eq.of Boc-ALA-PFP ester per eq. of 
mannose (scheme 64). The suspension was stirred at 500C. After 48h, no free mannose 
was left. Then the enzyme was removed by filteration over celite and the product was 
isolated and purified by silica gel flash chromatography followed by crystallization. 
 
The position of acylation at C6-hydroxyl group was confirmed by 13C-NMR and 1H-
NMR values which was matching the values of similar 6-O-acyl mannoses mentioned in 
literature [288, 308]. 
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Reagents and conditions: (i) Porcine pancreatic lipase, 500C, 24 h, 69%; (ii) TFA, rt, 0.5 
h, 91%. 
Scheme 64: Synthesis of 6´-O-(ALA) mannose 
 
6´-O- (Boc-ALA) mannose 25, thus prepared was deprotected by TFA to give pure 
regioisomer 6´-O- (ALA) mannose 26 (scheme 64) which was tested in various cancer 
cell lines for the induction of PpIX. 
5.3.1.3. Synthesis of 6´-O-(ALA) galactose 
The protocol applied in the case of mannose which is using Boc-ALA-PFP ester as 
activated ester and the enzyme porcine pancreatic lipase (PPL) did not provide good 
regioselectivity for galactose (scheme 65)  [288]. When we applied the protocol which 
was used for synthesizing 6´-O- (Boc-ALA) glucose (using Boc-ALA-PFP ester and the 
enzyme subtilisin proteinase) [320], we were not able to achieve good regioselectivity 
(scheme 38). The products of all these failed methods besides failing in high 
regioselectivity also contained sufficient Boc-ALA, which had been hydrolyzed from 
Boc-ALA-PFP ester.  We tried the regioselectivity using the enzyme Candida antarctica 
lipase (Novozyme 435) along with Boc-ALA- PFPester (scheme 65)  [287, 291]. 
Although we were able to achieve exclusive regioselectivity on C6 using this enzyme 
with moderate yield (49%), we had to use large amount of this enzyme; 1.5 g 
(activity=10 units/mg protein) for 1 mmole of galactose. Since this enzyme is expensive 
(~150 CHF for 1g) and also since we needed more amount of 6´-O- (Boc-ALA) galactose 
28, we had to search for other procedures for regioselectivity.  
(i)
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OH OH
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regioisomers
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BocHN O
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7; R1 =
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F
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F
F
F
N
(ii) or (iii)
;
;
Reagents and conditions: (i) Candida antarctica lipase (Novozyme 435), 500C, 48h.  (ii) 
Porcine pancreatic lipase, 500C, 48h; (iii) Subtilisin proteinase, 500C, 48h. 
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 Scheme 65: Enzymatic acylation of galactose with poor regioselectivity 
 
Finally, exclusive regioselectivity for obtaining 6´-O- (Boc-ALA) galactose 28 was 
achieved by regioselective enzyme catalyzed acylation (or trasnesterification) using the 
enzyme porcine pancreatic lipase (PPL) but performing the reaction with Boc-ALA-TCE 
ester 9 instead of Boc-ALA-PFP ester 7 [288] (scheme 66). Although the literature 
mentioned trichloro ethyl ester as activated ester, we were using initially Boc-ALA-PFP 
ester, because this was used for various ALA ester formations including for synthesizing 
6´-O- (Boc-ALA) mannose 25.  Our method employed 0.95 g (approximately 19eq. per 
eq. of galactose) of porcine pancreatic lipase (activity = 20 units per mg of protein) and 
6.4 eq.of Boc-ALA-TCE ester per eq. of galactose. The suspension was stirred at 500C. 
After 48h, no free galactose was left. Then the enzyme was removed by filtration over 
celite and the product was isolated and purified by silica gel flash chromatography 
followed by crystallisation.  
CF 3COOO
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Reagents and conditions: (i) Porcine pancreatic lipase, 500C, 60h, 44%; (ii) TFA, rt, 0.5 
h, 93%. 
Scheme 66: Enzymatic regioselective acylation of galactose 
 
6´-O- (Boc-ALA) galactose 28 (Yield=44%), thus prepared was deprotected by TFA 
(scheme 66) to give pure regioisomer 6´-O- (ALA) galactose 29 which was tested in 
various cancer cell lines for the induction of PpIX. 
 
In summary, as shown in scheme 67 we acylated regioselectively on C6 hydroxyl group 
of glucose, mannose and galactose. We used a proper combination of an enzyme and an 
activated ester to achieve this regioselectivity. 
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 Reagents and conditions: (i) Subtilisin proteinase, 500C, 24 h; (ii) Porcine pancreatic 
lipase (PPL), 500C, 60h; (iii) TFA, rt, 0.5 h. 
Scheme 67: Summary of enzymatic regioselective (C6) acylation of glucose, mannose 
and galactose by ALA. 
 
We observed that obtaining regioselectivity in the case of galactose was more difficult 
than in the case of mannose and glucose. We found that the ease of regioselectivity and 
efficiencies of the formation was in the following order: Mannose > glucose > galactose 
which was same as reported by Boyer et al for synthesizing 6-O-phenylalanine-
carbohydrate conjugates using enzyme protease subtilisin where he observed the 
preference based only on the stereochemistry of the parent carbohydrate [318]. 
5.3.1.4. Evaluation of PpIX production by cells by first generation ALA-
sugar conjugates - 6´-O- (ALA) glucose, 6´-O-(ALA) mannose and 6´-O-
(ALA) galactose 
5.3.1.4.1. Efficiency- PpIX generation 
 
PpIX production was evaluated for all the regiopure 6´-O- (ALA) glucose 15, 6´-O- 
(ALA) mannose 26 and 6´-O- (ALA) galactose 29 by measuring increase in fluorescence 
intensity in living cells at different times by incubating cells in medium containing ALA 
conjugate at concentrations from 0.1mM to 2 mM. Cells used for experiments were 
Human colon carcinoma HT29, breast T47D carcinoma, A549 lung carcinoma and 
HCEC human immortalized brain endothelial cells. 
 6´-O- (ALA) glucose, 6´-O- (ALA) mannose and 6´-O- (ALA) galactose induced strong 
PpIX production in all cell lines (the graphs of increase in PpIX level by certain selected 
cell lines are shown here). The increase in PpIX level from 0h to 3h (figure 9 to 11) 
shows that in all cell lines except T47 D, 6´-O- (ALA) glucose produces higher level of 
PpIX than that induced by standard ALA at any point of time. In T47D cells, 6´-O- 
(ALA) galactose produced highest level of PpIX than others. 
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       Figure 9: Increase in PpIX level due to 6´-O-(ALA) sugars and ALA in T47 D cells   
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      Figure 10: Increase in PpIX level due to 6´-O-(ALA) sugars and ALA in HCEC cells                               
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         Figure 11: Increase in PpIX level due to 6´-O-(ALA) sugars and ALA in HT29 cells                              
5.3.1.4.2. Cytotoxicity 
The alamar blue assay showed that all the 6´-O-(ALA) sugar conjugates are not cytotoxic 
in the absence of exposure to light. The data of this assay is explained in chapter 4.3.4 
where the alamar assay of all the ALA glycoconjugates was described. 
5.3.1.4.3. Selectivity 
 
The PpIX generation due to 6´-O-(ALA) sugar conjugates were compared with ALA in 
fibroblasts (VS 59). The PpIX generated by 6´-O-(ALA) sugar conjugates was in the 
same level as that of ALA. This means the selectivity of 6´-(ALA) sugar conjugates 
towards cancer cells is not better than ALA. The PpIX level is shown in chapter 4.3.4 
where the PpIX generation due to all the ALA glycoconjugates in fibroblasts is shown. 
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 5.3.2. Synthesis of 1´-O-(ALA) sugars (Second generation ALA-
glycoconjugates) 
 
As explained in the “metabolism of cancer cells” chapter 2 (Biological background 
behind Prodrugs design), the study on glycosidase activities performed by the group of 
Dr.L.Juillerat-Jeanneret and her PhD student Mr.F.Schmitt, Institute of Pathology at 
CHUV, Lausanne indicate that α-glucosidase, α-mannosidase and β-galactosidase are the 
potential targets in cancer cell lines as they have strong activities in cancer cell lines 
compared to normal cell lines.  
 
Based on this, we decided to synthesize specific anomeric ALA glyconjugates; 1´-O-
(ALA) α-glucose, 1´-O-(ALA) α-mannose and 1´-O-(ALA) β-galactose where ALA is 
linkes as an ester with C1 hydroxyl group of monosaccharides namely glucose, mannose 
and galactose (conjugated in a specific anomeric position) (scheme 68). 
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O
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1´-O-(ALA) α-glucose        1´-O-(ALA) α-mannose               1´-O-(ALA) β-galactose. 
Scheme 68: 1´-O-(ALA) sugars (Second generation ALA-glycoconjugates) 
5.3.2.1. Synthesis of 1´-O-(ALA) α-glucose 
The regioselective acylation of C1 hydroxyl group of sugars can be carried out in a 
stepwise manner: first, synthesizing properly protected sugar keeping C1 hydroxyl group 
free; second, coupling the protected sugar with an acid and then deprotecting the groups 
without hindering the ester functionality synthesized.  Another way is coupling an 
unprotected sugar with an activated ester [341, 342], but the available reported literature 
on this transformation are few.  
5.3.2.1.1. Attempted trials using unprotected glucose 
O
O
NHBoc
O
HO
HO
O
OH
OH
35
(i)
O
O
BocHN F
F
O
F
F
F
7
O
HO
HO
OH
OH
OH
13
Reagents and conditions: (i) catalytic NaH, rt, 12h. 
Scheme 69: Failed reaction using unprotected glucose for synthesizing 1´-O-(ALA) 
glucose 
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 The regioselective methods using unprotected glucose rely on the acidity of C1 hydroxyl 
group in the carbohydrates  [343]. The reported literature on these transformation used 
activated reactive amides or reactive azole derivatives for coupling with β-glucose. These 
reactive amides were reported to be synthesized by treating acyl chlorides with 8-
hydroxyquinoline or imidazole/ triazole /tetrazole. Then reactive amides (1eq) were 
treated with β-glucose (3eq) in the presence of catalytic NaH (0.16 eq). We attempted this 
protocol using activated ester Boc-ALA-PFP ester instead of reactive amides as 
mentioned in the literature, because we were using Boc-ALA-PFP ester for many 
coupling reactions. Also, those reactive amides were synthesized from acyl chloride 
which is not possible in our case, as the synthesis of Boc-ALA acid chloride was not 
feasible. First, we attempted (scheme 69) using 0.16 eq. NaH, Boc-ALA-PFP ester and α-
glucose and found that the conversion was poor. Second, we attempted using 0.32 eq 
NaH and the rest being the same. Although the conversion was better, to our surprise we 
found that the major product isolated comprised of 6´-O-(Boc-ALA) α-glucose. Repeated 
attempts by changing the NaH equivalents did not yield desired result and so we 
abandoned this route. 
Then, we decided to follow protection-deprotection methodology for synthesizing 1´-O-
(ALA) α-glucose. 
5.3.2.1.2. Protection-deprotection methodology 
5.3.2.1.2.1. Synthesis of 2, 3, 4, 6-tetra-O-benzyl glucose (TBG) 
O
HO
HO
OH
OH
OH
13
O
BnO
BnO
OBn
OBn
OH
(i)
(ii) or (iii)
31  
Reagents and conditions: (i) NaH, BnBr, TBAI, rt, 8 h, 74% (ii) CH3COOH, 6N HCl, 
600C, 4 h, 58%; (iii) Pd over alumina, HCOONH4, 10h, rt, 61%. 
Scheme 70: Synthesis of 2, 3, 4, 6-tetra-O-benzyl glucose (TBG) 
 
This methodology starts with synthesizing 1,2,3,4,6 - Penta-O- benzyl glucose (major β 
anomer) 30 from glucose 13 (scheme 70). Then, selective deprotection [344-346] at C1 
provided 2, 3, 4, 6-tetra-O-benzyl glucose (TBG) 31 α- anomer being major (scheme 43). 
The selective deprotection of benzyl group at C1 was carried out using either acidic 
hydrolysis (acetic acid/6N HCl) [346] or using catalytic hydrogenolysis (Pd over 
alumina) with ammonium formate as hydrogen source [345]. Attention should be paid 
while performing both these methods as longer duration of reaction maintenance will lead 
to deprotection of benzyl group substituted on other hydroxyl groups besides C1. Also, 
Pd over alumina was air sensitive and catches fire easily when it is dry. On larger scale, 
we preferred the selective deprotection using acetic acid/6N HCl as this protocol was not 
only safe to handle but also yielded consistent and better yield (60%). 
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BnO
BnO
OBn
OBn
OH
(i)
(ii)
31  
Reagents and conditions: (i) NaH, BnBr, TBAI, rt, 8 h, 91% (ii) CH3COOH, CF3SO3H, 
800C, 7 h, 58%. 
Scheme 71: Synthesis of TBG from α-methyl glucoside 
 
The synthesis of TBG was also performed via protection of all hydroxyl groups of methyl 
glycoside by benzyl groups and then hydrolyzing methyl group at C1 using 
trifluoromethanesulfonic acid [347] (scheme71). 
5.3.2.1.2.2. Coupling of TBG with Boc-ALA 
 
There exists in literature, various coupling procedures for obtaining 1-O-acyl glucose 
predominantly either in α form [348-353] or in β form [351, 354-363]. It is well known 
that the sterically hindered acid achlorides form mostly β ester on coupling with TBG 
[356]. The α:β ratio of the product depends on the first-order rate constants according to  
equaton 1. Since equatorial alcohols are acylated faster than axial [364], k3 would be 
expected to be larger than k2. Thus if k1 and k-1 were small (slow mutarotation) and k2 & 
k3 were large (fast acylation) the reaction would lead predominantly to α ester (α:β~k2.k3 / 
k1.k3), while the reverse (fast mutarotation and fast acylation) would result in 
predominantly β ester (α:β~k2k-1 / k3k1) (scheme 72).  
 
Equation 4                    α/β = k2(k-1+k3) / k1k3 
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R
O
R
O
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k2 k3
31
 
Scheme 72: Equlibrium between TBG anomers and acylation of the respective anomers 
 
We followed the coupling methods which can give predominantly α anomer product as 
we required product with α configuration.  
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 O
BnO
BnO
OH
OBn
OBn
(i) or (ii) or (iii) or (iv) or (v) or (vi) O
BnO
BnO
OBn
OBn
O
O
NHBocO
31 34Reagents & alpha : beta
Conditions
(i) 5, EDCI, DMAP, rt, 5 h 0.28 : 1
(ii) 10b, BuLi, -200C to rt, 1 h 2 : 1
(iii) 10b, NaH, -200C to rt, 1 h 2.7 : 1
(iv) 7, BuLi, -200C to rt, 1 h 5.6 : 1
(v) 10b, pyridine, rt, 5 h 1 : 2
(vi) 5, DEAD, PPh3 1 : 1  
Scheme 73: Trials of various couplings of TBG and Boc-ALA for synthesizing mjor α-
anomer product 
 
First, TBG was subjected to carbodiimide coupling using EDCI and DMAP [103], the 
predominant product was β anomer of 1´-O-(Boc-ALA)- 2´, 3´, 4´, 6´-tetra-O-benzyl 
glucose 34 instead of the required α anomer (scheme 73). Though β anomer product is 
not what we desired, we had taken this product for further steps which will be explained 
later.  
Metallation of TBG by n-butyl lithium followed by acylation with acyl halides is known 
to provide TBG esters with a preference for the α-configuration [348, 349]. As a second 
trial, we tried this coupling, instead of acyl halide which is mentioned in the literature, we 
used Boc-ALA-PFP ester as we could not synthesize Boc-ALA acid chlroide. Though 
this method using the metallation of TBG by n-butyl lithium gave α-anomer of 1´-O-
(Boc-ALA)-2´, 3´, 4´, 6´-tetra-O-benzyl glucose as a major product (α: β = 2:1), the ratio 
is still not sufficient enough to isolate α-anomer product by crystallization or by column 
chromatography (scheme 73). 
 
The third attempt was trying the same coupling as that of second trial but using NaH 
instead of n-butyl lithium. However, this method also gave similar α: β ratio (α: β = 
2.7:1) as that of n-butyl lithium (scheme 73). Later, we synthesized azidolevulinic acid 
chloride from azidolevulinic acid though it could not be isolated by distillation because of 
its thermal instability [267]. As a fourth trial, when we tried this metallation of TBG by 
n-butyl lithium followed by acylation with azidolevulinic acid chloride, we obtained 1´-
O-(azidolevulinic)-2´, 3´, 4´, 6´-tetra-O-benzyl glucose with α-anomer as a major product 
(α: β = 5.6:1) (scheme 73). We did not proceed with this coupling because of the poor 
yield (34%) probably owing to the not so stable azidolevulinic acid chloride. 
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 As a fifth trial, we tried the coupling of TBG and Boc-ALA-PFP ester in the presence of 
pyridine to obtain major α anomer product similar to the method done by Schmidt et al, 
Nishikawa et al and Bols et al  for obtaining major α anomer product [352, 356, 365]. 
This attempt was not successful as the acylation reaction is very slow and yielded β 
anomer as major product (scheme 73) which can be expected as the above suggested 
literature utilized reactive acyl halides. 
Sixth attempt was Mitsunobu reaction as followed by Lubineau et al [351] which 
provided mixture of anomers (α: β = 1:1) (scheme 73). Lubineau et al showed that ratio 
of α to β anomer ratio depends on the acidity of acyl group and α to β anomer ratio 
decreases with the increase of the pKa of the acid component under the conditions of 
Mitsunobu reaction. Their data indicates that starting from a mixture of α to β of 7:3 in 
the case of the most acidic compound (pKa=3.4), the less acidic compound (pKa= 4.8) 
gave exclusively the β anomer.  
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BocHN
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BnO
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OBn
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NHBoc
O
BnO
BnO
O
OBn
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31
(i)
34
Reagents and conditions: (i) DCC, Catalytic DMAP, 00C to rt, 5 h. 
Scheme 74:  Synthesis of α –anomer of 1´-O-(Boc-ALA)-TBG using DCC & catalytic 
DMAP 
Finally, the synthesis of the α anomer product (α: β = 7:1) was best carried out with the 
yield of 91% by coupling of TBG with Boc-ALA in the presence of DCC and a catalytic 
amount of DMAP [351, 353] (scheme 74). We found that when we carried out the 
coupling of TBG with Boc-ALA in the presence of only DCC and not DMAP, the yields 
were very low (29%) which can be ascribed to a lower degree of activation of the 
carboxylic acid [363]. We also found that when we carried out the coupling of TBG with 
Boc-ALA in the presence of DCC and equimolar DMAP, we obtained β anomer of 1´-O-
(Boc-ALA)- 2´, 3´, 4´, 6´-tetra-O-benzyl glucose in major quantity. 
5.3.2.1.2.3. Benzyl deprotection 
The next step was to deprotect the benzyl groups attached to the hydroxyl groups by 
catalytic hydrogenation (scheme 78). We experienced difficulties in isolating the pure 1´-
O- (Boc-ALA)- α -glucose 35. After doing the column chromatography using eluent 8:2 
CH2Cl2 : CH3OH and during the evaporation of solvent, there appeared two minor TLC 
spots besides the product spot. One spot corresponded to Boc-ALA methyl ester 
(confirmed by 1H-NMR after isolating the spot) and another spot was unknown. The 
formation of Boc-ALA methyl ester can be explained from the fact that the product in the 
presence of little acidity and methanol (used in eluent mixture) was undergoing 
transesterfication (scheme 75).  
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Scheme 75: Side reactions during work-up of benzyl group deprotection step  
 
In acyl glucoses and glucosides, each oxygen atom of a glucose unit is a site of migration 
origin; an acyl group migrates, in most cases, away from O-1 towards O-6 [366]. The O-
acyl migration from C1 to C2 in glucose derivatives catalyzed by acid or base has been 
extensively studied before (scheme 76 and scheme 77) [361, 366-368]. From these 
literature reports we could say that the second impurity spot might correspond to C2 acyl 
substituted isomer 216 (scheme 75). It has been reported earlier similar compounds such 
as 1-O-(Boc-alanine)-α –glucose 217 undergo rearrangement rapidly in silica gel to give 
2-O-(Boc-alanine)-α- glucose 218 (scheme 76) [361, 368]. It was also proved that N-
acetyl protected amino acid underwent less or no acyl migration compared to N-Boc 
protected aminoacid. The difference between the acyl and alkoxycarbonyl residues as 
protecting groups of the amino function was studied by Determann et al, who found that 
the nitrogen atom in urethane-type protecting group retains its basic character in contrast 
to that of normal amides. This suggests that the Boc group induces a higher positive 
charge on the ester carbonyl carbon thereby facilitating nucleophilic attack by the 
adjacent hydroxyl group. 
           
NHBoc
O
O
HO
HO
O
OH
OH
BocHN O
O
HO
HO
O
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OH
1 2 acyl migration
aqueous solution, silica gel
217 218  
Scheme 76: Literature example of acyl migration: 1-O-(Boc-L-alanine)-α –glucose to 2-
O-(Boc-L-alanine)-α- glucose.  
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Scheme 77: Literature example of acyl migration and hydrolysis with 1-O-(Boc-phenly 
alanine)-α-glucose 
The catalytic hydrogenation provided 1´-O- (Boc-ALA) glucose 35 as highly hygroscopic 
foam. So besides the difficulties of 1 Æ 2 acyl migrations and transesterification in the 
presence of methanol, we also encountered the problem of hydrolysis (Scheme 75) which 
led to glucose and Boc-ALA [368]. The competitive reactions 1 Æ 2 acyl migrations, 
transesterification and hydrolysis which give impurities while isolating the product are 
strongly affected by temperature, acidity and the nature of acyl group. Keglevic et al and 
others studied the relative rates of acyl migration and hydrolysis and they also found that 
the anomeric configuration also affects acyl migration [272, 369, 370]. They observed 
that under similar conditions α anomer experienced less acyl migration and hydrolysis 
[368]. When performing catalytic hydrogenolysis of 2,3,4,6-tetra-O-benzyl-1-O-(N-
nenzyloxybarbonyltripeptidyl)-D-glucose, Valentekovic et al  [355] experienced that in 
the absence of acid like TFA or oxalic acid, the acyl migration is more pronounced. They 
added TFA or oxalic acid in the catalytic hydrogenation to isolate the product as TFA or 
oxalate salt.  
There were also reports of literature mentioning facile cleavage of esters occurring during 
benzyl deprotection [319] . To overcome this problem, researchers preferred the 
substituted benzyl groups such as p-methoxybenzyl (PMB) protecting groups instead of 
simple benzyl groups. These substituted benzyl groups were very easy to deprotect under 
oxidative conditions without affecting the ester group. 
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Reagents and conditions: (i) H2 / Pd, rt, 10 h. 
Scheme 78: Benzyl deprotection using catalytic hydrogenation 
 
We were able to overcome all these side reactions while isolating the product by 
neutralizing the silica gel before doing column chromatography, neutralizing the eluents 
used for column chromatography, evaporating the column fractions below 300C. Thus we 
obtained pure 1´-O- (Boc-ALA)- α –glucose 35. Before obtaining 1´-O- (Boc-ALA)- α –
glucose 35, we carried out trials using the corresponding benzyl protected β anomer and 
we obtained 1´-O- (Boc-ALA)- β –glucose. 
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 5.3.2.1.2.4. Boc deprotection 
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Scheme 79: Lactam formation during ‘Boc’ deprotection 
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Reagents and conditions: (i) CF3COOH, CH2Cl2, 0-100C, 0.5 h. 
Scheme 80: Synthesis of 1´-O-(ALA) glucose by deprotecting ‘Boc’ 
Though the deprotection of “Boc” (scheme 80) appeared simple initially, we encountered 
difficulties of ester cleavage (hydrolysis) to give glucose and Boc-ALA or ester cleavage 
to give glucose and lactam-type derivatives. It is reported in literature that glcosyl esters 
of amino acids can undergo intramolecular aminolysis leading to glucose and piperazine-
type derivatives though it is more pronounced in β anomers than α anomers [360, 371] 
(scheme 79). The possibility of lactam-type 185 derivatives formed due to the 
intramolecular attack of amino group on the carbonyl carbon of a ALA ester has been 
reported before [108]. The product 1´-O-(ALA) α -glucose 36 (scheme 80) being highly 
hygroscopic and containing traces of trifluoro acetic acid (TFA) led to hydrolysis of ester 
bond easily. This problem of hydrolysis was overcome by removing the traces of TFA by 
co-distillation with dry ether, triturating the product with dry ether and then doing a  
precipitation using methanol and ether. The intramolecular aminolysis was avoided by 
adding excess of TFA by which the product is in the form of ammonium trifluoroacetate 
salt.  
Thus we synthesized in a stepwise manner by protection and deprotection, 1´-O-(ALA) α 
-glucose 36. There are reports in the literature that 1-O-(phenyl alanine)-α –glucose 
undergo not only rearrangement in aqueous solutionto give 2-O-(phenyl alanine)-α- 
glucose, but also hydrolyze rapidly in aqueous solution. We decided to examine the 
stability of 1´-O-(ALA) α -glucose 36 in aqueous solution as for the biological 
evaluation, the compound is normally dissolved in water which then is diluted with buffer 
medium. We dissolved 1´-O-(ALA) α -glucose 36 in D2O (which normally has H2O as 
well) and checked 1H-NMR and 13C-NMR for every 3h. We checked 3 times (9h totally) 
and found that the compound is quite stable. Peaks due to glucose did not appear at all, 
which meant clearly that the compound is not hydrolyzing rapidly. 
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 5.3.2.2. Synthesis of 1´-O-(ALA) α-mannose 
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Reagents and conditions: (i) NaH, BnBr, TBAI, rt, 8 h; (ii) CH3COOH, 6N HCl, 600C, 4 
h; (iii) DCC, Catalytic DMAP, 00C to rt, 5 h; (iv) H2 / Pd, rt, 10 h; (v) CF3COOH, 
CH2Cl2, 0-100C, 0.5 h. 
Scheme 81: Synthesis of 1´-O-(ALA) mannose 
 
Once the synthesis of 1´-O-(ALA) α-glucose was made in a standardized manner, the 
same protection-deprotection and coupling methods were followed for mannose also. The 
scheme starts with synthesizing 1,2,3,4,6 - Penta-O- benzyl mannose (major β anomer) 
38 from mannose 24 (scheme 81 ). Then, selective deprotection at C1 provided 2, 3, 4, 6-
tetra-O-benzyl mannose (TBM) α- anomer 39 being major [346]. Later the coupling of 
TBM with Boc-ALA in the presence of DCC and a catalytic amount of DMAP (scheme 
54) provided 1´-O-(Boc-ALA)- 2´, 3´, 4´, 6´-tetra-O-benzyl mannose, α- anomer product 
40 (α : β = 5:1) being major. We also experienced that the coupling when performed with 
equimolar DMAP formed α-anomer product as major while in the case of glucose, this 
coupling formed β-anomer product as major. The α-anomer product of 1´-O-(Boc-ALA)-
2´, 3´, 4´, 6´-tetra-O-benzyl mannose was isolated by column chromatography and then it 
was subjected to catalytic hydrogenation (scheme 81) to deprotect benzyl groups taking 
all the necessary precautions to avoid side reactions and impurities. This afforded pure 
1´-O- (Boc-ALA) - α-mannose 41 which on subsequent “Boc” deprotection (scheme 81) 
yielded pure 1´-O-(ALA) α-mannose 42 as trifluoroacetate salt.  
Thus we synthesized pure 1´-O-(ALA) α-mannose 42. 
5.3.2.3. Synthesis of 1´-O-(ALA) β-galactose 
5.3.2.3.1. Attempted trials using unprotected galactose 
 
O
O
NHBoc
O
HO
HO
O
OH
OH
47
(i)
O
O
BocHN F
F
O
F
F
F
7
O
HO
HO
OH
OH
OH
27
 
Reagents and conditions: (i) catalytic NaH, rt, 12h. 
Scheme 82: Failed reaction using unprotected galactose for synthesizing 1´-O-(Boc-
ALA) galactose 
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 Initially,we attempted to synthesize anomerically pure 1´-O-(Boc-ALA) β-galactose 47 
from unprotected galactose and Boc-ALA-PFP ester using catalytic amount of base 
which were not successful (scheme 82) [341, 342]. As mentioned in 4.3.2.1.1, these 
transformations were reported for β-glucose. 
5.3.2.3.2. Koenigs-Knorr type reaction 
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Reagents and conditions: (i) 5, Cs2CO3, 00C to rt, 1 h. 
Scheme 83: Synthesis of 2´,3´, 4´,5´ -tetracetyl 1´-O-(Boc-ALA)-Koenigs-Knorr reaction 
 
In order to obtain the acyl (ALA) substitution at C1 of galactose in β configuration , we 
then applied Koenigs-Knorr type reaction [359, 372, 373]. We carried out this reaction 
using Cs2CO3 instead of Ag2CO3 as reported earlier [374]. This method provided 1´-O-
(Boc-ALA) 2´,3´,4´,6´-O- tetra acetyl galactose (only β anomer) 50 from 2,3,4,6-O-tetra 
acetyl galactosyl bromide (acetobromo galactose) 49 which is commercially available 
and Boc-ALA (scheme 84). β-stereoselectivity in the glycosylation reaction was ensured 
by neighbouring-group  participation of acetyl groups at O-2 in the glycosyl donors 
(scheme 55). According to the literature [375, 376], the glycosylation reaction proceeds 
by activation of the glycosyl donor by the silver salt (Ag2CO3), leading to the irreversible 
formation of a glycosyl oxocarbenium ion 222 [377]. This ion due to neighbouring-group 
participation is in equilibrium with the corresponding carbocationic species 224 [378, 
379]. Nucelophilic attack of Boc-ALA on the carbocationic species can then result in the 
formation of desired product 50.   
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Scheme 84: Koenigs-Knorr reaction- mechanism for β stereoselectivity 
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Scheme 85: Failed attempts to deprotect selectively acetyl groups 
Various attempts (using NaOMe, K2CO3, BaO ) to deprotect acetyl groups preferentially 
in the presence of ester at C1 to obtain 1´-O- (Boc-ALA) -β-galactose 47 were not 
successful (scheme 85) despite that such transformations have been reported in the 
literature before [380-384]. So we abandoned this route and we thought of performing the 
same Koenigs-Knorr type reaction with the starting material galactosyl bromide 
containing monochloroacetyl group instead of acetyl group for protecting the hydroxyl 
groups. This was the route followed by Shimizu et al when they encountered difficulties 
in deprotecting acetyl group preferentially in the presence of a glycosyl ester [351, 385].  
One way of circumventing this problem is to start with 2,3,4,6-O-tetra benzyl galactosyl 
bromide which is not commercially available. But there are reports [386] that this 
compound is highly prone to decomposition and should be used immediately. 
Monochloroacetyl groups are known to be more labile than acetyl group during 
hydrolysis [387] and can be cleaved under neutral conditions (hydrazine dithiocarbonate) 
[388]  or under slightly basic conditions (thiourea) [389]. Though we synthesized the 
starting material 1,2,3,4,6-penta chloroacetyl galactose, we abandoned this route as the 
benzyl protection methodology explained here below gave better results. 
5.3.2.3.3. Benzyl Protection-deprotection 
We performed benzyl protection methodology which starts with synthesizing α- methyl 
2,3,4,6-Penta-O- benzyl galactoside 44 (major β anomer) from α- methyl galactoside 43 
(scheme 86). α- methyl galactoside was taken as starting material instead of galactose 
unlike the case of 1´-O-(ALA) α-glucose and 1´-O-(ALA) α-mannose where glucose and 
mannose were the starting materials, because Decoster et al found that 1,2,3,4,6- Penta-
O- benzyl galactose on selective deprotection at C1 provides the product 2,3,4,6-O- 
tetrabenzyl galactose of which more than 80% exists in furanose form. The selective 
deprotection at C1 of  benzyl protected methyl galatoside 44  provided 2, 3, 4, 6-tetra-O-
benzyl galactose (TBGa) α- anomer 45 in pyranose form being major (scheme 86) [346, 
390]. 
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Reagents and conditions: (i) NaH, BnBr, TBAI, rt, 8 h; (ii) CH3COOH, 6N HCl, 600C, 5 
h; (iii) EDCI, DMAP, 00C to rt, 7 h; (iv) H2 / Pd, rt, 10 h; (v) CF3COOH, CH2Cl2, 0-
100C, 0.5 h. 
Scheme 86: Synthesis of 1´-O-(ALA) galactose 
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 The carbodiimide coupling of 2, 3, 4, 6-tetra-O-benzyl galactose (TBGa) with Boc-ALA 
in the presence of  EDCI and DMAP [103], provided 1´-O-(Boc-ALA)- 2´, 3´, 4´, 6´-
tetra-O-benzyl β-galactose 46, β anomer product (β: α = 6.6:1) being major. The β 
anomer product was isolated by column chromatography and then it was subjected to 
catalytic hydrogenation to deprotect benzyl groups taking all the necessary precautions to 
avoid side reactions and impurities. This afforded pure 1´-O- (Boc-ALA) -β-galactose 47 
which on subsequent “Boc” deprotection yielded pure 1´-O-(ALA) β-galacose as 
trifluoroacetate salt 48.Thus we synthesized 1´-O-(ALA) β-galacose.  
 
5.3.2.4. Evaluation of PpIX production by cells by second generation 
ALA-sugar conjugates-  1´-O- (ALA) α- glucose, 1´-O-(ALA) α-mannose 
and 1´-O-(ALA) β-galactose 
5.3.2.4.1. Efficiency- PpIX generation 
PpIX production was evaluated for all the regiospecific and anomerically pure 1´-O- 
(ALA) α-glucose, 1´-O- (ALA) α-mannose and 1´-O- (ALA) β-galactose by measuring 
increase in fluorescence intensity in living cells at different times by incubating cells in 
medium containing ALA conjugate at concentrations from 0.1mM to 2 mM. Cells used 
for experiments were A549 lung carcinoma cells, HCEC human immortalized brain 
endothelial cells, breast MCF7 carcinoma and SW480 colon carcinoma cells. 
   1´-O- (ALA) α-glucose, 1´-O- (ALA) α-mannose and 1´-O- (ALA) β-galactose 
induced strong PpIX production in all cell lines (the graphs of increase in PpIX level by 
certain selected cell lines are shown here). The increase in PpIX level from 0h to 3 h 
(figure 12-15) shows that in all cell lines except MCF7, 1´-O- (ALA) α-glucose, 1´-O- 
(ALA) α-mannose and 1´-O- (ALA) β-galactose produce higher or equivalent level of 
PpIX than that induced by standard ALA at any point of time.  
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    Figure 12: Increase in PpIX level due to 1´-O-(ALA) sugars and ALA in A549 cells.      
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   Figure 13: Increase in PpIX level due to 1´-O-(ALA) sugars and ALA in HCEC cells.                                 
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   Figure 14: Increase in PpIX level due to 1´-O-(ALA) sugars and ALA in MCF7 cells.       
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 SW 480 
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   Figure 15: Increase in PpIX level due to 1´-O-(ALA) sugars and ALA in SW480 cells.  
                                                      
 
        Blank                   +1´-O- (ALA) α-glucose (2mM) 
     
 
Figure 16: Fluorescence microscopy of SW480 cells exposed to 1’-O-ALA-α-glucose 
(2mM) 
 
The fluorescence photographs of cells are shown here above in the figure 16. The cells 
without any derivative (blank) are shown in the left hand side and cells exposed to 1´-O- 
(ALA) α-glucose are shown in the right hand side. As can be seen clearly, 1´-O- (ALA) 
α-glucose induced sufficient PpIX generation which illuminates as red fluorescent spots 
inside the cells when exposed to 409nm wavelengh light. 
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 5.3.2.4.2. Cytotoxicity 
The alamar blue assay showed that all the 1´-O-(ALA) sugar conjugates are not 
cytotoxic. The data of this assay is explained in chapter 4.3.4 where the alamar assay of 
all the ALA glycoconjugates was described together. 
5.3.2.4.3. Selectivity 
The PpIX generation due to 1´-O- (ALA) sugar conjugates were compared with ALA in 
fibroblast cells (VS 59). The PpIX generated by 1´-(ALA) sugar conjugates was in the 
same level as that of ALA. This means the selectivity of 1´-O- (ALA) sugar conjugates 
towards cancer cells is not better than ALA. The PpIX level is shown in chapter 4.3.4 
where the PpIX generation due to all the ALA glycoconjugates in fibroblast cells is 
shown. 
 
5.3.3. Synthesis of 1-O-(ALA)- 2-O-(glycosyl) ethylene glycol 
(Third generation ALA-glycoconjugates) 
As advanced generation (third generation) of our ALA glycoconjugates to target our 
glycosidases enzymes namely α-glucosidase, α-mannosidase and β galactosidase, we 
decided to have the ALA coupled with carbohydrates via a linker. We chose ethylene 
glycol as linker as ALA-ethylene glycol esters induce not only high levels of PpIX, but 
also found to be non- toxic over a wide rangeof concnentrations compared to hexyl ALA 
ester, a well known ALA derivative known in the literature [102, 103]. 
We decided to couple ALA with the C1 hydroxyl group of glucose, mannose and 
galactose via an ethylene glycol linker (scheme 87). 
CF3COO
O
HO
HO
OH
O
OH
O NH3
O
O
CF3COO
O
HO
HO
O
OH
OH
O NH3
O
O
O
HO
HO
OH
O
OH
O
NH3
O
O CF3COO
54 57
61
1-O-(ALA)-2-O-(a-glucopyranosyl) ethylene glycol 1-O-(ALA)-2-O-(a-mannopyranosyl) ethylene glycol
1-O-(ALA)-2-O-(b-galactopyranosyl) ethylene glycol
 
Scheme 87: 1-O-(ALA)-2-O-(glycosyl) ethylene glycol (Third generation ALA-
glyvcoconjugates) 
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 5.3.3.1. Synthesis of 1-O-(ALA)-2-O-(α-glucopyranosyl) ethylene glycol 
and 1-O-(ALA)-2-O-(α-mannopyranosyl) ethylene glycol 
 
In the field of ‘glycopolymers’ (carbohydrate based polymers), glycosylated methacrylate 
derivatives had been reported as monomers which were further polymerized. The 
synthesis of methacrylate derivatives of glucose and galactose (acid moiety connected to 
C1 of glucose via an ethylene glycol linker) by glycosylation of 2-hydroxyethyl 
metharylate (HEMA) 189 have been reported earlier [382, 391-393]. Kitazawa et al 
synthesized  (scheme 88) 2-hydroxyethyl methacrylate 225 and then reacted this with 
methyl glucoside 33 as glycosyl donor in the presence of a heteropoly acid 
(phosphomolybdic acid ) in a catalytic quantity to afford 1- O- methacryl- 2-O-
(glucopyranosyl) ethylene glycol 226 having α anomer as major product [391].  
O
HO
HO
OH
OH
OCH3
HO
O
O
(i) O
HO
HO
OH
OH
O
O
O
glucopolymer
33 225 226  
Reagents and conditions: (i) catalytic phosphomolybdic acid, 2,4-dinitrochlorobenzene 
1120C, 3 h 
Scheme 88: Reported scheme for the synthesis of a glycomonomer with ethylene glycol 
as linker between glucose and acrylate ester [391] 
Similarly, the third generation ALA glyconjugate 1-O-(ALA)-2-O-(α-glucopyranosyl) 
ethylene glycol 54 can be synthesized (scheme 89) by first synthesizing mono Boc-ALA 
ester of ethylene glycol (2-hydroxyethyl ALA ester) 227 and then reacting this with 
methyl glucoside 33.  
HO
O NHBoc
O
O
O
HO
HO
OH
OH
OCH3
????
O
HO
HO
O H
OH
O
O NHBoc
O
O
33 227
53  
Scheme 89: Possible reaction scheme by coupling ethylene glycol and Boc-ALA first 
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O
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O
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Scheme 90: Reaction of ethylene glycol with Boc-ALA 
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The synthesis of mono Boc-ALA ester of ethylene glycol 227 has to go through 
protection of keto group of Boc-ALA as under the acidic conditions, ethylene glycol will 
add on the keto group first to form a cyclic ketal 228 (scheme 90) [394]. This makes the 
synthetic route longer by one step to deprotect the cyclic ketal. Also, we envisaged that 
this route could give rise to problems like ester cleavage etc under the harsh conditions of 
temperature (1200C) and heteropoly acid (phosphomolybdic acid).   
 
So, we decided to synthesize first 1-O-(α-D-glucopyranosyl) ethylene glycol 52 by 
Fischer method in order to obtain α anomer as major product and then perform the 
acylation regioselectively on the primary hydroxyl group of ethylene glycol using the 
enzyme Candida antarctica lipase (Novozyme 435) along with Boc-ALA-PFP ester 
[395].  
5.3.3.1.1. Fischer glycosidation 
We synthesized 1-O-(α-D-glucopyranosyl) ethylene glycol 52 by a modification (scheme 
64) of the method described by Mowery  [396-399]. Dowex 50WX 8-200 resin, ethylene 
glycol and glucose were stirred for 72 h at 70-800C. The resin was filtered off, excess 
ethylene glycol which was added as solvent was evaporated off and the residue was 
subjected to column chromatography providing 1-O-(α-D-glucopyranosyl) ethylene 
glycol 52 (scheme 91). In the case of 1-O-(α-D-mannopyranosyl) ethylene glycol 55 
(scheme 91), mannose was taken instead of glucose. 
 
CF3COO
O
R4
R3
H O
R2
R1
OH
O H
O
R4
R3HO
R2
OR1
OH
O NH3
O
O
(i), (ii), (iii)
54; R1=O H, R2=H, R3=OH, R4=H
57; R1=H , R2=O H, R3=OH, R4=H
13; R1=OH, R2=H, R3=OH, R4=H
24; R1=H, R2=OH, R3=OH, R4=H  
Reagents and conditions: (i) Dowex 50WX 8-200, ethylene glycol, 70-800C, 72 h; (ii) 
10b, Candida antarctica (Novozyme 435), 500C, 0.5 h; (iii) CF3COOH, CH2Cl2, 0-100C, 
0.5 h. 
Scheme 91: Synthesis of 1-O-(α-D-glycopyranosyl) ethylene glycol 54 
 
Fischer glycosidation is acid catalyzed and the reaction gives rise to the formation of a 
cyclic carbocation intermediate called a glycosyl cation 229. In a SN1 process, the 
glycosyl cation is then attacked by the alcohol in the second step to yield the product 
(scheme 92). 
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Scheme 92: Fischer glycosidation mechanism 
5.3.3.1.2. Regioselective enzymatic esterification 
 
(i) O
HO
HO
OH
O
OH
O
(CH2)4CH3
O
O
HO
HO
OH
O
OH
OH
60 231
 
Reagents and conditions [395]: (i) 2,2,2-trifluoroethyl hexanoate, Candida antarctica 
(Novozyme 435), 450C, 0.5 h  
Scheme 93: Reported example of regioselective enzymatic esterification preferentially 
on the hydroxyl group of ethylene glycol moiety by Colombo et al [395].  
 
Colombo et al (scheme 66) [395, 400, 401] had reported that the enzyme Candida 
antarctica lipase (Novozyme 435) can acylate preferentially at the glycerol/glycol moiety 
in the presence of primary and secondary hydroxyl groups in a sugar (scheme 93). They 
had also observed that this selectivity towards primary hydroxyl group of ethylene glycol 
decreases with increase in chain length of the acyl moiety.  
 
Following the method of Colombo et al, we acylated regioselectively (scheme 91) the 
primary hydroxyl group of ethylene glycol in 1-O-(α-D-glucopyranosyl) ethylene glycol 
52 using the activated ester Boc-ALA-PFP ester and the enzyme Novozyme 435. Thus 
we obtained 1-O-(Boc-ALA)-2-O-(α-glucopyranosyl) ethylene glycol 53 with a moderate 
yield (48%). Colombo et al carried out this regioselective esterification towards glycol 
moiety with trichloroethyl ester as an activated ester (3eq) and emplyoying 7.5 
equivalents of the enzyme Candida antarctica lipase (Novozyme 435) (1.0 g with the 
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 activity of 10 units / mg solid). We performed the reaction with 3eq of Boc-ALA-PFP 
ester as an activated ester. We had to use higher equivalents of enzyme (10 units / mg 
solid) minimum of 15 equivalents to achieve good regioselectivity in the case of glucose 
although lesser equivalents of enzyme were sufficient for the case of mannose. With less 
equivalents of enzyme, the selectivity of acylation towards primary hydroxyl group of 
ethylene glycol decreases as acylation on C6 primary hydroxyl group competes. The 
same mode of procedure also worked well for synthesizing 1-O-(Boc-ALA)-2-O-(α-
mannopyraoosyl) ethylene glycol 56 (scheme 94). 
5.3.3.1.3. ‘Boc’ deprotection 
 
Later, the ‘Boc’ group in both 1-O-(Boc-ALA)-2-O-(α -glucopyranosyl) ethylene glycol 
53 and 1-O-(Boc-ALA)-2-O-(α -mannpyranosyl) ethylene glycol 56 were deprotected 
following similar procedure (scheme 91) as we did for 1´-O-(ALA) glucose in order to 
avoid hydrolysis of the ester. Thus we obtained pure 1-O-(ALA)-2-O-(α -glucopyranosyl) 
ethylene glycol 54 and 1-O-(ALA)-2-O-(α -mannopyranosyl) ethylene glycol 57. These 
compounds were tested in various cancer cell lines. 
 
5.3.3.2. Synthesis of 1-O-(ALA)-2-O-(β-galactopyranosyl) ethylene 
glycol 
 
HO
O
O
(i)
glucopolymer
49
O
OAc
AcO
Br
O Ac
O Ac
O
OH
HO
OH
OH
O
O
O
(ii)+
225 232
 
Reagents and conditions: (i) AgOTf, -400C, 48h; (ii) NaOCH3; rt, 40min. 
Scheme 94: Reported scheme by Ambrosi et al for synthesis of a β-galactomonomer with 
ethylene glycol as linker between galactose and acrylate ester [382]. 
 
As mentioned in 4.3.3.1, in the field of glycopolymers, there are reports in the literature 
where 2-hydroxyethyl methacrylate 225 (HEMA) is reacted with 2,3,4,6-O-tetra acetyl 
galactosyl bromide (acetobromo galactose) 49 as glycosyl donor in the presence of silver 
or mercury salts to afford 1-O-methacryl- 2-O-(2´,3´,4´,6´-O-tetra acetyl-β-
galactopyranosyl) ethylene glycol  having β anomer as the only product [382, 392, 393]. 
The acetyl groups of this compound was later deprotected preferentially in the presence 
of acrylate ester to afford 1-O-methacryl- 2-O-(β-galactopyranosyl) ethylene glycol  
having β anomer 232 as the only product [382]. The authors polymerized this 
glycomonomer to have glycopolymers. 
 
In a similar manner, we thought that 1-O-(ALA)-2-O-(β -galactopyranosyl) ethylene 
glycol 62 can be synthesized by first synthesizing mono ALA ester of ethylene glycol (2-
hydroxyethyl ALA ester) (scheme 94) and then reacting this 2,3,4,6-O-tetra acetyl 
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 galactosyl bromide (acetobromo galactose) in the presence of silver or mercury salts.  
Although this route could provide only β anomer, we envisaged that the synthesis of 
mono Boc-ALA ester of ethylene glycol might be long (3 steps) as ethylene glycol can 
add to the keto group of Boc-ALA first before getting esterified (scheme 94). So we 
decided to follow Koenigs-Knorr type reaction to have β stereoslectivity as we needed β 
substituted product. 
5.3.3.2.1. Koenigs-Knorr reaction 
We planned to synthesize first 1-O-(2´, 3´, 4´, 6´tetraacetyl-β-D-galactopyranosyl) 
ethylene glycol 58 by Koenigs-Knorr type reaction [359, 372, 373] from 2,3,4,6-O-tetra 
acetyl galactosyl bromide (acetobromo galactose) 49 in order to obtain β anomer as major 
product. Now, we had two choices; As a first choice, we could couple Boc-ALA with the 
only free hydroxyl group of the glycol moiety to obtain 59 and then deprotect all the 
acetyl groups selectively to obtain 1-O-(Boc-ALA)-2-O-(β -galactopyranosyl) ethylene 
glycol 61 (Scheme 95). As a second choice, we could deprotect all the acetyl groups of 1-
O-(2´,3´,4´,6´-tetraacetyl-β-D-galactopyranosyl) ethylene glycol 58  to obtain 1-O-(β-D-
galactopyranosyl) ethylene glycol 60. Then carrying out acylation selectively on the 
primary hydroxyl group of ethylene glycol using the enzyme Candida antarctica lipase 
(Novozyme 435) along with Boc-ALA-PFP ester [395]  to obtain 61, a method reported 
by Colombo et al and also accomplished in the case of glucose and mannose derivatives 
by us. 
 
We synthesized first 1-O-(2´, 3´, 4´, 6´tetraacetyl-β-D-galactopyranosyl) ethylene glycol 
58 (only β anomer product) from 2,3,4,6-O-tetra acetyl galactosyl bromide (acetobromo 
galactose) 49 and ethylene glycol by Koenigs-Knorr type reaction (scheme 95). β-
stereoselectivity in the glycosylation reaction was ensured by neighbouring-group 
participation of acetyl groups at O-2 in the glycosyl donors.  
5.3.3.2.2. Coupling with Boc-ALA and Selective removal of acetyl group-
attempts 
(i)
49
O
AcO
AcO
OAc
O
OAc
O
NHBoc
O
O
O
HO
HO
OH
O
OH
O
NHBoc
O
O
(ii)
59 60
 
Reagents and conditions: (i) Ag2CO3, ethylene glycol, rt, 4 h; (ii) 5, EDC, DMAP; rt, 7 h. 
Scheme 95: Koneigs-Knorr type reaction and attempted trials to deprotect acetyl groups 
preferentially in the presence of ALA ester. 
 
In our first trial, we coupled this product with Boc-ALA using carbodimide coupling to 
obtain 59; the reaction is straight forward as there is only one free hydroxyl group which 
is from the glycol moiety as the hydroxyl groups of galactose are protected by acetyl 
groups (scheme 95). Though we were not able to deprotect acetyl group preferentially in 
the case of 1´-O-(Boc-ALA) 2´,3´,4´,6´-O- tetra acetyl galactose  50  (scheme 85; chapter 
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 5.3.2.3.2), we tried in this case again. Many attempts (using NaOMe, K2CO3, BaO ) to 
deprotect the acetyl groups of 59 preferentially in the presence of ALA ester attached to 
glycol moiety were not successful [380-384] (scheme 95).  
5.3.3.2.3. Regioselective enzymatic esterification 
 
(i), (ii), (iii)
38
O
HO
HO
OH
O
OH
O
NHBoc
O
O
O
HO
HO
OH
O
OH
O
NH3
O
O60 61
CF3COO
(iv)
 
Reagents and conditions: (i) Ag2CO3, ethylene glycol, rt, 4 h; (ii) NaOMe, rt, 2 h; (iii) 
Candida antarctica (Novozyme 435), 500C, 0.5 h; (iv) CF3COOH, CH2Cl2, 0-100C, 0.5 h. 
Scheme 96: Koneigs-Knorr type reaction, enzymatic regioselective esterification and 
‘Boc’ deprotection. 
 
In our second trial (scheme 96), we deprotected the acetyl groups from 1-O-(2´, 3´, 4´, 
6´tetraacetyl-β-D-galactopyranosyl) ethylene glycol 58 by using sodium methoxide to 
afford 1-O-(β-D-galactopyranosyl) ethylene glycol 59a. Then as in the case of glucose 
and mannose, we attempted to acylate regioselectively the primary hydroxyl group of 
ethylene glycol moiety in 1-O-(β-D-galactopyranosyl) ethylene glycol using the activated 
ester Boc-ALA-PFP ester and the enzyme Novozyme 435 (method of Colombo et al) 
[395]. We were successful to obtain 1-O-(Boc-ALA)-2-O-(β -galactopyranosyl) ethylene 
glycol 61 in moderate yield (40%) though we had to use more equivalent of the enzyme 
(20eq) than what we had used in the case of mannose and glucose (15eq) to achieve good 
regioselectivity.  
 
Like in the case of 6´-O-(Boc-ALA) sugars, we found that the ease of regioselectivity and 
efficiencies of the formation was in the following order: Mannose > glucose > galactose 
which was same as reported by Boyer et al for 6-O-phenylalanine-carbohydrate 
conjugates [318]. 
 
Deprotection of ‘Boc’ from 1-O-(Boc-ALA)-2-O-(β -galactopyranosyl) ethylene glycol 
61 using TFA led to our target compound 1-O-(ALA)-2-O-(β -galactopyranosyl) ethylene 
glycol 62 which was tested in various cancer cell lines. 
 
 
 
5.3.3.3. Evaluation of PpIX production by cells by third generation 
ALA-sugar conjugates - 1-O-(ALA)-2-O-(α-glucopyranosyl) ethylene 
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 glycol and 1-O-(ALA)-2-O-(α-mannopyranosyl) ethylene glycol and 1-
O-(ALA)-2-O-(β-galactopyranosyl) ethylene glycol 
5.3.3.3.1. Efficiency- PpIX generation 
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Figure 17: Increase in PpIX level due to 1´-O-EG-(ALA) sugars and ALA in HCEC cells 
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Figure 18: Increase in PpIX level due to 1´-O-EG-(ALA) sugars and ALA in SW480 
cells 
 
PpIX production was evaluated for  the regiospecific and anomerically pure 1-O-(ALA)-
2-O-(α-glucopyranosyl) ethylene glycol 54 and 1-O-(ALA)-2-O-(α-mannopyranosyl) 
ethylene glycol 57 and 1-O-(ALA)-2-O-(β-galactopyranosyl) ethylene glycol  62 by 
measuring increase in fluorescence intensity in living cells at different times by 
incubating cells in medium containing ALA conjugate at concentrations from 0.1mM to 2 
mM. Cells used for experiments were HCEC human immortalized brain endothelial cells, 
were A549 lung carcinoma, SW480 colon carcinoma and breast T47D carcinoma cells. 
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 1-O-(ALA)-2-O-(α-glucopyranosyl) ethylene glycol 54,1-O-(ALA)-2-O-(α-
mannopyranosyl) ethylene glycol 57 and 1-O-(ALA)-2-O-(β-galactopyranosyl) ethylene 
glycol 62 generate PpIX in all cell lines tested (the graphs of increase in PpIX level by 
certain selected cell lines are shown here). But, the increase in PpIX level from 0h to 3 h 
(figure 17 and 18) shows that in cell lines HCEC and SW 480, these conjugates with 
ethylene glycol linker produce PpIX comparable to that of ALA. In cell lines A549 and 
T47D, these conjugates produce PpIX lesser than that induced by standard ALA. This 
could be because these conjugates are not effectively internalized into the cells. Thus, the 
efficiency to generate PpIX induction by these ethylene glycol linker based conjugates is 
inferior to that of 6´-O-(ALA) sugars and 1´-O-(ALA) sugars. 
5.3.3.3.2. Cytotoxicity 
The alamar blue assay and MTT assay showed that all the ethylene glycol linker based 
ALA sugar conjugates (54, 57 and 62) were not cytotoxic. The data of this assay is 
explained in chapter 4.3.4 where the alamar assay of all the ALA glycoconjugates was 
described. 
5.3.3.3.3. Selectivity 
 The ethylene glycol linker based ALA sugar conjugates (54, 57 and 62) were 
comparable to ALA on targeting cancer cells. PpIX induction due to ALA and third 
generation conjugates (54, 57 and 62) in three different types of normal fibroblast cells 
SS 77, GS78 and GE 80 were checked (not shown in figure). In these cells, ALA 
generated PpIX where as the conjugates (54, 57 and 62) generated lower level of PpIX 
than that of ALA. Further evaluation of the conjugates (54, 57 and 62) in normal 
fibroblast cells is mentioned in chapter 4.3.4. 
        
    
5.3.4. Evaluation of PpIX production by first (6´-O-(ALA) 
sugars), second (1´-O-(ALA) sugars) and third (1´-O-(EG-
ALA) sugars) generation ALA-sugar conjugates  
5.3.4.1. Efficiency- PpIX generation 
In summary, we synthesized three different types of ALA-glycocongugates, ALA being 
substituted at C6-hydroxyl group of sugars (6´-O-(ALA) sugars), ALA being substituted 
at C1-hydroxyl group of sugars (1´-O-(ALA) sugars) and  ALA being substituted at C1-
hydroxyl group of sugars via ethylene glycol linker (1-O-(EG-ALA) sugars). 
 
We evaluated recently all the ALA- glycoside conjugates (nine compounds) together in a 
same well plate on various cancer cell lines (one among them HCEC cells, is shown 
here). As can be seen from figure 19, the conjugates with ethylene glycol linker on 
comparison to the standard ALA, though generate less PpIX in the initial 3h, it produced 
higher PpIX generation after 5h. This might be due to the slow cross over of the cell wall 
by these conjugates due to its liphilicity compared to other compounds. 
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Figure 19: Increase in PpIX level due to sugar-ALA conjugates 
5.3.4.2. Cytotoxicity tests 
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Figure 20: Cell survival measurements by alamar blue assay after 24h exposure. 
We also tested the dark cytotoxicity of all these compounds by alamar blue assay. As 
shown in the figure, cells treated with all the compounds show fluorescence which is due 
to the reduced form of alamar called resorufin 174 (refer chapter 2.3.2) which is a pink 
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 fluorescent dye. As this reduction is due to cell activity (likely to be by oxygen 
consumption through metabolism) we could conclude that all of these sugar conjugates 
showed no cytotoxicity. This is an advantage of these sugar conjugates compared to 
hexyl ALA ester, an ALA derivative which induces higher PpIX generation than that of 
ALA, but is cytotoxic. 
5.3.4.3. Selectivity  
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Figure 21: Increase in PpIX level due to 6´-O-ALA sugars and ALA in VS 59 fibroblasts 
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Figure 22: Increase in PpIX level due to 1´-O-ALA sugars and ALA in VS 59 fibroblasts 
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Figure 23: Increase in PpIX level due to 6´-O-ALA sugars and ALA in VS 59 fibroblasts 
 
We evaluated the induction of PpIX due to ALA-sugar conjugates and ALA in fibroblast 
cells (VS 59 cells). As these fibroblasts are normal cells, if there is no PpIX generation 
due to a derivative, then the compound can be termed as targeted ALA derivatives which 
selectively get internalized in cancer cells. 
 
We found that all our ALA-sugar conjugates generate PpIX in fibroblasts (VS 59 cells) 
however at much lower levels than in cancer cells. They induce PpIX level which is 
comparable to that of induced by ALA. We also observed that galactose derivatives 
(except 6´-O-(ALA) galactose) generate lower level of PpIX cpmpared to others, 
espically 1-EG-ALA-galactose 62, generate PpIX almost half the level than that of ALA.     
      
As concluding remarks for sugar-ALA conjugates with respect to PpIX generation, we 
can say that the order of efficiency of PpIX generation is as follows:  
1´-O-(ALA) sugars > 6´-O-(ALA) sugars > 1-O-(EG-ALA) sugars. 
5.4. Synthesis of Vitamin-ALA conjugates 
 
For synthesizing Vitamin-ALA conjugates, we chose three vitamins having hydroxyl 
functions namely Tocopherol (Vitamin E), Cholcalciferol (Vitamin D3) and Retinol 
(Vitamin A); and biotin (Vitamin H or B7), a vitamin having acid moiety to couple with 
Boc-ALA as a pseudopeptide. 
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Scheme 97: Structures of vitamins chosen for conjugation with ALA 
5.4.1. Synthesis of Tocopherol-ALA (Vitamin E-ALA) 
We synthesized tocopherol-ALA conjugate by two ways: First, we coupled tocopherol 67 
with azidolevulinic acid 10 and the resulting product was reduced by catalytic 
hydrogenation in the presence of TFA to afford tocopherol-ALA as trifluoroacetate salt 
65. Second, we coupled tocopherol 67 with Boc-ALA 5 and the resulting product was 
deprotected by TFA to afford tocopherol-ALA as trifluoroacetate salt 65.  
5.4.1.1. Synthesis of tocopherol-ALA starting from azidolevulinic acid 
 
O OH N3 OH
O
O
O
NH3
O
O
(i)
O
+
(ii)
CF3COO
63
65
10
 
Reagents and conditions: (i) DCC, DMAP, rt, 12h, 83%; (ii) H2/Pd, rt, TFA, 90% 
Scheme 98: Synthesis of tocopherol ester of azidolevulinic acid   
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 The coupling of azidolevulinic acid 10 with tocopherol 63 was mediated by DCC and 
DMAP. While DCC was added equimolar, DMAP was added in catalytic quantity. The 
crude after the purification by column chromatography afforded tocopherol ester of azido 
levulinic acid 66 in 83% yield. The azido group being a masked functionality of amine, 
the tocopherol-azidolevulinate was reduced by catalytic hydrogenation. The reduction in 
the presence of TFA proceeded in a straightforward manner with 90% yield and gave 
tocopherol ester of ALA 65 after purification. We triturated the product with hexane to 
remove traces of TFA. The solubility of the product was very high in many solvents as 
the product comprises lipophilic chain.  
5.4.1.2. Synthesis of tocopherol-ALA starting from Boc-ALA 
The coupling of Boc-ALA 5 with tocopherol 63 was performed in a similar manner as 
mentioned above. The DCC/DMAP mediated coupling gave tocopherol-Boc-ALA ester 
64 in 78% yield after the purification by column chromatography. The ‘Boc’ group was 
deprotected by TFA which after purification to remove traces of TFA afforded tocopherol 
ester of ALA 65 in 89% yield. 
(i)
(ii) CF 3COO
O OH BocHN OH
O
O
O NH3
O
O
O
+
63
5
65  
Reagents and conditions: (i) DCC, DMAP, rt, 12h, 78%; (ii) TFA, rt, 30min. 
Scheme 99: Synthesis of tocopherol ester of Boc-ALA 
5.4.2. Synthesis of cholcalciferol-ALA (Vitamin D3-ALA) 
5.4.2.1. Synthesis of cholcalciferol-azidolevulinate 
N3 OH
O
O
(i)
HO
N3
O
O
O
+
10 71
73
 
Reagents and conditions: (i) DCC, DMAP, rt, 60h, 30% 
Scheme 100: Synthesis of cholcalciferol ester of azidolevulinic acid 
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 The azidolevulinic acid 10 was reacted with cholcalciferol 71. We employed the same 
DCC/DMAP mediated coupling as before. The reaction was not completed even after 2 
days of maintaining at ambient temperature. This explains the reason for obtaining 
cholcalciferol ester of azidolevulinic acid 73 in low yield (30%). The unreacted DCC and 
the DHU was difficult to remove even after the reaction mass was filtered over celite. 
The low yield can be explained from the fact that acid moiety is not sufficiently activated 
enough to make coupling. A solution for this could be using azidolevulinic acid chloride 
or the pentafluorophenyl ester of azidolevulinic acid for coupling with cholcalciferol. 
5.4.2.2. Synthesis of cholcalciferol- Boc-ALA 
 
BocHN OH
O
O
HO
BocHN
O
O
O
+
(i)
5
71
72
 
Reagents and conditions: (i) EDCI, DMAP, rt, 60h, 29% 
Scheme 101: Synthesis of cholcalciferol ester of Boc-ALA 
 
As we had poor reactivity in the coupling of azidolevulinic acid with cholcalciferol and 
also difficulty in removal of DCC/DHU, for the coupling with Boc-ALA 5 with 
cholcalciferol 71, we used EDCI as coupling agent. DMAP was added in a catalytic 
quantity. Despite the addition of EDCI as coupling agent and maintenance at ambient 
temperature for 24 h, the reaction was not completed. The crude on purification by 
column chromatography afforded cholcalciferol ester of Boc-ALA 72 in 29% yield. 
5.4.2.3. Synthesis of cholcalciferol-ALA 
 
TFA
CH2Cl2
BocHN
O
O
O H3N
O
O
O
CF3COO
72 234
Scheme 102: Unsuccessful attempt for the deprotection of cholcalciferol-Boc-ALA 
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 The ‘Boc’ deprotection of cholciferol ester of Boc-ALA 72 was attempted by TFA. 
Despite the addition of TFA at low temperature (00C) and maintenance at 100C, we were 
surprised to find the reaction got degraded and the mass became dark black in colour. The 
product after evaporating TFA and triturating with ether was found to compose peaks of 
ALA but not the relevant peaks of cholcalciferol in 1H-NMR. This showed clearly that 
the product was degraded either during reaction or during purification. 
H3N
O
O
O
CF3COO
H3N
O
O
O
CF3COO
235
234
 
Scheme 103: Hypothesis for the failed deprotection of ‘Boc’ in cholcalciferol-Boc-ALA 
Our hypothesis is that cholcalciferol having three double bonds in a conjugated fashion, 
might have cyclized under the condition of ‘Boc’ deprotection to form 235. 
4.4.3. Synthesis of Biotin-ALA(OMe) pseudopeptide 
4.4.3.1. Synthesis of Biotin-PFP ester 
S
HNNH
O
OH
O
F
FF
FF
OH
(i)
S
HNNH
O
O
F
F
F
F
F
O
+
67
68
69  
Reagents and conditions: (i) DCC, DMF, rt, 6h, 76% 
Scheme 104: Synthesis of Biotin-PFP ester 
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 We synthesized Biotin-PFP ester by DCC mediated coupling of biotin with 
pentafluorophenol. Biotin being polar, we used DMF as solvent to dissolve. Once the 
reaction was completed, DHU was filtered. The crude product was then purified by 
crystallization in MeOH as solvent to afford a yield of 76%. 
4.4.3.2. Synthesis of Biotin-ALA pseudopeptide 
 
S
NHHN
O
O
O
F
F
F
F
F
O
O
O
N3
S
NHHN
O
O
O
O
OH
N
(i)
69
70
3
 
Reagents and conditions: (i)  H2/Pd, ambient temperature, 24h, 56% 
Scheme 105: Synthesis of Biotin-ALA pseudopeptide 
This reaction is a peptide coupling between azidomethyl levulinate 3 and biotin-PFP ester 
69 in the presence of hydrogen atmosphere and catalyst Pd over carbon. Azidomethyl 
levulinate is a mask of amino methyl levulinate. On reduction by catalytic hydrogenation, 
the amino methyl levulinate was formed from azidomethyl levulinate. The nitrogen of 
amine group being a good nucleophile attacks the carbonyl carbon of biotin-PFP ester 
which is more electropositive than in biotin. Biotin-PFP ester is required to be added on 
excess otherwise the amino methyl levulinate can condense with another molecule of 
amino methyl levulinate (intermolecular condensation) to form pyrazine type impurity. 
The crude on purification by column chromatography yielded biotin-ALA pseudo peptide 
70 in 56% yield. 
4.4.4. Synthesis of Retinol-ALA (Vitamin A-ALA) 
 
O H BocHN
O
O
F
O F
F
F
F
(i)
O NHBoc
O
O
233 7
236  
Reagents and conditions: (i) DMAP, rt, 24h. 
Scheme 106: Attempted synthesis of retinol ester of Boc-ALA  
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 We attempted the coupling of retinol 233 with Boc-ALA using Boc-ALA-PFP ester 7. 
Despite the addition of equimolar DMAP and maintaining at ambient temperature for 24 
h, the reaction was not completed. The crude on purification by column chromatography 
did not provide any fraction which contained the required product 236. 
N3 Cl
O
O
O N3
O
O
OH
(i)
(ii)
233
237
10a
 
Reagents and conditions: (i) NaH, THF, rt, 10h; (ii) THF, rt, 6h. 
Scheme 107: Synthesis of retinol ester of azidolevulinic acid. 
 
As a second trial, we attempted to deprotonate the hydroxyl proton of retinol and then 
couple with azidolevulinic acid chloride which was synthesized from azidolevulinic acid. 
As azidolevulinic acid chloride is thermally stable, we didnot isolate this and we used 
directly the crude of this reaction for coupling with retinolate of sodium. The crude of the 
reaction was not purified further due to time constraints. 
4.4.5. Evaluation of Vitamin-ALA conjugates 
 
We tested biotin-ALA peptide 70 and tocopherol-ALA ester 65. Tocopherol-ALA ester 
was not soluble in the water because of its lipophilic chain. Then, it was dissolved in 
DMSO, but the product got precipitated when it is diluted with the cell growth medium.  
As shown in the figure, biotin-ALA pseudo peptide 70 was not able to generate PpIX. 
This shows that the peptide derivatives have problems either to be internalized or they are 
not cleaved to release ALA. The cleavage of peptide might have been not possible due to 
the inability to recognize the pseudo-peptide.HCEC (human endothelial cells) was used 
for tests. 
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Figure 24: Increase in PpIX level due to biotin-ALA pseudo peptide 
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 5.5. Synthesis of Nucleoside-ALA conjugates 
 
As discussed in chapter 2 (Biological reasons behind Prodrugs ‘ design), to take 
advantage of nucleoside receptors for targeted-ALA-PDT, we chose two nucleosides, one 
from ribonucleoside series (adenosine) and one from deoxyribo nucleoside series 
(thymidine).  
5.5.1. Synthesis of Adenosine-ALA conjugate 
 
Similar to what we performed in sugars, in the case of adenosine, we first wanted to 
synthesize ALA coupled as ester in the primary hydroxyl group of ribose sugar part of 
adenosine. 
5.5.1.1. Synthesis of 5´-O-(Boc-ALA) adenosine 
 
With the rise in the significance of nucleoside derivatives in the field of medicinal 
chemistry, especially as antineoplastic and antiviral agents, the development of new and 
efficient synthetic methodology is also rising. Enzymatic regioselective acylation is one 
of the methods for achieving high regioselectivity. Moris et al reported that selective 
acylation on 3´-OH of deoxyribonucleosides and exclusive regioselective acylation on 5´-
OH of ribonucleosides could be achieved by the enzyme Candida antarctica lipase 
(Novozyme 435) and using oxime esters as activated ester [402].  
BocHN
O
O
N
O
N
NN
N
NH2
O
OHOH
HO
BocHN
O
O
N
NN
N
NH2
O
OHOH
O
(i)
12 74
75  
Reagents and conditions: (i) Lipase from Candida antarctica, 600C, 24h, 25%. 
Scheme 108: Syntesis of 5´-O-(Boc-ALA) adenosine. 
 
We employed the same protocol as mentioned by Moris et al. For an equivalent of 
adenosine, we used 3 equivalents of Boc-ALA-oxime ester 12 and 2 equivalents of the 
enzyme Candida antarctica lipase (Novozyme 435) (activity 10 units / mg of solid). 
After maintaining for 24 h at 600C, the reaction was worked up and purified (column 
chromatography) to afford exclusively 5´-O-(Boc-ALA) adenosine 75 in 25% yield. The 
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 yield is quite low as compared to what was achieved by Moris et al (82% to 92%) when 
they utilized alkyl chains of length C1 to C6. The activity of the enzyme used by Moris et 
al was not mentioned in the literature [402]. Also, the reaction what we performed has to 
be optimized. Further work on this including deprotection of ‘Boc’ has not yet been 
completed. 
5.5.2. Synthesis of Thymidine-ALA conjugate 
In the case of thymidine we decided to substitute ALA in both the hydroxyl groups of the 
ribose sugar part.  
5.5.2.1. Synthesis of 3´,5´-O-di (ALA) thymidine 
O
OH
H O
N
NH
O
O
OHBocHN
O
O
O
N
NH
O
O
OH 3N
O
O
O
NH3
O
O
(i)
165 2385
(ii) CF3COO
CF3COO  
Reagents and conditions: (i) Et3N, DCC, DMAP, rt, 2h, 90%; (ii) TFA,  rt, 30 min, 82%. 
Scheme 109: Synthesis of 3´, 5´-di (Boc-ALA)-thymidine. 
 
We synthesized 3´,5´-di (Boc-ALA) thymidine 238 by DCC/DMAP mediated coupling. 
thymidine 165 dissolved in dioxane was coupled with Boc-ALA using DCC and catalytic 
DMAP. Boc-ALA was used in excess (4 equivalents for each equivalent of thymidine) 
and DCC was added equimolar to that of Boc-ALA. The crude on purification by column 
chromatography yielded 3´,5´-di (Boc-ALA) thymidine 200 in 90% yield. This product 
on deprotection using TFA yielded 3´,5´-di (ALA) thymidine 238 in 82% yield. 
The evaluation of ALA-nucleoside conjugates on cells for PpIX induction has not yet 
been accomplished. 
5.6. Synthesis of ALA esters and pseudo peptide 
5.6.1. Synthesis of ALA-pseudo peptide (GABA-ALA-(OMe)), 
(Tyr-ALA-(OMe)) and (ALA-ALA-OMe) 
5.6.1.1. GABA-ALA pseudo peptide 
Gamma-aminobutyric acid (GABA) is the inhibitory neurotransmitter in the brain. ALA, 
being structurally similar to GABA, is incorporated into the cells by a carrier protein 
which is a GABA transporter [208, 209]. In view of this, we planned to synthesize 
GABA-ALA-OMe. We planned to synthesize Boc-GABA-ALA-OMe 78 in a similar 
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 manner as we accomplished for synthesizing Biotin-ALA (OMe) 70. Azidomethyl 
levulinate is a mask of amino methyl levulinate. On reduction by catalytic hydrogenation, 
the amino methyl levulinate was formed from azidomethyl levulinate. The nitrogen of 
amine group being a good nucleophile attacks the carbonyl carbon of pentafluorophenyl 
ester of Boc-GABA (Boc-GABA-PFP ester) which is more electropositive than in Boc-
GABA.  
  
O
BocHN
O
F
F
F
F
F
OH
BocHN
O
76 77
H
N O
O
O
O
H3N
CF3COO
79
(i) (ii)
(iii)
Reagents and conditions: (i) C6F5OH, DCC, rt, 2h, 98%; (ii) Azidomethyl levulinate, 
H2/Pd, rt, 8h, 87%; (iii) TFA, rt, 30min, 96%. 
Scheme 110: Synthesis of GABA-ALA(OMe) pseudopeptide. 
 
We synthesized first pentafluorophenyl ester of Boc-GABA 77 (Boc-GABA-PFP ester) 
from Boc-GABA 76. Then we coupled this with azidomethyl levulinate 3 in the presence 
of hydrogen atmosphere and catalyst Pd over carbon. Boc-GABA-PFP ester is required to 
be added on excess otherwise the amino methyl levulinate can condense with another 
molecule of amino methyl levulinate (intermolecular condensation) to form pyrazine type 
impurity as discussed in chapter 1.3. The product after coupling was purified by column 
chromatography to afford Boc-GABA-ALA(OMe) 78  in 87% yield. Boc-GABA-
ALA(OMe) 78, then was treated with TFA to deprotect ‘Boc’ to provide GABA-
ALA(OMe) peusdo peptide 79. 
5.6.1.2. Tyr-ALA pseudo peptide 
We synthesized Tyr-ALA pseudo peptide 83 in the same manner as we did for 
synthesizing GABA-ALA(OMe) peusdo peptide 79. 
 
OH
BocHN
O
O
BocHN
O
O
O
F
F
F
F
F
80 81
CF3COO
H3N
O
OH
O
H
N
O
O
83
(i) (ii)
(iii)
 
Reagents and conditions: (i) C6F5OH, DCC, rt, 2h, 97%; (ii) Azidomethyl levulinate, 
H2/Pd, rt, 12h, 90%; (iii) TFA, rt, 30min, 93%. 
Scheme 111: Synthesis of tyrosine-ALA pseudo peptide 
We synthesized pentafluorophenyl ester of Boc-Tyr-(O-tBu) 81 (Boc-Tyr-(O-tBu)-PFP) 
from Boc-Tyr-(O-tBu) 80. This activated ester was coupled with azidomethyl levulinate 3 
in the presence of hydrogen atmosphere and catalyst Pd over carbon to give Boc-Tyr-(O-
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 tBu)- ALA (OMe) pseudo peptide 82. The pseudo peptide of Boc-Tyr-(O-tBu)- ALA 
(OMe) 82 was then treated with TFA to provide Tyr-(OH)- ALA (OMe) 83. 
5.6.1.3. ALA-ALA(OMe) pseudo peptide 
In our desire to synthesize oligopeptides (pentamer, hexamer etc) containing ALA in 
solution based approach, as a first step, we wanted to synthesize dimer containing two 
ALA molecules coupled as a peptide. 
BocHN
O
O
F
O F
F
F
F
ON3
O
O
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O
O
O
H
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O
7 10
84
H3N
O
O
O
H
N
O
OCF3COO
(i)
(ii)
 
Reagents and conditions: (i) H2/Pd, rt, 12h, 18%; (iii) TFA, rt, 30min. 
Scheme 112: Synthesis of Boc-ALA-ALA (dimer) and attempted ‘Boc’ deprotection. 
We coupled Boc-ALA-PFP ester with azidomethyl levulinate in the presence of hydrogen 
atmosphere and catalyst Pd over carbon. The coupled product afer purification by column 
chromatography provided Boc-ALA-ALA (OMe) in 18% yield. We added Boc-ALA-
PFP ester in excess (2 equivalents), otherwise the amino methyl levulinate can condense 
with another molecule of amino methyl levulinate (intermolecular condensation) to form 
pyrazine type impurity as discussed in chapter 1.3. Despite this, we obtained a low yield. 
The reaction was not optimized further to improve yield. Our trials to deprotect ‘Boc’ 
group using TFA was unsuccessful and so we did not proceed further. 
5.6.2. Synthesis of ALA esters 
5.6.2.1. Synthesis of ALA-6-Ketocholestanol ester 
As mentioned in the objective chapter, we wanted to synthesize an ester coupling the 
hydroxyl function of 6-Ketocholestanol with the acid moiety of Boc-ALA. 
 
(ii)
(i)
(CH2)3
H3C
CH 3
HCH3
H
HH
H
O
HO
(CH2)3
H 3C
CH3
HCH3
H
HH
H
O
OH3N
O
O
CF3COO
239 241  
Regants and conditions: (i) EDCI, DMAP, Boc-ALA, rt, 12h, 67%; (ii) TFA, rt, 30mim, 
96%. 
Scheme 113: Synthesis of 6-Ketocholestanol ester of ALA. 
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 We accomplished the coupling of Boc-ALA and 6-ketocholestanol 239 using EDCI and 
DMAP. The product after column chromatography afforded 6-ketocholestanol ester of 
Boc-ALA 240 in 67% yield. This coupled ester was treated with TFA to remove ‘Boc’. 
This crude after purification by precipitation gave 6-ketocholestanol ester of ALA 241. 
As the final deprotected compound was still lipophilic, the trituration to remove excess 
TFA was done using the solvent hexane. 
5.6.2.2. Synthesis of Trichloro ethyl ester of ALA 
 
We used tricloroethyl ester of Boc-ALA as an activated ester for various enzymatic 
regioselective transformations for synthesizing sugar-ALA conjugates. It has been 
reported by Brunner et al [103] that ALA esters containing fluorinated alkyl chains (C5-
C7) are efficient in producing PpIX. In view of this report and also as we were using 
tricloroethyl ester of Boc-ALA for other reactions, we decided to deprotect the ‘Boc’ 
group by TFA and evaluate the trichloroethyl ester of ALA trifluoroacetate for its 
efficiency in generating PpIX. 
CF 3COO
(i)
OH3N
O
O
CCl3OBocHN
O
O
CCl3
9 242  
Regants and conditions: (i) TFA, rt, 30mim, 95%. 
Scheme 114: Synthesis of trichloroethyl ester of ALA 
5.6.3. Synthesis of ALA multisubstituted on poly hydroxyl 
compounds 
5.6.3.1. Synthesis of Tri-(ALA) Phloroglucinol 
Phloroglucinol which is a 1,3,5 trihydroxy benzene is commercially available. We 
planned to synthesize substitution of ALA as ester on all the three hydroxyl groups of 
phloroglucinol. We accomplished this using Boc-ALA in the presence of DCC and 
dimethyl amino pyridine salt of p-toulene sulphonic acid (DPTS) [403]. We isolated the 
tri substituted product 86 from other by-products like di and mono substituted products 
by column chromatography. 
OHHO
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H3N
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NH 3
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O NH3
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CF3CO OCF3COO
CF3COO
87
(i)
(ii)
 
Regants and conditions: (i) DCC, DPTS, Boc-ALA, rt, 24h, 94%; (ii) TFA, rt, 30mim, 
90%. 
Scheme 115: Synthesis of tri (ALA) phloroglucinol 
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 The tri Boc-ALA substituted phloroglucinol 86 was then treated with TFA to deprotect 
‘Boc’. The product on purification to remove excess TFA using co-evaporation, 
trituration etc using ether as solvent provided pure tri(ALA) phloroglucinol 87. 
5.6.3.2. Synthesis of Tri-(ALA) Glycerol 
Glycerol and triglycerides being an adjuvant for many formulations, triglycerides 
containing ALA as ammonium salt can provide a basis for either crossing lipid bilayer of 
cell wall or stratum corneum of skin (skin applications). 
HO
OH
HO
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Regants and conditions: (i) DCC, DPTS, Boc-ALA, rt, 24h, 73%; (ii) TFA, rt, 30mim, 
89%. 
Scheme 116: Synthesis of tri (ALA) glycerol 
We carried out the tri ALA substitution on glycerol in a similar manner as we did for 
phloroglucinol.  
5.6.4. Evaluation of ALA esters and ALA-pseudo peptides 
PpIX induction in different types of cancer cell lines were evaluated using the following 
derivatives: ALA pseudo peptides namely GABA-ALA(OMe) 79 and Tyr-ALA(OMe) 
83; ALA esters namely 6-ketocholestanol ester of ALA 241, tri (ALA) phloroglucinol 87, 
tri (ALA) glycerol 90 and trichloroethyl ester of ALA 242.  
5.6.4.1. Evaluation of ALA pseudo peptides 
As shown figures 25 and 26 which indicate the increase in level of PpIX level over a 
period of 3 h, the ALA pseudopeptides did not generate PpIX at all. Although GABA-
ALA (OMe) was not able to generate PpIX in many types of cancer cells (the graphs of 
increase in PpIX level by certain selected cell lines are shown here), it generated very low 
level of PpIX in breast MCF 7 carcinoma cells. This shows that the peptide derivatives 
have problems either to be internalized or they are not cleaved to release ALA. The 
cleavage of peptide might have been not possible due to the inability to recognize the 
pseudo-peptide. 
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Figure 25: Increase in PpIX level in cells exposed to GABA-ALA 79 
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Figure 26: Increase in PpIX level in cells due to tyrosine-ALA 83 
 
5.6.4.2. Evaluation of ALA esters 
5.6.4.2.1. Evaluation of ALA-6-ketocholestanol ester 241 
In the case of ALA esters, 6-ketocholestanol ester of ALA did not generate PpIX at all in 
all types of cancer cell lines (the graphs of increase in PpIX level by certain selected cell 
lines are shown here; figure 27). As we had the difficulty to dissolve 6-ketocholestanol 
ester of ALA as it is highly lipophilic, we used DMSO. The compound got precipitated 
when diluted by growth medium. So the reason for not generating PpIX could be that 
because of its high lipophilicity, the compound might not have penetrated the cell 
membrane. 
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Figure 27: Increase in PpIX level due to 6-ketocholestanol -ALA 241 
5.6.4.2.2. Evaluation of trichloroethyl ester of ALA 
Trichloroethyl ester of ALA 242 induced strong PpIX production in all cell lines (the 
graphs of increase in PpIX level by certain selected cell lines are shown here). As 
mentioned by Brunner et al [103] ALA derivatives when conjugated with functionalities 
containing electron withdrawing group generates higher production of PpIX as we see in 
the case of trichloroethyl ester of ALA (TCE-ALA). 
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Figure 28: Increase in PpIX level due to trichloroethyl ester of ALA 242 over a period of 
6h 
 
 
 
 124
 5.6.4.2.3. Evaluation of tri-(ALA) phloroglucinol (87) and tri-(ALA) glycerol (90) 
In the case of other ALA esters, tri-(ALA) phloroglucinol 87 and tri-(ALA) glycerol 90 
were tested only in human endothelial cells (HCEC). Both the derivatives induced strong 
PpIX production in human endothelial cells. Multi ALA substituted phloroglucinol ester 
derivative (tri–(ALA) phloroglucinol) induced higher level of PpIX than that induced by 
multi ALA substituted glycerol ester derivative (tri-(ALA) glycerol).  This again can be 
explained from the fact that in the case of phloroglucinol, the electron rich aromatic ring 
has better electron withdrawing effect than that of glycerol. But both the derivatives 
induced PpIX to a comparable level if not higher than that induced by standard ALA.  
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Figure 29: Increase in PpIX level due to tri-(ALA) ester of phloroglucinol 87 
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Figure 30: Increase in PpIX level due to Tri-(ALA) ester of glycerol 90 
 
From the graphs shown here for ALA esters, it can be concluded that the order of 
efficiency in generating PpIX in the case of ALA esters can be as follows:  
Trichloroethyl ester of ALA (TCE-ALA) >Tri(ALA) phloroglucinol > Tri(ALA) 
glycerol 
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 5.7. Synthesis of PBG derivatives 
 
To the best of our knowledge, not even a single publication is known in the literature 
where PBG as a precursor for photodynamic therapy or diagnosis had been tested in 
cancer cell lines though some mention that PBG has the potential for PDT use [404-406]. 
This is more than surprising given the fact that there are several reports describing 
synthesis of PBG [215, 218, 404, 405, 407-420] due to its significance in treating lead 
poisoning  [405, 417-419, 421, 422] despite its utility in the studies of biosynthesis [410, 
414, 415]. Porphobilinogen being a trialkyl substituted pyrrole, is not stable and highly 
reactive due to the lack of stabilizing substituents such as an electron withdrawing group 
or an aromatic ring [215]. Keeping this in mind, we planned to design a stable protected 
derivative of PBG. The biomimetic synthesis of porphobilinogen has been extensively 
studied by our group [215-218, 423-428]. This in-house expertise and the requirement for 
protecting groups in view of cellular mechanisms made us to design PBG where the acid 
moieties are protected as methyl ester and the amino group linked to acid moieties of 
different α-amino acids (scheme 117). We chose neutral amino acids (alanine and phenyl 
alanine), basic amino acid (lysine) and acidic amino acid (aspartic acid). We envisaged 
that the cellular esterases could cleave the methyl ester moiety and cellular peptidases 
could cleave the aminoacid-PBG bond thereby release free PBG. This free PBG released 
in turn can transform into PpIX. 
N
H
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O
O
H3N
O
R
H
N
CF3COO
R
CH3
NH3 CF3COO
OMe
O
Aminoacid
Alanine
Phenyl alanine
Lysine
Aspartic acid
methyl ester
 
Scheme 117: PBG-amino acid pseudo peptides synthesized 
5.7.1. Synthesis of PBG precursors 
We synthesized the PBG precursors required for the formation of PBG via a key step 
Mukaiyama aldol condensation. All the steps in the formation of PBG precursors have 
been well studied in our group before [216, 217, 428, 429]. 
The key step is Mukaiyama condensation which requires silyl enol ether 93 and azido 
ketal 91. 
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Scheme 118: Precursors for Mukaiyama aldol reaction 
5.7.1.1. Synthesis of silyl enol ether 
The synthesis of enol ether comprises 3 steps and it starts from levulinic acid 1. Levulinic 
acid was brominated to obtain 5-bromomethyl levulinate 2 as the major product as 
described in 5.1.5.2.1. SN2 reaction of 5-bromo methyl levulinate with formic acid under 
basic conditions (DBU) in benzene yielded 5-formyloxy methyl levulinate. This 
formyloxy compound was easily hydrolyzed to 5-hydoxy methyl levulinate 92 by passing 
through a column with basic alumina [430]. The 5-hydoxy methyl levulinate was 
deprotonated by lithium salt of hexamethyldisilazane to form the enolate and at -780C 
was silylated by trimethyl silyl chloride. Methyl iodide was added later for the formation 
of quaternary amine salt which can be eliminated by precipitation. This gave the 
regioselective silyl enol ether 93 required for Mukaiyama condensation.  
O
O
O
Si
O
Si
OH O
O
O
HO
O
O
(i)
(ii)
(iii)
1 92 93  
Reagents and conditions: (i) Br2, MeOH, reflux, 1.5h, 57%; (ii) HCOOH, DBU, neutral 
alumina, rt, 1h, 69%; (iii) LiHMDS, TMS-Cl, MeI, -780C, 3h, 63%. 
Scheme 119: Synthesis of silyl precursor for Mukaiyama aldol reaction 
5.7.1.2. Synthesis of azidoketals 
The synthesis of azidoketal comprises 3 steps starting from levulinic acid 1. Levulinic 
acid was brominated to obtain 5-bromomethyl levulinate 2 as the major product as 
described in 5.1.5.2.1. Then with a SN2 attack by azide nuclophile on 5-bromomethyl 
levulinate afforded 5-azidomethyl levulinate 3. This azide 3 on reacting with trimethyl 
orthoformate in the presence of catalytic p-toluene sulfonic acid gave azidoketal 91.  
ON3
O
O O
OH O
O
O
N3
O
O
(i)
(ii)
(iii)
1 3 91  
Reagents and conditions: (i) Br2, MeOH, reflux, 1.5h, 57%; (ii) NaN3, rt, 1h, 95%; (iii) 
(H3CO)3CH, p-TsOH, MeOH, reflux, 14h, 89%. 
Scheme 120: Synthesis of azido keteal precursor for Mukaiyama aldol reaction 
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 5.7.1.3. Mukaiyama aldol reaction 
ON3
O
O O
O
O
(i)
O
Si
O
Si
OO
HO N3
OO
O
O
H
93 91 94  
Reagents and conditions: (i) TiCl4, CH2Cl2, -780C to -550C, 16h, 44%. 
Scheme 121: Mukaiyama aldol reaction 
 
The Mukaiyama reaction was carried out between the silyl enol ether 93 and azido ketal 
91 in the presence of lewis acid TiCl4 (scheme 121). The silyl enol ether and azido ketal 
was dissolved in dichloromethane, cooled to -780C, added TiCl4 and maintained at -550C 
for 12h. The reaction is very sensitive to moisture, acidity in the solvent 
(dichloromethane) etc which otherwise affects the yield. The solvent dichloromethane 
was passed through basic alumina to remove any acidity. (Distillation over P2O5 makes 
the solvent more acidic, so not advisable). The starting materials were also dried for a 
long time (6 h) by high vacuum oil pump. The reaction mass was extracted between 2N 
NaOH and CHCl3. The crude on purification by column chromatography yielded the 
aldol product 94 with the alcohol functionality free, the desilylation being happened 
during the basic work-up. 
5.7.1.4. Mitsunobu reaction 
 
(i)
OO
N3
N3
OO
O
O
H
OO
HO N3
OO
O
O
H
94 95  
Reagents and conditions: (i) PPh3, DIAD, HN3, 100C, 2h, 93%. 
Scheme 122: Mitsunobu reaction 
 
Though the mukaiyama aldol product can be cyclized to form pyrrole ring using catalytic 
hydrogenation or Staudinger reaction, we decided to introduce a masking group of amine 
which is azido in the place of hydroxyl group and then cyclize to form PBG. So, the free 
hydroxyl group of aldol product 94 was converted to azido using hydrazoic acid (HN3) in 
the presence of PPh3 and DIAD (scheme 122). In a solution of PPh3 in benzene at 100C 
was added DIAD drop wise. To this solution of quaternary phosphonium salt, was added 
the solution of aldol product. Finally, we added dropwise the solution of HN3 in benzene 
which was freshly prepared and titrated before use. After maintaining at 100C for 2 h, the 
solvent was evaporated and subsequently the crude was purified by column 
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 chromatography.  We synthesized this Mitsunobu product 95 in sufficient quantity (~5g) 
and used this for coupling with various activated ester of amino acids. Since this 
Mitsunobu product is thick yellow oil, we dissolved this solvent to make like a stock 
solution and used the aliquot of it for further reactions. 
 
5.7.2. Synthesis of PBG-amino acid peptide 
 
The synthesis of stable derivative of PBG in the form of PBG-phenyl acetamide 244 
(scheme 123) had been studied before in the group by C.Soldermann-Pissot [429]. She 
had coupled the activated ester (pentafluoro phenyl) of phenyl acetic acid 243 with the 
above mentioned Mitsunobu product 95 under the conditions of catalytic hydrogenation 
to form PBG-phenyl acetamide 244. 
(i)
OO
N3 N3
OO
O
O
H
95
O
O
F
F
F
F
F
O
+
N
H
OO
OO
H
N
244243  
Reagents and conditions: (i) H2, Pd/C, MeOH, ambient temperature, 14h, 72%. 
Scheme 123: Synthesis of PBG-phenyl acetamide carried out by C.Soldermann-Pissot 
HN
N
H
O
OO
245
 
 
Scheme 124: PBG-lactam impuritiy 
 
This reaction was clean without the formation of any impurities like lactam 245 (scheme 
124) which could have formed if there is not sufficient pentafluorophenyl (PFP) ester of 
pheylacetic acid to couple with the Mitsunobu product 95. She proposed the sequence of 
reactions as follows: 
1) Reduction of azido function in α position of the keto function to amine. 
2) Nucleophilic attack of amine on the carbonyl carbon of pentafluoro phenyl ester of 
phenyl acetic acid and forming amide bond (protection of amine in the form of 
phenylacetamide) 
3) Reduction of azido function in neopentyl position to amine 
4) Formation of cyclic enamine. 
5) Aromatization leading to the formation of pyrrole.  
For synthesizing PBG-aminoacid pseudo peptides, we decided to follow the same 
methodology which had been used for synthesizing PBG-phenyl acetamide pseudo 
peptide. So, the first step is to synthesize pentafluorphenyl (PFP) esters of amino acids 
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 and then couple with Mitsunobu product to form pyrrole cyclization and peptide 
formation together. 
5.7.2.1. Synthesis of Pentafluoro phenyl esters of amino acids 
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O
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F
F
F
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F
 
Reagents and conditions: (i) DCC, EtOAc, 100C to ambient temperature, 2h, 86% to 
90%. 
Scheme 125: Synthesis of pentafluorophenyl ester of amino acids 
 
We synthesized pentafluorophenyl (PFP) ester of various protected amino acids (scheme 
125) [431-433] namely N-Boc-Alanine; N-Boc-Phenyl alanine; N-Boc,N´-Boc-Lysine 
and N-Boc-Aspartic acid-OMe. In the case of lysine and aspartic acid we did not isolate 
the activated ester. In the case of aspartic acid, we also synthesized pentafluorophenyl 
ester of N-Boc-Aspartic acid-OtBu. 
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 5.7.2.2. PBG-(Boc-aminoacid) pseudo peptides 
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Reagents and conditions: (i) H2, Pd/C, MeOH, rt, 14h. 
Scheme 126: Synthesis of PBG-(Boc-aminoacid) pseudo peptides 
Each of these activated esters of amino acid was coupled with the Mitsunobu product 95 
under the conditions of catalytic hydrogenation to provide Boc-amino acid coupled PBG 
(PBG-Boc-AA) (scheme 126). The PFP ester of amino acid and Mitsunobu product 95 
were dissolved in MeOH, 10% Pd over carbon was added as catalyst and then maintained 
the reaction with hydrogen atmosphere (hydrogen filled in gas bag) at rt for 24h. The 
reaction was clean, Pd was filtered, solvent evaporated off and the crude was purified by 
column chromatography to yield PBG-Boc-(aminoacid) pseudo peptide in very good 
yields (60% to 82%). The addition of two equivalents of PFP ester ensures the rapid 
protection of amine (formed from azide of alpha to ketone) to amide (peptide) thereby 
eliminates the chance for the formation of lactam impurity (scheme 124). 
OO
N3
OO
O
O
H
BocHN
O
R
N
H
R = CH3  
Scheme 127: Partially hydrogenated side product during the synthesis of PBG-(Boc-
amino acid) pseudo peptides. 
 131
 We also observed (in the case of alanine) that insufficient maintenance or insufficient 
hydrogen pressure leads to a product where the amine (formed from azide of alpha to 
ketone) of Mitsunobu product is coupled with Boc-alanine as a peptide but other azide 
function in neopentyl position intact without any cyclization (scheme 127). Thus we 
synthesized PBG- Boc-alanine pseudo peptide, PBG- Boc-phenyl alanine pseudo peptide, 
and PBG- (Boc), Boc-lysine pseudo peptide. In the case of aspartic acid, we synthesized 
PBG- Boc-aspartic acid (OMe) pseudo peptide and also PBG- Boc-aspartic acid (OtBu) 
pseudo peptide. 
5.7.2.3. PBG- (amino acid) pseudo peptides (Deprotection of ‘Boc’) 
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Reagents and conditions: (i) TFA, 00C to 50C, 30 min to 2h, 91% to 94%. 
Scheme 128: Boc deprotection of PBG-Boc-amino acid 
 
Though the coupling to form peptide bond between PBG and amino acid worked easily, 
the deprotection of ‘Boc’ using TFA was found to be problematic as PBG under highly 
acidic conditions degraded very fast. We tried different methods of deprotecting ‘Boc’ 
using reagents such as trimethyl sily iodide, trimethylsilyl trifluoromethane sulfonate, 
TBDMS trifluormethane sulfonate, TBAF etc [434-437] which were not successful. We 
overcame this problem of ‘Boc’ deprotection by performing the reaction below 00C and 
evaporating TFA below 200C. Also, co-evaporation, trituration with dry ether helped to 
remove traces of TFA. In the case of aspartic acid, repeated attempts [436, 438] to 
deprotect tert-butyl group alongwith ‘Boc’ for PBG- Boc-aspartic acid (OtBu) pseudo 
peptide, were not successful. So, keeping aside that, we deprotected ‘Boc’ from PBG- 
Boc-aspartic acid (OMe) pseudo peptide which we used for biological tests. 
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 Thus, we synthesized PBG- alanine pseudo peptide, PBG- phenyl alanine pseudo peptide, 
PBG- aspartic acid (OMe) pseudo peptide and PBG- lysine pseudo peptide having the 
amine of amino acid in the form of salt aminium trifluoroacetate salt. All these four 
pseudo peptides of PBG were used for biological tests. 
5.7.3. Evaluation of PBG-amino acid peptides 
PpIX production was evaluated for all the four PBG- amino acid pseudo peptides by 
measuring increase in fluorescence intensity in living cells at different times by 
incubating cells in medium containing ALA conjugate at concentrations from 0.1mM to 2 
mM. Cells used for experiments were A549 lung carcinoma cells, HCEC human 
immortalized brain endothelial cells and Human colon HT29 cells. 
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Figure 31: Increase in PpIX level due to PBG-alanine and PBG-phenyl alanine pseudo 
peptides in HT29 cells. 
 133
 H T  2 9  (P B G - lys ine )
0 . 0
5 0 . 0
10 0 . 0
15 0 . 0
2 0 0 . 0
2 5 0 . 0
3 0 0 . 0
3 5 0 . 0
4 0 0 . 0
0 3 0 6 0 12 0 18 0
T i m e  ( m i n )
0 . 5  m M
1 m M
2  m M
3 m M
A L A  3 m M
 
PB G - A sp  ( O M e)
0 . 0
5 0 . 0
10 0 . 0
15 0 . 0
2 0 0 . 0
2 5 0 . 0
3 0 0 . 0
3 5 0 . 0
4 0 0 . 0
0 3 0 6 0 12 0 18 0
T i m e  ( m i n )
0 . 5  m M
1 m M
2  m M
3 m M
A L A  3 m M
 
Figure 32: Increase in PpIX level due to PBG-lysine and PBG-aspartic acid methyl ester 
pseudo peptides in HT29 cells. 
 
The graphs showing increase in fluorescence intensity in HT29 cells are shown here for 
all the four PBG- amino acid pseudo peptides. As shown in the figures 31 and 32, all the 
PBG-amino acid pseudo peptides were not able to generate PpIX. The cleavage of 
peptide might have been not possible due to the inability to recognize the pseudo-peptide. 
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 6. Conclusions 
 
All the ALA bioconjugates synthesized by us are novel and some of them are very 
efficient in generating protoporphyrin (PpIX). The efficient ALA bioconjugates also has 
the advantage of being not cytotoxic in the absence of exposure of light. 
 
6.1. Sugar-ALA conjuagtes 
 
All the sugar-ALA conjugates induce PpIX generation, some are more efficient than the 
standard ALA and some are comparable to that of ALA. The efficiency factor of 
generating PpIX also varies with respect to the type of cells, as for example in human 
colon carcinoma HT29 cells, the PpIX induced is comparatively lower than in other types 
of cells. Sugar-ALA conjugates where ALA is conjugated via ethylene glycol linker (54, 
57 and 62) are less efficient than other sugar-ALA conjugates. Some sugar-ALA 
conjugates are efficient than ALA in generating PpIX while others are comparable to 
ALA. The main advantage of the sugar-ALA derivatives in comparison to other alkyl 
ALA esters such as hexyl ALA esters is that they are not cytotoxic in the absence of light 
exposure.  
 
The major drawback of sugar-ALA conjugates is selectivity. These bioconjugates are not 
superior to ALA in targeting cancer cells. Having said this, it should also be mentioned 
that results obtained in cell cultures may not be extrapolated to tumor organ cultures as in 
the case of hexyl-ALA ester. It was reported that though hexyl-ALA ester generated 
higher PpIX than ALA in mammary adenocarcinoma cell cultures, in tumor organ 
cultures of the same line hexyl ALA ester did not increase the rate of tumor porphyrin 
generation [439]. Keeping this in mind, it may be essential to test sugar-ALA conjugates 
in tumor organ cultures to find out its efficiency in generating PpIX and also its 
selectivity towards tumor cells. 
 
6.2. ALA-esters  
 
Although, ALA esters made from tocopherol 65 and 6-ketocholestanol 241 were novel, 
they have the inherent problem of solubility in the cell culture medium as these 
compounds have lipophilic chains. These conjugates did not generate higher PpIX than 
that of ALA which might be due to the difficulty in internalization into the cells because 
of their lipophilic nature. ALA esters synthesized from phloroglucinol 87 and glycerol 90 
contained three ALA molecules. The efficiency of PpIX generation is lesser than that of 
ALA. This is surprising given the fact that having three ALA molecules, it should 
generate very high PpIX generation. In between the esters synthesized from 
phloroglucinol 87 and glycerol 90, the one having phloroglucinol moiety 87 generated 
higher PpIX generation than that of the one having glycerol moiety. This could be due to 
the difference in lipophilicity. Also, it was reported that ALA attached to electron 
withdrawing group moiety was efficient in generating PpIX [103]. This could be the 
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 reason for a very high induction of PpIX due to ALA-trichloroethyl ester 242. The PpIX 
induction by this ester was superior to ALA. 
 
6.3. ALA-pseudo peptides 
 
All the bioconjugates where the amino group of ALA is protected as amide/peptide 
moiety (biotin-ALA(OMe) 70, GABA-ALA (OMe) 79 and  tyrosine-ALA (OMe) 83) did 
not generate any PpIX. This may not be surprising given the fact that many reported 
articles mentioned the poor efficiency for ALA when the amino group of ALA is 
protected [92, 102].  Despite these reports, we synthesized and tested ALA-
pseudopeptides because we believed that conjugate moiety attached to ALA, for example 
biotin could not only aid in targeting cancer cells but also will have unique cellular 
pathway to transport ALA easily. One of the main reasons for not generating PpIX by 
these pseudo peptide conjugates could be that these bioconjugates did not release the 
active ingredient ALA. This might be either due to the non-efficient localization of these 
conjugates or due to the fact that this unnatural peptide is not recognized by peptidase 
enzymes for releasing ALA. In a previous study done in our group we found that even in 
cancer cells which express basic aminopeptidases, ALA conjugated to basic amino acid 
(lysine)  was not efficient in generating PpIX [102]. However, ALA conjugated with N-
terminal blocked or N-terminal free dipeptides performed in our group was efficient in 
generating PpIX [107].  
 
The summary of the ALA bioconjugates synthesized and their evaluation on cell lines is 
given in a table form as below. The calculated log P of all the conjugates was included as 
this gives an idea of the lipophilicity of the conjugates. This lipophilicity index is one of 
the essential things necessary to understand a drug’s permeability and absorption as 
stated in the famous “the rule of 5” by Lipinski [440]. 
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 6.4. Summary of Conjugates synthesized and their evaluation 
 
Deriv. 
No 
Structure Type/ 
Name  
Log P 
calcul
ated 
PpIX 
compared 
to ALA 
Cytot
oxicity 
Selectivity 
and other 
comments 
15, 26, 
29 
O
O
NH3
O
R4
R3
HO
R2
R1
O
OH
15; R1=O H, R2=H, R3=OH, R4=H
26; R1=H , R2=OH, R3=OH, R4=H
29; R1=OH, R2=H, R3=H, R4=OH
CF3COO
 
6´-O-
(ALA) 
sugars 
-3.71 
(union
ized) 
superior No No; 6´-O-
(ALA) 
mannose is 
better than 
others in 
selectivity 
36, 42, 
48 
36; R1=H, R2=ALA, R3=OH,
R4=H, R5=OH , R6=H
42; R1=H, R2=ALA, R3=H,
R4=OH , R5=O H, R6=H
48; R1=ALA, R2=H, R3=OH,
R4=H, R5=H, R6=O H
O
R6
R5H O
R4
R2
R3
R1
O H
 
1´-O-
(ALA) 
sugars 
-3.71 
(union
ized) 
superior No No; 1´-O-
(ALA) 
galactose is 
better than 
others in 
selectivity 
54, 57, 
61 
54; R1=H, R2=EG-ALA, R3=OH,
R4=H, R5=OH, R6=H
57; R1=H, R2=EG-ALA, R3=H,
R4=OH , R5=OH, R6=H
61; R1=EG-ALA, R2=H, R3=OH,
R4=H, R5=H, R6=O H
O
R6
R5HO
R4
R2
R3
R1
O H
 
1´-O-
(EG-
ALA) 
sugars 
-3.87 
(union
ized) 
equal No No; 1´-O-
(EG-ALA) 
galactose is 
better than 
others in 
selectivity 
70  
S
NHHN
O
O
NH -ALA
 
 
 
 
Biotin-
ALA 
peptide 
-1.49 No 
generation 
-- ---- 
79 NH -ALA
O
H3N
 
GABA-
ALA 
peptide 
-1.59 No 
generation 
--- --- 
83 
H 3N
O
O H
NH -ALA
 
Tyr-
ALA 
peptide 
-1.5 No 
generation 
--- --- 
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 241 (CH2)3H 3CCH3
HCH3
H
HH
H
O
ALA- O
 
6-
ketochol
estanol -
ALA 
5.98 No 
generation 
--- Solubilty 
problem 
242 
OH3N
O
O
CCl3
Trichlor
o ethyl 
ester of 
ALA 
-0.17 superior To be 
tested 
To be 
tested 
87 
O - ALAALA- O
O -ALA
 
Tri 
(ALA) 
phlorogl
ucinol 
-3.66 equal To be 
tested 
To be 
tested 
90 
ALA- O
O -ALA
ALA - O
 
Tri 
(ALA) 
glycerol 
-4.6 inferior To be 
tested 
To be 
tested 
99,103, 
107, 
114 
N
H
OO
OO
R- HN
R
99 ; A la
103; P he
107; lys
114; A sp(O Me)
 
PBG-
amino 
acid 
peptides 
-1.09 
0.37 
-0.99 
-1.05  
No 
generation 
--- --- 
65          Tocopherol-ALA 
O O -ALA
9.14 -- -- Solubilty 
problem 
75a 
N
NN
N
NH 2
O
OHOH
ALA-O
 
5´-O-(ALA) adenosine 
-3.13 
(union
ized ) 
To be 
tested 
To be 
tested 
To be 
tested 
238 
O
O -ALA
ALA- O
N
NH
O
O
 
3´,5´-O- di (ALA) thymidine 
-3.78 
(union
ized ) 
To be 
tested 
To be 
tested 
To be 
tested 
 
 
Table 7: Summary of ALA and PBG conjugates synthesized and their evaluation 
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7. Perspectives 
 
When ALA conjugates are employed in vitro, it is possible to achieve higher levels of 
PpIX at lower concentrations than that of ALA. In vivo, a higher selectivity for tumoral 
cells is the main future of ALA based PDT. In this direction, ALA conjugates in future 
have to be designed not only in the view of higher PpIX generation but also selective 
affinity towards cancer cells. 
 
Monosaccharide based ALA conjugates (this thesis work) is efficient in transporting 
ALA inside the cells because of the well defined transport mechanism of sugar which 
aids ALA transport. But since these conjugates didn’t show better selectivity than ALA, 
it raises the doubt whether monosaccharide alone can provide necessary tool to identify 
and target cancer cells. In view of this, ALA conjugated to oligosaccharides might be a 
better option as the cell wall of cancer cells are composed of modified glycans which are 
mostly oligosaccharides [165]. 
 
An important determinant of successful ALA-PDT targeting is the localization of the 
ALA in cancer tissue. The molecular delivery systems or carrier molecules which have an 
ability to interact selectively with their targets have to be conjugated with ALA. However 
there are problems associated with the use of large molecules, such as complicated 
syntheses, transport barriers, and potential systemic toxicity etc.  The research strategy of 
using monoclonal antibodies (MAbs) (photoimmunotargeting) or low-density 
lipoproteins (LDLs) to couple with porphyrin based photosensitizers has been  reviewed 
[441, 442]. Tumor targeting with MAbs or LDLs coupled with ALA could be the next 
step to explore the better selectivity towards cancer cells. The unusual glycans expressed 
from the cancer cells contains oligosaccharides. The development made in solid phase 
synthesis of oligosaccharides [158, 159] can help us to synthesize such glycans in 
sufficient quantities. These synthesized glycans might be used for inducing new 
antibodies with high affinity which in turn could be coupled with ALA. 
 
The concept of engineering cell surface has been explored [166]. Based on this, the 
unusual group or moiety in the unusual glycans which are expressed from cancer cells 
can be exploited for chemical reaction with ALA-reactive conjugate. This could provide 
selectivity for cancer cells.   
 
For conjugates where there is a basic problem of internalization into the cells, for 
example PBG, the strategy of coupling with oligoarginine based cell penetrating peptides 
(CPPs) could be tried because it is reported that such conjugation had increased the 
efficacy of chlorin based photosensitizers [443].  
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 A selective and efficient ALA-PDT depends on the ALA conjugate which could generate 
more PpIX (say 10 fold) than that generated by ALA specifically in cancer cells. Besides 
this, efficient source of light is also necessary for a successful ALA-PDT. 
 
 
 
8. Experimental Part- General Methods 
 
8.1. Chromatography 
8.1.1. Thin layer chromatography 
Thin layer chromatography (TLC) was carried out in TLC plates made out of silica gel 60 
F254 (fluorescence indicator). The TLC plates are of 5 to 6 cm length, 2.5 cm width and 
0.2 mm thickness. After the elution in the eluent mentioned, the plates were dried, looked 
under UV (254 nm) lamp, marked and then looked for oxidized spots by spraying over 
aqueous alkaline solution of KMnO4.  
8.1.2. Column chromatography 
Silica gel 60A0, size of 0.04-0.063 mm (230-400 mesh ASTM) (Merck, Darmstadt). 
Eluent proportions are mentioned in the experimental part. The column chromatography 
was performed under pressure. 
8.1.3. Gas chromatography 
 
Agilent 6850 Series gas chromatography. Column used were HP-5 capillary column. 
Long 30 m, interior diameter = 0.32 mm, film thickness = 0.25 µm. nature of polymer: 
polysiloxane (crosslinked 5% Ph, me silixane). Programme: injection at 150°C or  170°C, 
2 min, 10°C/min till 290°C; Helium gas: 1.0 mL/minute; Injection temp: 250°C Detector 
temp (FID):  300°C; ChemStation programme.  
8.2. Infrared Spectroscopy (IR) 
Perkin Elmer Spectrum One version B FT-IR was used for obtaining IR spectra with the 
resolution of 2 cm-1. Software used: Spectrum version 5.0.1. The solid substances and 
thick oil like substances were analyzed by preparing KBr pellet (KBr – Fluka puris p. a). 
Liquid samples were analyzed as film (sandwich) by applying between two KBr salt 
plate. The absorption bands between 4000 and 400 cm-1 were measured. The intensity of 
the spectrum was divided into five equal parts for the abbreviations vs (the maximum 
intensity), s (intense), m (medium intensity), w (weak), br (broad) and vw (very weak).  
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 8.3. Nuclear Magnetic Spectroscopy (NMR) 
 
The NMR spectra were measured using spectrometer Gemini XL-200 of Varian at 298 K 
where   1H was measured at frequency of 200 and 13C was measured at frequency of 
50Hz. Also NMR spectra were measured using spectrometer Bruker Avance- 400 at 298 
K where   1H was measured at frequency of 400 and 13C was measured at frequency of 
100Hz. The NMR solvents were purchased from Cambridge Isotope Laboratories. The 
internal standard for the spectra of 1H: TMS (δ= 0.00 ppm) or CHCl3 (δ= 7.26 ppm) or 
CH3OH (δ= 3.31 ppm) or (CH3)2SO (δ= 2.50 ppm) or D2O (δ= 4.79 ppm). The internal 
standard for the spectra of 13C: TMS (δ= 0.00 ppm) or CHCl3 (δ= 77.16 ppm) or CH3OH 
(δ= 49.00 ppm) or (CH3)2SO (δ= 39.52 ppm). The 13C spectra were measure by 
decoupling from 1H. The chemical shift is given in ppm in the descending order and the 
coupling constant J in Hz. The multiplicity of signals were given abbreviations s 
(singlet), d (doublet), t (triplet), q (quartet), quint (quintet), dt (doublet of triplet), br 
(broad) and m (multiplet). The sign ‘≈’ denotes for the average value of J varying from 
0.2 to 0.4 Hz. The ratio of α to β is measured by area integration in the case of  1H and by 
the intensity (height) of peak in the case of 13C. All the products were measured for 
HETCOR (short range), COSY and DEPT 135 for the accurate interpretation of signals. 
The numbering of carbons for ALA derivatives were defined from the thesis of Y.Berger 
[250] .  
 
8.4. Mass Spectroscopy 
 
The mass spectra measurements for ESI (electro-spray ionization) and for APCI 
(atmospheric pressure chemical ionization) were carried out by an instrument 
ThermoFinnigan LCQ (San Jose, California, USA). Software used: Tune Plus version 
1.2. The values given here are average mass of ion with precision in the range of ±0.1 
values. The nature of ion pattern is written in parenthesis with intensity. The ion peaks 
due to deuterium isotope (probably comes from proton exchange by deuterium as some 
samples were dissolved in deuteriated solvents) were not considered. The mass 
corresponding to the highest abundant isotope is written. The high resolution mass 
spectroscopy (HR-MS) was measured at University of Fribourg (Switzerland) in the 
group of Professor A. Gossauer by Mr.F.Nydegger. The instrument used was Brucker 
BioAPEX II daltonics. The ionization used was ESI (electro-spray ionization). 
 
8.5. Glass apparatus 
 
For reactions where argon or nitrogen atmosphere was used, the glass apparatus were 
dried by keeping in the hot oven at 150°C for at least two hours. The apparatus were 
removed from hot oven and cooled to ambient temperature with argon or nitrogen 
atmosphere. For reactions at low temperature, ice bath with salt (0°C to -5°C) and 
acetone/liquid nitrogen bath (-80°C) were used. For reactions of long maintenance hours 
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 at low temperature (-50°C to 0°C), cryostat was used. For heating reactions, PEG bath 
(160°C) or oil bath (200°C) were used.  
 
8.6. Karl-Fischer titration 
 
For reactions where the moisture content is very critical such as Mukaiyama reaction, 
Mitsunobu reaction etc, the purified solvents, reactants and reagents if possible were 
checked for moisture content using the Karl-Fischer coulometer (Metler Toledo DL 32). 
For the moisture critical reactions, reactants and solvents were dried till the moisture 
content is less than 0.05% and then only reactions were carried out. 
8.7. Hydrogenation 
 
The hydrogenation reactions were carried out at ambient temperature under magnetic 
stirring, with hydrogen filled ‘gas bag’ (Aldrich) whose volume is approximately 1 gallon 
(3.8 L).  
8.8. Solvents 
8.8.1. Standard solvents 
 
For the purpose of chromatography and extractions, technical grade solvents were 
distilled over drying agent. 
  
Solvent                                           Abbreviation used                       Drying agent 
 
Ethyl acetate                                     AcOEt                                           K2CO3 
 
Hexane                                              hexane                                          CaCl2 
 
Dichloromethane                              CH2Cl2                                         CaCl2 
 
Diethyl ether                                     Et2O                                             CaCl2 
 
Methanol                                           MeOH                                          CaO 
 
Chloroform                                       CHCl3                                          CaCl2 
 
8.8.2. Solvents for reactions- with distillation  
 
 
Solvent                                  Abbreviation used                 Drying agent 
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Hexane                                     hexane                                     P2O5 
 
Dichloromethane*                    CH2Cl2                                   P2O5 
                                                                                                      
Diethyl ether **                        Et2O                                        LiAlH4 
 
Tetrahydrofuran                        THF                                        sodium (benzophenone) 
 
Toluene                                     toluene                                    sodium (benzophenone) 
                  
 
* Dichloromethane after distilling over P2O5 was passed through basic alumina to remove 
the acidic traces. 
 
** Only distilled diethyl ether (over LiAlH4)  is used for precipitations and triturations  
8.8.3. Solvents for reactions- without distillation  
 
Solvent                                  Abbreviation used                 Quality 
 
Pyridine                                    pyridine                                 Fluka, puriss., ≥ 99.5% 
                                                                                               (with crown cap) 
  
Dimethyl formamide                DMF                                     Fluka, puriss., ≥ 99.5% 
                                                                                               (with crown cap) 
  
                                                                                                   
Methanol                                  MeOH                                  Acros, p. a. 
 
Dioxane                                    dioxane                                 Fluka, puriss., ≥ 99.5% 
 
Dichloromethane                     CH2Cl2                                  Fluka, puriss., ≥ 99.5% 
 
Toluene                                    toluene                                  Fluka, puriss., ≥ 99.5% 
8.9. Reagents, enzymes and products 
8.9.1. Reagents 
                                            
Reagent    Abbreviation used Quality 
 
   
Acetic acid                                             
 
CH3COOH        Acros, p. a. 
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Acetobromo α-D-galactose  - Fluka, technical ≥ 90% 
   
Acetone oxime                                       -    Fluka, puriss., ≥ 99% 
   
Adenosine                                             -   Acros , ≥ 99% 
   
Alumina neutral                                     -      Fluka 
   
Alumina basic                                        -             Fluka 
   
Ammonium chloride  NH4Cl Fluka, purum 
   
Ammonium formate HCOONH4 Acros  
   
Argon Ar Carbagas, tech. 
   
Barium oxide BaO Fluka, tech. 95% 
   
Benzyl alcohol BnOH Fluka, puris, ≥ 99% 
   
Benzyl bromide                                      BnBr Fluka, purum 
   
Biotin - Fluka 
   
Boc-Alanine Boc-Ala Novobiochem ≥ 95% 
   
Boc-γ-aminobutyric acid Boc-GABA Novobiochem ≥ 95% 
   
   
Boc-Aspartic acid –O-methyl ester Boc-Asp-OMe Novobiochem ≥ 95% 
   
Boc-Aspartic acid –O-tert-butyl ester. 
Dicyclohexyl amine salt 
Boc-Asp-OtBu Novobiochem ≥ 95% 
 
   
Nα-Boc-Nε-Boc) lysine –dicyclohexyl 
amine salt 
Boc-Boc-lys.DCHA Novobiochem ≥ 95% 
   
Boc-Phenyl alnaine Boc-Phe Novobiochem ≥ 98% 
   
   
Bromine  Br2 Acros p.a 
   
tert-butyl diphenyl silyl chloride TBDPSCl Acros, purum 
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 n-butyl lithium BuLi ~1.6M or ~2.5M in 
hexans Acros 
 
Celite 535 .- Fluka (10- 40µm) 
   
Cesium carbonate Cs2CO3 Fluka, puriss., ≥ 99% 
   
Chlorotrimethyl silane TMSCl Fluka, puriss., ≥ 99% 
   
Cholcalciferol (+)-Vitamin D3  Vitamin D3 Fluka, puriss., ≥ 99% 
   
1,8-Diazabicyclo undec-7-ene  DBU Acros 97% + 
   
N, N´-Dicyclohexyl carbodimide DCC Fluka, 99% (GC) 
   
Diethyl azodicarboxylate DEAD Fluka, technical., ≥ 94% 
   
Diisopropyl azodicarboxylate DIAD Fluka, technical., ≥ 94% 
   
4-(N,N´-Dimethyl) amino pyridine DMAP Fluka, puriss., ≥ 99% 
   
1-(3-dimethyl-aminopropyl)-3-   
ethylcarbodiimide hydrochloride 
EDCI Acros, 98+% 
   
di-tert-butyl-dicarbonate Boc2O Fluka, purum≥98% 
   
Dowex 50WX resin 
 
Dowex Acros 
   
Dimethylamino pyridine-p-toluene 
sulfonate 
DPTS Prepared from DMAP 
and TsOH 
   
Esterase (Pig liver esterase) PLE Sigma-Aldrich, from 
porcine liver, 24 units 
per mg of protein 
   
Ethylene glycol EG Fluka, purum≥98% 
   
Formic acid HCOOH Fluka, puriss., ≥ 99% 
   
D-(+)-Galactose  Fluka, Biochemika, ≥ 
99.5% 
   
D-(+)-Glucose  Fluka, Biochemika, ≥ 
99.5% 
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 Glycerol - Fluka, purum≥98% 
   
Hexamethyl disilazane HMDS Fluka, puriss., ≥ 99% 
   
Hydrochloric acid HCl 32% Fluka 
 
 
 
  
Hydrogen  H2 Carbagas, tech. 
   
Iodomethane MeI Fluka, puriss., ≥ 99% 
   
Imidazole - Fluka, puriss., ≥ 99% 
   
Levulinic acid - Acros p.a 
   
Lipase from Candida antarctica Novozyme 435 or 
LCA 
Sigma Aldrich, 10 unites 
per mg protein  
   
Lipase from Porcine pancreatic PPL Fluka, 24 units per mg 
of protein 
   
Lithium aluminium hydride LiAlH4 Fluka, purum 
   
Lithium bis (trimethylsilyl) amide 
solution 
LiHMDS Fluka, 1M in hexane or 
1M in THF 
   
D-(+)-Mannose  Fluka, Biochemika, ≥ 
99.5% 
   
Nitrogen  N2 Carbagas, tech. 
   
Palladium on activated carbon Pd/C Acros 10% unreduced 
   
Palladium over alumina Pd/Al2O3 Acros 5% 
   
Pentafluorphenol PFP-OH Acros 98% 
   
Phenyl boronic acid . Fluka, purum ≥ 97% 
   
Phloroglucinol  Fluka, puriss., ≥ 99% 
   
Potassium carbonate K2CO3 Siegfreid 
   
Potassium permanganate KMnO4 Siegfreid 
Proteinase Bacillus subtilis  Sigma Aldrich, 5 units 
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 per mg of protein 
   
Retinol 
 
 FLUKA, all trans, 
≥97,0%(HPLC) 
   
Silvercarbonate Ag2CO3 Fluka, purum ≥ 99% 
   
Sodium azide NaN3 Fluka, purum≥99,0% 
 
Sodium hydride  
 
NaH Fluka ~60%  suspension 
Sodium hydroxide NaOH Fluka , Puriss, p. a 
   
   
Sodium methoxide  NaOMe Fluka, purum ≥ 99% 
   
Sodium dihydrogen phosphate NaH2PO4. 2H2O Fluka, purum ≥ 99% 
   
Sodium hydrogen phosphate Na2HPO4. 2H2O Fluka, purum ≥ 99% 
   
Sulfuric acid H2SO4 96% Prochimie 
 
   
Tetrabutyl ammonium fluoride TBAF Fluka, purum ~1M in 
THF 
   
Tetrabutyl ammonium iodide TBAI Fluka, puriss≥99% 
 
   
Thionyl chloride SOCl2 Fluka, purum ≥ 98% 
   
Titanium tetrachloride TiCl4 Fluka, purum ≥ 98% and 
then distilled over poly 
vinyl pyridine 
   
Thymidine  Acros 98% 
   
DL-all-rac-(±)-α-tocopherol Vitamin E Fluka, Biochemika, 
≥97%(HPLC) 
   
p-tolune sulfonic acid monohydrate p-TsOH. H2O Fluka, puriss ≥ 98.5% 
   
2,2,2-Trichloro ethanol TCE-OH Fluka, purum ≥ 98% 
   
Trifluoroacetic acid TFA  
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 Trifluoromethane sulfonic acid CF3SO3H Fluka, puriss≥99.5% 
 
   
Trimethyl orthoformate (H3CO)3HC Fluka, puriss≥99% 
 
   
Triphenyl phosphine PPh3 Fluka, puriss≥98.5% 
 
   
   
                    
8.9.2. Preparation of HCl gas, HN3 gas and destruction of 
NaN3. 
 
1. Preparation of HCl gas: 
 
In a two necked dry flask, fitted with a gas outlet, a thermometer and an addition funnel 
was taken 200 ml conc.sulfuric acid (98%). Under stirring, to this was added conc.HCl 
(32%) drop wise. The flask was cooled by cold water bath outside. The HCl gas liberated 
from the gas outlet was connected to the reaction flask where HCl gas is required. 
 
 
2. Preparation of HN3 gas: 
 
In a two necked dry flask, fitted with a gas outlet, a thermometer and an addition funnel 
was taken 5 g (77 mmole) sodium azide. This was dissolved in 5 ml deionised water.  
Under stirring, 30 ml benzene was added. Then, to this reaction mass was added 2.1 ml 
(3.7 g, 38.5 mmol) of conc.sulfuric acid (98%). drop wise. The flask was cooled by cold 
water bath outside. The HN3 gas was dissolved in benzene. From this benzene solution 
containing HN3, a sample was taken, diluted with water and titrated against 0.1 N NaOH 
to determine the concentration of HN3. Later this benzene solution containing HN3 was 
added to the reaction flask where HN3 is required.  
 
3. Destruction of NaN3 
 
All the aqueous phases containing HN3 and NaN3 were stored separately for treating the 
solution and then were discarded. The aqueous solution containing NaN3 comes from the 
extraction of azido products. The excess solution containing HN3 was always mixed with 
2N NaOH and the benzene layer was decanted. 
 
Treatment:  The treatment is performed in a hood. In a three necked flask placed over a 
magnetic stirrer, was fixed an addition funnel and an outlet for gas. In the aqueous 
solution containing NaN3, was added under stirring sodium nitrite solution (7.5 g of 
NaNO2 in 38 ml water for 5 g of NaN3) in a drop wise manner. After the addition, 20% 
H2SO4 was added slowly to obtain acidic pH. The nitrogen oxide gas evolved on the 
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 addition sulfuric acid. The completion of destruction is verified by change in color of 
iodide paper from white to blue (presence of excess nitrite).  
 
Equation 5 
 
               2 NaN3 + 2 HNO2   3 N2 + 2 NO + 2 NaOH 
 
The aqueous solution was discarded after destruction. The nitrous oxide (NO) evolved 
gets oxidized to nitric oxide (NO2) which is dark brown, irritating and toxic.  
 
 
9. Experimental Part- Synthesis 
 
9.1. Synthesis of starting materials 
9.1.1. Synthesis of 5-BOC-amino-4-oxo-penatanoic acid (BOC-
ALA)  
 
The synthesis of 5- BOC-aminolevulinic acid was carried out by two methods. The first 
method used levulinic acid as starting material and the second method used 5-
aminolevulinic acid hydrochloride as starting material. The first method comprises four 
steps of which first two steps were carried out many a times by the previous doctorates 
and students of the group. 
 
9.1.1.1. Synthesis of 5- BOC-amino-4-oxo-pentanoic acid (BOC-ALA) 
from levulinic acid 
9.1.1.1.1. Synthesis of 5-bromo-4-oxo methyl pentanoate (5-bromo methyl 
levulinate) 
OH O
O
O
Br
O
O
Br2
MeOH
[116.12]
C6H9BrOC5H8O3
[209.04]
1 2
 
The assembly set-up consists of a sulfonation flask of 1500 ml capacity, an overhead 
mechanical stirrer, an addition funnel, a condenser and a thermometer. The outlet of the 
condenser is connected to a beaker containing 1N NaOH solution for scrubbing the HBr 
gases which evolved.  
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 A solution of 100 g (861 mmol, 1.0 eq) levulinic acid in 860 ml methanol was charged in 
the sulfonation flask. This solution was cooled to 0 0C and then 44ml (861 mmol, 1.0eq) 
of bromine was added drop wise through addition funnel. The addition of bromine was 
carried out in such a way that the reaction temperature never exceeds 30 0C. The addition 
took approximately 3 hours. At the end of the addition, the solution was dark orange. The 
reaction mass was brought to room temperature and was kept stirring overnight at room 
temperature. The resultant colourless solution was refluxed for 90 minutes. The solution 
was brought to room temperature and then methanol was evaporated off by rotavapor. 
The yellow residue was dissolved in 400 ml dichloromethane and this solution was 
extracted with 400 ml of H2O. The organic phase was further extracted with 200 ml 
saturated solution of NaHCO3 and then with 3 × 200 ml H2O. Then the organic phase was 
dried over MgSO4, filtered by filter paper and then the solvent was evaporated off by 
rotavapor.The yellow residue of 156 g was subjected to fractional distillation by means of 
a Widmer column of 40cm under reduced pressure of 4×10 -2 mbar obtained by high 
vacuum oil pump.The fractions were changed in accordance with vapour temp and totally 
8 fractions were collected keeping the distillation system under vacuum using perkin 
triangle. One of the fractions contained 81 g of 5-Bromo-4-oxo methyl pentanoate, the 
required product with 98% purity by 1H-NMR and with 45% yield. (Best yield obtained 
so far = 57%) 
OBr
O
O
12
3
4
5
11
 
Rf: (Hexane / AcOEt 1: 1): 0.50 
 
Bpt: ~ 80 0C at pressure = 0.045 mbar 
 
nD 20: 1.4820 
 
IR (film) : 3000m, 2953m, 2849w, 1734s, 1722s, 1439s, 1411s, 1359s, 1322m, 1207s, 
1177s, 1079m, 1025m, 988m, 862w, 768vw, 694w, 595vw, 496vw, 464w. 
 
1H-NMR (200 MHz, CDCl3, 298 K): δH (ppm) = 3.95 (s, 2H, H2C(5)); 3.67 (s, 3H, 
H3C(11); 2.95 (t, 3J3-2=6.4, 2H, H2C(3)); 2.64 (t, 3J2-3= 6.4, 2H, H2C(2)). 
 
13C-NMR (50 MHz, CDCl3, 298K) : δC (ppm) = 201.3 (C(4)) ; 173.4 (C(1)) ; 52.6 
(C(11)) ; 35.1 (C(3)) ; 34.7 (C(2)) ; 28.8 (C(5)). 
 
MS (ESI (+)): [M (79Br) + Na]+ =231.1, [M (81Br+Na]+ =233.0 
 
10.1.1.1.2. Synthesis of 5-azido-4-oxo methyl pentanoate (5-azido methyl 
levulinate) 
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 OBr
O
O
ON3
O
O
NaN3
THF/H2O
C6H9BrO3 C6H9N3O3
[209.04] [171.16]
2 3
 
To a solution of 17.68 g (272 mmol, 2eq) of NaN3 in 68ml deionised water at 0 0C and 
under magnetic stirring, was added drop wise by an addition funnel a solution of 28.43 g 
(136mmol, 1eq) of  5-Bromo-4-oxo methyl pentanoate in 70ml of THF. The yellow 
coloured reaction mass was brought to room temperature and then was stirred at that 
temperature for an hour. Later, the two phases were separated. The aqueous phase was 
extracted with 3 × 200ml AcOEt. All the organic phases were combined together and 
then it was washed with 2×200ml H2O. Then the organic phase was dried over MgSO4, 
filtered over filter paper, and the solvent was evaporated off by rotavapor. A yellow oil of 
22.05 g 5-azido-4-oxo methyl pentanoate was obtained with 95% yield. (Best yield 
obtained so far = 98%) 
ON3
O
O
12
3
4
5
11
 
Rf: (Hexane / AcOEt 2: 1): 0.50; 0.33 (UV 254 active, vanillin) 
 
IR (film) : 3445w, 3366w, 3001m, 2956m, 2914m, 2850w, 2543vw, 2202m, 2106vs, 
1732vs, 1619w, 1438s, 1417s, 1361s, 1280s, 1210s,1172s, 1096s, 1028m, 1008m, 988m, 
921m, 885w, 843w, 799vw, 705vw, 607vw, 556m, 489vw. 
 
1H-NMR (200 MHz, CDCl3, 298 K): δH (ppm) = 4.03 (s, 2H, H2C(5)) ; 3.69 (s, 3H, 
H3C(11); 2.76-2.72 (m, AA’ part of a system AA’BB’, 2H, H2C(3)) ; 2.70-2.66 (m, BB’ 
part of a system AA’BB’, 2H, H2C(2)). 
 
13C-NMR (50 MHz, CDCl3, 298K) : δC (ppm) = 202.9 (C(4)) ; 173.0 (C(1)) ; 57.3 (C(5); 
51.9 (C(11)) ; 34.3 (C(3)) ; 27.4 (C(2)). 
 
MS (ESI(+)): m/z relative intensity [M + Na]+ = 194    
9.1.1.1.3. Synthesis of 5-BOC-amino-4-oxo methyl pentanoate (5-BOC-amino 
methyl levulinate) 
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 ON3
O
O
OBocHN
O
O
H2 / Pd
C6H9N3O3 C11H19NO5
[171.16] [245.16]
Boc2O
3 4
 
 
In a hydrogenation autoclave reactor, a solution of 23 g (134.37 mmol, 1eq) of 5-azido-4-
oxo methyl pentanoate in 250ml AcOEt was charged. Then 29.63 g (135.76 mmol, 
1.01eq) of BOC anhydride was charged followed by 5 g (4.7 mmol, 0.035 eq) of 10% 
palladium on activated charcoal. The mass was subjected to hydrogenation in ambient 
temperature with the pressure of 60psi H2 under mechanical agitation. Once the reaction 
was completed, (approximately 24hrs; TLC eluent: CH2Cl2/AcOEt 95:5) the H2 pressure 
was released. The reaction mass was filtered over celite bed to get rid off palladium, the 
celite bed was washed with 3 × 25ml AcOEt. The solvent in the filtrate was evaporated 
off by rotovapor and a yellow oily mass was obtained. This yellow crude mass was 
purified by flash chromatography using gradient eluent system. (from CH2Cl2/AcOEt 
95:5 to CH2Cl2/AcOEt 85:15). The pure fraction of 23.05 g 5-BOC-amino-4-oxo methyl 
pentanoate was thus obtained as yellow oil. (Yield = 70%; best yield so far = 74%) 
 
OHN
O
O
12
3
4
5
11O
O
6
7
8182
83
 
Rf: (CH2Cl2/ AcOEt 9: 1): 0.25-0.30 (UV 254 active, KMnO4) 
 
IR (film) : 3387s, 2979s, 2932s, 1735s, 1719s,1701s, 1697s, 1523s, 1518s, 1508s, 1500s, 
1438s, 1412s, 1392s, 1252s, 1209s,1165s, 1098m, 1060m, 1024m, 983m, 737m. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.24 (sbr, 1H, NH) ; 4.03 (d, 3J5-NH=3.6 
Hz, 2H, H2C(5)) ; 3.64 (s, 3H, H3C(11); 2.71-2.68 (m, 2H, H2C(3)) ; 2..63-2.59 (m, 2H, 
H2C(2)) ; 1.40 (s, 9H, H3C(81,82,83). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.5 (C(4)) ; 173.0 (C(1)) ; 155.7 
(C(6)) ; 79.9 (C(7)) ; 52.0 (C(11)) ; 50.3 (C(5)) ; 34.4 (C(3)) ; 28.4 (C(81,82,83)) ; 27.6 
(C(2)).  
 
MS (APCI (+)): m/z relative intensity (15, [M + Na]+ ) = 269.1 
9.1.1.1.4. Synthesis of 5-BOC-amino-4-oxo pentanoic acid (BOC-ALA) 
 
 152
 OBocHN
O
O
C11H19NO5
[245.16]
OHBocHN
O
O
C10H17NO5
[231.16]
PLE
Tampon phosphate
pH=9
4 5
 
 
In a 1lit Erlenmeyer flask, 500ml 0.1M tampon phosphate buffer solution was charged. 
(Preparation of 0.1 M tampon phosphate, pH=9.0: 1.58 g NaH2PO4 and 5.66 g Na2HPO4 
was dissolved in 1lit of deionised water.) The pH of the buffer is brought to 9 by 5M 
NaOH. Then, 22.85 g (93.2 mmol 1eq) of 5-BOC-amino-4-oxo methyl pentanoate ( ) was 
charged under agitation. Then 300 mg of pig liver esterase (PLE) enzyme (24 units per 
mg of protein; 1unit hydrolyses 1µmol or 0.001mmol of an ester; approximately 7.2 
mmol; 0.077eq) was added under agitation. The pH of the reaction mass was 
continuously maintained at pH 9 using 5N NaOH by means of a Dosimeter connected 
with a pH meter. The reaction was completed approximately after 4 days (TLC eluent: 
CH2Cl2/AcOEt 90:10).The reaction mass was then extracted with 3 × 200ml AcOEt. The 
aqueous phase was acidified till pH 2 with 6N HCl. This was followed by extraction of 
the aqueous phase with 4 × 500ml AcOEt. All the organic phases were combined 
together and it was washed with 500 ml saturated NaCl solution followed by 500 ml 
deionised water. The organic phase was then dried over MgSO4 and the solvent was 
evaporated off by rotavapor. A yellow crude solid product thus obtained was taken for 
trituration with ether at 0 0C. The white pure solid thus obtained was filtered and dried. 
Thus 13.7 g of pure white 5-BOC-amino-4-oxo pentanoic acid was obtained. (Yield= 
63.6%; best yield obtained so far = 85%) 
OHHN
O
O
1
2
3
4
5
O
O
6
7
8182
83
 
Rf: ( AcOEt 100%): 0.47 (KMnO4, tailing) 
 
IR (KBr) : 3379s, 2986mbr, 2919mbr, 2765w, 2692w, 2571w, 1707vs, 1686vs, 1506s, 
1429s, 1407m, 1392m,  1383m, 1371m, 1363m, 1349m, 1295w, 1278m, 1240s, 
1209s,1170s, 1098w, 1065m, 1039vw, 1015m, 943m, 894m, 872m, 843vw, 803w, 787w, 
759w, 741w, 653w, 575m. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 11.30 (s, 1H, COOH); 5.35 (sbr, 1H, 
NH) ; 4.03 (d, 3J5-NH= 4.8 Hz, 2H, H2C(5)) ;  2.69-2.62 (m, 4H, H2C(2 and 3)) ; 1.40 (s, 
9H, H3C(81,82,83). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.5 (C(4)) ; 177.4 (C(1)) ; 156.0 
(C(6)) ; 80.2 (C(7)) ; 50.3 (C(5)) ; 34.2 (C(3)) ; 28.4 (C(81,82,83)) ; 27.7 (C(2)).  
 
MS (APCI (-)): m/z relative intensity (95, [M - H]- = 230.1 
 
 153
 9.1.1.2. Synthesis of 5- BOC-amino-4-oxo-pentanoic acid (BOC-ALA) 
from 5-aminolevulinic acid hydrochloride (ALA-HCl) 
OHH3N
O
O
C5H10NO3Cl
[167.60]
OHBocHN
O
O
C10H17NO5
[231.16]
Cl Boc2O
pH= 8 ; dioxane
6 5
 
 In a 1lit Erlenmeyer flask, 11g (65.63 mmol, 1.0eq) was charged and it was dissolved in 
170 ml deionised water. The pH of the solution was adjusted to 8 by 1N NaOH. Then 30 
g (137.07 mmol, 2.0eq) of BOC anhydride dissolved in 100ml 1, 4-dioxane was added. 
The pH of the reaction mass was continuously maintained at pH 8 using 1N NaOH by 
means of a Dosimeter connected with a pH meter. After 18hrs, the reaction was 
completed. The reaction mass was extracted with 3 × 400ml ether to remove excess BOC 
anhydride. The aqueous phase was acidified till pH 2 by 10% HCl and then was extracted 
with 5 × 300ml AcOEt. All the organic phases were combined together, dried over 
MgSO4 and solvent evaporated off by rotavapor. The remaining pale yellow solid was 
washed with cold ether and filtered. Thus 7.84 g of pure 5- BOC-amino-4-oxo-pentanoic 
acid was obtained. (Yield = 52%) 
OHHN
O
O
1
2
3
4
5
O
O
6
7
8182
83
 
Rf: ( AcOEt 100%): 0.47 (KMnO4, tailing) 
 
IR (KBr) : 3379s, 2986mbr, 2919mbr, 2765w, 2692w, 2571w, 1707vs, 1686vs, 1506s, 
1429s, 1407m, 1392m,  1383m, 1371m, 1363m, 1349m, 1295w, 1278m, 1240s, 
1209s,1170s, 1098w, 1065m, 1039vw, 1015m, 943m, 894m, 872m, 843vw, 803w, 787w, 
759w, 741w, 653w, 575m. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 11.30 (s, 1H, COOH); 5.35 (sbr, 1H, 
NH) ; 4.03 (d, 3J5-NH= 4.8 Hz, 2H, H2C(5)) ;  2.69-2.62 (m, 4H, H2C(2 and 3)) ; 1.40 (s, 
9H, H3C(81,82,83). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.5 (C(4)) ; 177.4 (C(1)) ; 156.0 
(C(6)) ; 80.2 (C(7)) ; 50.3 (C(5)) ; 34.2 (C(3)) ; 28.4 (C(81,82,83)) ; 27.7 (C(2)).  
 
MS (APCI (-)): m/z relative intensity (95, [M - H]- = 230.1 
9.1.2. Synthesis of pentafluorophenyl ester of 5- BOC-amino-4-
oxo-pentanoic acid (BOC-ALA-PFP ester) 
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 OHBocHN
O
O
C10H17NO5
[231.16]
C16H16NO5F5
[397.23]
OH
F
F
F
F
F
DCC
OBocHN
O
O F
F
F
F
F
5 7
 
In a dry flask under argon atmosphere, 3g (12.97 mmol, 1eq) of BOC-ALA was charged. 
This was dissolved in 50 ml CH2Cl2 and the mass was cooled to 0 0C. Then 2.7g (14.27 
mmol, 1.1eq) of pentafluorophenol was added followed by 3g (14.54 mmol, 1.12eq) of 
DCC. The reaction was brought to room temperature and was kept at room temperature 
overnight. The reaction mass was then filtered over celite bed to get rid off DCU and the 
solvent was evaporated off by rotovapor. The thick yellow oily mass obtained was 
triturated with hexane to remove excess pentafluorphenol and the white solid obtained 
was filtered off. The white solid was dried which yielded 5.1g of BOC-ALA-PFP ester. 
(Yield= 98%) 
HN
O
O
12
34
O
O
O
F
F
F
F
F
11 12
13
14
5
68a
8b
8c
7
 
Rf: (CH2Cl2/ AcOEt 95: 5): 0.33 (UV 254 active; KMnO4) 
 
IR (KBr) : 3009w, 2982w, 2948w, 2920w, 2669vw, 2458vw, 1798m,1725s, 1694vs, 
1656w, 1626w, 1527vs, 1518vs, 1468w, 1446w, 1426w, 1401w, 1392w, 1370m, 1359w, 
1328w,  1271s, 1253m, 1235w, 1170m, 1146m, 1111s, 1042m, 1031m, 1007s, 989s, 
977m, 895w, 864w, 828vw, 781vw, 751vw, 713vw, 666vw, 609w, 556w, 465vw. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.25 (sbr, 1H, NH) ; 4.06 (d, 3J5-NH= 4.9 
Hz, 2H, H2C(5)) ;  2.99 (t, 3J2-3 = 6.5Hz, 2H, H2C(3)) ; 2.87 (t, 3J3-2 = 6.5Hz, 2H, H2C(2)); 
1.43 (s, 9H, H3C(8a,8b,8c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 203.6 (C(4)) ; 168.8 (C(1)) ; 155.8 
(C(6)) ; 142.4 (d × m, 1JC-F= 248Hz, C(12) or C(13) or C(14)); 139.9 (d × m, 1JC-F= 244Hz, 
C(12) or C(13) or C(14)); 137.5 (d × m, 1JC-F= 240Hz, C(12) or C(13) or C(14)); 125.0 
(C11); 80.2 (C(7)) ; 50.3 (C(5)) ; 34.2 (C(3)) ; 28.4 (C(81,82,83)) ; 27.0 (C(2)).  
 
19F-NMR (188 MHz, CDCl3, 298K) : δF (ppm) = -152.9 (m, 2F, (F- C(12) and (F- C(12´)); 
-158.2 (t, 3JF-F ≈ 21.0Hz, 1F, (F- C(14));  -162.6 (m, 2F, (F- C(13) and (F- C(13´)). 
 
MS (APCI (-)): m/z relative intensity (95, [M - H]- = 230.1 
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 9.1.3. Synthesis of 2, 2, 2-trichloroethyl ester of 5- BOC-amino-
4-oxo-pentanoic acid (BOC-ALA-TCE ester) 
OHBocHN
O
O
C10H17NO5
[231.16]
C12H18Cl3NO5
[362.63]
E DCI
OBocHN
O
O
DMAP
CCl3HO CCl3+
C2H3OCl3
[149.4]
5 8 9
 
 
In a dry flask under argon atmosphere, 1.267g (8.48 mmol, 2eq) of 2, 2, 2-
trichloroethanol was charged and then 80ml CH2Cl2 was added. The mass was cooled to 
0 0C, then 0.528 g (4.32 mmol, 1eq) of DMAP was added followed by 0.912 g (4.75 
mmol, 1.1eq) of EDCI. Finally, 1g (4.32 mmol, 1eq) of BOC-ALA was charged. The 
reaction was brought to room temperature and was kept at room temperature overnight. 
The solvent was evaporated off by rotovapor. The crude mass was dissolved in 100ml 
AcOEt and extracted with 200ml H2O.The organic phase is washed with 170 ml cold 1N 
citric acid solution, followed by 200ml saturated NaHCO3 solution and finally by 200ml 
saturated NaCl solution. The organic phase is dried over MgSO4 and the solvent was 
evaporated off by rotavapor. The remaining mass was purified by trituration with hexane 
to remove excess alcohol and the white solid obtained was filtered off. The white solid 
was dried which yielded 1.33g of BOC-ALA-TCE ester. (Yield= 85%) 
HN
O
O
12
345
O
O
6
7
81
82
83 CCl3O 1
1
12
 
Rf: (Hexane / AcOEt   7: 3): 0.17 (UV 254 active; KMnO4) 
 
IR (KBr) : 3361s, 3000w, 2981w, 2932w, 1759vs, 1721vs, 1688vs, 1528vs, 1477w, 
1452w, 1408m, 1387m,  1369s, 1357m, 1333w, 1283vs, 1252m,  1195m, 1175s, 1156vs, 
1134vs, 1084w, 1070w, 1043m, 1029w, 1006vw, 968w, 904w, 867vw, 831m, 797m, 
768vw, 753vw, 716s, 681w, 654w, 584vw, 571w, 487vw, 465vw. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.24 (sbr, 1H, NH) ; 4.70 (s, 2H, H2C 
(11)) ; 4.04 (d, 3J5-NH= 5.0 Hz, 2H, H2C(5)) ;  2.77 (s, 4H, H2C(2 and 3)) ; 1.41 (s, 9H, 
H3C(81,82,83). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.0 (C(4)) ; 170.9 (C(1)) ; 155.7 
(C(6)) ; 94.8 (C(12)) ; 80.0 (C(7)) ; 74.2 (C(11)) ; 50.3 (C(5)) ; 34.2 (C(3)) ; 28.4 
(C(81,82,83)) ; 27.5 (C(2)).  
 
MS (APCI (+)): m/z relative intensity (95% intensity) [M + H]+ = 363.9 ; (90% intensity) 
[M + H]+ = 362.0 ; (32% intensity) [M + H]+ = 365.9 
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 9.1.4. Synthesis of 5-azido-4-oxo pentanoic acid (5-
azidolevulinic acid) 
ON3
O
O
C6H9N3O3
[171.16]
OHN3
O
O
C5H7N3O3
[157.13]
PLE
Tampon phosphate
pH=9
3 10
 
In a 1lit Erlenmeyer flask, 500ml 0.1M tampon phosphate buffer solution was charged. 
(Preparation of 0.1 M tampon phosphate, pH=9.0: 1.58 g NaH2PO4 and 5.66 g Na2HPO4 
was dissolved in 1lit of deionised water.) The pH of the buffer is brought to 9 by 5M 
NaOH. Then, 22.05 g (128.8 mmol 1eq) of 5-azido-4-oxo methyl pentanoate ( ) was 
charged under agitation. Then 300 mg of pig liver esterase (PLE) enzyme (24 units per 
mg of protein; 1unit hydrolyses 1µmol or 0.001mmol of an ester; approximately 7.2 
mmol; 0.077eq) was added under agitation. The pH of the reaction mass was 
continuously maintained at pH 9 using 5N NaOH by means of a Dosimeter connected 
with a pH meter. The reaction was completed approximately after 4 days (TLC eluent: 
Hexane / AcOEt   1:1).The reaction mass was then extracted with 3 × 200ml AcOEt. The 
aqueous phase was acidified till pH 2 with 6N HCl. This was followed by extraction of 
the aqueous phase with 4 × 500ml AcOEt. All the organic phases were combined 
together and it was washed with 500 ml saturated NaCl solution followed by 500 ml 
deionised water. The organic phase was then dried over MgSO4 and the solvent was 
evaporated off by rotavapor. A yellow crude solid product thus obtained was taken for 
trituration with ether at 0 0C. The pale brown pure solid thus obtained was filtered and 
dried. Thus 17.61 g of pure white 5-azido-4-oxo pentanoic acid was obtained. (Yield= 
87%). 
OHN3
O
O
12
345
 
   Rf: (AcOEt 100%): 0.35;  (CH2Cl2 / MeOH 4:1) : 0.91  (UV 254 active, KMnO4) 
 
IR (KBr) : 3035m, 2914s, 2685m, 2557m, 2221m, 2110vs, 1720vs, 1411s, 1399s, 1374s, 
1344m, 1288s, 1262s, 1235s, 1224s, 1173m, 1088s, 1046m, 1005w, 927s, 887m, 828w, 
689w, 648w, 633m, 557m, 526w. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 9.48 (s, 1H, COOH); 4.02 (s, 2H, 
H2C(5)) ;  2.77-2.69 (m, 4H, H2C(2 and 3)) . 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 203.0 (C(4)) ; 178.4 (C(1)) ; 57.6 
(C(5)) ; 34.3 (C(3)) ; 27.7 (C(2)).  
 
MS (APCI (+)): m/z relative intensity (60, [M - H]- = 156.8 
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 9.1.5. Synthesis of oxime ester of 5- BOC-amino-4-oxo-
pentanoic acid (BOC-ALA-oxime ester) 
 
OHBocHN
O
O
C10H17NO5
[231.16]
C13H22N2O5
[286.32]
EDCI
DMAP
+
C3H7NO
[73.09]
N
HO BocHN
O
O
N
O
5 111 2
 
 
In a dry flask under argon atmosphere, 2.03g (8.80 mmol, 1eq) BOC-ALA of was 
charged and then 85ml CH2Cl2 was added. The mass was cooled to 0 0C, then 1.18 g 
(9.68mmol, 1.1eq) of DMAP was added followed by 2.05 g (10.69 mmol, 1.2eq) of 
EDCI. Finally, 0.643 (8.8 mmol, 1eq) of acetone oxime was charged. The reaction was 
brought to room temperature and was kept at room temperature overnight. The solvent 
was evaporated off by rotovapor. The remaining residue was purified by flash 
chromatography (100% ether) and the pure fraction yielded 2.13 g of BOC-ALA-oxime 
ester. (Yield= 84.5%) 
N
HN
O
O
12
345
O
O
67
81
82
83 O
11
12a
12b
 
Batch : VW32, RV 278 
 
Rf: (100% ether): 0.19 (UV 254 active; KMnO4) 
 
IR (KBr):3353vs, 3005m, 2978s, 2922m, 1771vs, 1705vs, 1651m, 1519vs, 1457m, 
1440m, 1411s, 1397s, 1367vs, 1287vs, 1251s, 1164vs, 1127vs, 1070s, 1054m, 1944m, 
1027m, 935m, 952w, 935w, 885vs, 838vw, 804vw, 784m, 771w, 747w, 721vw, 588m, 
577w,   548w, 464w. 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.24 (sbr, 1H, NH); 4.03 (d, 3J5-NH= 5.0 
Hz, 2H, H2C(5)) ;  2.76-2.69 (m, 4H, H2C(2 and 3)); 1.99 (s, 3H, H3C(12a) or H3C(12b)); 
1.96 (s, 3H, H3C(12a) or H3C(12b));  1.45 (s, 9H, H3C(81,82,83). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.4 (C(4)); 170.4 (C(1)); 164.2 
(C(11)); 155.7 (C(6)); 80.0 (C(7)); 50.3 (C(5)); 34.2 (C(3)); 28.4 (C(81), C(82), C(83));  
26.6 (C(2)); 21.9, 17.0 (C(12a), C(12b)).  
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 9.2. Synthesis of sugar-ALA derivatives 
9.2.1. Synthesis of 6´-O-(ALA) -α/β-D-sugars 
9.2.1.1. Synthesis of 6´- O-(ALA) -α/β-D-glucose 
 
The synthesis of 6´-O- (ALA) glucose was carried out by two different methods; one by 
the imidazole catalyzed esterification of glucose and another by the enzymatic 
transestrification.Also the synthesis of 6´-O- (ALA) glucose was attempted via two 
different protection & deprotection strategies: one via benzyl protective group and the 
other via boronate protective group. 
9.2.1.1.1. Synthesis of 6´- O-(ALA) -α/β-D-glucose catalyzed by Imidazole: 
9.2.1.1.1.1. Synthesis of 6´- O-(BOC-ALA) glucose 
OHO
HO
OH
OH
OH
Imidazole
C16H16NO5F5
[397.23]
OBocHN
O
O F
F
F
F
F
NHBoc
O
O
OHO
HO
OH
O
OH
C6H12O6
[180.16]
C16H27NO10
[393.39]
13 7 14
 
1081 mg (6 mmol,3 eq) of glucose was taken in a dry flask under argon atmosphere and 
was dissolved in 40 ml anhydrous pyridine. The solution was cooled to 0 0C and 795 mg 
(2 mmol,1 eq) of Boc-ALA-PFP ester was added to the solution, followed by the addition 
of  14mg (0.205 mmol, 0.1 eq) of imidazole. The reaction was brought to room 
temperature. After keeping the reaction for approximately 12hrs at room temperature, the 
starting material Boc-ALA-PFP ester was consumed totally. (controlled by 19F NMR). 
The solvent pyridine was evaporated off by rotovapor and the residue was taken for flash 
chromatography.(gradient eluent from 100% CH2Cl2 to 80:20 CH2Cl2 : MeOH). The pure 
fraction of 550 mg was obtained thus as white solid. (Yield = 69%).                                                         
 
NH
O
O
O
HO
HO
OH
O
OH
O
O
1 2
3 4
5 6
7
8a
1´
2´3´
4´ 5´
6´
8b
8c
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 Batch: RV84; RV 80 
 
Rf: (CH2Cl2 / MeOH 8:2): 0.37; (KMnO4) 
 
IR (KBr) : 3407vs, 2978m, 2928m, 1726vs, 1518s, 1453w, 1392w, 1368s, 1285m, 1253m,  
1167vs, 1055s, 902w, 869w, 776w, 560w. 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 5.08 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α) ); 
4.51 (d, 3J1´-2´ =7.8Hz, 1H, HC(1´β) );4.40 (dd, 3J5´-6´a =2.1Hz, 3J6´a - 6´b =11.8Hz ,1H, 
HC(6´a α or β)) ;4.35 (dd, 3J5´-6´a =2.1Hz, 3J6´a - 6´b =11.8Hz ,1H, HC(6´a α or β)); 4.21 
(dd, 3J5´-6´b =5.5Hz, 3J6´a - 6´b =11.8Hz ,1H, HC(6´b α or β) ); 4.18 (dd, 3J5´-6´b ≈5.5Hz, 3J6´a - 
6´b =11.8Hz ,1H, HC(6´b α or β) ); 3.98-3.89 (m, 3H, H2C(5) and HC (5´α));3.68 (t, 3J3´-
4´≈9.3Hz, 3J3´-2´ ≈9.3Hz,1H, HC(3´α)) ; 3.52-3.47 (m, 1H, HC (5´β)); 3.41-3.28 (m, 4H, 
HC(2´α),HC (3´β),HC(4´α) and HC (4´β)); 3.16 (dd, 3J2´-1´ = 7.8Hz, 3J2´ - 3´ ≈ 9.0Hz ,1H, 
HC(2´β)) ; 2.81-2.63 (m, 4H, H2C(2 and 3)); 1.46 (s, 9H, H3C(8a, 8b and 8c) and all other 
peaks due to minor regioisomers. 
 
α/β ratio by 1H-NMR ≈ 1: 1 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) = 207.4 (C(4)) ; 174.1 (C(1α or β)) ; 
174.0 (C(1α or β)); 158.2 (C(6)) ; 98.0 (C(1´β)); 93.7 (C(1´α)); 80.5 (C(7)); 76.0 
(C(2´β)); 75.0 (C(5´β)); 74.5(C(3´α)); 77.6, 73.5, 71.6, 71.4 (C(2´α),C( 3´β), C(4´α) and 
C(4´β)) ; 70.4 (C(5´α)); 65.0, 64.9 (C(6´α) and C(6´β)); 50.6 (C(5)); 34.8 (C(3)) ;28.6 
(C(8a,8b and8c); 28.5 (C(2)) and all other peaks due to minor regioisomers. 
 
α/β ratio by 13C-NMR ≈ 1 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 653.5 
 
HR-MS [M+ Na] + = 416.1528 (calculated = 416.1533) 
9.2.1.1.1.1.2. Synthesis of 6´- O-(ALA) α/β-D-glucose       
NH3
O
O
O
HO
HO
OH
O
OH
C13H20F3NO10
[407.29]
NHBoc
O
O
O
HO
HO
OH
O
OH
C16H27NO10
[393.39]
CF3COOH
CF3COO
M+=294.28 ; CF3COO = 113.01
14 15
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 420 mg (1.067 mmol, 1eq) of 6´-O-(BOC-ALA) glucose was taken and cooled to -100C. 
To this, 12.16 g (8ml, 106.7 mmol, 100 eq) of trifluoroacetic acid was added dropwise by 
syringe. The reaction mass was allowed to come to ambient temperature and maintained 
at ambient temperature for an hour. Once the BOC group is absent (controlled by 1H-
NMR), trifluoroacetic acid was evaporated off. The product dried under high vacuum oil 
pump yielded 425 mg highly hygroscopic white solid. (Yield=98%). 
NH3
O
O
O
HO
HO OH
O
OH
1 2
3 4
5
1´
2´3´
4´ 5´
6´
CF3COO
 
Batch: RV 72 RV 75 RV 77 
 
IR (KBr) : 3373vs, 2926m, 1786m, 1730vs, 1677vs, 1512w, 1429m, 1390m, 1317w, 
1204vs, 1137vs, 1080m, 1054m, 913w, 839m, 800m, 772w, 723m, 632w, 597w, 559w, 
519w, 500w. 
 
1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) 8.09 (s, 3H, NH3); 4.90 (d, 3J1´-2´ 
=3.6Hz, 1H, HC(1´α) ); 4.30 (d, 3J1´-2´ =7.7Hz, 1H, HC(1´β) );4.28-4.23 (m, 2H, HC(6´a α 
and β)) ; 4.03-3.99 (m,5H,  HC (6´bα and β) and H2C(5)); 3.79- 3.75 (m, 1H, HC(5´α ); 
3.42 (t, 3J3´-4´= 9.2Hz, 3J3´-2´ =9.2Hz,1H, HC(3´α)); 3.32 (m,1H, HC (5´β)); 3.54 (dd, 3J1´-2´ 
=3.6 Hz, 3J3´-2´ =9.5Hz,1H, HC(2´α)) ;3.46 (t, J3´-4´ ≈ 9.0Hz, 3J3´-2´ ≈9.0Hz, 1H, HC(3´β)); 
3.05-3.00 (m, 2H HC(4´α) and HC (4´β)); 2.90 (dd, 3J2´-1´ ≈ 7.8Hz,  3J2´ - 3´ ≈ 9.0 Hz ,1H, 
HC(2´β)) ; 2.79-2.75 (m, 2H, H2C(3)); 2.60-2.54 (m,2H, H2C(2)); 1.51(Boc protected) 
and all other peaks due to minor regioisomers. 
 
α/β ratio by 1H-NMR ≈ 0.4: 1 
 
13C-NMR (100 MHz, DMSO-d6,, 298K) : δC (ppm) 202.9 (C(4)); 172.2 (C(1)); 158.5 
(q,2JC-F ≈ 36.0 (CF3COO¯ ); 115.7 (q,1JC-F = 291.5, CF3COO¯ ); 96.9 (C(1´β)); 92.3 
(C(1´α)); 76.4 (C(2´α) or C(3´β)); 74.7 (C(2´β)); 73.5 (C(5´β)); 72.9(C(3´α)); 72.2 
(C(2´α) or C(3´β)); 70.6, 70.2 (C(4´α) and C(4´β)) ; 69.2 (C(5´α)); 64.6, 64.5 (C(6´α and 
6´β)); 46.8 (C(5)); 34.2(C(3)); 27.5 (C(2)); 27.2 (Boc protected) and all other peaks due 
to minor regioisomers. 
 
α/β ratio by 13C-NMR ≈ 0.66 : 1 
 
MS (APCI (+)): m/z relative intensity [M+ Na] + = 416.1 
 
HR-MS [M- CF3COO¯] + = 294.1184 (calculated = 294.1189) 
9.2.1.1.2. Synthesis of 6´-O- (ALA) α/β-D- glucose catalyzed by enzyme 
9.2.1.1.2.1. Synthesis of 6´-O-(BOC-ALA) α/β-D-glucose 
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 OHO
HO OH
OH
OH
Subtilisin
Proteinas
e
C16H16NO5F5
[397.23]
OBocHN
O
O F
F
F
F
F
NHBoc
O
O
OHO
HO OH
O
OH
C6H12O6
[180.16]
C16H27NO10
[393.39]
13 7 14
 
360.4 mg (2 mmol, 1eq) of glucose was taken in a dry flask under argon atmosphere and 
was dissolved in 10 ml anhydrous pyridine. 1000 mg (5 units per mg of protein; 1unit 
hydrolyses 1µmol or 0.001mmol of an ester; approximately, 5 mmol, 2.5eq) of subtilisin 
proteinase enzyme (before use dried by keeping at vacuum 10-2 mbar for 3-4 days) was 
added and then 2400 mg (6mmol, 3eq) of Boc-ALA-PFP ester was added to the solution. 
The reaction was heated to 500C and maintained at this temperature for 24 hrs (controlled 
by TLC eluent : AcOEt: MeOH 1:1). The mass was cooled to rt and then the enzyme was 
filtered over celite bed, the filtered cake was washed with 3× 10ml pyridine. The solvent 
pyridine was evaporated off by rotovapor and the residue was taken for flash 
chromatography. (gradient eluent from 100% CH2Cl2 to 85:15 CH2Cl2 : MeOH). The 
main fractions were concentrated and the mass was further purified by dissolving the 
mass in 5ml CH2Cl2 and precipitated by 5ml hexane. 375 mg of pure product was 
obtained as white solid. (Yield = 47.66%). 
NH
O
O
O
HO
HO
OH
O
OH
O
O
1 2
3 4
5 6
7
8a
1´
2´3´
4´ 5´
6´
8b
8c
 
Batch : RV 313 mix 
 
Rf: (CH2Cl2 / MeOH 85:15): 0.28; (KMnO4) 
 
IR (KBr) : 3411vs, 2979m, 2930m,2509w, 1724vs, 1519s, 1424w, 1393m, 1368s, 1282m, 
1254m,  1167vs, 1056s, 913w, 869w, 778w,734w,640w, 560w. 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 5.10 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α) ); 
4.48 (d, 3J1´-2´ =7.8Hz, 1H, HC(1´β) );4.38 (dd, 3J5´-6´a ≈ 2.1Hz, 3J6´a - 6´b =11.8Hz ,1H, 
HC(6´a β)) ;4.32 (dd, 3J5´-6´a ≈ 2.1Hz, 3J6´a - 6´b =11.8Hz ,1H, HC(6´a α )); 4.21 (dd, 3J5´-6´b 
≈ 5.5Hz, 3J6´a - 6´b ≈ 11.9Hz ,1H, HC(6´b α ) ); 4.16 (dd, 3J5´-6´b ≈ 5.5Hz, 3J6´a - 6´b ≈11.8Hz 
,1H, HC(6´b β) ); 3.97-3.93 (m, 3H, H2C(5) and HC (5´α));3.67 (t, 3J3´-4´≈9.3Hz, 3J3´-2´ 
=9.3Hz,1H, HC(3´α)); 3.46 (ddd, 3J5´-6´a ≈ 2.1Hz, 3J5´-6´b ≈ 5.5Hz, 3J5´-4´ = 9.5Hz,1H, HC 
(5´β)); 3.40-3.25 (m, 4H, HC(2´α),HC (3´β),HC(4´α) and HC (4´β)); 3.16 (dd, 3J2´-1´ = 
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 7.8Hz, 3J2´ - 3´ ≈ 9.3Hz ,1H, HC(2´β)) ; 2.75 (t, 3J3-2 ≈6.4Hz, 2H, H2C(3)); 2.64 (t, 3J2-3 
≈6.4Hz, 2H, H2C(2)); 1.43 (s, 9H, H3C (8a, 8b and 8c)). 
 
α/β ratio by 1H-NMR ≈ 1.25 : 1 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) = 207.0 (C(4)) ; 173.9 (C(1α or β)) ; 
173.8 (C(1α or β)); 157.9 (C(6)) ; 97.7 (C(1´β)); 93.5 (C(1´α)); 80.5 (C(7)); 75.7 
(C(2´β)); 74.8 (C(5´β)); 74.4(C(3´α)); 77.4, 73.2, 71.4, 71.2 (C(2´α),C( 3´β), C(4´α) and 
C(4´β)) ; 70.2 (C(5´α)); 64.9  (C(6´α)), 64.8 (C(6´β)); 50.6 (C(5)); 34.7 (C(3)) ;28.6 
(C(8a,8b and8c); 28.4 (C(2)). ; α/β ratio by 13C-NMR ≈ 1.24 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.1; [M+ H] + = 393.9 
 
HR-MS [M+ Na] + = 416.1524 (calculated = 416.1533) 
9.2.1.1.2.2. Synthesis of 6´- O-(ALA) α/β-D-glucose 
NH3
O
O
O
HO
HO
OH
O
OH
C13H20F3NO10
[407.29]
NHBoc
O
O
O
HO
HO
OH
O
OH
C16H27NO10
[393.39]
CF3COOH
CF3COO
CH2Cl2
M+=294.28 ; CF3COO = 113.01
14 15
 
 
480 mg (1.22 mmol, 1eq) of 6´-O-(BOC-ALA) glucose was dissolved in 8ml CH2Cl2 and 
cooled to -100C. To this solution, 7g (4.7ml, 61 mmol, 50 eq) of trifluoroacetic acid was 
added dropwise by syringe. The reaction mass was allowed to come to ambient 
temperature and maintained at ambient temperature for an hour. Once the deprotection of 
BOC was completed (controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and 
trifluoroacetic acid was evaporated off. The product was triturated with dry ether and 
ether solution was decanted. The trituration with ether and decanting top clear ether 
solution after centrifuge was repeated 2 times more. Then, the settled solid product was 
dried under high vacuum oil pump and thereby yielded 457 mg of highly hygroscopic 
white solid. (Yield=92%). 
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2´3´
4´ 5´
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CF3COO
 
Batch : RV 320 
 
[α]D = +24.2 (c=0.49; deionized H2O) 
 
IR (KBr): 3388vs, 2923m, 1730vs, 1679vs, 1512w, 1429m, 1390m, 1317w, 1204vs, 
1137vs, 1081m, 1056m, 913w, 839m, 800m, 772w, 723m, 632w, 597w.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.21 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α) ); 
4.65 (d, 3J1´-2´ =7.9Hz, 1H, HC(1´β) );4.41 (dd, 3J5´-6´a = 2.2 Hz, 3J6´a - 6´b =12.2Hz ,1H, 
HC(6´a α or β)) ;4.37 (dd, 3J5´-6´a ≈ 2.2Hz, 3J6´a - 6´b ≈12.2Hz ,1H, HC(6´a α or β )); 4.34 - 
4.25 (m, 3J5´-6´b ≈ 5.3Hz, 3J6´a - 6´b ≈ 12.2Hz ,2H, HC(6´b α and 6´b β) ); 4.13 (s, 2H, 
H2C(5)); 4.03-3.99 (m,1H,  HC (5´α)); 3.71 (t, 3J3´-4´= 9.4Hz, 3J3´-2´ =9.4Hz,1H, HC(3´α)); 
3.65 (ddd, 3J5´-6´a ≈ 2.2Hz, 3J5´-6´b ≈ 5.3Hz, 3J5´-4´ = 9.5Hz,1H, HC (5´β)); 3.54 (dd, 3J1´-2´ 
=3.7Hz, 3J3´-2´ =9.4Hz,1H, HC(2´α)) ;3.46 (m, J3´-4´ ≈ 9.4Hz, 3J3´-2´ ≈9.4Hz, J5´-4´ ≈ 9.4Hz, 
3H, HC(3´β), HC(4´α) and HC (4´β)); 3.16 (dd, 3J2´-1´ ≈ 7.8Hz,  3J2´ - 3´ ≈ 9.4 Hz ,1H, 
HC(2´β)) ; 2.75 (t, 3J3-2 =6.0Hz, 2H, H2C(3)); 2.64 (t, 3J2-3 ≈6.4, 2H, H2C(2)). 
 
α/β ratio by 1H-NMR ≈ 0.71 : 1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.0 (C(4α and β)) ; 174.6 (C(1α or β)) ; 
174.5 (C(1α or β)); 116.7 (q,1JC-F = 292.2, CF3COO¯ ); 96.1 (C(1´β)); 92.3 (C(1´α)); 74.1 
(C(2´β)); 73.5 (C(5´β)); 72.7(C(3´α)); 75.6, 71.5, 69.7, 69.6 (C(2´α),C( 3´β), C(4´α) and 
C(4´β)) ; 69.3 (C(5´α)); 63.8(C(6´α and 6´β)); 47.2 (C(5)); 34.3(C(3)); 27.5 (C(2)).  
 
α/β ratio by 13C-NMR ≈ 0.76 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 293.9;  
 
HR-MS [M- CF3COO¯] + = 294.1181 (calculated = 294.1189) 
9.2.1.1.3. Synthesis of 6´-O- (ALA) α/β-D- glucose by protection & 
deprotection method (using benzyl protective group): 
9.2.1.1.3.1. Synthesis of Benzyl- α/β-D-glucose 
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[180.16]
C13H18O6
[270.28]
Dry HCl gas
OH
C7H8O
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O
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HO
OH
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13 16 17
 
 
A solution of 73.08 g (70 ml, 674 mmol, 12.15eq) dry benzyl alcohol containing 2% of 
HCl ( dry HCl gas was generated and passed through benzyl alcohol) was heated to 
1000C and treated portionwise with 10 g (55.49 mmol, 1eq) of dry D-glucose and the 
mixture was maintained at that temparetaure for 3hrs. The solution was neutralized by 
adding solid 5 g Na2CO3, filtered over celite bed and evaporated to dryness at 800C and 
0.01 mbar. The residue was purified by flash chromatography (silica gel- 70 times of the 
residue mass; CH2Cl2 : MeOH 90:10) to afford 8.68 g benzyl α/β-D-glucose. (Yield= 
57.9%). 
O
HO
HO
OH
OH
O
1
23
4 5
6
11
12
13
14
15
 
Batch: RV128, RV302 
 
Rf: (CH2Cl2 / MeOH 90:10): 0.14 (KMnO4) 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 7.44-7.26 (m, 5H, Haromatic); 4.96 – 
4.92 (m, 2H, HC(11a β) and HC(1α)); 4.78 (d, 2J11a-11a´=11.8Hz, 1H, HC(11a α)); 4.68 (d, 
2J11a-11a´=11.8Hz, 1H, HC(11a´ β)); 4.57 (d, 2J11a-11a´=11.8Hz, 1H, HC(11a´ α)); 4.39 (d, 
3J1-2 =7.7Hz, 1H, HC(1β)); 3.93 (dd, 3J5-6 ≈ 2.0Hz, 3J6 – 6´ =11.9Hz ,1H, HC(6 β)) ;3.83 
(dd, 3J5-6 ≈ 2.0Hz, 3J6 – 6´ ≈11.9Hz ,1H, HC(6 α)); 3.77- 3.64  (m, 5H, HC(6´ α), HC(6´ β), 
HC(5α), HC(3 α) and HC(3 β)); 3.47 (dd, 3J1-2 ≈2.3Hz,  3J3-2 =8.8Hz 1H, HC(2α)); 3.45-
3.29 (m, 4H, HC(2β), HC(4α), HC(4β) and HC(5β)). 
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) = 138.8 ((C12)); 129.2-128.6 ((C13,C14, 
C15);103.1 (C(1β)); 99.1 (C(1α)); 77.8 (C(5β)); 73.4 (C(2α)); 77.7, 74.9, 73.7, 71.6, 71.4 
((C(2β), C(3α), C(3β), C(4α), C(4β) and C(5α)); 70.1 (C(11)); 62.6 and 62.5 (C(6α) and 
C(6β)) 
 
α/β ratio by 13C-NMR ≈ 1.5 : 1 
  
MS (ESI (+)): m/z relative intensity [2×M] - = 539.1 
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 9.2.1.1.3.2. Synthesis of Benzyl 6-tert-Butyldiphenylsilyl- α/β-D-glucose 
 
C29H36O6Si
[508.67]
C13H18O6
[270.28]
O
HO
HO
OH
OTBDPS
O
O
HO
HO
OH
OH
O
TBDPSCl
Imidazole
17 18
 
To a solution of 2.43 g (9 mmol, 1eq) benzyl α/β glucose and 1.35 g (19.8 mmol, 2.2eq) 
imidazole in 30 ml DMF at -300C, was added drop wise by syringe, a solution of 2.72 g 
(9.9 mmol, 1.1eq) tert-butyldiphenylsilyl chloride in 20 ml DMF. After 3.5 h, the 
reaction was poured into aqueous NaHCO3 solution and ether. The aqueous layer was 
further extracted with ether. The combined organic layer were dried over MgSO4 , 
filtered and evaporated. The residue on flash chromatography (CH2Cl2 : MeOH 95:5) 
afforded 4.12 g benzyl 6-tert-Butyldiphenylsilyl- α/β-D-glucose. (Yield = 90%). 
O
HO
HO
OH O
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Batch: RV158, RV159, VW35 
 
Rf: (CH2Cl2 / MeOH 90:10): 0.48 (UV active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.73-7.19 (m, 15H, Haromatic); 4.87 (d, 
3J1-2 =3.5Hz, 1H, HC(1α)); 4.85 (d, 2J11a-11a´≈11.0Hz,1H, HC(11a β) ; 4.70 (d, 2J11a-
1
1
a´=11.8Hz, 1H, HC(11a α)); 4.55 (d, 2J11a-11a´=11.6Hz, 1H, HC(11a´ β)); 4.46 (d, 2J11a-
1
1
a´=11.8Hz, 1H, HC(11a´ α)); 4.33 (d, 3J1-2 =7.7Hz, 1H, HC(1β)); 3.98 (dd, 3J5-6 ≈ 3.0Hz, 
3J6 – 6´ =11.0Hz ,1H, HC(6 β)) ;3.91 (dd, 3J5-6 ≈ 3.0Hz, 3J6 – 6´ ≈11.0Hz ,1H, HC(6 α)); 
3.87- 3.34  (m, 10H, HC(6´ α), HC(6´ β), HC(5α), HC(5β), HC(4α), HC(4β),HC(3α), 
HC(3 β), HC(2α) and HC(2β)); 
1.05, 1.04 (s, 9H, H3C(61a, 61b,61c). 
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 137.2,137.1,133.4,133.3 ((C12), 
C(62),C(63) of α and β); 135.6-134.8,129.6-127.6 ((C(13),C(14), C(15), C(62a), C(62b), 
C(62c),C(63a), C(63b), C(63c) );101.2 (C(1β)); 97.1 (C(1α)); 70.4, 68.8 ((C(11)) of α and β); 
64.0, 64.1 (C(6α) and C(6β)); 76.7, 75.9, 74.6, 73.6, 72.1, 72.0, 71.0, 70.9, 77.8 (C(5β), 
C(5α), C(4α), C(4β), C(3α), C(3β),C(2α) and (C(2β)); 26.8-26.6 (C(61a, 61b,61c)). 
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 α/β ratio by 13C-NMR ≈ 1.4 : 1 
  
MS (ESI (+)): m/z relative intensity [2×M+Na] + = 1038.7 
9.2.1.1.3.3. Synthesis of Benzyl 6-tert-Butyldiphenylsilyl- 2,3,4-tri-O-benzyl α/β-D-
glucose 
 
C50H54O6Si
[779.04]
O
BnO
BnO
OBn
OTBDPS
O
NaH, DMF
C29H36O6Si
[508.67]
O
HO
HO
OH
OTBDPS
O
Br
BnBr =
C7H7Br
[171.04]
BnBr,TBAI
18 19
 
 
To a solution of 390 mg (0.77 mmol, 1eq) benzyl 6-tert-Butyldiphenylsilyl- α/β-D-
glucose in 5ml DMF at 00C, was added 110mg (2.68 mmol, 3.5eq) of NaH (60% 
dispersion in mineral oil).The reaction was allowed to reach ambient temperature and 
kept at that temperature for 1h.Then 440 mg (0.3ml, 2.57 mmol, 3.3eq) of Benzyl 
bromide was added drop wise via syringe.After 7h, the reaction mass was poured into 
aqueous NaHCO3 solution and EtOAc.The aqueous layer was further extracted with 
EtOAc, and the combined organics were dried, filtered and evaporated. The residue on 
flash chromatography (Hexane: Ether 90:10) afforded 400 mg of pure Benzyl 6-tert-
Butyldiphenylsilyl- 2,3,4-tri-O-benzyl α/β-D-glucose.(Yield= 66.9%) 
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Batch: RV160, RV171, VW36 
 
Rf: (Hexane: Ether 90:10): 0.19(UV active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.13-7.49 (m, 30H, Haromatic); 5.35-
4.85 (m, 18H, 4×H2CPh (α and β), HC(1α) and HC(1β)); 4.44 ((t, 3J3´-4´≈9.2Hz, 3J3´-2´ =9.1 
Hz,1H, HC(3´α)); 4.29 (m, 2H, H2C(6 β)); 4.20-4.19 (m, 2H, H2C(6 α)); 4.13-4.10 (m, 
2H, HC(5α) and  HC(4β)); 4.03-3.98 (m, 2H, HC(3 β) and HC(4α)); 3.93-3.88 (m, 2H, 
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 HC(2α) and HC(2β)); 3.69-3.66 (m, 1H, HC(5β); 1.42-1.39 (3×s, 9H, H3C(61a, 61b,61c). 
All peaks considered without solvent reference as CDCl3 peak overlaps with aromatic 
peaks. 
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. 
 
13C-NMR (100MHz,CDCl3,298K): δC(ppm) = 138.8-137.1,133.6-133.1 ((C11), (C21), 
(C31),  (C41), C(62), C(63) of α and β); 135.9-135.5,129.6-127.6 ((C12),C(13), C(14), 
C(22), C(23),  C(24), C(32), C(33), C(34), C(42), C(43), C(44), C(62a), C(62b), C(62c),C(63a), 
C(63b), C(63c)); 102.2 (C(1β)); 94.7 (C(1α)); 82.3 (C(3α)); 75.7 (C(5β)); 62.8, 62.7 (C(6α) 
and C(6β)); 84.7, 82.6, 80.3, 77.8, 77.7, 71.8 (C(5α), C(4α), C(4β), C(3β), C(2α) and 
(C(2β)); 75.9, 75.8, 75.2, 75.1, 74.9, 72.9, 70.6, 68.5 (4×H2CPh (α and β)); 26.8 (C(61a, 
61b,61c)); 19.3 (C(61). 
 
α/β ratio by 13C-NMR ≈ 1.4 : 1 
  
MS (ESI (+)): m/z relative intensity [M-Ph] + = 702.5 
9.2.1.1.3.4. Synthesis of Benzyl-2,3,4-tri-O-benzyl α/β-D-glucose 
 
C50H54O6Si
[779.04]
OBnOBnO
OBn
OH
OBn
TBAF
C34H36O6
[540.64]
OBnOBnO
OBn
OTBDPS
OBn
THF
H2C
Bn =
19 20
 
 
To a solution of 400 mg (0.51 mmol, 1eq) Benzyl 6-tert-Butyldiphenylsilyl- 2,3,4-tri-O-
benzyl α/β-D-glucose in 5ml THF at 00C, was added drop wise a solution of 0.6 ml 
(0.564 mmol, 1.1eq) of 1M TBAF in THF. The reaction was allowed to reach ambient 
temperature and kept at that temperature for 9-10h. Then, the reaction mass was poured 
into aqueous NaHCO3 solution and EtOAc. The aqueous layer was further extracted with 
EtOAc, and the combined organics were dried, filtered and evaporated. The residue on 
flash chromatography (Hexane: EtOAc 70:30) afforded 204 mg of pure Benzyl-2,3,4-tri-
O-benzyl α/β-D-glucose.(Yield= 73.5%) 
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Batch: RV169, VW37 
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 Rf: (Hexane: EtOAc 70:30): 0.19 for β anomer and 0.14 for α anomer (UV active; 
KMnO4) 
 
IR (KBr) :  3368m, 3088vw, 3063w, 3029m, 2955w, 2918m, 2868m, 2346vw, 2056vw, 
1945vw, 1869vw, 1803vw, 1706vw, 1606vw, 1586vw, 1497m, 1453s, 1399w, 1360m, 
1327w, 1308vw, 1261vw, 1236w, 1211m, 1161vw, 1083vs, 1070vs, 1042vw,1027vs,  
991s, 909w, 831vw, 730vs, 694vs, 641w, 618w, 604vw, 558w, 531vw, 499w, 461w. 
 
α- anomer: 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.39-7.27 (m, 20H, Haromatic); 5.01 (d, 
2J1a-1a´=10.8Hz, 1H, HC(1a)); 4.88 (d, 2J2a-2a´=11.0Hz, 1H, HC(2a)); 4.84 (d, 2J1a-
1a´=10.8Hz, 1H, HC(1a´ )); 4.79 (d, 3J1-2 =3.5Hz, 1H, HC(1α)); 4.67 (2×d, 2J3a-3a´=12.1Hz, 
1H, HC(3a)), 2J4a-4a´=12.1Hz, 1H, HC(4a)); 4.64 (d, 2J2a-2a´=11.3Hz, 1H, HC(2a´ )); 4.55 (d, 
2J ≈12.1Hz, 1H, HC(4a´) or HC(3a´)); 4.53  (d, 2J ≈12.1Hz, 1H, HC(4a´) or HC(3a´)); 4.07 
(t, 3J3-2  = 9.2Hz, 3J3-4 = 9.2Hz, 1H, HC(3α)); 3.72-3.65 (m,3H, HC(5α) and H2C(6α)); 
3.54 (t, 3J4-3  ≈ 9.2Hz, 3J4-5 ≈ 9.2Hz, 1H, HC(4α)); 3.50 (dd, 3J2-1 ≈ 3.6Hz, 3J2 -3 ≈ 9.5Hz 
,1H, HC(2α)); 1.26, 0.88 (traces of hexane). 
 
α/β ratio by 1H-NMR : Only α anomer 
 
13C-NMR (100MHz,CDCl3,298K): δC(ppm) = 138.7-137.0 ((C11), (C21), (C31) and 
(C41)); 128.4-127.6 ((C12),C(13), C(14), C(22), C(23),  C(24), C(32), C(33), C(34), C(42), 
C(43) and C(44)); 95.5 (C(1α)); 81.9 (C(3α)); 79.9 (C(2α)); 77.3 (C(4α)); 70.9 (C(5α)); 
61.7 (C(6α)); 75.7, 75.0, 73.0, 69.2 (4×H2CPh); 29.7, 14.1 (traces of hexane). 
 
α/β ratio by 13C-NMR : Only α anomer 
 
β- anomer: 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.38-7.26 (m, 20H, Haromatic); 4.95 (d, 
2J1a-1a´=11.0Hz, 1H, HC(1a)); 4.93 (d, 2J2a-2a´=10.8Hz, 1H, HC(2a)); 4.92 (d, 2J3a-
3a´=12.3Hz, 1H, HC(3a)); 4.86 (d, 2J4a-4a´=10.9Hz, 1H, HC(4a)); 4.80 (d, 2J1a-1a´ ≈11.0Hz, 
1H, HC(1a´ )); 4.73 (d, 2J2a-2a´=10.8Hz, 1H, HC(2a´ )); 4.69 (d, 2J3a-3a´≈12.0Hz , 1H, 
HC(3a´)); 4.64  (d, 2J4a-4a´=10.9Hz, 1H, HC(4a´)); 4.57 (d, 3J1-2 =7.8Hz, 1H, HC(1β)); 3.87 
(dd, 3J5-6a ≈ 2.4Hz, 3J6a -6a´ =11.8Hz ,1H, HC(6a β)); 3.72-3.60 (m,1H, HC(6b β)); 3.67 (t, 
3J3-2  = 9.0Hz, 3J3-4 = 9.0Hz, 1H, HC(3β)); 3.57 (t, 3J4-3  ≈ 9.0Hz, 3J4-5 ≈ 9.5Hz, 
1H,HC(4β)); 3.48 (dd, 3J2-1 ≈ 7.8Hz, 3J2 -3 ≈ 9.0Hz ,1H, HC(2β)); 3.36 (ddd, 3J5-6a ≈ 
2.8Hz, 3J5-6b ≈ 4.5Hz, 3J5-4 = 9.5Hz,1H, HC (5β)); 1.25, 0.86 (traces of hexane). 
 
α/β ratio by 1H-NMR : Only β anomer 
 
13C-NMR (100MHz,CDCl3,298K): δC(ppm) = 138.6-137.2 ((C11), (C21), (C31) and 
(C41)); 128.9-128.1 ((C12),C(13), C(14), C(22), C(23),  C(24), C(32), C(33), C(34), C(42), 
C(43) and C(44)); 103.2 (C(1β)); 84.9 (C(3β)); 82.8 (C(2β)); 78.0 (C(4β)); 75.5 (C(5β)); 
62.4 (C(6α)); 76.2, 75.5, 75.4, 72.1 (4×H2CPh); 29.8, 14.6 (traces of hexane). 
 169
  
α/β ratio by 13C-NMR : Only β anomer 
9.2.1.1.3.5. Synthesis of Benzyl 6´-O-(BOC-ALA) - 2´,3´,4´-tri-O-benzyl α/β-D-
glucose 
O
BnO
BnO
OBn OBn
DMAP
EDCI
OHBocHN
O
O
C10H17NO5
[231.16]
BocHN
O
O
C44H51NO10
[753.87]
O
O
BnO
BnO
OBn
OH
OBn
C34H36O6
[540.64]
20 5 21
 
161 mg (0.298 mmol, 1eq) of Benzyl-2,3,4-tri-O-benzyl α/β-D-glucose was taken in a 
dry flask under argon atmosphere and was dissolved in 6.7 ml CH2Cl2. The solution was 
cooled to 00C, added 40 mg (0.327 mmol, 1.1eq) of DMAP, then 69.4 mg (0.362mmol, 
1.2eq) of EDCI and finally 75.7 mg (0.327mmol, 1.1eq) of Boc-ALA acid. The reaction 
was warmed to ambient temperature and maintained at that temperature for 8 hrs 
(controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). The mixture was concentrated 
and the residue was subjected to flash chromatography  (silica gel- 60times of the residue 
mass) which further afforded 167 mg pure Benzyl 6´-O-(BOC-ALA) - 2´,3´,4´-tri-O-
benzyl α/β-D-glucose (Yield= 74%) 
2a
3a
4a
O
O
O
O O
1´
2´3´
4´ 5´6´
1a
11
12
13
141
2
3
45
6
7
81
82
83
NH
O
OO
O O
 
 
Batch: VW33, VW34. 
 
Rf: (Hexane: EtOAc 70:30, 2 times ): 0.18  (UV active; KMnO4) 
 
IR (KBr) :  3425m, 3088vw, 3063w, 3031m, 3005vw, 2976w, 2925s, 2872m, 2315vw, 
1955vw, 1877vw, 1807vw, 1733vs, 1713vs, 1624vw, 1605vw, 1586vw, 1497s, 1455s, 
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 1392m, 1366s, 1332vw, 1308vw, 1267vw, 1250m, 1207w, 1164vs, 1071vs, 1028vs,  
912m, 873w, 822w, 737vs, 699vs, 677vw, 611w, 559w, 531vw, 464w. 
 
1H-NMR (200 MHz, CDCl3, 298 K): δH (ppm) = = 7.33-7.16 (m, 20H, Haromatic); 5.15 
(sbr, 1H, HN ); 4.94 (d, 2J=10.8Hz, 1H, H2CPh); 4.87 (d, 2J=10.8Hz, 1H, H2CPh); 4.86 
(d, 2J=10.8Hz, 1H, H2CPh); 4.83 (d, 2J=12.5Hz, 1H, H2CPh);  4.78 (d, 2J=11.0Hz, 1H, 
H2CPh); 4.76 (d, 2J=10.6Hz, 1H, H2CPh); 4.71 (d, 2J=10.0Hz, 1H, H2CPh); 4.62 (d, 3J1-
2=3.5Hz, 1H, HC(1´α)); 4.60 (d, 2J=11.9Hz, 1H, H2CPh); 4.58 (d, 2J=11.5Hz, 1H, 
H2CPh); 4.49 (d, 2J=11.0Hz, 1H, H2CPh); 4.47 (d, 2J=12.5Hz, 1H, H2CPh); 4.46 (d, 
2J=12.4Hz, 1H, H2CPh); 4.43 (d, 3J1-2= 7.8Hz, 1H, HC(1´β));  4.26 (dd, 3J5´-6´a ≈ 2.0Hz, 
3J6´a - 6´b =11.7Hz ,1H, HC(6´a α or β)); 4.20 (dd, 3J5´-6´b ≈ 4.5Hz, 3J6´a - 6´b =11.7Hz ,1H, 
HC(6´b α or β) ); 4.07 (dd, 3J5´-6´a ≈ 2.0Hz, 3J6´a - 6´b =11.8Hz ,1H, HC(6´a α or β )); 4.00-
3.95 (m, 3H, HC(6´b α or β) and H2C(5)); 3.78 (ddd, 3J5´-6´a ≈ 2.0Hz, 3J5´-6´b ≈ 4.0Hz, 3J5´-4´ 
= 10.0Hz,1H, HC (5´α)); 3.58 (t, 3J3´-4´≈9.3Hz, 3J3´-2´ =9.3Hz,1H, HC(3´α)); )); 3.45 (dd, 
3J2´-1´ ≈ 3.7Hz, 3J2´ - 3´ ≈ 9.6Hz ,1H, HC(2´α)); 3.44-3.37 (m, 4H, HC(2´β),HC 
(3´β),HC(4´α) and HC (4´β)); 2.65-2.53 (m, 4H, H2C(3) and H2C(2)); 1.35 (s, 9H, H3C 
(81, 82 and 83)); 1.18, 0.82-0.76 peaks due to traces of solvent and impurity. 
 
α/β ratio by 1H-NMR : could not be determined because of peaks overlap. 
 
13C-NMR (50MHz,CDCl3,298K): δC(ppm) = 204.1,204.0 (C(4) of α and β); 172.2, 172.1 
(C(1) of α and β); 155.6 (C(6)) ; 138.7-137.0 ((C11), (C21), (C31) and (C41) of α and β); 
128.5 - 127.0 ((C12,C13,C14, C22,C23,C24, C32,C33,C34, C42,C43,C44,) of α and β); 102.4 
(C(1´β)); 95.5 (C(1´α)); 84.6, 82.2, 82.0, 80.0, 77.4, 77.3, 72.8, 68.8 (C(5´α), C(5´β), 
C(4´α), C(4´β), C(3´α)), C(3´β), (C(2´α) and (C(2´β)); 63.3 (C(6´α) and C(6´β)); 75.8, 
75.7, 75.1, 75.0, 74.9, 73.0, 71.2, 69.3  (C(2a), C(3a), C(4a) and C(1a) of α and β anomer); 
50.3 (C(5)); 34.2 (C(3) ); 28.3 (C(81,82 and 83); 27.8  (C(2)). 
 
α/β ratio by 13C-NMR ≈1.44 : 1 
9.2.1.1.4. Synthesis of 6´-O- (ALA) α/β-D- glucose by protection & 
deprotection method (using boronate protective group): 
9.2.1.1.4.1. Synthesis of α-D-glucofuranose 1,2:3,5-bis phenyl boronate 
 
OHO
HO
OH
OH
OH
C6H12O6
[180.16]
OO
OOHO O
B
BPh Ph
2 PhB(OH)2
C6H7BO2
[121.93]
C18H18B2O6
[351.95]
4H2O
13 22 23
 
To a mixture of 968 mg (5.37 mmol, 1eq) of D-glucose and 40 ml toluene, was added 
1310 mg (10.74 mmol, 2eq) of phenyl boronic acid. The reaction was refluxed with 
Dean-Stark apparatus to distil off the toluene-water azeotrope. The reaction was kept 
 171
 under reflux (approximately for 12 h) till the water collection is stopped and the 
disappearance pf the precipitate. The toluene was later evaporated completely. To the 
white residue was added 20 ml toluene, heated 700C to dissolve the residue completely, 
cooled slowly to crystallise pure α-D-glucofuranose 1,2:3,5-bis phenyl boronate and 
filtered which on after drying afforded 840 mg.(Yield=44.4%) 
                                            
O
O
O
OHO O
B
B
1
23
4
5
6
11 12
13
14
31
32
33
34  
Batch: RV115, RV124, RV127 
 
IR (KBr): 3482vs, 3077vw, 3054vw, 3043vw, 3025vw, 2996vw, 2947w, 2933w, 2907w, 
2877vw, 1973vw, 1912vw, 1836vw, 1602s, 1574vw, 1498w, 1459vw, 1446s, 1416m, 
1403w, 1373w, 1355vs, 1345vs, 1330s, 1305vs, 1286m, 1258m, 1226w, 1209m, 1163s, 
1099s, 1082m, 1055w, 1045w, 1035w, 1025m, 1007s, 997m, 965w, 947vw, 933vw, 874w, 
864w, 851w, 830m, 802w, 761s, 746m, 708vw, 701s, 666w, 658vw, 642m, 622w, 568w, 
527w, 505w.     
  
1H-NMR (400 MHz, CD2Cl2, 298 K): δH (ppm) = 7.71-7.25 (m, 10H, Haromatic); 6.17  
(d, 3J1-2 =4.2Hz, 1H, HC(1)); 4.98  (d, 3J1-2 ≈4.2Hz, 1H, HC(2)); 4.72 (d, 3J3-4 =2.6Hz, 1H, 
HC(3)); 4.45 (t, 3J5-6a  = 3.6Hz, 3J5-6b = 3.6Hz, 1H, HC(5)); 4.32  (d, 3J4-3 ≈2.6Hz, 1H, 
HC(4)); 3.88 (dd, 3J6a-5 ≈ 4.0Hz, 3J6a -6b =11.6Hz ,1H, HC(6a)); 3.74 (dd, 3J6b-5 =3.6Hz, 
3J6a -6b =11.6Hz ,1H, HC(6b));  
 
13C-NMR (100MHz,CD2Cl2,298K): δC(ppm) = 136.7-124.0 ((C11), (C12),C(13), C(14), 
(C31) , C(32), C(33), C(34)); 104.7 (C(1)); 86.5 (C(2)); 75.4 (C(4)); 74.4 (C(3)); 71.3 
(C(5)); 63.9 (C(6));   
 
MS (ESI (+)): m/z relative intensity [M-H] + = 351.4 
9.2.1.2. Synthesis of 6´- O-(ALA) -α/β-D-mannose 
9.1.2.1. Synthesis of 6´-O-(BOC-ALA) α/β-D-mannose 
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OH
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(PPL)
C16H16NO5F5
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O
O F
F
F
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F
NHBoc
O
O
OHOHO
O
OH
C6H12O6
[180.16]
C16H27NO10
[393.39]
OH OH
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360.4 mg (2 mmol, 1eq) of mannose was taken in a dry flask under argon atmosphere and 
was dissolved in 6 ml anhydrous pyridine. 650 mg (24 units per mg of protein; 1unit 
hydrolyses 1µmol or 0.001mmol of an ester; approximately, 15.6 mmol, 7.8eq) of 
porcine pancreatic lipase (PPL) enzyme (before use dried by keeping at vacuum 10-2 
mbar for 3-4 days) was added and then 1600 mg (4mmol, 2eq) of Boc-ALA-PFP ester 
was added to the solution. The reaction was heated to 500C and maintained at this 
temperature for approximately 48 hrs (controlled by TLC eluent : AcOEt: MeOH 1:1). 
The mass was cooled to room temperature and then the enzyme was filtered over celite 
bed, the filtered cake was washed with 3× 10ml pyridine. The solvent pyridine was 
evaporated off by rotovapor .The residue was extracted with 100ml toluene, centrifuged 
to remove the unreacted Boc-ALA-PFP ester and Pentafluoro phenol which got dissolved 
in the toluene and separated as a clear top supernatant solution. The settled residue after 
the centrifuge was taken for flash chromatography. (gradient eluent from 100% CH2Cl2 
to 85:15 CH2Cl2 : MeOH). The main fractions were concentrated to give 539 mg of pure 
product was obtained as white solid. (Yield = 68.5%). 
NH
O
O
O
HO
HO
O
OH
O
O
1 2
3 4
5 6
7
8a
1´
2´3´
4´
5´
6´
8b
8c
OH
 
Batch : VW 56 and VW4048 
 
Rf: (CH2Cl2 / MeOH 85:15): 0.24; (KMnO4) 
 
IR (KBr) : 3420vs, 2978m, 2931m,2509w, 1717vs, 1520s, 1419w, 1393m, 1368s, 1283m, 
1253m,  1167vs, 1059s, 868w, 806w,781w,674w,600w, 499w. 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 5.10 (d, 3J1´-2´ ≈1.7Hz, 1H, HC(1´α) ); 
4.48 (d, 3J1´-2´ =1.0Hz, 1H, HC(1´β) );4.32 (dd, 3J5´-6´a ≈ 2.1Hz, 3J6´a - 6´b =11.8Hz ,1H, 
HC(6´a α)) ;4.25 (dd, 3J5´-6´b ≈ 5.4Hz, 3J6´a - 6´b =11.8Hz ,1H, HC(6´b α ));3.95-3.88 (m, 
3H, H2C(5) and HC (5´α));3.82 (dd, 3J2´-1´ =1.7Hz, 3J3´-2´ =3.4Hz,1H, HC(2´α)); 3.76 (dd, 
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 3J2´-3´ ≈ 3.4Hz, 3J3´-4´≈9.7Hz,1H, HC (3´α)); 3.57 (t, 3J4´ - 3´ ≈ 9.7Hz, 3J4´ -5´ ≈ 9.7Hz 1H, 
HC(4´α));2.75-2.63 (m, 4H ,H2C(3) and H2C(2)); 1.42 (s, 9H, H3C (8a, 8b and 8c)). 
 
α/β ratio by 1H-NMR ≈ 5.2 : 1 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 207.0 (C(4)); 173.6 (C(1)); 157.4 
(C(6)) ; 95.0 (C(1´α)); 94.8 (C(1´β)); 80.4 (C(7)); 71.8 (C(2´α)); 71.5 (C(3´α)); 70.6 
(C(5´α)); 68.0 C(4´α)); 64.7 (C(6´α)),49.6 (C(5)); 34.5 (C(3)) ;28.5 (C(8a,8b and8c); 28.3 
(C(2)).  
 
α/β ratio by 13C-NMR ≈ 3.8 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.2; [M+ H] + = 393.9; [M-tBu + Na] 
+ = 360.4; [M-Boc + Na] + = 316.1; [M-Boc- (CONH2) + Na] + = 256.0   
 
HR-MS [M+ Na] + = 416.1523 (calculated = 416.1533) 
 
9.1.2.2. Synthesis of 6´-O-(ALA) α/β-D-mannose 
NH3
O
O
O
HO
HO
O
OH
C13H20F3NO10
[407.29]
NHBoc
O
O
O
HO
HO
O
OH
C16H27NO10
[393.39]
CF3COOH
CF3COO
CH2Cl2
M+=294.28 ; CF3COO = 113.01
OH OH
25 26
 
315 mg (0.8 mmol, 1eq) of 6´-O-(BOC-ALA) mannose was dissolved in 20ml CH2Cl2 
and cooled to -100C. To this solution, 4.58g (3ml, 40 mmol, 50 eq) of trifluoroacetic acid 
was added dropwise by syringe. The reaction mass was allowed to come to ambient 
temperature and maintained at ambient temperature for 30 minutes. Once the 
deprotection of BOC was completed (controlled by the absence of BOC peak in 1H-
NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. The product was triturated 
with dry ether and ether solution was decanted. The trituration with ether and decanting 
top clear ether solution after centrifuge was repeated 2 times more. Then, the settled solid 
product was dried under high vacuum oil pump and thereby yielded 297 mg of highly 
hygroscopic white solid. (Yield=91%). 
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Batch: RV 345 
 
[α]D = +14.4 (c=0.21; deionized H2O) 
 
IR (KBr): 3388vs, 2928m, 1788w, 1731vs, 1678vs, 1517w, 1429m, 1391m, 1327w, 
1204vs, 1138vs, 1068m, 913w, 839m, 800m, 776w, 723m, 598w, 520w,500w.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.06 (d, 3J1´-2´ =1.7Hz, 1H, HC(1´α) ); 
4.82 (d, 3J1´-2´ =1.0Hz, 1H, HC(1´β) );4.32-4.18 (m, 4H, H2C (6`α) and H2C (6`β)); 4.05 
(s, 2H, H2C (5)); 3.89 (ddd, 3J5´-6´a ≈ 2.6 Hz, 3J5´-6´b ≈ 4.7Hz, 3J5´-4´ = 9.9Hz ,1H, HC 
(5`α)); 3.85 (dd, 3J2´-1´ =1.7Hz, 3J3´-2´ ≈3.4Hz,1H, HC(2´α)); 3.75 (dd, 3J2´-3´a ≈ 3.4Hz, 3J3´-4´ 
≈9.8 Hz,1H, HC (3´α)); 3.60 (t, 3J4´ - 3´ ≈ 9.8Hz, 3J4´ -5´ = 9.8Hz 1H, HC(4´α)); 3.57-3.44 
(m,1H, HC (5`β) and peaks due to ether solvent )); 2.85 (t, 3J2-3 = 6.5Hz, 2H, H2C(3)) ; 
2.69 (t, 3J3-2 = 6.5Hz, 2H, H2C(2)) ; 1.07-1.15 (peaks due to ether solvent). 
  
α/β ratio by 1H-NMR ≈ 3.67 : 1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.4 (C(4)) ; 174.9 (C(1α or β)) ; 174.8 
(C(1α or β)); 163.5 (q,2JC-F = 35.5, CF3COO¯ ); 116.7 (q,1JC-F ≈ 291.0, CF3COO¯ ); 94.6 
(C(1´α)); 94.2 (C(1´β)); 70.9, 70.4, 67.0 (C(2´α),C( 3´α), and C(5´α)); 
73.8,71.4,66.7(C(2`β), C(3`β) and C(5`β)); 66.4(C(4´α and 4`β)); 64.2(C(6´α and 6´β)); 
47.4 (C(5)); 34.6(C(3)); 27.7 (C(2)).  
 
α/β ratio by 13C-NMR ≈ 2.4 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 294.0  
 
HR-MS [M- CF3COO¯] + = 294.1184 (calculated = 294.1189) 
9.1.3. Synthesis of 6´- O-(ALA) -α/β-D-galactose 
9.1.3.1. Synthesis of 6´-O-(BOC-ALA) α/β-D-galactose 
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360.4 mg (2 mmol, 1eq) of galactose was taken in a dry flask under argon atmosphere 
and was dissolved in 16 ml anhydrous pyridine. 1900 mg (20 units per mg of protein; 
1unit hydrolyses 1µmol or 0.001mmol of an ester; approximately, 38 mmol, 19.0eq) of 
porcine pancreatic lipase (PPL) enzyme (before use dried by keeping at vacuum 10-2 
mbar for 3-4 days)  was added and then 4680 mg (12.8mmol, 6.4eq) of Boc-ALA-TCE 
ester was added to the solution. The reaction was heated to 500C and maintained at this 
temperature for approximately 60hrs (controlled by TLC eluent : AcOEt: MeOH 1:1). 
The mass was cooled to room temperature and then the enzyme was filtered over celite 
bed, the filtered cake was washed with 3× 10ml pyridine. The solvent pyridine was 
evaporated off by rotovapor .The residue was extracted with 100ml toluene, centrifuged 
to remove the unreacted Boc-ALA-TCE ester and Trichloro ethanol which got dissolved 
in the toluene and separated as a clear top supernatant solution. The settled residue after 
the centrifuge was taken for flash chromatography. (gradient eluent from 100% CH2Cl2 
to 85:15 CH2Cl2 : MeOH). The main fractions were concentrated and the mass was 
further purified by dissolving the mass in 8ml CH2Cl2 and precipitated by 8ml hexane. 
348 mg of pure product was obtained as white solid. (Yield = 44.2%). 
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Batch :RV337 
 
Rf: (CH2Cl2 / MeOH 85:15): 0.29 (KMnO4) 
 
IR (KBr): 3414vs, 2981m, 2931m,2347w,1736vs,1715vs,1684vs, 1536s, 1416w, 1393w, 
1368m,1323w,1301m,1253m,1200m,1174s,1149s,1105m,1091m,1074s,1030s,997w,921w
, 859w,800m,692m,645w,568w,468w. 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 5.16 (d, 3J1´-2´ =3.5Hz, 1H, HC(1´α) ); 
4.42 (d, 3J1´-2´ =7.2Hz, 1H, HC(1´β) ); 4.26-4.16 (m, 5H, H2C(6´α and β) and HC(5´α )); 
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 3.95-3.93 (m, 3H, H2C(5) and HC (4´ α )); 3.86 (m,1H, HC(3´α)); 3.75 (dd, 3J2´-1´ ≈3.5Hz, 
3J3´-2´ =9.8Hz,1H, HC(2´α)); 3.72-3.69 (m,1H, HC(5´β)); 3.47 (dd, 3J2´-1´ ≈7Hz, 3J3´-2´ 
=9.8Hz,1H, HC(2´β)); 2.77-2.63 (m, 4H ,H2C(3) and H2C(2)); 1.43 (s, 9H, H3C (8a, 8b 
and 8c)). 
 
α/β ratio by 1H-NMR ≈ 2.8 : 1 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) = 207.2 (C(4)); 173.8 (C(1)); 158.0 
(C(6)) ; 98.2 (C(1´β)); 93.7 (C(1´α)); 80.5 (C(7)); 70.6 (C(2´α)); 70.5, 69.9 (C(3´α) and 
C(4´α)); 68.7 (C(5´α)); 64.9 (C(6´α)), 74.3,73.4,73.2,64.6 (peaks due to β anomer); 50.5 
(C(5)); 34.7 (C(3)) ;28.6 (C(8a,8b and8c); 28.4 (C(2)).  
 
α/β ratio by 13C-NMR ≈ 3.4 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.1 
 
HR-MS [M+ Na] + = 416.1526 (calculated = 416.1533) 
 
9.1.3.2. Synthesis of 6´- O-(ALA) α/β-D-galactose 
NH3
O
O
O
HO
OH
O
OH
C13H20F3NO10
[407.29]
NHBoc
O
O
O
HO
OH
O
OH
C16H27NO10
[393.39]
CF3COOH
CF3COO
CH2Cl2
M+=294.28 ; CF3COO = 113.01
OH OH
28 29
 
280 mg (0.71 mmol, 1eq) of 6´-O-(BOC-ALA) galactose was dissolved in 20ml CH2Cl2 
and cooled to -100C. To this solution, 4.07g (2.75ml, 35.55 mmol, 50 eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was allowed to 
come to ambient temperature and maintained at ambient temperature for 30 minutes. 
Once the deprotection of BOC was completed (controlled by the absence of BOC peak in 
1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. The product was triturated 
with dry ether and ether solution was decanted. The trituration with ether and decanting 
top clear ether solution after centrifuge was repeated 2 times more. Then, the settled solid 
product was dried under high vacuum oil pump and thereby yielded 270 mg of highly 
hygroscopic white solid. (Yield=93.2%). 
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 NH3
O
O
O
OH
HO
OH
O
OH
1 2
3 4
5
1´
2´3´
4´ 5´
6´
CF3COO
 
Batch: RV 347 
 
[α]D = -48.5 (c=0.47; deionized H2O) 
 
IR (KBr): 3392vs, 2929m, 2027w,1731vs, 1678vs, 1512w, 1430m, 1384m, 1317w, 
1205vs, 1138vs, 1073m,1038w, 917w, 872w,839m, 800m, 723m, 598w, 520w,500w.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.23 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α) ); 
4.55 (d, 3J1´-2´ =7.9Hz, 1H, HC(1´β) );4.48-4.11 (m,5H, H2C (6`α),H2C (6`β) and HC 
(5´α); 4.10 (s, 2H, H2C (5)); 3.97 (m, 1H, HC (3`α)); 3.92 (dd, 3J4´-5´ =0.9Hz, 3J4´-3´ 
=3.5Hz,1H, HC(4´β)); 3.88 (ddd, 3J5´-4´ ≈ 0.9Hz, 3J5´-6´a = 4.3Hz, 3J5´-6´b = 7.8Hz ,1H, HC 
(5`β)); 3.84-3.83 (m, 1H, HC(4´α)); 3.80(dd, 3J2´-1´ ≈3.7Hz, 3J3´-2´ =11Hz,1H, HC(2´α)); 
3.62 (dd, 3J3´-4´ =3.5Hz, 3J3´-2´ ≈10 Hz,1H, HC (3´β)); 3.55-3.48 (q,2H, peaks due to ether 
solvent );3.46 (dd, 3J2´-1´ =7.9Hz, 3J3´-2´ =10Hz,1H, HC(2´β)); 2.95 (t, 3J2-3 ≈6.5Hz, 2H, 
H2C(3)) ; 2.72 (t, 3J3-2 ≈ 6.5Hz, 2H, H2C(2)) ; 1.07-1.15 (peaks due to ether solvent). 
  
α/β ratio by 1H-NMR ≈ 0.60: 1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.4 (C(4)) ; 174.8 (C(1α or β)) ; 174.7 
(C(1α or β)); 163.3 (q,2JC-F = 35.0, CF3COO¯ ); 116.6 (q,1JC-F ≈ 291.0, CF3COO¯ ); 96.8 
(C(1´β)); 92.7 (C(1´α));72.9 (C(3´β));72.7 (C(4´β));72.0(C(2´β));69.6,69.2,69.0,68.5,68.4 
(C(3´α),C(5´β),C(2´α),C(5´α) and C(4´α));64.7,64.5(C(6´α and 6´β)); 47.4 (C(5)); 
34.6(C(3)); 27.7 (C(2)).   
 
α/β ratio by 13C-NMR ≈ 0.47 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 294.0; [M-CF3COO¯+ H] 
+=295.0; [M-CF3COO¯-NH3] +=276.1 
 
HR-MS [M- CF3COO¯] + = 294.1181 (calculated = 294.1189) 
 
 
9.2.2. Synthesis of 1´-O-(ALA)-sugars  
9.2.2.1. Synthesis of 1´- O-(ALA) α/β-D-glucose  
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 The synthesis of 1´-O-(ALA)-α/β-D-glucose was carried out using Boc-ALA-acid and 
benzyl protection &deprotection methodology. This method employed DMAP & EDCI 
coupling method to obtain β anomer and catalytic DMAP & DCC coupling method to 
obtain α anomer. Also the synthesis of 1´-O-(ALA)-α-D-glucose was attempted using 
activated ester (Boc-ALA-PFPester) and azido levulinic acid chloride and deprotonation 
by BuLi or NaH. 
9.2.2.1.1. Synthesis of 1´- O-(ALA) α/β-D-glucose using Boc-ALA acid 
9.2.2.1.1.1. Synthesis of 1,2,3,4,6-Penta-O-benzyl α/β-D-glucose (penta benzyl 
glucose)      
O
HO
HO
OH
OH
OH
O
BnO
BnO
OBn
OBn
C6H12O6
[180.16]
C41H42O6
[630.77]
BnBr, TBAI
NaH, DMF
Br
BnBr =
C7H7Br
[171.04]
OBn
13 30
 
 
541 mg (3.0 mmol, 1eq) of glucose was taken in a dry flask under argon atmosphere and 
was dissolved in 20 ml anhydrous DMF. The mass was cooled to -200C and added 730 
mg (30.0 mmol, 10eq, 2eq per –OH) sodium hydrid (purity=99%) in portionwise. The 
reaction mass was warmed to ambient temperature and kept at that temperature for 2hrs. 
Then the mass was cooled to 50C, added 55.5 mg (0.15 mmol, 0.05eq) of tetra butyl 
ammonium iodide (TBAI) and then 5.13 g (3.6 ml, 30.0mmol, 10eq, 2 eq per –OH) of 
Benzyl bromide was added drop wise by syringe. The reaction mass was maintained at 
ambient temperature for 48hrs.Later, the mass was cooled to 50C and quenched with 
20ml methanol. The crude product was extracted with 200ml EtOAc and 200ml water. 
The aqueous layer is extracted with 3×200ml EtOAc. The organic layer was combined 
and washed with 200ml brine. The organic layer was dried over MgSO4 and the solvent 
was evaporated off till 600C /40 mbar to remove DMF. The crude residue was subjected 
to flash chromatography (silica gel- 50 times of the residue mass) using gradient eluent 
from 100% hexane to 80:20 Hexane: Ether. The pure fractions were collected and 
concentrated to afford 1.4g pure 1,2,3,4,6-Penta-O-benzyl α/β-D-glucose (penta benzyl 
glucose). (Yield=74%). 
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Batch: RV81, RV137, RV229, RV248, VW24 
 
Rf: (Hexane / Ether 80:20): 0.36 (UV 254 active; KMnO4) 
 
IR (KBr) :   3435w,  3088w,  3064w, 3031m, 2914m , 2868m, 2809w, 1956w, 1874w, 
1808w, 1636w, 1605w, 1587w,1496m, 1453m, 1402w, 1363m, 1314w, 1277w, 1236w, 
1215m, 1197w, 1157w, 1120s, 1074vs, 1041m, 1028s, 1002m, 949m, 909m, 831w, 753s, 
736s, 698vs, 679w, 630w, 610w, 587w, 576w, 558w, 532w, 508w, 500w, 459w. 
   
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.44-7.21 (m, 25H, Haromatic); 5.01(d, 
2J1a-1a´=11.9Hz, 1H, HC(1a)); 4.99 (d, 2J2a-2a´=10.9Hz, 1H, HC(2a)); 4.96 (d, 2J3a-
3a´=10.9Hz, 1H, HC(3a)); 4.89 (d, 3J1-2=3.6Hz, 1H, HC(1α)); 4.86 (d, 2J4a-4a´=10.8Hz, 1H, 
HC(4a)); 4.82 (d, 2J3a-3a´=10.9Hz, 1H, HC(3a´)); 4.76 (d, 2J2a-2a´=10.9Hz, 1H, HC(2a´)); 
4.71 (d, 2J1a-1a´ ≈11.9Hz, 1H, HC(1a´ )); 4.67 (d, 2J6a-6a´=12.2Hz, 1H, HC(6a)); 4.64 (d, 2J6a-
6a´ ≈12.2Hz, 1H, HC(6a´ ); 4.61 (d, 2J4a-4a´ ≈10.8Hz, 1H, HC(4a´)); 4.55 (d, 3J1-2 =7.9Hz, 
1H, HC(1β)); 3.80 (dd, 3J5-6 ≈ 2.0Hz, 3J6 – 6´ ≈11.0Hz ,1H, HC(6β)) ;3.74 (dd, 3J5-6a ≈ 
5.0Hz, 3J6 – 6´ =11.8Hz ,1H, HC(6´β)); 3.73-3.50 (m, 4H, HC(2β), HC(3β), HC(4β) and 
HC(5β)). 
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.8-137.2 ((C11), (C21), (C31), (C41) 
and (C61) of α and β); 128.4-127.5 ((C12,C13,C14, C22,C23,C24, C32,C33,C34, 
C42,C43,C44, C62,C63,C64) of α and β);102.6 (C(1β)); 95.7 (C(1α)); 84.7, 82.3, 77.9, 74.9 
(C(2β), C(3β), C(4β), C(5β)); 75.6, 75.0, 74.8, 73.5, 71.1 (C(1a), C(2a), C(3a), C(4a), 
C(6a)); 68.9 (C(6β)) 
 
α/β ratio by 13C-NMR ≈ 0.21 : 1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 653.5 
 
9.2.2.1.1.2. Synthesis of 2,3,4,6-tetra-O-benzyl α/β-D glucose from 1,2,3,4,6-penta-O-
benzyl α/β-D-glucose by catalytic hydrogenolysis 
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 C34H36O6
[540.64]
HCOONH4
H2C
Bn =
C41H42O6
[630.77]
Pd-Al2O3O
BnO
BnO
OBn
OBn
OBn
O
BnO
BnO
OBn
OBn
OH
30 31
 
 630.7mg (1.0 mmol, 1eq) of 1,2,3,4,6-Penta-O-benzyl α/β-D-glucose was dissolved in 
50ml methanol at ambient temperature. Then, 986mg (15.6 mmol, 15.6 eq) of ammonium 
formate was added followed by the addition of 2000mg (0.94 mmol, 0.94 eq) of 5% 
Palladium over alumina. The reaction mixture was maintained at ambient temperature for 
10hrs. Once the starting material is absent (controlled by TLC Hexane: Ether = 80:20), 
the palladium is filtered over celite and the solvent evaporated off. The crude is subjected 
to flash chromatography (silica gel- 50 times of the residue mass; eluent =9:1 CH2Cl2: 
EtOAc) which afforded 329mg of pure 2,3,4,6-tetrabenzyl glucose. (Yield= 60.8%)                                         
O
O
O
O
O
12
3
4 56
21
22
23
24
2a
3a
4a
6a
OH
 
Batch: RV96, RV137. 
 
Rf: (CH2Cl2: EtOAc  9:1): 0.37 (UV 254 active; KMnO4) 
 
IR (KBr) : 3367s, 3107w, 3088w, 3063m, 3030s, 2916s, 2861s, 2759w, 1947w, 1870w, 
1806w, 1724w, 1604w, 1586w,1496m, 1470w,1453s, 1400m, 1358s, 1326w, 1311w, 
1275w, 1260w, 1213m, 1147vs, 1088vs, 1073vs, 1047vs, 1028vs, 1002m, 936w, 905w, 
858w, 837w, 782w, 744vs, 695vs, 627w, 609w, 597w, 576w, 547w, 560w, 528w, 500w, 
463w. 
   
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.40-7.16 (m, 20H, Haromatic); 5.27 (d, 
3J1-2=3.5Hz, 1H, HC(1α)); 5.01- 4.50 (m, H2CPh (α and β) and HC(1β)); 4.10-4.07 (m, 
1H, HC(5α)); 4.03  (t, 3J3-2= 9.3Hz, 1H, HC(3α)); 3.76-3.56 (m, 8H, H2C(6α), H2C(6β), 
HC(4α),HC(4β)),HC(5β), HC(3β)); 3.62 (dd, 3J1-2=3.6Hz, 3J2-3=9.5Hz, 1H, HC(2α)); 3.45 
(dd, 3J1-2=7.8Hz, 3J2-3=9.5Hz, 1H, HC(2β))  
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. (α anomer= 
major) 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 139.1-138.2 ((C21), (C31), (C41) and 
(C61) of α and β );128.9-128.0 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) 
of α and β; 97.9 (C(1β)); 91.7 (C(1α)); 83.5(C(2β)); 82.2 (C(3α)); 80.4(C(2α)); 
70.7(C(5α)); 69.3(C(6β)); 69.0 (C(6α)); 85.0, 78.2, 78.1, 75.0 (C(3β), C(4β), C(5β) and 
C(4α)); 76.2, 76.1,75.4, 75.2, 75.0, 73.9, 73.6 (C(2a), C(3a), C(4a) and C(6a) of both α and 
β). 
 
α/β ratio by 13C-NMR ≈ 2.6 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 563.3 
9.2.2.1.1.3. Synthesis of 2,3,4,6-tetra-O-benzyl α/β-D glucose from 1,2,3,4,6-penta-O-
benzyl α/β-D-glucose by acidic hydrolysis 
 
C34H36O6
[540.64]
H2C
Bn =
C41H42O6
[630.77]
O
BnO
BnO
OBn
OBn
OBn
O
BnO
BnO
OBn
OBn
OH
6N HCl
CH3COOH
30 31
 
 5500 mg (8.72 mmol, 1eq) of 1,2,3,4,6-Penta-O-benzyl α/β-D-glucose was taken in a dry 
flask and was dissolved in 110 ml acetic acid. Then 16.5 ml of 6N HCl was added. The 
solution is heated to 600C. The mass was maintained at 600C and was taken for workup 
once the starting material was absent by TLC (approximately 4 to 6hrs, TLC eluent = 
Hexane: EtOAc 8:2). The mixture was diluted with 400ml water, extracted with 3×250ml 
CH2Cl2. The organic layer was washed with 300ml saturated NaHCO3 aqueous solution 
and then with 300ml water. The organic layer was dried over MgSO4, concentrated and 
the residue was subjected to flash chromatography which further afforded 2.74 g pure 
2,3,4,6-tetra-O-benzyl α/β-D glucose (major α anomer; Yield= 58.1%)  
O
O
O
O
O
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OH
 
Batch: RV232, RV252, VW27 
 
Rf: (CH2Cl2: EtOAc  9:1): 0.34 (UV 254 active; KMnO4) 
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IR (KBr) : 3435s, 3065w, 3031w, 2919m, 2863m, 1629m, 1497m, 1453s, 1400m, 1363m, 
1327w, 1259w, 1209m, 1147vs, 1088vs, 1073vs, 1028vs, 1001m, 858w, 837w, 745vs, 
696vs,  608w, 500w, 462w. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.37-7.16 (m, 20H, Haromatic); 5.26 (d, 
3J1-2=3.5Hz, 1H, HC(1α)); 4.99- 4.50 (m, H2CPh (α and β) and HC(1β)); 4.07 (ddd, 1H, 
3J5´-6´a ≈ 2.0 Hz, 3J5´-6´b ≈ 4.0Hz, 3J5´-4´ =10.0Hz,1H, HC(5α)); 4.00  (t, 3J3-2= 9.3Hz, 1H, 
HC(3α)); 3.75-3.65 (m, 8H, H2C(6α), H2C(6β), HC(4α).HC(4β)), HC(5β) and 
HC(3β)););3.62 (dd, 3J1-2=3.6Hz,3J2-3=9.5Hz, 1H, HC(2α)); 3.43 (dd, 3J1-2=7.7Hz, 3J2-
3=9.5Hz, 1H, HC(2β)).  
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. (α anomer= 
major) 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.6-137.7 ((C21), (C31), (C41) and 
(C61) of α and β );128.5-127.6 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) 
of α and β; 97.4 (C(1β)); 91.3 (C(1α)); 83.1(C(2β)); 81.7 (C(3α)); 80.0(C(2α)); 
70.3(C(5α)); 68.8(C(6β)); 68.50 (C(6α)); 84.5, 77.7, 77.6, 74.7 (C(3β), C(4α), C(4β) and 
C(5β)); 75.7, 75.6, 75.0, 74.7, 73.5, 73.4, 73.2 (C(2a), C(3a), C(4a) and C(6a) of both α 
and β). 
 
α/β ratio by 13C-NMR ≈ 2.7 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 563.3 
9.2.2.1.1.4. Synthesis of α-Methyl 2,3,4,6-tetra-O-benzyl glucoside 
   
O
HO
HO
OH
OH
C7H14O6
[194.18]
C35H38O6
[554.67]
BnBr, TBAI
NaH, DMF
Br
BnBr =
C7H7Br
[171.04]
OCH3
O
BnO
BnO
OBn
OBn
OCH3
32 33
 
3890 mg (20.0 mmol, 1eq) of α-methyl glucoside was taken in a dry flask under argon 
atmosphere and was dissolved in 100 ml anhydrous DMF. The mass was cooled to -100C 
and added 7000 mg (160.0 mmol, 8eq, 2eq per –OH) sodium hydrid (55% dispersion in 
mineral oil) in portionwise. The reaction mass was warmed to ambient temperature and 
kept at that temperature for 2hrs. Then the mass was cooled to 50C, added 370 mg (1.0 
mmol, 0.05eq) of tetra butyl ammonium iodide (TBAI) and then 20.5 g (14.2 
ml,120.0mmol, 6eq, 1.5 eq per –OH) of Benzyl bromide was added drop wise by syringe. 
The reaction mass was maintained at ambient temperature for 24hrs.Later, the mass was 
cooled to 50C and quenched with 40ml methanol. The crude product was extracted with 
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 300ml EtOAc and 400ml water. The aqueous layer is extracted with 3×200ml EtOAc. 
The organic layer was combined and washed with 300ml brine. The organic layer was 
dried over MgSO4 and the solvent was evaporated off till 600C /40 mbar to remove DMF. 
The crude residue was subjected to flash chromatography (silica gel- 40 times of the 
residue mass) using 80:20 Hexane:EtOAc eluent. The pure fractions were collected and 
concentrated to afford 10.1g pure of α-Methyl 2,3,4,6-tetra-O-benzyl glucoside. 
(Yield=91%).           
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Batch: RV103, RV142, RV148 
 
Rf: (Hexane: EtOAc 8:2): 0.26 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.49-7.26 (m, 25H, Haromatic); 5.12 (d, 
2J2a-2a´=10.9Hz, 1H, HC(2a)); 4.97 (d, 2J3a-3a´=10.8Hz, 1H, HC(3a)); 4.96 (d, 2J2a-
2a´=10.9Hz, 1H, HC(2a´ )); 4.91 (d, 2J4a-4a´=12.1Hz, 1H, HC(4a)); 4.78 (d, 2J4a-4a´ ≈12.1Hz, 
1H, HC(4a´)); 4.77 (d, 3J1-2 ≈3.5Hz, 1H, HC(1α)); 4.72 (d, 2J6a-6a´=12.1Hz, 1H, HC(6a)); 
4.61 (d, 2J3a-3a´=10.8Hz, 1H, HC(3a´)); 4.59 (d, 2J6a-6a´ =12.1Hz, 1H, HC(6a´ ); 4.14 (t, 3J3-2 
≈ 10Hz, 3J3-4 ≈ 10Hz, 1H, HC(3α)); 3.90-3.75 (m,3H, HC(4α),HC(5α) and HC(6α)); 3.70 
(dd, 3J2-1 ≈ 3.5Hz, 3J2 -3 ≈10.0Hz ,1H, HC(2α)); 3.50 (s,3H, H3C(11). 
 
α/β ratio by 1H-NMR = Only α anomer. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 139.3-138.5((C21), (C31), (C41)and 
(C61) ); 128.9-128.1 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64); 
98.7(C(1α)); 82.7 (C(3α)); 80.4(C(2α)); 78.2,70.6 (C(5α) and C(4α)); 69.0(C(6α)); 76.2, 
75.5, 74.0, 73.9(C(2a), C(3a), C(4a) and C(6a); 55.7 (C(11)).; α/β ratio by 13C-NMR = 
Only α anomer. 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 577.5 
9.2.2.1.1.5. Synthesis of 2,3,4,6-tetra-O-benzyl α/β-D glucose from α-methyl 2,3,4,6-
tetra-O-benzyl glucoside  
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BnO
BnO
OBn
OBn
C35H38O6
[554.67]
Br
BnBr =
C7H7Br
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CH3COOH
CF3SO3H
C34H36O6
[540.64]
33 31
 
4458 mg (8.03 mmol, 1eq) of α-Methyl 2,3,4,6-Tetra-O-benzyl glucoside was taken in a 
dry flask under argon atmosphere and was dissolved in 80 ml acetic acid. The solution is 
heated to 800C and then 16ml (32 mmol, 4eq) of 2M aqueous trifluoromethanesulfonic 
acid was added drop wise. The mass was maintained at 800C for 7hrs, cooled and diluted 
with 150ml CH2Cl2. The mixture was washed with 2×100ml saturated NaHCO3 aqueous 
solution and then with 2×200ml water. The organic layer was dried over MgSO4, 
concentrated and the residue was taken for crystallisation with minimum quantity of 
EtOAc which afforded 1.44 g pure 2,3,4,6-Tetra-O-benzyl α/β-D glucose. The filtrate 
after crystallisation was concentrated and was subjected to flash chromatography which 
further afforded 1.1 g pure 2,3,4,6-tetra-O-benzyl α/β-D glucose. (Yield= 58.5%) 
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Batch: RV110, RV144, RV149 
 
Rf: (CH2Cl2: EtOAc  9:1): 0.38 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.40-7.16 (m, 20H, Haromatic); 5.27 (d, 
3J1-2=3.5Hz, 1H, HC(1α)); 5.01- 4.50 (m, H2CPh (α and β) and HC(1β)); 4.10-4.07 (m, 
1H, HC(5α)); 4.03  (t, 3J3-2= 9.3Hz, 1H, HC(3α)); 3.76-3.56 (m, 8H, H2C(6α), H2C(6β), 
HC(4α),HC(4β)),HC(5β), HC(3β)); 3.62 (dd, 3J1-2=3.6Hz, 3J2-3=9.5Hz, 1H, HC(2α));  
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap.(α anomer= 
major) 
 
9.2.2.1.1.6. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA)  β-D-glucose 
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2440 mg (4.51 mmol, 1eq) of  2,3,4,6-Tetra- O-benzyl glucose (α anomer major ≈ 70%) 
was taken in a dry flask under argon atmosphere and was dissolved in 50 ml CH2Cl2. The 
solution was cooled to 00C, added 607 mg (4.97 mmol, 1.1eq) of DMAP, then 1052 mg 
(5.49 mmol, 1.2eq) of EDCI and finally 1150 mg (4.97 mmol, 1.1eq) of Boc-ALA acid. 
The reaction was warmed to ambient temperature and maintained at that temperature for 
5 hrs (controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). The mixture was then 
diluted with 300ml water, extracted with 2×250ml EtOAc. The organic layer was washed 
with 300ml 1M citric acid aqueous solution  followed by  300ml NaHCO3 aqueous 
solution and then with 300ml brine. The organic layer was dried over MgSO4, 
concentrated and the residue was subjected to flash chromatography  (silica gel- 70times 
of the residue mass) which further afforded 3.0 g pure  2´,3´,4´,6´-tetra-O- benzyl 1´-O-
(BOC-ALA) α / β-D-glucose (major β anomer; Yield= 88.1%) 
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Batch: RV 119, RV130, RV138, RV152, VW39 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.19 (UV 254 active; KMnO4) 
 
IR (KBr) : 3426w, 3089w, 3063m, 3031m, 2977s, 2923s, 2869s, 2315w, 1954w, 1876w, 
1809w, 1755vs, 1738vs, 1713vs, 1605w, 1586w, 1497s, 1454s, 1392w, 1366s, 1309w,  
1250m, 1159s, 1075vs, 1028m,  910w, 873w, 780w, 737s, 698s, 603w, 560w, 463w. 
   
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.38-7.15 (m, 20H, Haromatic); 6.35 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.64 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 5.22 (s, 1H, HN); 4.99- 
4.49 (m, H2CPh (α and β)) ; 4.05 (d, 3J5-NH=4.6Hz, H2C(5)); 3.95  (t, 3J3-2= 9.3Hz, 1H, 
HC(3´α)); 3.89 (m, 1H, HC(5´α)); 3.79-3.69 (m, 6H, HC(3´β), HC(4´α),HC(4´β) , 
HC(5´β)), H2C(6´α)  and H2C(6´β)) ; 3.69-3.66 (m, 1H, HC(2´α)); 3.64-3.57 (m, 1H, 
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 HC(2´β)); 2.77-2.60 (m, 4H ,H2C(3) and H2C(2)); 1.48 (s, 9H, H3C (8a, 8b and 8c)) ; 
4.80, 4.17-4.11, 2.0, 1.29-1.26 (EtOAc solvent impurity). 
 
α/β ratio by 1H-NMR = 0.28 : 1  
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.2 (C(4)); 171.6 (C(1)); 156.1 
(C(6)) ; 139.0-138.0 ((C21), (C31), (C41) and (C61) of α and β); 128.9-128.1 
((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) of α and β); 94.77 (C(1´β)); 90.9 
(C(1´α)); 82.0 (C(3´α)); 81.4 (C(2´β)); 80.3 (C(7)); 79.2 (C(2´α)); 73.3(C(5´α)); 68.5 
(C(6´β) and C(6´α)); 85.2, 77.6, 77.2, 76.0 (C(3´β), C(4´α) C(4´β) and  C(5´β)); 76.1, 
75.7, 75.4, 74.0, 73.6  (C(2a), C(3a), C(4a) and C(6a) of both α and β); 50.7 (C(5)); 34.6 
(C(3) of α) ;34.4 (C(3) of β) ;28.7 (C(8a,8b and8c); 28.3 (C(2)) and other peaks due to 
traces of EtOAc solvent.; α/β ratio by 13C-NMR ≈ 0.4 : 1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 776.3 
 
HR-MS [M+ Na] + = 776.3400 (Calculated =776.3410) 
9.2.2.1.1.7. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α -D-glucose 
using cat.DMAP & DCC 
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1520 mg (2.81 mmol, 1eq) of 2,3,4,6-Tetra- O-benzyl glucose (α anomer major ≈ 73%) 
was taken in a dry flask under argon atmosphere and was dissolved in 50 ml CH2Cl2. The 
solution was cooled to 00C, added 1050 mg (4.54 mmol, 1.6eq) of Boc-ALA acid  
followed by 930 mg (4.50 mmol, 1.6eq) of DCC and finally 10 mg (0.082 mmol, 0.03 eq) 
of DMAP in a catalytic amount. The reaction was warmed to ambient temperature and 
maintained at that temperature for 5 hrs (controlled by TLC, eluent 7:3 Hexane: EtOAc 2 
times). The mixture was filtered over celite bed  and the filtrate was concentrated .The 
residue was subjected to flash chromatography  (silica gel- 70times of the residue mass) 
which afforded 1931 mg pure  2´,3´,4´,6´-Tetra-O- benzyl 1´-O-(BOC-ALA) α -D-
glucose (major α anomer; Yield= 91.1%) 
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Batch: RV 268, RV269, VW 28 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.19 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.39-7.19 (m, 20H, Haromatic); 6.39 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.68 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 5.30 (s, 1H, HN); 5.01 (d, 
2J2a-2a´=10.9Hz, 1H, HC(2a)); 4.90 (d, 2J3a-3a´=10.7Hz, 1H, HC(3a)); 4.89 (d, 2J2a-
2a´=10.9Hz, 1H, HC(2a´ )); 4.72 (d, 2J4a-4a´=11.5Hz, 1H, HC(4a)); 4.67 (d, 2J4a-4a´ =11.5Hz, 
1H, HC(4a´)); 4.65 (d, 2J6a-6a´=12.1Hz, 1H, HC(6a))  ; 4.57 (d, 2J3a-3a´=10.7Hz, 1H, 
HC(3a´)); 4.52 (d, 2J6a-6a´ =12.1Hz, 1H, HC(6a´ ) and other small peaks in this region due to 
H2CPh of  β anomer); 4.05 (d, 3J5-NH ≈ 4.0Hz, 2H, H2C(5)); 3.99  (t, 3J3-2= 9.3Hz, 1H, 
HC(3´α)); 3.93 (m, 1H, HC(5´α)); 3.83 - 3.69 (m, 6H, HC(3´β), HC(4´α),HC(4´β) , 
HC(5´β)), H2C(6´α), H2C(6´β), HC(2´α)); 3.68-3.61 (m, 1H, HC(2´β)); 2.76 - 2.67 (m, 4H 
,H2C(3) and H2C(2)); 1.49 (s, 9H, H3C (8a, 8b and 8c)) ; 3.53 – 3.42, 1.50 (peaks due to 
traces of impurity). 
 
α/β ratio by 1H-NMR = 6.9 : 1  
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 203.9 (C(4)); 171.0 (C(1)); 155.6 
(C(6)) ; 138.5-137.5 ((C21), (C31), (C41) and (C61) of α and β); 128.4 - 127.6 
((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) of α and β); 94.3 (C(1´β)); 90.4 
(C(1´α)); 81.6 (C(3´α)); 80.8 (C(2´β)); 79.7  (C(7)); 78.7  (C(2´α)); 72.8 (C(5´α)); 68.0 
(C(6´α) and C(6´β)); 84.7, 77.1, 76.8, 75.5  (C(3´β), C(4´α) C(4´β) and  C(5´β)); 75.6, 
75.2,  73.4, 73.1  (C(2a), C(3a), C(4a) and C(6a) of α anomer); 50.2 (C(5)); 34.1 (C(3) ); 
28.3 (C(8a,8b and8c); 27.8  (C(2)). 
 
α/β ratio by 13C-NMR ≈ 4.2 : 1 
 
MS (ESI (+)): m/z relative intensity [M+Na] + = 776.4  
 
HR-MS [M+ Na] + = 776.3407 (calculated =776.3410) 
9.2.2.1.1.8. Synthesis of 1´- O-(BOC-ALA) α / β-D-glucose 
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3000 mg (3.98 mmol, 1eq) of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α /β -D-
glucose (to obtain β anomer product as major, starting material having major β anomer 
was taken and to obtain α-anomer product as major, starting material having major α 
anomer was taken) was taken in a dry flask under argon atmosphere and was dissolved in 
100 ml CH2Cl2 and then 50 ml EtOH was added. To this solution was added 4234 mg 
(3.98 mmol, 1.0eq) of 10% Pd over activated carbon. The reaction mass was agitated 
under H2 pressure of 60psi for 12 hrs. Later, the mixture was filtered over celite bed  and 
the filtrate was concentrated .The residue was subjected to flash chromatography  (silica 
gel- 40times of the residue mass) which afforded 1513 mg pure  1-O-(BOC-ALA) α/β -
D-glucose (major β anomer; Yield= 96.7%). In the case of α- anomer, the residue after 
flash chromatography furnished 97% yield composing approximately 65-70% α- anomer  
which was further subjected to flash chromatography to afford  1´-O-(BOC-ALA) α -D-
glucose (~90% α- anomer) with 50% yield. 
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Batch: RV 120, RV146, RV154 (β anomer); RV 272, RV 288 (α anomer) 
 
Rf: (CH2Cl2 / MeOH 8:2):   = 0.37 (KMnO4) 
 
Major β- anomer: 
 
IR (KBr) : 3398s, 2924vs, 2854m, 2508vw, 2046vw, 1730vs, 1688vs, 1517m, 1433s, 
1368s, 1255s, 1167vs, 1082s, 1041s, 992s, 897w, 780w, 736w, 581vw, 464vw. 
 
1H-NMR (400 MHz, CDCl3 and CD3OD, 298 K): δH (ppm) = 6.78 (sbr, NH); 6.10 (d, 
3J1´-2´=3.5Hz, 1H, HC(1´α)); 5.47 (d, 3J1´-2´=8.0Hz, 1H, HC(1´β)); 3.94 (s, H2C(5)); 3.84 
(dd, 3J6´a -5´ ≈2.0Hz, 3J6´a -6´b ≈12.0Hz 1H, HC(6´a β)); 3.78 (dd, 3J6´a -5´ ≈2.5Hz, 3J6´a -6´b 
≈12.0Hz 1H, HC(6´a α)); 3.73-3.62  (m, 4H, HC(6´bα),HC(6´bβ),HC(5´α) and HC(3´α)); 
3.58 (dd,3J1´-2´≈3.5Hz,3J2´-3´=9.5Hz,1H,HC(2´α));3.43-3.32 (m, 5H, HC(2´β), HC(3´β), 
HC(4´β), HC(5´β) and HC(4´α))); 2.82 - 2.70 (m, 4H ,H2C(3) and H2C(2)); 1.46 (s, 9H, 
H3C (8a, 8b and 8c)) ; 5.51(CH2Cl2) 
α/β ratio by 1H-NMR ≈ 0.30 : 1  
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 13C-NMR (100 MHz, CDCl3 and CD3OD, 298K) : δC (ppm) = 207.2 (C(4)); 173.2 
(C(1α)); 173.1 (C(1β); 158.4 (C(6)) ; 95.8 (C(1´β)); 93.7 (C(1´α)); 80.6 (C(7)); 78.7, 
77.8, 73.9,70.9 (C(2´β), C(3´β), C(4´β) and C(5´β)); 72.2 (C(2´α)); 75.9, 74.8,70.9 
((C(3´α)), C(4´α) and (C(5´α)); 62.2 (C(6´β)); 62.1 (C(6´α); 54.8 (CH2Cl2); 50.7 (C(5)); 
34.9 (C(3 of α)); 34.7 (C(3 of β));28.7 (C(8a,8b and8c) and (C(2)). 
 
α/β ratio by 13C-NMR ≈ 0.30 : 1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.1 
 
HR-MS [M+ Na] + = 416.1528 (calculated = 416.1533) 
 
Major α- anomer: 
 
IR (KBr) : 3410vs, 2978m, 2925m, 1730vs, 1698vs, 1518m, 1393s, 1368s, 1254s, 
1167vs, 1085s, 1049m, 1025m, 992m, 896w, 781w, 582vw, 464vw. 
 
1H-NMR (400 MHz, CDCl3 and CD3OD, 298 K): δH (ppm) = 6.68 (sbr, NH); 6.08 (d, 
3J1´-2´=3.5Hz, 1H, HC(1´α)); 5.45 (d, 3J1´-2´=8.0Hz, 1H, HC(1´β)); 3.93 (s, H2C(5)); 3.78 
(dd, 3J6´a -5´ ≈2.5Hz, 3J6´a -6´b ≈12.0Hz 1H, HC(6´α)); 3.73-3.61  (m, 3H, HC(6´bα),HC(5´α) 
and HC(3´α)); 3.55 (dd, 3J1´-2´ ≈3.5Hz, 3J2´ -3´ =9.7Hz 1H, HC(2´α)); 3.42 (t, 3J3´-4´ ≈9.5Hz, 
3J3´ -4´ ≈9.5Hz 1H, HC(4´α)); 2.81 - 2.68 (m, 4H ,H2C(3) and H2C(2)); 1.43 (s, 9H, H3C 
(8a, 8b and 8c)) ; 5.23-4.81, 4.73-3.97, 1.39-1.23 (peaks due to impurity). 
 
α/β ratio by 1H-NMR ≈ 7 :1  
 
13C-NMR (100 MHz, CDCl3 and CD3OD, 298K) : δC (ppm) = 206.8 (C(4)); 172.9 
(C(1)); 157.9 (C(6)) ;  93.5 (C(1´α)); 80.5 (C(7)); 71.8 (C(2´α)); 75.4, 74.4, 70.5 
((C(3´α)), C(4´α) and (C(5´α)); 61.9 (C(6´α); 50.5 (C(5)); 34.7 (C(3)); 28.6 (C(8a,8b 
and8c) ; 28.5 (C(2)). 
 
α/β ratio by 13C-NMR ≈ 7.7 : 1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.1 
 
HR-MS [M+ Na] + = 416.1529 (calculated = 416.1533) 
 
9.2.2.1.1.9. Synthesis of 1´- O-(ALA) α / β-D-glucose: 
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1240 mg (3.15 mmol, 1eq) of 1´-O-(BOC-ALA) α / β- glucose was dissolved in 50ml 
CH2Cl2 and cooled to -100C. To this solution, 28.7g (19.3ml, 252mmol, 80 eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was triturated with dry ether and the ether solution was decanted. The 
trituration with ether and decanting top clear ether solution after centrifuge was repeated 
2 times more. Then, the settled solid product was purified by dissolving in 4ml MeOH 
and precipitated by adding 20ml ether. The mass was centrifuged, the settled solid on 
drying yielded 818 mg of highly hygroscopic white solid. (Yield=64 % for β anomer and 
73% for α anomer). 
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Batch:  RV 125, 146, RV155, RV167 (β anomer); RV 277, RV 293 (α anomer) 
 
Major β- anomer: 
 
IR (KBr) : 3054s, 2922s, 2681m, 2630w, 2046vw, 1738vs, 1688vs, 1635w, 1577m, 
1540w, 1453m, 1433s, 1407m, 1392m, 1381vw, 1373vw, 1362w, 1343w, 1276w, 1255s, 
1207vs 1181vs, 1135vs, 1096w, 1041s, 1000w, 966w, 944m, 907vw, 871w, 839s, 797s, 
723vs,  670vw, 604w, 560w, 519w, 500w, 462vw. 
   
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 6.06 (d, 3J1´-2´=3.5Hz, 1H, HC(1´α)); 5.51 
(d, 3J1´-2´=8.0Hz, 1H, HC(1´β)); 4.10 (s, H2C(5)); 3.85 (dd, 3J6´a -5´ ≈2.0Hz, 3J6´a -6´b 
≈12.0Hz 1H, HC(6´a β)); 3.81- 3.73 (m,2H,6´a α and 6´b α); 3.68 (dd, 3J6´b -5´ ≈ 5.4Hz, 
3J6´a -6´b ≈12.0Hz 1H, HC(6´b β)); 3.56-3.49  (m, 2H, HC(3´β) and HC(5´β)); 3.46-3.37 (  
(m, 2H, HC(2´β) and HC(4´β)); 2.85 - 2.68 (m, 4H ,H2C(3) and H2C(2)); other peaks due 
to ether solvent. 
 
α/β ratio by 1H-NMR ≈ 0.1 : 1  
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 13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.3 (C(4 of α); 203.9 (C(4) of β) ; 
173.9 (C(1) of α); 173.6 (C(1) of β) ; 163.1 (q,2JC-F ≈ 36.0, CF3COO¯ ); 116.6 (q,1JC-F 
=291.0, CF3COO¯ ); 94.5 (C(1´β)); 92.8 (C(1´α)); 77.1 (C(5´β)); 75.7 (C(3´β)); 72.2 
(C(2´β)); 69.4 (C(4´β)); 60.7 (C(6´β ));  47.3 (C(5)); 34.3 (C(3)); 27.7 (C(2)) and peaks 
due to ether solvent.  
  
α/β ratio by 13C-NMR ≈ 0.15 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 294.1; [M-H+Na] + = 316.2;   
  
HR-MS [M- CF3COO¯] + = 294.1185 (calculated = 294.1189) 
 
Major α- anomer: 
 
[α]D = +128.1 (c=0.24; deionized H2O) 
 
IR (KBr) : 3379vs, 2929s, 2345vw, 1789s,1734vs, 1678vs, 1516m, 1428s, 1384s, 1356m,   
1204vs 1190vs, 1139vs, 1083s, 1050s, 1029s, 992m, 957w, 905w, 839m, 801m, 775w, 
723m,  598w, 552w, 521w, 464vw. 
   
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.95 (d, 3J1´-2´=3.5Hz, 1H, HC(1´α)); 5.38 
(d, 3J1´-2´=8.0Hz, 1H, HC(1´β)); 3.97 (s, H2C(5)); 3.66 – 3.50 (m, 5H, 2´α, 3´α, 5´α, 6´a α 
and 6´b α); 3.33 (t, 3J4´ -3´ ≈ 9.2Hz, 3J4´ -5´ ≈ 9.2Hz 1H, HC(4´α);  2.81 - 2.65 (m, 4H 
,H2C(3) and H2C(2)); other small peaks due to β anomer and ether solvent . 
 
α/β ratio by 1H-NMR ≈ 13 :1  
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 203.9 (C(4); 173.9 (C(1) ; 163.0 (q,2JC-F 
≈ 36.0, CF3COO¯ ); 116.4 (q,1JC-F ≈ 291.0, CF3COO¯ ); 94.4 (C(1´β)); 92.7 (C(1´α)); 
74.2 (C(5´α)); 73.0 (C(3´α)); 70.3 (C(2´α)); 69.0 (C(4´α)); 60.4 (C(6´α ));  47.2 (C(5)); 
34.3 (C(3)); 27.6 (C(2)) and other small peaks due to β anomer and ether solvent 
 
α/β ratio by 13C-NMR ≈ 13 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 293.9; [M- CF3COO¯+H+Na] + = 
316.1; [M- CF3COO¯+H2O] + = 276.0;   
  
HR-MS [M- CF3COO¯] + = 294.11910 (calculated = 294.1189) 
9.2.2.1.2. Synthesis of 1´- O-(ALA) α-D-glucose (using activated ester or 
azidolevulinic acid)  
9.2.2.1.2.1. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α -D-glucose 
using BuLi and act.ester 
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541 mg (1.0 mmol, 1eq) of 2,3,4,6-tetra- O-benzyl glucose (α anomer major ≈ 73%) was 
taken in a dry flask under argon atmosphere and was dissolved in 15 ml THF. The 
solution was cooled to -200C, added 0.45 ml (1.05 mmol, 1,05eq) of 2.5M n-BuLi 
solution in hexane, and followed by 440 mg (1.1 mmol, 1.1eq) of Boc-ALA-PFP ester.  
The reaction was allowed to reach ambient temperature and maintained at that 
temperature for 1 hr (controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). The 
reaction was quenched by adding 20 ml satd.NH4Cl solution, extracted with 4 × 50 ml 
CH2Cl2 . The organic layer was dried over MgSO4 and was concentrated .The residue was 
subjected to flash chromatography  (silica gel- 80times of the residue mass) which 
afforded 230 mg pure  2´,3´,4´,6´-Tetra-O- benzyl 1´-O-(BOC-ALA) α -D-glucose (major 
α anomer; Yield= 30.5%) 
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Batch: RV 257 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.19 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.39-7.18 (m, 20H, Haromatic); 6.37 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.66 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 5.26 (sbr, 1H, HN); 5.00 
(d, 2J2a-2a´=10.9Hz, 1H, HC(2a)); 4.90 (d, 2J3a-3a´=10.6Hz, 1H, HC(3a)); 4.88 (d, 2J2a-
2a´=10.9Hz, 1H, HC(2a´ )); 4.72 (d, 2J4a-4a´=11.5Hz, 1H, HC(4a)); 4.67 (d, 2J4a-4a´ =11.5Hz, 
1H, HC(4a´)); 4.65 (d, 2J6a-6a´=12.1Hz, 1H, HC(6a)); 4.55 (d, 2J3a-3a´=10.7Hz, 1H, HC(3a´)); 
4.51 (d, 2J6a-6a´ =12.1Hz, 1H, HC(6a´ ) and other small peaks in this region due to H2CPh 
of  β anomer); 4.05 (d, 3J5-NH ≈ 4.6Hz, 2H, H2C(5)); 3.99  (t, 3J3-2= 9.3Hz, 1H, HC(3´α)); 
3.92 (m, 1H, HC(5´α)); 3.83 - 3.69 (m, 6H, HC(3´β), HC(4´α),HC(4´β) , HC(5´β)), 
H2C(6´α), H2C(6´β), HC(2´α)); 3.68-3.61 (m, 1H, HC(2´β)); 2.77 - 2.69 (m, 4H ,H2C(3) 
and H2C(2)); 1.49 (s, 9H, H3C (8a, 8b and 8c)). 
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 α/β ratio by 1H-NMR = 2.14 : 1  
 
9.2.2.1.2.2. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α -D-glucose 
using NaH and act.ester 
 
C16H16NO5F5
[397.23]
OBocHN
O
O F
F
F
F
F THF
O
BnO
BnO
OBn
OBn
OH
C34H36O6
[540.64]
NaH O
BnO
BnO
OBn
OBn
NHBoc
O
O
C44H51NO10
[753.87]
O
34 7 35
 
 
271 mg (0.5 mmol, 1eq) of 2,3,4,6-tetra- O-benzyl glucose (α anomer major ≈ 73%) was 
taken in a dry flask under argon atmosphere and was dissolved in 10 ml THF. The 
solution was cooled to -200C, added 21 mg (0.525 mmol, 1,05eq) of sodium hydride 
(60% dispersion in mineral oil). The reaction mixture was brought to 100C and kept at 
100C for an hour. The mixture was again cooled to -200C, added 220 mg (0.55 mmol, 
1.1eq) of Boc-ALA-PFP ester.  The reaction was allowed to reach 00C (starting material 
controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). The reaction was quenched by 
adding 1 ml MeOH and was concentrated .The residue was subjected to flash 
chromatography  (silica gel- 80times of the residue mass) which afforded 100 mg pure  
2´,3´,4´,6´-Tetra-O- benzyl 1´-O-(BOC-ALA) α -D-glucose (major α anomer; Yield= 
26.5%) 
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Batch: RV 258 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.19 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.35-7.14 (m, 20H, Haromatic); 6.37 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.66 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 4.96 (m, 8H, H2CPh of α 
and β anomer); 4.07 (d, 3J5-NH ≈ 4.6Hz, 2H, H2C(5)); 3.93  (t, 3J3-2= 9.3Hz, 1H, HC(3´α)); 
3.92 (m, 1H, HC(5´α)); 3.83 - 3.69 (m, 6H, HC(3´β), HC(4´α),HC(4´β) , HC(5´β)), 
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 H2C(6´α), H2C(6´β), HC(2´α)); 3.68-3.61 (m, 1H, HC(2´β)); 2.78 - 2.69 (m, 4H ,H2C(3) 
and H2C(2)); 1.46 (s, 9H, H3C (8a, 8b and 8c)); other peaks due to Boc-ALA-Ome 
impurity. 
 
α/β ratio by 1H-NMR = 2.76 : 1  
9.2.2.1.2.3. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(Azidolevulinic) α -D-glucose 
using BuLi and act.ester 
THF
O
BnO
BnO
OBn
OBn
OH
C34H36O6
[540.64]
n-BuLi O
BnO
BnO
OBn
OBn
N3
O
O
C39H41N3O8
[679.76]
O
OHN3
O
O
C5H6ClN3O2
[175.57]
ClN3
O
O
C5H7N3O3
[157.13]
C5H6ClN3O2
[175.57]
ClN3
O
O
SOCl2
THF
10 11
34 11 37
 
 
600 mg (3.82 mmol, 1eq) of azidolevulinic acid was taken in a dry flask under argon 
atmosphere and was dissolved in 10 ml THF. Cooled the solution to 00C, added 0.8 ml 
(11.5 mmol, 3eq) of SOCl2 drop wise via syringe. The mixture was brought to ambient 
temperature and kept for 2h. Then the solvent THF and excess SOCl2 were evaporated to 
get azidolevulinic acid chloride. (90% yield assumed 3.44 mmol). 
 
620 mg (1.145 mmol, 1eq) of 2,3,4,6-tetra- O-benzyl glucose (α anomer major ≈ 73%) 
was taken in a dry flask under argon atmosphere and was dissolved in 15 ml THF. The 
solution was cooled to -200C, added 0.5 ml (1.26 mmol, 1.1eq) of 2.5M n-BuLi solution 
in hexane, and followed by the above freshly prepared azidolevulinic acid chloride (3.44 
mmol, 3eq).  The reaction was allowed to reach ambient temperature and maintained at 
that temperature for 1 hr (controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). The 
reaction was quenched by adding 10 ml MeOH and was concentrated .The residue was 
subjected to flash chromatography  (silica gel- 80times of the residue mass) which 
afforded 267 mg pure  2´,3´,4´,6´-Tetra-O- benzyl 1´-O-(Azidolevulinic) α -D-glucose 
(major α anomer; Yield= 34.3%) 
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Batch: RV 260, RV263 
 
Rf: (CH2Cl2 / EtOAc 95:5): 0.37 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.38-7.18 (m, 20H, Haromatic); 6.35 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.66 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 5.00 (d, 2J2a-2a´=10.9Hz, 
1H, HC(2a)); 4.88 (d, 2J3a-3a´=10.7Hz, 1H, HC(3a)); 4.87 (d, 2J2a-2a´=10.9Hz, 1H, HC(2a´ )); 
4.71 (d, 2J4a-4a´=11.5Hz, 1H, HC(4a)); 4.67 (d, 2J4a-4a´ =11.5Hz, 1H, HC(4a´)); 4.64 (d, 2J6a-
6a´=12.1Hz, 1H, HC(6a));  4.55 (d, 2J3a-3a´=10.7Hz, 1H, HC(3a´)); 4.50 (d, 2J6a-6a´ =12.1Hz, 
1H, HC(6a´ ) and other small peaks in this region due to H2CPh of  β anomer); 4.00 (s, 
2H, H2C(5)); 3.99-3.91 (m, 2H, HC(3´α) and HC(5´α)); 3.82 - 3.69 (m, 6H, HC(3´β), 
HC(4´α),HC(4´β) , HC(5´β)), H2C(6´α), H2C(6´β), HC(2´α)); 3.67-3.62 (m, 1H, 
HC(2´β)); 2.78 - 2.67 (m, 4H ,H2C(3) and H2C(2)); 4.14, 3.99, 1.28 (peaks due to solvent 
and impurity). 
 
α/β ratio by 1H-NMR = 5.6 : 1  
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 203.0 (C(4)); 171.0 (C(1)); 138.5-
137.5 ((C21), (C31), (C41) and (C61) of α and β); 128.4 - 127.6 ((C22,C23,C24, 
C32,C33,C34, C42,C43,C44, C62,C63,C64) of α and β); 94.3 (C(1´β)); 90.5 (C(1´α)); 81.6 
(C(3´α)); 78.7 (C(2´β)); 76.7 (C(2´α)); 72.8 (C(5´α)); 68.0 (C(6´α) and C(6´β)); 75.6, 
75.2,  73.4, 73.1  (C(2a), C(3a), C(4a) and C(6a) of α anomer); 57.3 (C(5)); 34.3 (C(3) ); 
27.8   (C(2)); 202.5, 172.2, 57.2, 60.8, 14.0 (peaks due to solvent and impurity). 
 
α/β ratio by 13C-NMR ≈ 4.3 : 1 
9.2.2.1.2.4. Synthesis of 1´- O-(ALA) α -D-glucose 
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485 mg (0.713 mmol, 1eq) of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(Azidolevulinic) α -D-
glucose was taken in a dry flask under argon atmosphere and was dissolved in 40 ml 
methoxy ethanol. To this solution was added 760 mg (0.713mmol, 1.0eq) of 10% Pd over 
activated carbon, followed by 250 mg (0.2 ml, 2.14 mmol, 3eq) of trifluoroacetic acid . 
The reaction mass was agitated under H2 pressure of 60psi for 12 hrs. Later, the mixture 
was filtered over celite bed and the filtrate was concentrated. The product was triturated 
with dry ether and the ether solution was decanted. The trituration with ether and 
decanting top clear ether solution after centrifuge was repeated 2 times more. Then, the 
settled solid product on drying yielded 280 mg of highly hygroscopic white solid. 
(Yield=96.5 %).  
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Batch:  RV 267 
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.92 (d, 3J1´-2´=3.5Hz, 1H, HC(1´α)); 5.38 
(d, 3J1´-2´=8.0Hz, 1H, HC(1´β)); 3.96 (s, H2C(5)); 3.72 – 3.44 (m, 5H, 2´α, 3´α, 5´α, 6´a α 
and 6´b α); 3.32 (t, 3J4´ -3´ ≈ 9.2Hz, 3J4´ -5´ ≈ 9.2Hz 1H, HC(4´α);  2.81 - 2.68 (m, 4H 
,H2C(3) and H2C(2)); 3.96, 3.54, 3.45, 3.27,2.74, 2.61 due to solvent and impurity. 
 
α/β ratio by 1H-NMR ≈ 4 :1  
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.0 (C(4); 174.0 (C(1) ; 163.4 (q,2JC-F 
≈ 35.0, CF3COO¯ ); 116.7 (q,1JC-F ≈ 291.0, CF3COO¯ ); 94.5 (C(1´β)); 92.8 (C(1´α)); 
74.3 (C(5´α)); 73.1 (C(3´α)); 70.4 (C(2´α)); 69.1 (C(4´α)); 60.5 (C(6´α ));  57.8 (C(5)); 
34.5 (C(3)); 27.7 (C(2)); 204.3, 175.3, 73.4, 58.3, 60.5, 47.4, 34.6, 27.9, 17.2 (peaks due 
to solvent and impurity). 
 
 α/β ratio by 13C-NMR ≈ 4 :1 
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 9.2.2.2. Synthesis of 1´- O-(ALA) -α-D-mannose 
9.2.2.2.1. Synthesis of 1,2,3,4,6-Penta- O-benzyl β-mannose (penta benzyl mannose)  
          
OHOHO
OHOH
OH
OBnOBnO
BnOOBn
C6H12O6
[180.16]
C41H42O6
[630.77]
BnBr, TBAI
NaH, DMF
Br
BnBr =
C7H7Br
[171.04]
OBn
24 38
 
2162 mg (12.0 mmol, 1eq) of mannose was taken in a dry flask under argon atmosphere 
and was dissolved in 80 ml anhydrous DMF. The mass was cooled to -200C and added 
4800 mg (120.0 mmol, 10eq, 2eq per –OH) sodium hydride (60% dispersion in mineral 
oil) in portionwise. The reaction mass was warmed to ambient temperature and kept at 
that temperature for 2hrs. Then the mass was cooled to 50C, added 222 mg (0.6 mmol, 
0.05eq) of tetra butyl ammonium iodide (TBAI) and then 20.52 g (14.2 ml, 120.0mmol, 
10eq, 2 eq per –OH) of Benzyl bromide was added drop wise by syringe. The reaction 
mass was maintained at ambient temperature for 48hrs.Later, the mass was cooled to 50C 
and quenched with 40ml methanol. The crude product was extracted with 200ml EtOAc 
and 200ml water. The aqueous layer is extracted with 3×200ml EtOAc. The organic layer 
was combined and washed with 200ml brine. The organic layer was dried over MgSO4 
and the solvent was evaporated off till 600C /40 mbar to remove DMF. The crude residue 
was subjected to flash chromatography (silica gel- 50 times of the residue mass) using 
gradient eluent from 100% hexane to 70:30 Hexane: Ether. The pure fractions were 
collected and concentrated to afford 3.91g pure 1,2,3,4,6-Penta- O-benzyl β-mannose 
(only β anomer). (Yield=52%).                       
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Batch: RV219, VW20, RV273 
 
Rf: (Hexane / Ether 70:30): 0.21 (UV 254 active; KMnO4) 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.49-7.20 (m, 25H, Haromatic); 5.04 (d, 
2J1a-1a´=12.5Hz, 1H, HC(1a)); 5.03 (d, 2J2a-2a´=12.0Hz, 1H, HC(2a)); 4.94 (d, 2J3a-
3a´=10.8Hz, 1H, HC(3a)); 4.92 (d, 2J1a-1a´ ≈11.9Hz, 1H, HC(1a´ )); 4.69 (d, 2J4a-4a´=12.1Hz, 
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 1H, HC(4a)); 4.63  (d, 2J2a-2a´ ≈12.0Hz, 1H, HC(2a´)); 4.62 (d, 2J4a-4a´ =12.1Hz, 1H, 
HC(4a´)); 4.57  (d, 2J3a-3a´=10.8Hz, 1H, HC(3a´)); 4.53 (d, 2J6a-6a´=11.9Hz, 1H, HC(6a)); 
4.46 (d, 2J6a-6a´ ≈11.9Hz, 1H, HC(6a´ );  4.70-4.45 (m, 1H, HC(1β)); 3.95-3.90 (m,1H, 
HC(2β)); 3.93 (t, 3J3-4=9.8Hz, 3J4–5 ≈ 9.8Hz,1H, HC(4β)); 3.87 (dd, 3J5-6 ≈ 2.0Hz, 3J6–6´ 
≈11.0Hz ,1H, HC(6β)); 3.81 (dd, 3J5-6 ≈ 6.0 Hz, 3J6–6´ =11.0Hz ,1H, HC(6´β)); 3.52 (dd, 
3J2-3 ≈ 3.0Hz, 3J3-4 ≈9.8Hz ,1H, HC(3β)); 3.49 (ddd, 3J5-6 ≈ 2.0Hz, 3J5-6´ ≈6.0Hz , 3J5-4 
≈9.8Hz 1H, HC(5β)). 
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.8-137.6 ((C11), (C21), (C31), (C41) 
and (C61) α and β); 128.4-127.5 ((C12,C13,C14, C22,C23,C24, C32,C33,C34, C42,C43,C44, 
C62,C63,C64) of α and β);100.4 (C(1β)); 82.5, 76.1, 75.1, 73.9 (C(2β), C(3β), C(4β), 
C(5β)); 75.2, 74.0, 73.6, 71.6, 70.9 (C(1a), C(2a), C(3a), C(4a), C(6a)); 69.8 (C(6β)) 
 
α/β ratio by 13C-NMR  Only β anomer  
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 653.6 
9.2.2.2.2. Synthesis of 2,3,4,6-tetra-O-benzyl α-D mannose 
 
OBnOBnO
OBn
OBn
C41H42O6
[630.77]
OBn
OBnOBnO
OBn
OBn
C34H36O6
[540.64]
6N HCl
H2C
Bn =
CH3COOH
OH
38 39
 
850 mg (1.35 mmol, 1eq) of 1,2,3,4,6-Penta- O-benzyl β-mannose was taken in a dry 
flask and was dissolved in 20 ml acetic acid. Then 3ml of 6N HCl was added. The 
solution is heated to 600C. The mass was maintained at 600C and was taken for workup 
once the starting material was absent by TLC (approximately 4 to 6hrs, TLC eluent = 
Hexane: EtOAc 8:2). The mixture was diluted with 50ml water, extracted with 3×75ml 
CH2Cl2. The organic layer was washed with 100ml saturated NaHCO3 aqueous solution 
and then with 100ml water. The organic layer was dried over MgSO4, concentrated and 
the residue was subjected to flash chromatography (silica gel- 60 times of the residue 
mass) which further afforded 517 mg pure 2,3,4,6-tetra-O-benzyl α -D mannose (major α 
anomer; Yield= 70.8%) 
 199
 O
O
O
O
1
23
4
5
6
2a
3a
4a
6a
O
OH
 
                                          
Batch: RV226, VW23, VW44 
 
Rf: (Hexane : EtOAc  6:4): 0.28 (UV 254 active; KMnO4) 
 
IR (KBr) : 3400s, 3087m, 3063m, 3030s, 3006w, 2918s, 2866s, 1952vw, 1877vw, 
1811vw, 1737w, 1605w, 1586vw, 1546vw, 1496s, 1453vs, 1393m, 1364s, 1265m, 1244m, 
1208s, 1095vs, 1027vs, 910m, 843m, 820w, 797w, 736w, 697w, 607m, 528vw, 486vw, 
464vw. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.43-7.21 (m, 20H, Haromatic); 5.28(d, 
3J1-2 ≈ 2.0Hz, 1H, HC(1α)); 4.93 (d, 2J2a-2a´=10.9Hz, 1H, HC(2a)); 4.78 (d, 2J3a-3a´=12.5Hz, 
1H, HC(3a)); 4.74 (d, 2J3a-3a´≈12.5Hz, 1H, HC(3a´)); 4.67 (d, J1-2 =1.1Hz 1H, HC(1β)); 
4.61 (d, 2J4a-4a´=12.1Hz, 1H, HC(4a)); 4.59 (d, 2J2a-2a´ ≈10.9Hz, 1H, HC(2a´)); 4.58 (d, 2J6a-
6a´=11.5Hz, 1H, HC(6a)); 4.56 (d, 2J4a-4a´ =12.1Hz, 1H, HC(4a´)); 4.55 (d, 2J6a-6a´ =11.5 Hz, 
1H, HC(6a´ ); 4.13-4.08 (m,1H, HC(5α)); 4.02 (dd, 3J2-3 ≈ 3.0Hz, 3J3-4 ≈9.8Hz ,1H, 
HC(3α)); 3.90 (t, 3J3-4=9.8Hz, 3J4–5 ≈ 9.8Hz,1H, HC(4α)); 3.83(dd, 3J1-2 ≈ 2.0Hz, 3J2-3 
≈3.0Hz ,1H, HC(2α)); 3.76 (dd, 3J5-6 ≈ 2.0Hz, 3J6–6´ ≈11.0Hz ,1H, HC(6α)); 3.71 (dd, 3J5-6 
≈ 6.5 Hz, 3J6–6´ ≈11.0Hz ,1H, HC(6´β)); 3.60 (dd, 3J2-3 ≈ 3.0Hz, 3J3-4 ≈9.8Hz ,1H, 
HC(3β)); 4.65 (s, impurity); 4.19-4.13q, 2.08s, 1.3t (peaks due to EtOAc solvent)  
 
α/β ratio by 1H-NMR  could not be determined because of peaks overlap. (α anomer= 
major) 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.5-137.9 ((C21), (C31), (C41) and 
(C61) α and β); 128.7-127.0 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) of α 
and β); 94.0 (C(1β)); 92.6(C(1α)); 83.0(C(3β)); 79.8(C(3α)); 75.3(C(4α)); 75.00(C(2α)); 
71.3(C(5α)); 75.1, 73.3, 72.6, 72.1 ((C(2a), C(3a), C(4a), C(6a)); 69.7 (C(6α)); 171.3, 60.5, 
21.0, 14.2 (peaks due to EtOAc solvent)  
 
α/β ratio by 13C-NMR ≈ 5.2 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 563.3; [M+ H] + = 541.1 
 
 
9.2.2.2.3. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α -D-mannose   
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2000 mg (3.70 mmol, 1eq) of 2,3,4,6-tetra- O-benzyl α-mannose (α anomer major ≈ 
85%) was taken in a dry flask under argon atmosphere and was dissolved in 50 ml 
CH2Cl2. The solution was cooled to 00C, added 1370 mg (5.93 mmol, 1.6eq) of Boc-ALA 
acid  followed by 1225 mg (5.93 mmol, 1.6eq) of DCC and finally 10 mg (0.082 mmol, 
0.02 eq) of DMAP in a catalytic amount. The reaction was warmed to ambient 
temperature and maintained at that temperature for 5 hrs (controlled by TLC, eluent 7:3 
Hexane: EtOAc 2 times). The mixture was filtered over celite bed  and the filtrate was 
concentrated .The residue was subjected to flash chromatography  (silica gel- 70times of 
the residue mass) which afforded 2292 mg pure  2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-
ALA) α -D-mannose (major α anomer; Yield= 82.2%) 
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Batch: RV 270, VW 25, RV231 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.15 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.41-7.15 (m, 20H, Haromatic); 6.22 (d, 
3J1-2=1.9Hz, 1H, HC(1´α)); 5.60 (m, 1H, HC(1´β)); 5.18 (s, 1H, HN); 4.90 (d, 2J2a-
2a´=10.7Hz, 1H, HC(2a)); 4.78 (d, 2J3a-3a´=12.3Hz, 1H, HC(3a)); 4.73 (d, 2J3a-3a´=12.3Hz, 
1H, HC(3a´));  4.67 (d, 2J4a-4a´=12.1Hz, 1H, HC(4a)); 4.63 (d, 2J6a-6a´=12.0Hz, 1H, 
HC(6a));  4.59 (d, 2J6a-6a´ =12.0Hz, 1H, HC(6a´ ); 4.55(d, 2J2a-2a´≈10.7Hz, 1H, HC(2a´)); 
4.54 (d, 2J4a-4a´ ≈12.1Hz, 1H, HC(4a´));and other small peaks in this region due to H2CPh 
of  β anomer); 4.08 ((t, 3J3-4= 9.6Hz, 1H, HC(4´α)); 4.03 (d, 3J5-NH =5.0Hz, H2C(5)); 3.87 
(d, 3J2-3≈3Hz, 3J3-4=9.4Hz, 1H,  HC(3´α); 3.89-3.84 (m, 1H, HC(5´α); 3.80 - 3.76 (m, 2H, 
HC(2´α) and  HC(6´α); 2.79 - 2.57 (m, 4H ,H2C(3) and H2C(2)); 1.45 (s, 9H, H3C (8a, 8b 
and 8c)); 4.16-4.10q, 2.05s, 1.27t (peaks due to EtOAc solvent).  
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α/β ratio by 1H-NMR  ≈ 5 : 1 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 204.1 (C(4)); 171.1 (C(1β)); 170.7 
(C(1α)); 155.7 (C(6)) ; 138.4-137.9 ((C21), (C31), (C41) and (C61) of α and β); 128.5 - 
127.6 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) of α and β); 93.6 (C(1´β)); 
92.4 (C(1´α)); 80.0 (C(7)); 79.2 ((C(3´α) or (C(5´α)); 74.5 ((C(3´α) or (C(5´α)); 74.2 
(C(4´α)); 73.4 (C(2´α)); 68.9 (C(6´α)); 75.4, 73.5, 72.6, 72.1 (C(2a), C(3a), C(4a) and 
C(6a) of α anomer); 50.3 (C(5)); 34.2 (C(3) ); 28.4 (C(8a,8b and8c); 27.8  (C(2)). 
 
α/β ratio by 13C-NMR ≈ 7.5 : 1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 776.3 
 
HR-MS [M+ Na] + = 776.3409 (calculated =776.3410) 
 
9.2.2.2.4. Synthesis of 1-O-(BOC-ALA) α-D-mannose 
 
EtOH
H2 / Pd
O
BnO
BnO
BnO
OBn
NHBoc
O
O
C44H51NO10
[753.87]
C16H27NO10
[393.39]
O
O
HO
HO
HO
OH
NHBoc
O
O
O
40 41
 
   
2240 mg (2.97 mmol, 1eq) of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α -D-
mannose  was taken in a dry flask under argon atmosphere and was dissolved in 60 ml 
CH2Cl2 and then 20 ml EtOH was added. To this solution was added 3160 mg (2.97 
mmol, 1.0eq) of 10% Pd over activated carbon. The reaction mass was agitated under H2 
pressure of 60psi for 12 hrs. Later, the mixture was filtered over celite bed  and the 
filtrate was concentrated .The residue was subjected to flash chromatography  (silica gel- 
40times of the residue mass) which afforded 1000 mg pure  1-O-(BOC-ALA) α -D-
glucose (major α anomer; Yield= 85.6%). 
1 2
3 4 5
6 7
81
82
83
O
OH
HO
HO
OH
1´
2´3´
4´
5´
6´
H
N O
O
OO
O
 
Batch: RV 274 
 
 202
 Rf: (CH2Cl2 / MeOH 8:2):   = 0.38 (KMnO4) 
 
IR (KBr) : 3435vs, 2992vw, 2978vw, 2950vw, 2933m, 2942vw, 2536w, 2495w, 1731vs, 
1682vs, 1518vs, 1461vw, 1423w, 1408vw, 1392w, 1368s, 1349w, 1335vw, 1248s, 1183m, 
1139s, 1116vw, 1097m, 1075w, 1055m, 1043m, 1025vw, 1014vw, 990m, 973s, 950vw, 
899w, 870w, 828w, 815vw, 800m, 781vw, 767vw, 684vw, 667vw, 649vw, 585w, 566vw, 
538w, 501vw, 460vw. 
 
1H-NMR (400 MHz, CDCl3 and CD3OD, 298 K): δH (ppm) = 5.99 (d, 3J1´-2´=1.7Hz, 1H, 
HC(1´α)); 4.75 (d, 3J1´-2´=1.6Hz, 1H, HC(1´β)); 3.92 (s, H2C(5)); 3.78 (dd, 3J6´a -5´ ≈2.5Hz, 
3J6´a -6´b ≈12.0Hz 1H, HC(6´a α)); 3.76-3.60  (m, 5H, HC(6´b α), HC(5´α), (4´α), HC(3´α)) 
and HC(2´α)); 2.81 - 2.63 (m, 4H ,H2C(3) and H2C(2)); 1.44 (s, 9H, H3C (8a, 8b and 8c)). 
 
α/β ratio by 1H-NMR = 8:1 
 
13C-NMR (100 MHz, CDCl3 and CD3OD, 298K) : δC (ppm) = 207.1 (C(4)); 172.3 
(C(1)); 158.1 (C(6)) ;  101.0 (C(1´β); 95.3 (C(1´α)); 80.5 (C(7));76.6, 71.9, 70.6, 
67.6(C(2α), (C(3´α)), C(4´α) and (C(5´α)); 62.3 (C(6´α); 50.5 (C(5)); 34.7 (C(3)); 28.6 
(C(8a,8b and8c) ; 28.5 (C(2)). 
 
α/β ratio by 13C-NMR ≈ 16:1 
  
MS (ESI (+)): m/z relative intensity [M+ Na] + = 416.1; [M-H+H2O] - =428.1 
 
HR-MS [M+ Na] + = 416.1524 (calculated = 416.1533) 
 
9.2.2.2.5. Synthesis of 1-O-(ALA) α-D-mannose 
 
 
CH2Cl2
CF3COOH
C16H27NO10
[393.39]
O
HO
HO
HO
OH
NHBoc
O
O
O
O
HO
HO
HO
OH
NH3
O
O
O
CF3COO
C13H20F3NO10
[407.29]
M+=294.28 ; CF3COO = 113.01
41 42
 
850 mg (2.16 mmol, 1eq) of 1´-O-(BOC-ALA) mannose was dissolved in 30ml CH2Cl2 
and cooled to -100C. To this solution, 12.38 g (8.3ml, 108mmol, 50 eq) of trifluoroacetic 
acid was added dropwise by syringe. The reaction mass was maintained at 0-50C for 2h. 
Once the deprotection of BOC was completed (controlled by the absence of BOC peak in 
1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. The product was co-
evaporated with dry ether, triturated with dry ether and the ether solution was decanted. 
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 The trituration with ether and decanting top clear ether solution after centrifuge was 
repeated 2 times more. Then, the settled solid on drying yielded 795 mg of highly 
hygroscopic white solid. (Yield=90.3 %). 
       
1 2
3 4 5
O
OH
HO
HO
OH
1´
2´3´
4´
5´
6´
NH3
O
O
O CF3COO
 
Batch: RV 276 
 
[α]D = +228.7 (c=0.12; deionized H2O) 
 
IR (KBr) : 3392vs, 2943w, 2527vw, 1731m, 1677vs, 1516vw, 1428m, 1203vs, 1137vs,  
1068m, 960vw, 840w, 801m,  723m, 600vw, 518vw. 
   
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.77 (d, 3J1´-2´=1.8Hz, 1H, HC(1´α)); 4.66 
(d, 3J1´-2´=1.5Hz, 1H, HC(1´β)); 3.92 (s, H2C(5)); 3.78 (dd, 3J1´-2´ ≈1.8Hz, 3J2´ -3´ =3.3Hz 
1H, HC(2´α)); 3.71 (dd, 3J1´-2´ ≈1.8Hz, 3J2´ -3´ =3.4Hz 1H, HC(2´β)); 3.67-3.59 (m, 2H, 
HC(3α) and HC(6´a α)); 3.57-3.49  (m, 3H, HC(6´b α), HC(5´α) and HC(4´α)); 2.74 (t, 
3J2-3 ≈6.5Hz, 2H, H2C(3)) ; 2.57 (t, 3J3-2 ≈ 6.5Hz, 2H, H2C(2)) ; 1.03- 0.94 (peaks due to 
traces impurity). 
 
α/β ratio by 1H-NMR ≈ 14:1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) =  203.9 (C(4)) ; 173.1 (C(1)) ; 162.7 
(q,2JC-F ≈ 36.0, CF3COO¯ ); 116.3 (q,1JC-F ≈ 290.0, CF3COO¯ );  99.6 (C(1´β)); 94.2 
(C(1´α)); 69.1 (C(2´α));  60.8(C(6´α )); 75.1, 70.4, 66.3 (C(3´α), C(5´α) and C(4´α)); 47.2 
(C(5)); 34.3 (C(3)); 27.5 (C(2)).   
 
α/β ratio by 13C-NMR ≈ 15 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 294.1; [M- CF3COO¯+H+Na] + = 
316.2.  
 
HR-MS [M- CF3COO¯] + = 294.1184 (calculated = 294.1189) 
 
9.2.2.3. Synthesis of 1´- O-(ALA) -β-D-galactose 
9.2.2.3.1. Synthesis of α-methyl 2,3,4,6-tetra-O-benzyl galactoside 
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 C7H14O6
[194.18]
C35H38O6
[554.67]
BnBr, TBAI
NaH, DMF
Br
BnBr =
C7H7Br
[171.04]
O
HO
OH
OH
OCH3
OH
O
BnO
OBn
OBn
OCH3
OBn
43 44
 
2500 (12.87mmol, 1eq) of α-methyl galactoside was taken in a dry flask under argon 
atmosphere and was dissolved in 140 ml anhydrous DMF. The mass was cooled to -100C 
and added 3370 mg (77.2 mmol, 6eq, 1.5eq per –OH) sodium hydride (55% dispersion in 
mineral oil) in portion wise. The reaction mass was warmed to ambient temperature and 
kept at that temperature for 2hrs. Then the mass was cooled to 50C, added 240 mg (0.65 
mmol, 0.05eq) of tetra butyl ammonium iodide (TBAI) and then 13.2g (9.2 ml, 77.2 
mmol, 6eq, 1.5eq per –OH) of Benzyl bromide was added drop wise by syringe. The 
reaction mass was maintained at ambient temperature for 24hrs.Later, the mass was 
cooled to 50C and quenched with 40ml methanol. The crude product was extracted with 
300ml EtOAc and 400ml water. The aqueous layer is extracted with 3×200ml EtOAc. 
The organic layer was combined and washed with 300ml brine. The organic layer was 
dried over MgSO4 and the solvent was evaporated off till 600C /40 mbar to remove DMF. 
The crude residue was subjected to flash chromatography (silica gel- 50 times of the 
residue mass) using 70:30 Hexane:EtOAc eluent. The pure fractions were collected and 
concentrated to afford 6.35g pure of α-methyl 2,3,4,6-tetra-O-benzyl galactoside. 
(Yield=89%). 
O
O
O
O
123
4 5
6
21
22
23
24
2a
3a
4a
6a
11
OCH3
O
 
Batch: RV271, RV287, RV298, VW 51 
 
Rf: (Hexane: EtOAc 7:3): 0.33 (UV 254 active; KMnO4) 
 
IR (KBr) : 3445w, 3087vw, 3063w, 3030m, 2917s, 2867m, 1951vw, 1874vw, 1809vw, 
1736w, 1677w, 1606vw, 1586vw, 1496m, 1454s, 1351m, 1308vw, 1241w, 1194m, 
1152vw, 1133w, 1099vs, 1051vs, 1028w, 911w, 839vw, 736vs, 697vs, 607w, 547w, 
464vw. 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.38-7.19 (m, 25H, Haromatic); 4.94 (d, 
2J2a-2a´=11.5Hz, 1H, HC(2a)); 4.82 (d, 2J3a-3a´=11.7Hz, 1H, HC(3a)); 4.79 (d, 2J4a-
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 4a´=11.6Hz, 1H, HC(4a)); 4.70 (d, 2J3a-3a´≈11.7Hz, 1H, HC(3a´)); 4.68 (d, 3J1-2 ≈3.8Hz, 1H, 
HC(1α)); 4.65 (d, 2J4a-4a´ ≈11.61Hz, 1H, HC(4a´)); 4.56 (d, 2J2a-2a´=11.5Hz, 1H, HC(2a´ )); 
4.45 (d, 2J6a-6a´=11.8Hz, 1H, HC(6a)); 4.36 (d, 2J6a-6a´ =11.8Hz, 1H, HC(6a´ ); 4.04 (dd, 3J2-
1 ≈ 3.8Hz, 3J2 -3 ≈10.0Hz ,1H, HC(2α));4.03-3.92 (m,2H, HC(3α) and HC(4α));3.90 (t, 3J5-
6≈6.4Hz, 3J5-6´≈6.4Hz, 3J5-4≈1.0Hz, 1H, HC(5α)); 3.52 (d, 2J5-6=6.4Hz, 3J5-6´=6.4Hz, 2H, 
H2C(6α)); 3.34 (s,3H, H3C(11). 
 
α/β ratio by 1H-NMR = Only α anomer. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.7-137.9 ((C21), (C31), (C41)and 
(C61) ); 128.3-127.4 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64); 
98.7(C(1α)); 79.0, 75.1 (C(3α) and C(4α)); 76.4(C(2α)); 69.1 (C(5α); 69.0(C(6α)); 74.7, 
73.5, 73.4, 73.2(C(2a), C(3a), C(4a) and C(6a); 55.3 (C(11)). 
 
α/β ratio by 13C-NMR = Only α anomer. 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 577.5 
 
9.2.2.3.2. Synthesis of 2,3,4,6-tetra-O-benzyl α- galactose 
 
C34H36O6
[540.64]
H2C
Bn =
6N HCl
CH3COOH O
BnO OBn
OBn
OH
OBn
C35H38O6
[554.67]
O
BnO
OBn
OBn
OCH3
OBn
44 45
 
  4700 mg (8.47 mmol, 1eq) of α-methyl 2,3,4,6-tetra-O-benzyl galactoside was taken in 
a dry flask and was dissolved in 100 ml acetic acid. Then 15 ml of 6N HCl was added. 
The solution is heated to 600C. The mass was maintained at 600C and was taken for 
workup once the starting material was absent by TLC (approximately 5 to 6hrs, TLC 
eluent = Hexane: EtOAc 8:2). The mixture was diluted with 150ml water, extracted with 
3×300ml CH2Cl2. The organic layer was washed with 250ml saturated NaHCO3 aqueous 
solution and then with 250ml water. The organic layer was dried over MgSO4, 
concentrated and the residue was subjected to flash chromatography (silica gel- 80 times 
of the residue mass) which further afforded 2.1 g pure 2,3,4,6-tetra-O-benzyl α-D 
galactose (major α anomer; Yield= 45.7%) 
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Batch: RV275, RV 280, RV 301, VW 26, VW 53 
 
Rf: (Hexane: EtOAc 7:3): 0.33 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.49-7.23 (m, 20H, Haromatic); 5.37 (d, 
3J1-2=3.5Hz, 1H, HC(1α)); 5.03 (d, 2JHC-HC = 11.6Hz, H2CPh);  5.02 (d, 2JHC-HC = 11.5Hz, 
H2CPh); 4.89 (d, 2JHC-HC = 11.7Hz, H2CPh); 4.88 (d, 2JHC-HC = 11.0Hz, H2CPh); 4.87 (d, 
2JHC-HC = 11.8Hz, H2CPh); 4.83 (d, 2JHC-HC = 11.8Hz, H2CPh); 4.81 (d, 2JHC-HC = 13.0Hz, 
H2CPh); 4.78 (d, 2JHC-HC = 11.8Hz, H2CPh); 4.72 (d, 3J1-2=7.6Hz, 1H, HC(1β)); 4.68 (d, 
2JHC-HC = 11.6Hz, H2CPh); 4.66 (d, 2JHC-HC = 11.5Hz, H2CPh); 4.56 (d, 2JHC-HC = 11.9Hz, 
H2CPh); 4.54 (d, 2JHC-HC = 11.8Hz, H2CPh); 4.47 (d, 2JHC-HC = 11.9Hz, H2CPh); 4.46 (d, 
2JHC-HC = 11.9Hz, H2CPh); 4.26 (t, 3J5-6a =6.3 Hz, 3J5-6b = 6.3Hz, 3J5-4 =1.0Hz,1H, 
HC(5α)); 4.12 (dd, 3J1-2≈3.6Hz,3J2-3=9.6Hz, 1H, HC(2α)); 3.87 (dd, 3J1-2=7.6Hz,3J2-
3=9.6Hz, 1H, HC(2β)); 4.08-3.51  (m, 9H, H2C(6α), H2C(6β), HC(4α), HC(4β)), HC(5β), 
HC(3α)) and HC(3β); 2.13, 1.66,1.43, 0.95 peaks due to traces of solvent and impurity. 
 
α/β ratio by 1H-NMR = 2.2 : 1.0 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 138.6-137.7 ((C21), (C31), (C41) and 
(C61) of α and β ); 128.8-127.4 ((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) 
of α and β; 98.3 (C(1β)); 92.3 (C(1α)); 79.2, 77.0, 75.3, 69.8 (C(2α), (C(3α), C(4α) and 
C(5α)); 82.6, 81.2, 74.1, 71.7 ((C(2β)), C(3β), C(4β) and C(5β)); 75.1, 73.9, 73.8, 73.4 
(CH2Ph of α anomer); 75.5, 75.0, 73.9, 73.4 (CH2Ph of βanomer); 69.6 (C(6α)); 69.4 
(C(6β)).  
 
α/β ratio by 13C-NMR = 2.5:1 
 
9.2.2.3.3. Synthesis of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) β -D-galactose  
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 C34H36O6
[540.64]
O
BnO
OBn
OBn
OH
OBn
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O
OBn
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OBn
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OHBocHN
O
O
C10H17NO5
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O
O
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[753.87]
O
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1976 mg (3.65 mmol, 1eq) of  2,3,4,6-tetra- O-benzyl galactose (α anomer major ≈ 70%) 
was taken in a dry flask under argon atmosphere and was dissolved in 80 ml CH2Cl2. The 
solution was cooled to 00C, added 491 mg (4.02 mmol, 1.1eq) of DMAP, then 851 mg 
(4.44 mmol, 1.21eq) of EDCI and finally 929 mg (4.02 mmol, 1.1eq) of Boc-ALA acid. 
The reaction was warmed to ambient temperature and maintained at that temperature for 
7-8 hrs (controlled by TLC, eluent 7:3 Hexane: EtOAc 2 times). Once the reaction was 
complete, the mixture was concentrated and the residue was subjected to flash 
chromatography  (silica gel- 80times of the residue mass) which afforded  2.66g pure  
2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA) α / β-D-galactose (major β anomer; Yield= 
96.5 %)                                     
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Batch: RV 279, VW30 
 
Rf: (Hexane / EtOAc  70:30, 2 times): 0.15 (UV 254 active; KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) =7.38-7.24 (m, 20H, Haromatic); 6.33 (d, 
3J1-2=3.5Hz, 1H, HC(1´α)); 5.57 (d, 3J1-2=8.0Hz, 1H, HC(1´β)); 5.19 (s, 1H, HN); 4.93 (d, 
2J2a-2a´=11.5Hz, 1H, HC(2a)); 4.83 (d, 2J3a-3a´=11.3Hz, 1H, HC(3a)); 4.81  (d, 2J4a-
4a´=11.7Hz, 1H, HC(4a)); 4.75 (d, 2J3a-3a´=11.3Hz, 1H, HC(3a´)); 4.74 (d, 2J4a-4a´ ≈11.7Hz, 
1H, HC(4a´)); 4.61 (d, 2J2a-2a´=11.5Hz, 1H, HC(2a´ )); 4.43 (d, 2J6a-6a´=11.7Hz, 1H, 
HC(6a)); 4.38 (d, 2J6a-6a´ =11.7Hz, 1H, HC(6a´ ) and other small peaks in this region due to 
H2CPh of  α anomer); 4.00 (d, 3J5-NH ≈ 4.7Hz, H2C(5)); 3.95 (dd, 3J2´-1´=8.0Hz, 3J2´-
3´≈10.0Hz, 1H, HC(2´β)); 3.59 (dd, 3J3´-4´≈2.0Hz, 3J3´-2´≈10.0Hz, 1H, HC(3´β)); 3.68 - 
3.51 (m, 3H, HC(4´β),HC(5´β)) and H2C(6´β); 2.70 - 2.58 (m, 4H ,H2C(3) and H2C(2)); 
1.44 (s, 9H, H3C (81, 82 and 83)); 4.13-4.08, 2.03 1.25 (peaks due to EtOAc). 
 
α/β ratio by 1H-NMR = 0.15 : 1.0 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 203.7 (C(4)); 171.0 (C(1)); 155.5 
(C(6)) ; 138.3-137.6 ((C21), (C31), (C41) and (C61) of α and β); 128.3 - 127.3 
((C22,C23,C24, C32,C33,C34, C42,C43,C44, C62,C63,C64) of α and β); 94.5 (C(1´β)); 91.1 
(C(1´α)); 82.2, 77.9, 74.0, 72.9 (C(2´β),C(3´β), C(4´β) and  C(5´β)); 67.8 C(6´β));75.2, 
74.6, 73.4, 72.7 (C(2a), C(3a), C(4a) and C(6a)); 50.1 (C(5)); 33.8 (C(3) ); 28.2 (C(8a,8b 
and8c); 27.7  (C(2)). 
 
α/β ratio by 13C-NMR ≈ 0.15 : 1.0 
 
MS (ESI (+)): m/z relative intensity [M+Na] + = 776.4  
 
HR-MS [M+ Na] + = 776.3406 (calculated =776.3410) 
9.2.2.3.4. Synthesis of 1´-O-(BOC-ALA) β- galactose 
 
EtOH
H2 / Pd
C16H27NO10
[393.39]
O
OBn
BnO
OBn
OBn
NHBoc
O
O
C44H51NO10
[753.87]
O
O
OH
HO
OH
OH
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O
O
O
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2300 mg (3.05 mmol, 1eq) of 2´,3´,4´,6´-tetra-O- benzyl 1´-O-(BOC-ALA)-β -D-
galactose  was taken in a dry flask under argon atmosphere and was dissolved in 60 ml 
CH2Cl2 and then 30 ml EtOH was added. To this solution was added 3250 mg (3.98 
mmol, 1.0eq) of 10% Pd over activated carbon. The reaction mass was agitated under H2 
pressure of 60psi for 12 hrs. Later, the mixture was filtered over celite bed  and the 
filtrate was concentrated .The residue was subjected to flash chromatography (silica gel- 
70times of the residue mass) which afforded 890 mg pure  1-O-(BOC-ALA)-β -D-
galactose (major β anomer; Yield= 74.2%). 
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Batch: RV 286 
 
Rf: (CH2Cl2 / MeOH 8:2):   = 0.21 (KMnO4) 
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 IR (KBr) : 3411vss, 2977w, 2926m, 1732vs, 1695vs, 1520s, 1394vw, 1368s, 1336vw, 
1253m, 1167s, 1073vs,1058w, 873vw, 782w, 767w, 686w, 538vw, 494vw. 
 
1H-NMR (200 MHz, CDCl3 and CD3OD, 298 K): δH (ppm) = 6.12 (d, 3J1´-2´=3.8Hz, 1H, 
HC(1´α)); 5.42 (d, 3J1´-2´=7.8Hz, 1H, HC(1´β)); 3.93 (s, H2C(5)); 3.88 (dd, 3J4´-5´ ≈ 0.8Hz, 
3J4´-3´ =2.2Hz, 1H, HC(4´β)); 3.84-3.58  (m,4H, HC(2´β), HC(5´β) and H2C(6´ β)); 3.53 
(dd, 3J3´-4´ ≈ 3.3Hz, 3J3´-2´ =10.0Hz, 1H, HC(3´β)); 2.80-2.68 (m, 4H, H2C(3) and H2C(2)); 
1.44 (s, 9H, H3C (81, 82 and 83)). (other peaks due to α anomer and ether solvent). 
 
α/β ratio by 1H-NMR = 0.07 : 1 
 
13C-NMR (50 MHz, CDCl3, 298K) : δC (ppm) = 207.2 (C(4)); 173.2 (C(1)); 96.4 
(C(1´β)); 80.6 (C(7)); 77.5 (C(5´β)); 74.7, 71.2, 70.0 (C(4´β), (C(2´β) and C(3´β)); 62.2 
(C(6´β)); 50.7 (C(5)); 34.6 (C(3)); 28.7 (C(81, 82 and 83) and (C(2)). 
 
 α/β ratio by 13C-NMR ≈ only β anomer. 
 
MS (ESI (+)): m/z relative intensity [M+Na] + = 416.1.  
  
HR-MS [M+ Na] + = 416.1526 (calculated = 416.1533) 
 
9.2.2.3.5. Synthesis of 1-O-(ALA) β- galactose 
 
C16H27NO10
[393.39]
O
OH
HO
OH
OH
NHBoc
O
O
O
CH2Cl2
CF3COOH
CF3COO
C13H20F3NO10
[407.29]
M+=294.28 ; CF3COO = 113.01
O
OH
HO
OH
OH
NH3
O
O
O
47 48
 
810 mg (2.06 mmol, 1eq) of 1´-O-(BOC-ALA) galactose was dissolved in 30ml CH2Cl2 
and cooled to -100C. To this solution, 14.9 g (10ml, 130mmol, 63 eq) of trifluoroacetic 
acid was added dropwise by syringe. The reaction mass was maintained at 0-50C for an 
hour. Once the deprotection of BOC was completed (controlled by the absence of BOC 
peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. The product was 
triturated with dry ether and the ether solution was decanted. The trituration with ether 
and decanting top clear ether solution after centrifuge was repeated 2 times more. Then, 
the settled solid product was purified by dissolving in 4ml MeOH and precipitated by 
adding 20ml ether. The mass was centrifuged, the settled solid on drying yielded 334 mg 
of highly hygroscopic white solid. (Yield=40 %). 
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OH
HO
OH
2´
3´
4´ 5´
6´
OH
1 2
3 4 5
NH3
O
O
O
1´
CF3COO
 
Batch: RV 291 
 
[α]D = +40.9 (c=0.33; deionized H2O) 
 
IR (KBr) : 3378vs, 2933w, 1732vs, 1678vs, 1513m, 1428m, 1315w, 1204vs, 1136vs, 
1071vs, 1021vw, 955vw, 892w, 839m, 800m, 781w, 723s, 704vw, 599vw, 530w. 
   
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.99 (d, 3J1´-2´=3.6Hz, 1H, HC(1´α)); 5.36 
(d, 3J1´-2´=7.6Hz, 1H, HC(1´β)); 3.99 (s, H2C(5)); 3.82 (d, 3J4´-3´ =2.2Hz, 1H, HC(4´β)); 
3.67 (m,1H, HC(5´β)); 3.60-3.59 (m, 4H, HC(2´β),HC(3´β),HC(6´a β) and HC(6´bβ); 
2.82 (t, 3J2-3 ≈6.5Hz, 2H, H2C(3)) ; 2.69 (t, 3J3-2 ≈ 6.0Hz, 2H, H2C(2)) ; (other peaks due 
to α anomer and ether solvent). 
 
α/β ratio by 1H-NMR ≈ 0.18 :1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) =  204.0 (C(4)) ; 173.7 (C(1)) ; 163.3 
(q,2JC-F = 35.3, CF3COO¯ ); 116.6 (q,1JC-F = 291.9, CF3COO¯ );  95.0 (C(1´β)); 93.0 
(C(1´α)); 76.5 (C(5´β)); 68.6(C(4´β)); 72.7, 69.6 (C(2´β) and C(3´β)); 61.1(C(6´β)); 47.3 
(C(5)); 34.3 (C(3)); 27.2 (C(2)) and other peaks due to α anomer and ether solvent.  
 
α/β ratio by 13C-NMR ≈ 0.11 : 1 
  
MS (ESI (+)): m/z relative intensity [M- CF3COO¯] + = 294.1 
 
HR-MS [M- CF3COO¯] + = 294.11869 (calculated = 294.1189) 
 
9.2.2.3.6. Synthesis of 1´-O-(BOC- ALA) - 2´, 3´, 4´, 6´tetraacetyl-β-D-
galactopyranose 
 
C14H19BrO9
[411.20]
O
AcO
OAc
OAc
Br
OAc
MeOH, DMF
Cs2CO3 O
OAc
AcO
OAc
OAc
OHBocHN
O
O
C10H17NO5
[231.16]
NHBoc
O
O
C24H35NO14
[561.53]
O
49 5 50
 
1387 mg (6 mmol, 1eq) of Boc-ALA acid was taken in a dry flask under argon 
atmosphere and was dissolved in 25 ml MeOH. The solution was cooled to 00C, added 
978 mg (3 mmol, 0.5eq) of Cs2CO3. The reaction was warmed to ambient temperature 
and maintained at that temperature for 1h. (controlled by TLC, eluent 100% EtOAc). The 
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 solution then was concentrated to remove methanol, then added 25 ml DMF. The solution 
was cooled to 00C, added 2467 mg (6 mmol, 1.0eq) of 2, 3, 4, 6-β-D-galactopyranosyl 
bromide (acetobromogalactose). The reaction was mainatained at ambient temperature 
for an hour, filtered CsBr, distilled off DMF and was subjected to flash chromatography  
(silica gel- 80times of the residue mass) which afforded 2130 mg pure 1´-O-(BOC- ALA) 
- 2´, 3´, 4´, 6´tetraacetyl-β-D-galactopyranose (only β anomer; Yield= 63.2 %). 
 
O
O
O
O
2´
3´
4´ 5´
6´
2´a
3´a
4´a
6´a
O
1´
O
O
O
O
2´b
3´b
4´b 6´b
1 2
3 4 5
6 7 8a
8b
8c
H
N O
O
OO
O
 
Batch : RV 225, RV 230, RV 236 
 
Rf: (100% ether): 0.29 (KMnO4) 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.65 (d, 3J1´-2´=8.0Hz, 1H, HC(1´β); 
5.35 (d, 3J4´-3´=3.8Hz, 1H, HC(4´β);5.26 (sbr, 1H, NH); 5.22 (dd, 3J2´-1´≈ 8.0Hz, 3J2´-
3´=10.7Hz,1H, HC(2´β)); 5.02 (dd, 3J3´-4´ =3.4Hz, 3J3´-2´=10.4Hz, 1H, HC(3´β)); 4.09-4.05 
(m, 2H, H2C(6´)); 4.04-4.01 (m, 1H, HC(5´)); 3.96 (t, 3J15-NH≈ 6.0Hz, 2H, H2C(15)); 2.70-
2.60 (m, 4H, H2C(13) and H2C(12)); 2.10, 2.02, 1.97, 1.92 (4 × s, 12H, H3C(2´b), 
H3C(3´b), H3C(4´b) and H3C(6´b); 1.37 (s, 9H, H3C (18a, 18b and 18c)); 4.94 (q), 1.28 (d) 
due to impurity. 
 
α/β ratio by 1H-NMR ≈ Only β anomer 
 
13C-NMR (100 MHz, CDCl3 & CD3OD, 298K) : δC (ppm) = 204.1 (C(14)); 170.3 
(C(11)); 170.1, 170.0, 169.9, 169.8 (C2´a), (C3´a), (C4´a) and (C6´a)); 155.8 (C(16)); 92.2 
((C(1´β)); 79.8 (C(17)); 71.6 (C(5´β); 70.6 (C(3´β)); 67.6 (C(2´β)); 66.7 (C(4´β)); 61.0 
(C(6´β)); 50.0 (C(15)); 33.8 (C(13)) ; 28.3 (C(18a,18b and18c); 27.6 (C(12)); 20.7, 20.6, 
20.5, 20.4 ((C2´b), (C3´b), (C4´b) and (C6´b)); 104.0, 18.0 due to impurity. 
 
 α/β ratio by DEPT ≈ Only β anomer 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 584.1; [M + Na-tBu] += 528.2. 
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 9.2.3. Synthesis of 1-O-(ALA)-2-O-(glycosyl) ethylene glycol 
The synthesis of 1-O-(ALA)-2-O-(α-D-glucopyranosyl) ethylene glycol and 1-O-(ALA)-
2-O-(α-D-mannopyranosyl) ethylene glycol were carried out vis Fischer glycosidation to 
get predominantly α anomer and the synthesis of 1-O-(ALA)-2-O-(β-D-galactopyranosyl) 
ethylene glycol was carried out vis Koenigs-Knorr synthesis to get prodominantly β 
anomer. 
9.2.3.1. Synthesis of 1-O-(ALA)-2-O-(α-D-glucopyranosyl) ethylene 
glycol 
9.2.3.1.1. Synthesis of 1-O-(α-D-glucopyranosyl) ethylene glycol 
 
O
HO
HO
OH
OH
OH
C6H12O6
[180.16]
Dowex 50W X resin
O
HO
HO
OH
OH
HO
OH
C8H16O7
[224.21]
O
C2H6O2
[62.07]
OH13 51 52
 
 5700 mg (31.64 mmol, 1eq) D-Glucose was taken in a dry flask under argon atmosphere. 
To this were added 40g (633 mmol, 20 eq) of ethylene glycol and then 12g of dried 
Dowex 50WX 8-200 resin. The mixture was then heated to 750C and maintained at 70- 
800C for 72h. The resin was filtered over alumina sandwiched between celite bed, 
washed with ethylene glycol. Ethylene glycol was evaporated off from the filtrate and the 
crude was subjected to flash chromatography (silica gel- 70times of the residue mass; 
gradient eluent from 9:1 CH2Cl2 / MeOH to 7:3 CH2Cl2 / MeOH) which afforded 2570 
mg of pure 1-O-(α-D-glucopyranosyl) ethylene glycol. (major α-anomer; yield= 46.2%). 
                                      
O
HO
HO
OH
OH
O
OH
2
1
1´2´3´
4´ 5´6´
 
Batch: RV 178, RV 198, RV332 
 
Rf: (CH2Cl2 / MeOH 3:1):   = 0.23 (KMnO4) 
 
IR (KBr): 3369vs, 2927m, 2148vw, 1643w, 1415w, 1342w, 1261w, 1229w, 1151m, 
1075w, 1028vs, 938w, 880w, 752vw, 702vw, 665vw, 604vw, 531vw, 496w, 458vw.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.93 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α)); 4.47 
(d, 3J1´-2´ =7.9Hz, 1H, HC(1´β)); 3.88-3.58 (m,8H, H2C (6`α),H2C (1), H2C (2), HC (5´α)  
and HC(4´α); 3.54 (dd, 3J2´-1´ ≈3.7Hz, 3J3´-2´ =11Hz,1H, HC(2´α)); 3.39  (t, 3J3´-4´ =9.5Hz, 
3J3´-2´ =9.5 Hz,1H, HC (3´α)). 
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α/β ratio by 1H-NMR ≈ 0.11 : 1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 105.0(C(1´β)); 100.9(C(1´α)); 
74.1(C2´α)); 72.2((C(3´α)); 75.7, 74.4, (C(4´α) and (C(5´α)); 71.6, 63.3, 63.2(C(1), C(2) 
and C(6´α));   
 
α/β ratio by 13C-NMR ≈ 0.11 : 1 
 
MS (ESI (+)): m/z relative intensity [M with OH/OD + Na] + = 252.1 
 
HR-MS [M+ Na] + = 247.0783 (calculated =247.0794) 
 
9.2.3.1.2. Synthesis of 1-O-(BOC- ALA) -2-O-(α-D-glucopyranosyl) ethylene glycol 
 
O
HO
HO
OH
OH
C8H16O7
[224.21]
O
OH
Lipase f rom
Cand ida
antarctica
(L CA)OPFPBocHN
O
O
C16H16F5NO5
[397.29]
O
HO
HO
OH
OH
O
NHBoc
O
O
O
C18H31NO11
[437.44]
52 7 53
 
225mg (1 mmol, 1eq) of 1-O-(α-D-glucopyranosyl) ethylene glycol.was taken in a dry 
flask under argon atmosphere and was dissolved in 5 ml anhydrous pyridine. 1500 mg 
(10 units per mg of protein; 1unit hydrolyses 1µmol or 0.001mmol of an ester; 
approximately, 15 mmol, 15eq) of lipase from Candida antarctica (LCA, Novozyme 
435) enzyme (before use dried by keeping at vacuum 10-2 mbar for 3-4 days) was added 
and then 1200 mg (3mmol, 3eq) of Boc-ALA-PFP ester was added to the solution. The 
reaction was heated to 500C and maintained at this temperature for 30min. (controlled by 
TLC eluent : CH2Cl2: MeOH 3:1). The mass was cooled to room temperature and then 
the enzyme was filtered over celite bed, the filtered cake was washed with 3× 10ml 
pyridine. The solvent pyridine was evaporated off by rotovapor .The residue was taken 
for flash chromatography. (silica gel- 90times of the residue mass; gradient eluent from 
100% CH2Cl2 to 85:15 CH2Cl2 : MeOH). The main fractions were concentrated to give 
210 mg of pure product 1-O-(BOC- ALA) -2-O-(α-D-glucopyranosyl) ethylene glycol 
was obtained as white solid. (Yield = 48%). 
 
O
HO
HO
OH
OH
O
2
1
1´
2´3´
4´ 5´6´
11
N
H
O
O
OO
O
12
14
15 16 17
13
18a
18b
18c
 
Batch : RV 206, RV 220 
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Rf: (CH2Cl2 / MeOH 85:15): 0.28; (KMnO4) 
 
IR (KBr) : 3395vs, 2977s, 2929s, 2355vw, 1728vs, 1709vs, 1517m, 1453vw, 1392vw, 
1368m, 1285vw, 1254w,  1163s, 1076vw, 1024s, 887w, 782vw, 763vw, 703vw, 
602vw,562vw, 530vw, 500w. 
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.82 (d, 3J1´-2´=3.7Hz, 1H, HC(1´α)); 4.32-
4.24 (m, 3H, H2C(1) and HC(1´β)); 3.94 (s, 2H, H2C(15)); 3.89 (ddd, 3J1b-2a≈3.3Hz, 3J1a-
2a=6.4Hz vicinal, 3J2b-2a=11.5Hz geminal, 1H, HC(2a)); 3.79 (dd, 3J5´-6´a≈2.6Hz, 3J6´a - 6´b 
=11.9Hz ,1H, HC(6´a α)) ;3.71 (dd, 3J5´-6´b ≈ 5.3Hz, 3J6´a - 6´b ≈ 11.9Hz ,1H, HC(6´b α ) ); 
3.70-3.66 (m, 1H, HC (2b)); 3.63 (t, 3J3´-4´≈9.3Hz, 3J3´-2´ =9.3Hz,1H, HC(3´α)); 3.58 (ddd, 
3J5´-6´a ≈ 2.7Hz, 3J5´-6´b≈5.0Hz, 3J5´-4´≈9.9Hz,1H, HC (5´α)); 3.41 (dd, 3J2´-1´ = 3.7Hz, 3J2´ - 
3´= 9.7Hz ,1H, HC(2´α)); 3.33 (t, 3J3´-4´=9.2Hz, 3J4´-5´ ≈9.3Hz,1H, HC(4´α)); 2.75 (t, 3J13-12 
≈6.5Hz, 2H, H2C(13)); 2.64 (t, 3J12-13 ≈6.5Hz, 2H, H2C(12)); 1.42 (s, 9H, H3C (18a, 18b and 
18c)). 
 
α/β ratio by 1H-NMR ≈ could not be determined because of overlap 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 206.7 (C(14)); 173.6 (C(11)); 157.4 
(C(16)); 103.7 ((C(1´β) by DEPT); 99.5 (C(1´α)); 80.4 (C(17)); 74.3(C(3´α)); 72.8 
(C(5´α)); 72.6  (C(2´α)); 70.8 (C(4´α)); 66.3 (C(2)); 64.2(C(1)); 62.0 (C(6´α)); 50.4 
(C(15)); 34.6 (C(13)) ; 28.5 (C(18a,18b and18c); 28.2 (C(12)).  
 
α/β ratio by 13C-NMR ≈ 9.5 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 460.2;  
 
HR-MS [M+ Na] + = 460.1795 (calculated =460.1795) 
 
9.2.3.1.3. Synthesis of 1-O-(ALA) -2-O-(α-D-glucopyranosyl) ethylene glycol 
 
O
HO
HO
OH
OH
O
NH3
O
O
O
O
HO
HO
OH
OH
O
NHBoc
O
O
O
C18H31NO11
[437.44]
CF3COOH
C15H24F3NO11
[451.34]
CF3COO
M+=338.33 ; CF3COO = 113.01
CH2Cl2
53 54
 
220 mg (0.50 mmol, 1eq) of 1-O-(BOC- ALA) -2-O-(α-D-glucopyranosyl) ethylene 
glycol was dissolved in 15ml CH2Cl2 and cooled to -100C. To this solution, 5.73g 
(3.85ml, 50mmol, 100 eq) of trifluoroacetic acid was added dropwise by syringe. The 
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 reaction mass was maintained at 0-50C for an hour. Once the deprotection of BOC was 
completed (controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and 
trifluoroacetic acid was evaporated off. The product was co evaporated 2times with 
distilled ether, then triturated with dry ether and the ether solution was decanted. The 
trituration with ether and decanting top clear ether solution after centrifuge was repeated 
2 times more. Then, the settled solid product was purified by dissolving in 5ml MeOH 
and precipitated by adding 30ml ether. The mass was centrifuged, the settled solid on 
drying yielded 149 mg of 1-O-( ALA) -2-O-(α-D-glucopyranoosyl) ethylene glycol  
which was a highly hygroscopic white solid. (Yield=66%). 
 
O
HO
HO
OH
OH
O
2
1
1´
2´3´
4´ 5´6´
11
NH3
O
O
O
12
14
15
13
CF3COO
 
Batch: RV 222, RV359 
 
[α]D = +246.1 (c=0.10; deionized H2O) 
 
IR (KBr): 3426vs, 2924m, 1789m, 1731m, 1679vs, 1521vw, 1399m, 1207vs, 1179vs, 
1051w, 838w, 802w, 723m, 519vw, 501vw.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.91 (d, 3J1´-2´ =3.7Hz, 1H, HC(1´α));  
4.31-4.26 (m, 3H, H2C(1));4.09 (s, 2H, H2C(15)); 3.92-3.88 (m, 1H, HC(2a)); 3.80 (dd, 
3J5´-6´a≈2.0Hz, 3J6´a - 6´b =12.1Hz ,1H, HC(6´a α)) ;3.72 (dd, 3J5´-6´b ≈ 5.3Hz, 3J6´a - 6´b ≈ 
12.2Hz ,1H, HC(6´b α ) ); 3.70-3.66 (m, 2H, HC (2b) and (5´α)); 3.66 (t, 3J3´-4´≈9.5Hz, 
3J3´-2´ =9.2Hz,1H, HC(3´α)); 3.51 (dd, 3J2´-1´ = 3.7Hz, 3J2´ - 3´= 9.8Hz ,1H, HC(2´α)); 3.45-
3.34 (m, 1H, HC(4´α)); 2.89 (t, 3J13-12 ≈6.5Hz, 2H, H2C(13)); 2.72 (t, 3J12-13 ≈6.5Hz, 2H, 
H2C(12)); 
 
α/β ratio by 1H-NMR ≈:only α anomer 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.0 (C(14)) ; 174.8 (C(13)) ; 163.1 
(q,2JC-F = 35.2, CF3COO¯ ); 116.5 (q,1JC-F ≈ 291.9, CF3COO¯ ); 98.5 (C(1´α)); 73.1 
(C(5´α)); 72.0(C(3´α)); 71.4 (C(2´α)); 69.6 (C(4´α)); 65.8 (C(2)); 64.4(C(1)); 60.6 
(C(6´α)); 47.1 (C(15)); 34.3 (C(13)) ; 27.5 (C(12)).  
 
 α/β ratio by 13C-NMR : only α anomer 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯+H] + = 340.1; [M-CF3COO¯] 
+=339.1.  
 
HR-MS [M- CF3COO¯] + = 338.1441 (calculated =338.1451) 
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9.2.3.2. Synthesis of 1-O-(ALA)-2-O-(α-D-mannopyranosyl) ethylene 
glycol 
9.2.3.2.1. Synthesis of 1-O-(α-D-mannopyranosyl) ethylene glycol 
 
OHO
HO
OHOH
OH
C6H12O6
[180.16]
Dowex 50WX resin O
HOHO
OHOH
HO
OH
C8H16O7
[224.21]
O
C2H6O2
[62.07]
OH24 51 55
 
2850 mg (15.82 mmol, 1eq) D-mannose was taken in a dry flask under argon atmosphere. 
To this were added 24.5 g (395 mmol, 25 eq) of ethylene glycol and then 6g of dried 
Dowex 50WX 8-200 resin. The mixture was then heated to 750C and maintained at 70- 
800C for 72h. The resin was filtered over alumina sandwiched between celite bed, 
washed with ethylene glycol. Ethylene glycol was evaporated off from the filtrate and the 
crude was subjected to flash chromatography (silica gel- 70times of the residue mass; 
gradient eluent from 9:1 CH2Cl2 / MeOH to 7:3 CH2Cl2 / MeOH) which afforded 2230 
mg of pure 1-O-(α-D-mannopyranosyl) ethylene glycol. (major α-anomer; yield= 62.8%). 
 
O
HO
HO
OHOH
O
OH
2
1
1´2´3´
4´ 5´6´
 
Batch: RV 181, RV 333 
 
Rf: (CH2Cl2 / MeOH 3:1) = 0.28 (KMnO4) 
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.87 (d, 3J1´-2´ =1.7Hz, 1H, HC(1´α)); 4.68 
(d, 3J1´-2´ =0.8Hz, 1H, HC(1´β)); 3.96 (dd, 3J2´-1´ =1.7Hz, 3J3´-2´ =3.4Hz,1H, HC(2´α)); 3.87 
(dd, 3J6´a-5´ ≈2.0Hz, 3J6´a-6´b =11.4Hz,1H, HC(6´α a));3.84-3.71 (m,5H, HC(6`α b),H2C(2), 
HC(1a),  and HC(3´α); 3.65 -3.57 (m,3H, HC(5`α), HC(4´α) and HC(1b);  
 
α/β ratio by 1H-NMR ≈ 8 : 1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 100.7(C(1´β)); 100.6(C(1´α)); 
73.4(C(5´α); 71.2((C(3´α)); 70.7((C2´α)); 69.2(C(1)); 67.5(C(4´α); 61.7(C(6´α)); 61.2 
((C(2)). 
 
α/β ratio by 13C-NMR ≈ 10 : 1 
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 MS (ESI (+)): m/z relative intensity [M with OH/OD + Na] + = 252.1 
 
HR-MS [M+ Na] + = 247.0786 (calculated =247.0794) 
 
9.2.3.2.2. Synthesis of 1-O-(BOC- ALA) -2-O-(α-D-mannopyranosyl) ethylene glycol 
 
O
HO
HO
OH
OH
C8H16O7
[224.21]
O
OH
Lipase f rom
Cand ida
antarctica
(LCA)
OPFPBocHN
O
O
C16H16F5NO5
[397.29]
O
HO
HO
OHOH
O
NHBoc
O
O
O
C18H31NO11
[437.44]
55 7 56
 
540 mg (2.4 mmol, 1eq) of 2´-O-(α-D-mannopyranosyl) ethylene glycol.was taken in a 
dry flask under argon atmosphere and was dissolved in 13 ml anhydrous pyridine. 3600 
mg (10 units per mg of protein; 1unit hydrolyses 1µmol or 0.001mmol of an ester; 
approximately, 36 mmol, 15eq) of lipase from Candida antarctica (LCA, Novozyme 
435) enzyme (before use, dried by keeping at vacuum 10-2 mbar for 3-4 days) was added 
and then 2850 mg (7.18 mmol, 3eq) of Boc-ALA-PFP ester was added to the solution. 
The reaction was maintained at ambient temperature and maintained for 30min. 
(controlled by TLC eluent : CH2Cl2: MeOH 3:1). The mass was filtered over celite bed, 
the filtered cake was washed with 3× 10ml pyridine. The solvent pyridine was evaporated 
off by rotovapor .The residue was triturated with 2×50 ml dry 1:1 toluene : hexane and 
the top clear supernatant solution was removed, thesettled sticky residue was taken for 
flash chromatography. (silica gel- 100times of the residue mass; gradient eluent from 
100% CH2Cl2 to 85:15 CH2Cl2 : MeOH). The main fractions were concentrated to give 
440 mg of pure product 1-O-(BOC- ALA) -2-O-(α-D-mannopyranosyl) ethylene glycol 
was obtained as white solid. (Yield = 42%). 
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Batch : RV 186, RV207, RV 338 
 
Rf: (CH2Cl2 / MeOH 85:15): 0.20 (KMnO4) 
 
IR (KBr) : 3390vs, 2924vs, 1728vs, 1694vs, 1516m, 1384w, 1368m, 1252w, 1203w, 
1175s, 1137s, 1063s, 977m, 915w, 878w, 804w, 723w, 680w, 579vw, 513vw. 
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 1H-NMR (400 MHz, CDCl3 & CD3OD, 298 K): δH (ppm) = 4.78 (d, 3J1´-2´=1.6Hz, 1H, 
HC(1´α)); 4.26 (ddd, 3J1a-2b≈3.1 Hz, 3J1a-2a≈6.3 Hz vicinal, 3J1a-1a´=11.9Hz geminal, 1H, 
HC(1a)); 4.00 (ddd, 3J1b-2a≈3.1Hz, 3J1b-2b=6.4Hz vicinal, 3J1b-1b´=11.9Hz geminal, 1H, 
HC(1b)); 3.92 (s, 2H, H2C(15)); 3.87 (ddd, 3J1b-2a≈3.1Hz, 3J1a-2a≈6.3Hz vicinal, 3J2b-
2a=11.5Hz geminal, 1H, HC(2a)); 3.82 (dd, 3J5´-6´a≈2.5Hz, 3J6´a - 6´b =11.5Hz ,1H, HC(6´a 
α)); 3.84- 3.80 (m, 1H, HC(2´α)); 3.75- 3.60 (m, 1H, HC(2b)); 3.73 (dd, 3J5´-6´b ≈ 5.3Hz, 
3J6´a - 6´b ≈ 11.5Hz ,1H, HC(6´bα ); 3.69 (dd, 3J3´-2´≈3.3Hz, 3J3´-4´ =9.2Hz,1H, HC(3´α)); 
3.63 (t, 3J3´-4´=9.5Hz, 3J4´-5´ ≈9.5Hz,1H, HC(4´α); 3.54 (ddd, 3J5´-6´a ≈ 2.5Hz, 3J5´-6´b≈5.3Hz, 
3J5´-4´≈9.3Hz,1H, HC (5´α)); 2.76 (t, 3J13-12 ≈6.5Hz, 2H, H2C(13)); 2.62 (t, 3J12-13 ≈6.5Hz, 
2H, H2C(12)); 1.43 (s, 9H, H3C (18a, 18b and 18c)). 
 
α/β ratio by 1H-NMR ≈ could not be determined because of overlap 
 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 207.0 (C(14)); 173.8 (C(11)); 157.9 
(C(16)); 101.4 ((C(1´β) by DEPT); 101.1 (C(1´α)); 80.5 (C(17)); 74.1 (C(5´α)); 
72.1(C(3´α)); 71.5  (C(2´α)); 68.1 (C(4´α)); 65.9 (C(2)); 64.4(C(1)); 62.5 (C(6´α)); 50.5 
(C(15)); 34.7 (C(13)) ; 28.6 (C(18a,18b and18c); 28.4 (C(12)).  
 
α/β ratio by DEPT ≈ 14 : 1 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 460.1;  
 
HR-MS [M+ Na] + = 460.1790 (calculated =460.1795) 
 
9.2.3.2.3. Synthesis of 1-O-(ALA) -2-O-(α-D-mannopyranosyl) ethylene glycol 
 
 
O
HO
HO
OHOH
O
NH3
O
O
O
O
HO
HO
OHOH
O
NHBoc
O
O
O
C18H31NO11
[437.44]
CF3COOH
C15H24F3NO11
[451.34]
CF3COO
M+=338.33 ; CF3COO = 113.01
CH2Cl2
56 57
 
400 mg (0.91 mmol, 1eq) of 1-O-(BOC- ALA) -2-O-(α-D-mannopyranosyl) ethylene 
glycol was dissolved in 20ml CH2Cl2 and cooled to -100C. To this solution, 5.24g (3.5ml, 
45.72 mmol, 50eq) of trifluoroacetic acid was added dropwise by syringe. The reaction 
mass was maintained at 0-50C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was co evaporated 2times with distilled ether, then 
triturated with dry ether and the ether solution was decanted. The trituration with ether 
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 and decanting top clear ether solution after centrifuge was repeated 2 times more. Then, 
the settled solid product was purified by dissolving in 7ml MeOH and precipitated by 
adding 35ml ether. The mass was centrifuged, the settled solid on drying yielded 309 mg 
of 1-O-( ALA) -2-O-(α-D-mannopyranosyl) ethylene glycol  which was a highly 
hygroscopic white solid. (Yield=74.6%). 
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Batch: RV 202, RV223, RV348 
 
[α]D = +85.7 (c=0.31; deionized H2O) 
 
IR (KBr): 3394s, 2929s, 1789s, 1732vs, 1678vs, 1516w, 1428vw, 1389vw, 1355vw, 
1319vw,  1205vs, 1180vs, 1136vs, 1092w, 1064w, 975w, 884vw, 839m, 801m, 774w, 
723m, 680w, 600vw, 519vw, 500w. 
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.83 (d, 3J1´-2´=1.7Hz, 1H, HC(1´α)); 4.29 
(ddd, 3J1a-2b≈2.7 Hz, 3J1a-2a≈6.3 Hz vicinal, 3J1a-1a´=12.3Hz geminal, 1H, HC(1a)); 4.22 
(ddd, 3J1b-2a≈2.7Hz, 3J1b-2b≈6.3Hz vicinal, 3J1b-1b´=12.3Hz geminal, 1H, HC(1b)); 4.06 (s, 
2H, H2C(15)); 3.90-3.85 (m, 1H, HC(2a)); 3.88 (dd, 3J1´-2´≈1.7Hz, 3J3´-2´=3.3Hz, 1H, 
HC(2´α)); 3.85-3.67  (m, 2H, HC(2b) and HC(6´bα ); 3.82 (dd, 3J5´-6´a≈2.0 Hz, 3J6´a - 6´b 
=11.6Hz ,1H, HC(6´a α));  3.71 (dd, 3J3´-2´≈3.7Hz, 3J3´-4´ =9.1Hz,1H, HC(3´α)); 3.63 (m, 
2H, HC (5´α) and HC(4´α); 2.87 (t, 3J13-12 ≈6.0Hz, 2H, H2C(13)); 2.69 (t, 3J12-13 ≈6.0Hz, 
2H, H2C(12)); 
 
α/β ratio by 1H-NMR ≈: 12.5:1 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.6 (C(14)) ; 175.5 (C(13)) ; 163.8 
(q,2JC-F = 36.2, CF3COO¯ ); 117.3 (q,1JC-F ≈ 292, CF3COO¯ ); 100.9 ((C(1´β) by DEPT); 
100.7 (C(1´α)); 73.8 (C(5´α)); 71.5(C(3´α)); 70.9 (C(2´α)); 67.7 (C(4´α)); 66.1 (C(2)); 
65.0(C(1)); 61.9 (C(6´α)); 47.9 (C(15)); 35.2 (C(13)) ; 28.3 (C(12)).  
 
 α/β ratio by DEPT ≈ 14 : 1 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 338.1; [M-CF3COO¯-H+Na] 
+=360.1;  
 
HR-MS [M- CF3COO¯] + = 338.1440 (calculated =338.1451) 
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 9.2.3.3. Synthesis of 1-O-(ALA)-2-O-(α-D-galactopyranosyl) ethylene 
glycol 
9.2.3.3.1. Synthesis of 1-O-(2´, 3´, 4´, 6´tetraacetyl-β-D-galactopyranosyl) ethylene 
glycol 
 
C14H19BrO9
[411.20]
C16H24O11
[392.35]
O
AcO
OAc
OAc
Br
OAc
O
AcO
OAc
OAc
OAc
OH
O
HO
OH
C2H6O2
[62.07]
Ag2CO3
49 51 58
 
To 13.14 g (215 mmol, 22 eq) of ethylene glycol were added 4 g (9.73 mmol, 1 eq) of 2, 
3, 4, 6-β-D-galactopyranosyl bromide (acetobromogalactose) and 4.8 g (17.4 mmol, 1.8 
eq) of silver carbonate. The mixture was stirred until the CO2 evolution ceased, 50ml 
toluene was added and stirred and precipitated silver salts were filtered. The filtrate was 
separated into two layers, a toluene and an ethylene glycol layer. The latter was 
repeatedly extracted with 3× 50 ml toluene. The combined toluene layer was evaporated 
under vacuum. The residue was crystallised with 10 ml ether to give pure 2.66g 1-O-(2´, 
3´, 4´, 6´ tetraacetyl-β-D-galactopyranosyl) ethylene glycol. (Yield= 70%). Alternatively, 
the residue can also be purified by flash chromatography. (Eluent EtOAc : Hexane 3:1). 
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Batch: RV 177, RV200, RV327 
 
Rf: (EtOAc / Hexane 3:1) = 0.21 (KMnO4) 
 
IR (KBr): 3580w, 3477vw, 2981vw, 2956vw, 2885vw, 1750vs, 1639vw, 1486vw, 1429w, 
1368m, 1338vw, 1315w, 1254s, 1232s,1219s, 1166vw, 1156w, 1128m, 1102vw, 1084w, 
1067m, 1041s, 1022m, 969vw, 953w, 927w, 917vw, 899w, 875vw, 855w, 733w, 716w, 
650vw, 629vw, 587w, 540w, 502vw, 493vw, 475vw.   
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.29 (d, 3J4´-3´=3.8Hz, 1H, HC(4´β); 
5.10 (dd, 3J2´-1´=8.0Hz, 3J2´ -3´=10.4Hz,1H, HC(2´β)); 4.94 (dd, 3J3´-4´ =3.4Hz, 3J3´-
2´=10.4Hz, 1H, HC(3´β)); 4.44 (d, 3J1´-2´=8.0Hz, 1H, HC(1´β); 4.05 (m, 2H, H2C(6´)); 
3.89 (t,3J5´-6´a ≈ 6.6Hz, 3J5´-6´b≈6.6Hz,1H, HC (5´)); 3.77 (ddd, 3J1a-2b≈4.0Hz, 3J1a-2a≈5.4Hz 
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 vicinal, 3J1a-1b=11.0Hz geminal, 1H, HC(1a)); 3.72 (ddd, 3J1b-2a≈3.5Hz, 3J1b-2b≈5.4Hz 
vicinal, 3J1b-1a=11.0Hz geminal, 1H, HC(1b)); 3.87 (m, 2H, H2C(2)); 2.71 (d, 3J2-OH ≈ 
5.7Hz, 1H, OH ); 2.06, 1.97, 1.96, 1.88 (4 × s, 12H, H3C(2´b), H3C(3´b), H3C(4´b) and 
H3C(6´b). 
 
α/β ratio by 1H-NMR : Only β anomer 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 170.3, 170.1, 169.9, 169.5 (C2´a), 
(C3´a), (C4´a) and (C6´a)); 101.7(C(1´β)); 72.7((C(1)); 70.7, 70.6(C(5´) andC(3´)); 
68.8((C2´)); 66.9(C(4´);  61.7, 61.4 (C(6´) and (C(2)); 20.6, 20.5, 20.4 ((C2´b), (C3´b), 
(C4´b) and (C6´b)). 
 
α/β ratio by 13C-NMR: Only β anomer 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 415.1 
9.2.3.3.2. Synthesis of 1-O-(BOC- ALA) -2-O-(2´, 3´, 4´, 6´tetraacetyl-β-D-
galactopyranosyl) ethylene glycol 
 
C16H24O11
[392.35]
O
AcO
OAc
OAc
OAc
OH
O O
AcO
OAc
OAcOAc
C26H39NO15
[605.59]
O
O NHBoc
O
O
58 59
DCC, DPTS
5
 
In a dry flask under argon atmosphere, 196 mg (0.5 mmol, 1.0eq) of 1-O-(2´, 3´, 4´, 6´ 
tetraacetyl-β-D-galactopyranosyl) ethylene glycol was dissolved in 10ml CH2Cl2, 
followed by addition of 40 mg (0.13 mmol, 0.27eq) of DPTS and 10 ml CH2Cl2. Then, 
124 mg (0.6 mmol, 1.2eq) of DCC was added and finally 139 mg (0.6 mmol, 1.2eq) of 
Boc-ALA was added. The reaction was kept at room temperature for overnight. The 
reaction mixture was filtered over celite bed and the solvent was evaporated off by 
rotovapor. The crude mass was purified by flash chromatography (3:1 ether: hexane; 
silica gel mass- 60 times the crude mass) which yielded 251 mg of 1-O-(BOC- ALA) -2-
O-(2´, 3´, 4´, 6´tetraacetyl-β-D-galactopyranosyl) ethylene glycol. (Yield= 82.9%) 
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 Batch : RV 194 
 
Rf: (ether/ hexane 3:1): 0.33 (KMnO4) 
 
1H-NMR (400 MHz, CDCl3 & CD3OD, 298 K): δH (ppm) = 5.31 (dd, 3J4´-5´=1.0Hz, 3J4´-
3´=3.8Hz, 1H, HC(4´β);5.25 (sbr, 1H, NH);  5.17 (dd, 3J2´-1´=8.0Hz, 3J2´-3´=10.5Hz,1H, 
HC(2´β)); 5.00 (dd, 3J3´-4´ =3.4Hz, 3J3´-2´=10.4Hz, 1H, HC(3´β)); 4.51 (d, 3J1´-2´=8.0Hz, 
1H, HC(1´β); 4.20-4.18 (m, 2H, H2C(1)); 4.15-4.10 (m, 2H, H2C(6´)); 4.03 (d, 3J15-
NH=5Hz , 2H, H2C(15)); 3.96 (ddd, 3J2a-1b≈4.0Hz, 3J2a-1b≈6.0Hz vicinal, 3J2a-2b=11.0Hz 
geminal, 1H, HC(2a)); 3.91 (triplotide, 3J5´-4´ ≈1.0Hz, 3J5´-6´a ≈ 6.6Hz, 3J5´-6´b≈6.6Hz,1H, 
HC (5´)); 3.74 (ddd, 3J2b-1a≈4.5Hz, 3J2b-1b≈6.0Hz vicinal, 3J2b-2a=11.0Hz geminal, 1H, 
HC(2b)); 2.71-2.61 (m, 4H, H2C(13) and H2C(12)); 2.12, 2.04, 2.02, 1.95 (4 × s, 12H, 
H3C(2´b), H3C(3´b), H3C(4´b) and H3C(6´b); 1.41 (s, 9H, H3C (18a, 18b and 18c)). 
 
α/β ratio by 1H-NMR ≈ Only β anomer 
 
13C-NMR (100 MHz, CDCl3 & CD3OD, 298K) : δC (ppm) = 204.4 (C(14)); 172.3 
(C(11)); 170.5, 170.3, 170.2, 169.5 (C2´a), (C3´a), (C4´a) and (C6´a)); 155.7 (C(16)); 
101.4 ((C(1´β)); 80.0 (C(17)); 70.9, 70.8  (C(5´β) and (C(3´β)); 68.7 (C(2´β)); 67.4 
(C(2)); 67.0 (C(4´β)); 63.7 (C(1)); 61.3 (C(6´β)); 50.3 (C(15)); 34.3 (C(13)) ; 28.4 
(C(18a,18b and18c); 27.7 (C(12)); 20.8, 20.7, 20.6, 20.5 ((C2´b), (C3´b), (C4´b) and 
(C6´b)). 
 
 α/β ratio by DEPT ≈ Only β anomer 
 
9.2.3.3.3. Synthesis of 1-O-(β-D-galactopyranosyl) ethylene glycol 
 
C16H24O11
[392.35]
O
AcO
OAc
OAc
OAc
OH
O
C8H16O7
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O
HO
OH
OH
OH
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O
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58 59a
 
                      
2500mg (6.37 mmol, 1eq) of 1-O-(2´, 3´, 4´, 6´ tetraacetyl-β-D-galactopyranosyl) 
ethylene glycol was dissolved in 20 ml MeOH. 0.625 ml (0.0625 mmol, 0.01eq) of 0.1N 
sodium methoxide solution in MeOH was added slowly at ambient temperature and 
maintained at ambient temperature till the starting material was absent. (2-3hrs; TLC 
eluent : 3:1 CH2Cl2 :MeOH). The reaction mass was then neutralised by adding dried 
dowex resin, filtered over basic alumina sandwiched between celite bed. The filtrate is 
concentrated and the residue was crystallised using ether as solvent. 1.29 g of 1-O-(β-D-
galactopyranosyl) ethylene glycol was obtained. (Yield = 90.3%) 
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Batch: RV 193, RV201, RV211, RV 336, RV355 
 
Rf: (CH2Cl2 / MeOH 3:1) = 0.24 (KMnO4) 
 
IR (KBr): 3407vs, 3338vs, 2971vw, 2917m, 2893m, 2867m, 2657vw, 2157vw, 2041vw, 
1635vw, 1471vw, 1482vw, 1457w, 1449w, 1406w, 1372w, 1343vw, 1288m, 1241w, 
1225w, 1164m, 1146m, 1130m, 1118m, 1078vs, 1054w, 1031s, 1019s, 1000w, 945m, 
907m, 889m, 835w, 780m, 706m, 632w, 604w, 548vw, 502w, 470vw.  
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.43 (d, 3J1´-2´ =7.8Hz, 1H, HC(1´β)); 
4.05-3.98 (m, 1H, HC(1a); 3.93 (dd, 1H, HC(4´β); 3.83-3.73 (m, H2C(6`), H2C(2) and 
HC(1b); 3.71 ((dd, 3J6´a-5´ ≈4.2Hz, 3J5´-6´b =7.9Hz,1H, HC(5´β)); 3.67 (dd, 3J3´-4´ =3.4Hz, 
3J3´-2´ =9.9Hz,1H, HC(3´β));  3.56 (dd, 3J2´-1´ =7.8Hz, 3J3´-2´ =9.9Hz,1H, HC(2´β));  
 
α/β ratio by 1H-NMR ≈ Only β anomer 
 
13C-NMR (100 MHz, CDCl3, 298K): δC (ppm) = 103.4 (C(1´β)); 75.5 (C(5´β); 
73.1((C(3´β)); 71.5 (C(1)); 71.2((C2´β)); 69.0(C(4´β); 61.4 , 61.1 (C(6´β) and ((C(2)). 
 
α/β ratio by 13C-NMR ≈ Only β anomer 
 
MS (ESI (+)): m/z relative intensity [M with OH/OD + Na] + = 247.1 
 
HR-MS [M+ Na] + = 247.0783 (calculated =247.0794) 
9.2.3.3.4. Synthesis of 1-O-(BOC- ALA) -2-O-(β-D-galactopyranosyl) ethylene glycol 
 
O
HO
OH
OHOH
C8H16O7
[224.21]
Lipase f rom
C and id a
antarctica
(LCA)
C18H31NO11
[437.44]
O
O NHBoc
O
O
O
HO
OH
OHOH
O
OH
59a
7
60
 
115 mg (0.51 mmol, 1eq) of 2´-O-(α-D-galactopyranosyl) ethylene glycol.was taken in a 
dry flask under argon atmosphere and was dissolved in 3.5 ml anhydrous pyridine. 1000 
mg (10 units per mg of protein; 1unit hydrolyses 1µmol or 0.001mmol of an ester; 
approximately, 10 mmol, 20eq) of lipase from Candida antarctica (LCA, Novozyme 
435) enzyme (before use, dried by keeping at vacuum 10-2 mbar for 3-4 days) was added 
and then 1000 mg (2.5 mmol, 5eq) of Boc-ALA-PFP ester was added to the solution. The 
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 reaction was maintained at ambient temperature and maintained for 10min. (controlled by 
TLC eluent : CH2Cl2: MeOH 3:1). The mass was filtered over celite bed, the filtered cake 
was washed with 3× 10ml pyridine. The solvent pyridine was evaporated off by 
rotovapor .The residue was triturated with 2×50 ml dry 1:1 toluene : hexane and the top 
clear supernatant solution was removed, thesettled sticky residue was taken for flash 
chromatography. (silica gel- 100times of the residue mass; gradient eluent from 100% 
CH2Cl2 to 90:10 CH2Cl2 : MeOH). The main fractions were concentrated to give 108 mg 
of pure product 1-O-(BOC- ALA) -2-O-(α-D-galactopyranosyl) ethylene glycol was 
obtained as white solid. (Yield = 48%). 
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Batch : RV 227, RV 344, RV356 
 
Rf: (CH2Cl2 / MeOH 85:15): 0.23 (KMnO4) 
 
IR (KBr) : 3405vs, 2977m, 2930m, 1732vs, 1709vs, 1520m, 1393w, 1368m, 1286w, 
1253w, 1165s, 1076s,  921w, 891w, 878w, 780m, 702w, 600vw, 548vw, 500vw. 
 
1H-NMR (400 MHz, CDCl3 & CD3OD, 298 K): δH (ppm) = 4.25-4.22 (m, 3H, H2C(1) 
and HC(1´β)); 4.03 (ddd, 3J1b-2a≈4.0Hz, 3J1a-2a≈6.0Hz vicinal, 3J2b-2a=11.1Hz geminal, 1H, 
HC(2a)); 3.91 (s, 2H, H2C(15)); 3.82 (d, 3J3´-4´≈3.0Hz, 1H, HC(4´β); 3.79-3.65 (m, 3H, 
H2C(6´) and HC(2b)); 3.56- 3.47 (m, 2H, HC (5´β) and HC(2´β)); 3.45 (dd, 3J3´-2´≈3.0Hz, 
3J3´-4´ =9.2Hz,1H, HC(3´β)); 2.75 (t, 3J13-12 ≈6.5Hz, 2H, H2C(13)); 2.61 (t, 3J12-13 ≈6.5Hz, 
2H, H2C(12)); 1.43 (s, 9H, H3C (18a, 18b and 18c)). 
 
α/β ratio by 1H-NMR ≈ Only β anomer 
 
13C-NMR (100 MHz, CDCl3 & CD3OD, 298K) : δC (ppm) = 205.9 (C(14)); 174.0 
(C(11)); 157.0 (C(16)); 104.7 ((C(1´β)); 80.0 (C(17)); 76.5 (C(5´β)); 74.6(C(3´β)); 72.2 
(C(2´β)); 70.0 (C(4´β)); 68.2 (C(2)); 64.8 (C(1)); 62.3 (C(6´β)); 50.7 (C(15)); 34.8 (C(13)) 
; 28.7 (C(18a,18b and18c); 28.6 (C(12)).  
 
α/β ratio by DEPT ≈ Only β anomer 
 
MS (ESI (+)): m/z relative intensity [M+Na] + = 460.3. 
 
HR-MS [M+ Na] + = 460.1791 (calculated =460.1795) 
9.2.3.3.5. Synthesis of 1-O-(ALA) -2-O-(β-D-galactopyranosyl) ethylene glycol 
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 O
HO
OH
OHOH
O
O NH3
O
O
C18H31NO11
[437.44]
CF3COOH
C15H24F3NO11
[451.34]
CF3COO
M+=338.33 ; CF3COO = 113.01
CH2Cl2
O
HO
OH
OHOH
O
O NHBoc
O
O
60 61
 
170 mg (0.39 mmol, 1eq) of 1-O-(BOC- ALA) -2-O-(β-D-galactopyranosyl) ethylene 
glycol was dissolved in 15ml CH2Cl2 and cooled to -100C. To this solution, 4.5g (3.0ml, 
39.0mmol, 100eq) of trifluoroacetic acid was added dropwise by syringe. The reaction 
mass was maintained at 0-50C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was co evaporated 2times with distilled ether, then 
triturated with dry ether and the ether solution was decanted. The trituration with ether 
and decanting top clear ether solution after centrifuge was repeated 2 times more. Then, 
the settled solid product was purified by dissolving in 2ml MeOH and precipitated by 
adding 15ml ether. The mass was centrifuged, the settled solid on drying yielded 100 mg 
of 1-O-( ALA) -2-O-(α-D-mannopyranosyl) ethylene glycol  which was a highly 
hygroscopic white solid. (Yield=56.8%). 
 
O
O
O
OH
HO
OH
2´3´
4´ 5´
6´OH
1
2
O
O
1´
NH311 12
14
15
13
CF3COO
 
Batch: RV 228, RV204, RV350, RV358 
 
[α]D = -55.9 (c=0.5; deionized H2O) 
 
IR (KBr): 3407s, 2924s, 2854w, 1787s, 1733vs, 1677vs, 1513vw, 1431w, 1393w, 1205vs, 
1182vs, 1135vs, 1078s, 1063w, 839m, 800m, 777w, 723m, 706w, 665vw, 598vw, 519vw. 
 
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 4.43 (d, 3J1´-2´ = 7.8Hz 1H,  HC(1´β)); 
4.31(t, 3J1-2≈4.5Hz  H2C(1)); 4.13 (s, 2H, H2C(15)); 4.12-4.09 (m, 1H, HC(2a)); 3.92 
(ddd, 3J1b-2a≈4.0Hz, 3J1a-2a≈5.0Hz vicinal, 3J2b-2a=12Hz geminal, 1H, HC(2b)); 3.91 (t, 3J3´-
4´≈3.0Hz, 1H, HC(4´β)); 3.78-3.74 (m, 2H, H2C(6´)); 3.69 (ddd,  3J5´-4´ ≈1.0Hz, 3J5´-
6´a≈3.5Hz, 3J5´-6´b≈ overlap, 1H, HC (5´β)); 3.65 (dd,  3J3´-4´ ≈3.5Hz, 3J3´-2´ ≈10.0Hz,  1H, 
HC(3´β)); 3.51 (dd, 3J2´-1´=7.8Hz, 3J2´-3´ ≈10.0Hz,1H, HC(2´β)); 2.93 (t, 3J13-12 ≈6.5Hz, 
2H, H2C(13)); 2.75 (t, 3J12-13 ≈6.5Hz, 2H, H2C(12)). 
  
α/β ratio by 1H-NMR ≈ Only β anomer 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) = 204.4 (C(14)) ; 175.0 (C(13)) ; ~165 
(CF3COO¯ ); 115.3 ( CF3COO¯ );  103.3 ((C(1´β)); 75.5 (C(5´)); 73.0 (C(3´)); 71.0 
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 (C(2´)); 68.9 (C(4´)); 68.0 (C(2)); 64.7 (C(1)); 61.3 (C(6´)); 47.4 (C(15)); 34.8 (C(13)) ; 
27.8 (C(12)).  
 
α/β ratio by 13C-NMR ≈ Only β anomer 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 338.1 
 
HR-MS [M- CF3COO¯] + = 338.1445 (calculated =338.1451) 
 
9.3. Synthesis of vitamin-ALA derivatives 
9.3.1. Synthesis of (±)-α-tocopherol-ALA ester 
 
The synthesis of (±)-α-tocopherol-ALA ester was carried out using Boc-ALA acid and 
also using azidolevulinic acid. 
9.3.1.1. Synthesis of (±)-α-tocopherol-Boc-ALA ester 
O OH OHBocHN
O
O
62
C29H50O2
[430.71]
5
C10H17NO5
[231.25]
O O NHBoc
O
O
DCC, DMAP
CH2Cl2
63
C39H65NO6
[643.94]  
In a dry flask under argon atmosphere, 2150 mg (5.0 mmol, 1eq) of (±)-α-tocopherol was 
charged and then 25ml CH2Cl2 was added. The mass was cooled to 0 0C, 61.8 mg (0.5 
mmol, 0.1eq) of DMAP was added followed by 1281 mg (6.2 mmol, 1.2eq) of DCC. 
Finally, 1308 mg (5.66 mmol, 1.1eq) of BOC-ALA was charged. The reaction was 
brought to room temperature and was kept at room temperature overnight. Once the 
reaction was completed (Hex/AcOEt 8:2), the mixture was filtered through celite bed.The 
solvent was evaporated off by rotovapor. The crude mass was purified by flash 
chromatography (Hex/AcOEt 8:2, silica gel- 60 times the crude mass) which yielded 
2524 mg of (±)-α-tocopherol-Boc-ALA ester. (Yield= 78.4%). 
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Rf : 0.2 (Hex/AcOEt 8:2) 
 
IR (film) : 3433wb; 2927s; 2868m; 2253w; 1740s; 1714s; 1502m; 1462m; 1413m; 1367s; 
1247s; 1154s; 1108m; 1049w; 910w; 874vw; 781vw; 734m; 648vw 
 
1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 5.25 (s, 1H, NH) ; 4.08 (d, 3J5’’-NH=4.9, 
CH2(5’’) ; 2.96 (t, 2H, 3J2’’-3’’=5.9, 3J2’’-3’’=6.7, CH2(2’’)); 2.83 (t, 2H, 3J3’’-2’’=5.9, 3J3’’-
2’’=6.6, CH2(3’’)); 2.58 (t, 2H, 3J4-3=6.5, 3J4-3=6.8, CH2(4)); 2.08 (s, 3H, CH3(12)); 2.00 
(s, 3H, CH3(11)); 1.96 (s, 3H, CH3(13)); 1.84-1.72 (m, 2H, CH2(3)); 1.60-1.47 (m, 1H, 
CH(12’)); 1.44 (s, 9H, 3xCH3(8’’) ; 1.43-1.32 (m, 2H, CH(4’,8’)); 1.28-1.24 (m, CH2(2’, 
6’ and 10’), CH2(3’ or 5’ or 7’ or 9’)) ; 1,23 (s, 3H, CH3(14)) ; 1,21-1,03 (m, CH2(1’ and 
11’), CH2(3’ or 5’ or 7’ or 9’)) ; 0,87-0,83 (3d, 12H, 3J=6,5, 3J=5,7, 3J=6,5, CH3(13’, 14’, 
15’, 16’)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 204.3 C(4’’); 171.4 C(1’’); 155.7 C(6’’) ; 
149.5 C(10) ; 140.5 C(9) ; 126.7 C(7) ; 125.0 C(8) ; 123.1 C(6) ; 117.5 C(5) ; 79.9 
C(7’’) ; 75.1 C(2) ; 50.4 C(5’’) ; 39.4 C(1’,11’) ; 37.6 C(3’ or 5’ or 7’ or 9’) ; 37.5 C(3’ 
or 5’ or 7’ or 9’) ; 37.5 C(3’ or 5’ or 7’ or 9’) ; 37.4 C(3’ or 5’ or 7’ or 9’) ; 34.3 C(3’’) ; 
32.9 C(8’) ; 32.8 C(4’) ; 31.1 C(3) ; 28.4 3xC(8’’) ; 28.1 C(12’) ; 27.6 C(2’’) ; 24.9 
C(10’) ; 24.5 C(6’) ; 23.8 C(14)* ; 22.8 C(13’ or 16’) ; 22.7 C(13’ or 16’) ; 21.1 C(2’)* ; 
20.7 C(4) ; 19.8 C(14’ or 15’) ; 19.8 C(14’ or 15’) ; 13.0 C(11) ; 12.2 C(13) ; 11.9 C(12) 
(* peaks visible by DEPT) 
 
APCI ((+), solution in ethyl acetate diluted in acetone + CH3COONa (10% in H2O )): 
544,3 (Toc-ALA-NH3)+; 666,4 (M+Na)+ 
 
APCI ((+), solution in ethyl acetate diluted in acetone): 544,3 (Toc-ALA-NH3)+; 
9.3.1.2. Synthesis of (±)-α-tocopherol-ALA 
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 O O NHBoc
O
O
63
C39H65NO6
[643.94]
CH2Cl2
O O NH3
O
O CF3COO
CF3COOH
64
C36H58F3NO6
[657.84]  
522 mg (0.811 mmol, 1eq) of (±)-α-Tocopherol-Boc-ALA ester was dissolved in 2.5 ml 
CH2Cl2 and cooled to -100C. To this solution, 4.6 g (3.1 ml, 40.48 mmol, 50eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was co evaporated 2times with distilled ether, then the solid on drying 
yielded 472 mg of (±)-α-tocopherol-ALA which was an oil of yellow colour. 
(Yield=89%). 
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CF3COO  
1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 7.54 (sb, 3H, NH3) ; 3.85 (sb, 2H, 
CH2(5’’)) ; 2.94 (s, 2H, CH2(2’’)); 2.77 (s, 2H, CH2(3’’)); 2.59 (s, 2H, CH2(4)); 2.09 (s, 
3H, CH3(12)); 1.98 (s, 3H, CH3(11)); 1.93 (s, 3H, CH3(13)); 1.77 (sb, 2H, CH2(3)); 1.60-
1.50 (sept, 1H, 3J=6.6, CH(12’)); 1.45-1.40 (m, 2H, CH(4’,8’)); 1.34-1.26 (m, CH2(2’, 6’ 
and 10’), CH2(3’ or 5’ or 7’ or 9’), CH3(14)) ; 1.19-0.98 (m, CH2(1’ and 11’), CH2(3’ or 
5’ or 7’ or 9’)) ; 0.90-0.86 (3d, 12H, 3J=6.6, 3J=5.9, 3J=6.6, CH3(13’, 14’, 15’, 16’)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 201.4 C(4’’); 172.7 C(1’’); 149.8 C(10) ; 
140.4 C(9) ; 126.8 C(7) ; 125.2 C(8) ; 123.4 C(6) ; 118.0 C(5) ; 75.5 C(2) ; 47.5 C(5’’) ; 
39.5 C(1’,11’) ; 37.6 C(3’ or 5’ or 7’ or 9’) ; 37.5* C(3’ or 5’ or 7’ or 9’) ; 37.5 C(3’ or 5’ 
or 7’ or 9’) ; 37.4 C(3’ or 5’ or 7’ or 9’) ; 34.1 C(3’’) ; 32.9 C(8’) ; 32.9 C(4’) ; 31.1 
C(3) ; 28.1 C(12’) ; 27.3 C(2’’) ; 25.0 C(10’) ; 24.6 C(6’) ; 24.5* C(14) ; 22.8 C(13’ or 
16’) ; 22.7 C(13’ or 16’) ; 21.2 C(2’) ; 20.6 C(4) ; 19.9 C(14’ or 15’) ; 19.8 C(14’ or 
15’) ; 12.8 C(11) ; 11.9 C(13) ; 11.8 C(12) 
(* peaks visible by DEPT) 
9.3.1.3. Synthesis of (±)-α-tocopherol-azido levulinate ester 
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 O OH N3 OH
O
O
DCC, DMAP
CH2Cl2
O O
O
O
N3
62
C29H50O2
[430.71]
10
C5H7N3O3
[157.13]
65
C34H55N3O4
[569.82]  
In a dry flask under argon atmosphere, 431 mg (1.0 mmol, 1eq) of (±)-α-tocopherol was 
charged and then 20ml CH2Cl2 was added. The mass was cooled to 0 0C, 12.3 mg (0.1 
mmol, 0.1eq) of DMAP was added followed by 227 mg (1.1 mmol, 1.1eq) of DCC. 
Finally, 173 mg (1.1 mmol, 1.1eq) of azido levulinic acid was charged. The reaction was 
brought to room temperature and was kept at room temperature overnight. Once the 
reaction was completed (Hex/AcOEt 8:2), the mixture was filtered through celite bed.The 
solvent was evaporated off by rotovapor. The crude mass was purified by flash 
chromatography (Hex/AcOEt 8:2, silica gel- 60 times the crude mass) which yielded 471 
mg of (±)-α-tocopherol-azido levulinate ester. (Yield= 82.6%). 
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Rf : 0.6 (100% AcOEt) ; 0,24 (Hex/AcOEt 8:2) 
 
IR (film) : 2926s ; 2103s; 1748s; 1576w; 1462m; 1414m; 1377m; 1280m; 1244m; 1187m; 
1153s; 1092m; 923w; 735w; 554w 
 
1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 4.05 (s, 2H, CH2(5’’)); 3.01-2.98 (m, 2H, 
AA’ of a system AA’BB’, CH2(2’’)) ; 2.85-2.81 (m, 2H, BB’ of a system AA’BB’, 
CH2(3’’)) ; 2.59 (t, 2H, 3J4-3=6.7, CH2(4)) ; 2.09(s, 3H, CH3(12)) ; 2.01 (s, 3H, CH3(11)) ; 
1.97 (s, 3H, CH3(13)) ; 1.84-1.73 (m, 2H, CH2(3)) ; 1.63-1.32 (m, CH(4’, 8’, 12’)) ; 1.28-
1.25 (m, CH2(1’ or 2’ or 3’ or 5’ or 6’ or 7’ or 9’ or 10’ or 11’)) ; 1.24 (s, 3H, CH3(14)) ; 
1.21-1.03 (m, CH2(1’ or 2’ or 3’ or 5’ or 6’ or 7’ or 9’ or 10’ or 11’)) ; 0.88-0.84 (3d, 
12H, 3J=6.48, 3J=5.80, 3J=6.56, CH3(13’, 14’, 15’, 16’)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 203.0 (C4’’) ; 171.3 (C1’’) ; 149.6 
(C10) ; 140.5 (C9) ; 126.7 (C7) ; 125.0 (C8) ; 123.2 (C6) ; 117.5 (C5) ; 75.2 (C2) ; 57.7 
(C5’’) ; 39.5 (C1’+11’); 37.6 (C3’or 5’ or 7’ or 9’) ; 37.6 (C3’or 5’ or 7’ or 9’) ; 37.5 
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 (C3’or 5’ or 7’ or 9’) ; 37.4 (C3’or 5’ or 7’ or 9’) ; 34.5 (C3’’) ; 32.9 (C8’) ; 32.8 (C4’) ; 
31.1* (C3) ; 28.1 (C12’) ; 27.7 (C2’’) ; 24.9 (C10’) ; 24.5 (C6’) ; 24.2* (C14) ; 22.8 (C16’ 
or C13’) ; 22.7 (C16’ or C13’) ; 21.1 (C2’) ; 20.7 (C4) ; 19.9 (C14’ or C15’) ; 19.8 (C14’ 
or C15’) ; 13.0 (C11) ; 12.2 (C13) ; 11.9 (C12) 
(* peaks visible by DEPT) 
 
ESI (mode positive, acetone) : 153,3 (major peak). Probably, the product had 
decomposed as it is very sensitive to light and air. 
 
9.3.1.4. Synthesis of (±)-α-tocopherol-ALA 
 
O O
O
O
N3
65
C34H55N3O4
[569.82]
C
F
F
F
O
OH
66
C2HF3O2
[114.02]
H2, Pd/C O O
O
O
NH3
CF3COO
64
C36H58F3NO6
[657.84]  
471 mg (0.827 mmol, 1eq) of (±)-α-Tocopherol-Azido levulinate ester taken in a dry 
flask was dissolved in 35 ml isoprpanol and added dropwise by syringe 0.15 ml (1.96 
mmol, 2.4eq) of trifluoroacetic acid. To this solution, 52.8 mg (0.05 mmol, 0.06eq) of Pd 
over activated carbon. The mass was subjected to hydrogenation in ambient temperature 
with the pressure of 60psi H2 under mechanical agitation. Once the reaction was 
completed (Hex/AcOEt 8:2), the Pd was filtered over celite bed and then the solvent was 
evaporated off. The product was co evaporated 2times with distilled ether, then the solid 
on drying yielded 488 mg of (±)-α-tocopherol-ALA which was an oil of yellow colour. 
(Yield=90%). 
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CF3COO  
        
IR (film) : 2928m; 2868m; 2253w; 1737m; 1677m; 1463w; 1378w; 1205m; 1169m; 
1108w; 909s; 840vw; 800vw; 735s; 650w 
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 1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 8.03 (sb, 3H, NH3) ; 3.91 (s, 2H, 
CH2(5’’)) ; 2.89 (s, 2H, CH2(2’’)); 2.77 (s, 2H, CH2(3’’)); 2.58 (s, 2H, CH2(4)); 2.09 (s, 
3H, CH3(12)); 1.97 (s, 3H, CH3(11)); 1.93 (s, 3H, CH3(13)); 1.77-1.74 (mb, 2H, CH2(3)); 
1.60-1.50 (sept, 1H, 3J=6,6, CH(12’)); 1.46-1.35 (m, 2H, CH(4’,8’)); 1.31-1.24 (m, 
CH2(2’, 6’ and 10’), CH2(3’ or 5’ or 7’ or 9’), CH3(14)) ; 1.19-1.04 (m, CH2(1’ and 11’), 
CH2(3’ or 5’ or 7’ or 9’)) ; 0.90-0.86 (3d, 12H, 3J=6.6, 3J=6.6, 3J=5.9, CH3(13’, 14’, 15’, 
16’)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 201.8 C(4’’); 171.8 C(1’’); 162.0-161.0 
(COOCF3) ; 149.6 C(10) ; 140.5 C(9) ; 126.8 C(7) ; 125.2 C(8) ; 123.1 C(6) ; 117.7 
C(5) ; 114.8 (CF3) ; 75.3 C(2) ; 47.4 C(5’’) ; 39.5 C(1’,11’) ; 37.7 C(3’ or 5’ or 7’ or 9’) ; 
37.6 C(3’ or 5’ or 7’ or 9’) ; 37.5 C(3’ or 5’ or 7’ or 9’) ; 37.4 C(3’ or 5’ or 7’ or 9’) ; 
34.2 C(3’’) ; 32.9 C(8’) ; 32.8 C(4’) ; 31.1 C(3) ; 28.1 C(12’) ; 27.2 C(2’’) ; 24.9 C(10’) ; 
24.6 C(6’) ; 24.4 C(14) ; 22.8 C(13’ or 16’) ; 22.7 C(13’ or 16’) ; 21.1 C(2’) ; 20.5 C(4) ; 
19.8 C(14’ or15’) ; 19.8 C(14’ or 15’) ; 12.8 C(11) ; 11.9 C(13) ; 11.8 C(12) 
 
ESI ((+), solution in ethyl acetate diluted in acetone): 544.5 (M)+ ; 584,6 (major peak) ; 
((-),solution in ethyl acetate diluted in acetone) : 113 (CF3COO)- 
 
APCI ((+), solution in ethyl acetate diluted in acetone) : 544.5 (M)+ ; 584.5 (major peak) 
9.3.2. Synthesis of biotin-ALA peptide 
9.3.2.1. Synthesis of biotin PFP ester 
 
S
NHHN
O
OH
O
F F
F
FF
HO
DCC
DMF
S
NHHN
O
O
O
F
F
F
F
F
67
C10H16N2O3S
[244.31]
68
C6HF5O
[184,06]
69
C16H15F5N2O3S
[ 410,36]  
In a dry flask under argon atmosphere, 244 mg (1 mmol, 1eq) of biotin was charged. This 
was dissolved in 4ml DMF with heating over hot gun and the mass was cooled to 0 0C. 
Then 240 mg (1.3 mmol, 1.3eq) of pentafluorophenol was added followed by 312 mg 
(1.5 mmol, 1.5eq) of DCC. The reaction was brought to room temperature and was kept 
at room temperature overnight. The reaction mass was then filtered over celite bed to get 
rid off DCU and the solvent DMF was evaporated off by distillation. The white solid 
mass obtained was recrystallised with 20ml methanol. The white solid obtained was 
filtered off which on drying yielded 311 mg of biotin-PFP ester. (Yield= 75.9%) 
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Rf : 0,5 (Hex/AcOEt 1:1) 
 
19F-NMR (200 MHz, CDCl3, 300K, δ (ppm)) : -153.1 (d, 2F, 3Jortho-meta= 17,3, Fortho-2’’ et 
Fortho-6’’); -158.3 (t, 1,4F, 3J= 21, Fpara-4’’); -162.5 (dd, 2,1F, 3J=17,3, 3J=21,9, Fmeta-3’’ 
et Fmeta-5’’) 
 
1H-NMR (400 MHz, DMSO, 300K, δ (ppm)) : 6.44 (d, 2H, J=3.0, NH(1’ and 2’)); 4.34 
(t, 1H, 3J=4.9, 3J=7.2, CH(4)); 4.18-4,15 (m, 1H, CH(3)); 3.16-3.11 (m, 1H, CH(2)); 
2.85-2.81 (dd, 1H, 3JH5-H4=4,8, 2JH5α-H5β=12.6, CH2(5α)); 2.77 (t, 2H, 3J=7.1, CH2(9)); 
2.60 (d, 1H, 2JH5α-H5β=12.5, CH2(5β); 1.69 (s, 2H, CH2(6 or 7 or 8)); 1.52-1.41 (m, 4H, 
CH2(6 or 7 or 8)) 
 
13C-NMR (100 MHz, DMSO, 300K, δ (ppm)) : 170.5 C(10); 163.8 C(2’); 163.8 2xC(ar); 
142.6 C(ar); 1401 C(ar); 139.6 C(ar); 125.2 C(ar); 61.9 C(3); 60.0 C(4); 56.1 C(2); 40.6 
C(9); 33.1 C(5); 28.7 C(6 or 7); 28.6 C(6 or 7); 25.1 C(8) 
 
APCI ((+), DMSO diluted in acetone): 410.9 (M+H)+. 
9.3.2.2. Synthesis of biotin-ALA (OMe) peptide 
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3
C6H9N3O3
[171.15]
69
C16H15F5N2O3S
[410.36]
S
NHHN
O
O
O
O
O
H
N
H2, Pd/C
MeOH
70
C16H25N3O5S
[371.45]
 
To a solution of 205 mg (0.5 mmol, 1.5eq) biotin-PFP ester in 30 ml MeOH, was added 
69 mg (0.40 mmol, 1eq) of  5-azido-4-oxo methyl pentanoate (5-azido methyl levulinate) 
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 in 10 ml MeOH. To this mixture was added 25 mg (0.02 mmol, 0.06eq) of 10% 
Palladium over activated carbon. The mass was subjected to hydrogenation in ambient 
temperature with the pressure of 60psi H2 under mechanical agitation. Once the reaction 
was completed, (approximately 24hrs; TLC eluent: Hex/AcOEt 2:1, CH2Cl2/MeOH 9:1) 
the H2 pressure was released. The reaction mass was filtered over celite bed to get rid off 
palladium, the celite bed was washed with 3 × 10ml MeOH. The solvent in the filtrate 
was evaporated off by rotovapor and a yellow oily mass was obtained. This yellow crude 
mass was purified by flash chromatography.(eluent = CH2Cl2/MeOH 9:1). The pure 
fraction of 104.5 mg biotin-ALA (OMe) peptide was thus obtained. (Yield = 56.4%) 
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Rf : 0.34 (CH2Cl2/MeOH 9:1) 
 
IR (KBr pellet) : 3343m ; 2946m ; 2925m ; 2877w ; 2860w; 1709s; 1632s; 1535m; 
1467m; 1437m; 1423m; 1388w; 1357m; 1308m; 1270m; 1251w; 1204m; 1171m; 1134w; 
1116m; 1040w; 976w; 888vw; 869w; 828vw; 760vw; 733vw; 697vw; 645w; 605w; 583w; 
521w 
 
1H-NMR (400 MHz, DMSO, 300K, δ (ppm)) : 8.16 (t, 1H, J=5.5,  peptide NH) ; 6.45 (d, 
2H, J=28.0, NH(1’ et 2’)); 4.35-4.32 (dd, 1H, J=5, J=7.3, J=5, CH(4)); 4.16 (t, 1H, J=4.7, 
J=5.8, CH(3)); 3.95 (d, 2H, J=5.6, CH2(11)) ; 3.61 (s, 3H, CH3(16)) ; 3.19-3.10 (m, 1H, 
CH(2)); 2.87-2.82 (dd, 1H, 3JH5-H4=5, 2JH5α-H5β=12.5, CH2(5α)); 2.71 (t, 2H, J=6.4, J=6.6, 
CH2(13)) ; 2.60 (d, 1H, 2JH5α-H5β=12.5, CH2(5β); 2.54-2.46 (m, 2H, CH2(14)) ; 2.16 (t, 
2H, J=7.4, CH2(9) ; 1.68-1.59 (m, 2H, CH2(6)); 1.56-1.40 (m, 2H, CH2(7)) ; 1.39-1.23 
(m, 2H, CH2(8)) 
 
13C-NMR (100 MHz, DMSO, 300K, δ (ppm)) : 205.7 C(12) ; 173.5 C(15); 172.7 C(10) ; 
162.8 C(2’); 61.1 C(3); 59.3 C(4); 55.5 C(2); 51.5 C(16) ; 48.3 C(11) ; 40.1 C(5); 34.9 
C(9) ; 33.9 C(13); 28.2 C(6); 28.1 C(8); 27.2 C(14) ; 25.3 C(7) 
 
ESI ((+), DMSO diluted in acetone): 372.1 (M+H)+ 
                                
9.3.3. Synthesis of cholcalciferol –ALA ester (vitamin D3- ALA) 
9.3.3.1. Synthesis of cholcalciferol-Boc-ALA ester (vitamin D3-Boc-ALA ester) 
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 HO
OHBocHN
O
O
EDCI, DMAP
CH2Cl2
OBocHN
O
O
71
C27H44O
[384.64]
5
C10H17NO5
[231.25]
72
C37H59NO5
[597.87]  
 
In a dry flask under argon atmosphere, 614 mg (1.60 mmol, 1eq) of cholcalciferol 
(vitamin D3) was charged and then 25ml CH2Cl2 was added. The mass was cooled to 0 
0C, 219.5 mg (1.77 mmol, 1.1eq) of DMAP was added followed by 371 mg (1.93 mmol, 
1.2eq) of EDCI. Finally, 410 mg (1.77 mmol, 1.1eq) of BOC-ALA was charged. The 
reaction was brought to room temperature and was kept at room temperature overnight. 
The reaction was not completed even after 2 days (Hex/AcOEt 7:3), so the solvent was 
evaporated off by rotovapor. The crude mass was purified by flash chromatography 
(Hex/AcOEt 7:3, silica gel- 40 times the crude mass) which yielded 278 mg of 
cholcalciferol-Boc-ALA ester.(vitamin D3-Boc-ALA ester)(Yield= 29%). 
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Rf : 0.3 (Hexane/AcOEt 7:3) ; 0.13 (Hexane/AcOEt 8:2)  
 
IR (film) : 3431bw; 2950s; 2869m; 2253w; 1719vs; 1502m; 1440m; 1367s; 1249s; 1170s; 
1047m; 1017m; 910s; 781vw; 734s; 648w 
 
 
1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 6.16 (d, 1H, 3J6-7= 11.2, CH(6)) ; 5.99 (d, 
1H, 3J7-6= 11.3, CH(7)) ; 5.22 (s, NH) ; 5.02 (s, 1H, CH2(19E)) ; 4.93-4.89 (quin, 1H, 
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 J=3,8, CH(3α)) ; 4.80 (d, 1H, 2J=2.3, CH2(19Z)); 3.99 (t, 2H, J=3.6, J=4.3, CH2(5’)) ; 
2.78 (d, 1H, 3J9-11= 12.3, CH2(9β)) ; 2.66 (d, 2H, J=4.4, CH2(3’)) ; 2.60 (d, 2H, J=5.4, 
CH2(2’) ; 2.53-2.48 (dd, 1H, J=3.6, J=13.5, CH2(4α)) ; 2.34-2.29 (m, 2H, CH2(1β+4β)) ; 
2.19-2.12 (m, 1H, CH2(1α)) ; 1.98-1.93 (m, CH(14), CH2(12β)) ; 1.88-1.82 (m, CH2(2α 
+ 16α) ; 1.76-1.68 (m, 1H, CH2(2β)) ; 1.65-1.61 (m, 2H, CH2(9α + 11α)) ; 1.57-1.43 (m, 
CH(25), CH2(15 + 11β)) ; 1.41 (s, 9H, 3xCH3(8’)) ; 1.32-1.23 (m, 7H, CH(17), CH2(12α 
+ 16β + 22 + 23(1))) ; 1.10-1.07 (m, CH2(23(2) + 24)) ; 1.01-0.96 (m, 1H, CH(20)) ; 
0.89-0.88 (d, 3H, J=6.4, CH3(21)) ; 0.84-0.82 (dd, 6H, J=1.8, J=6.6, CH3(26 + 27)) ; 0.50 
(s, 3H, CH3(18)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 204.4 (C4’); 171.8 (C1’); 155.7 C(6’) ; 
144.5 (C10) ; 142.6 (C8) ; 134.2 (C5) ; 122.6 (C6) ; 117.5 (C7) ; 112.9 (C19) ; 79.8 
C(7’) ; 72.2 (C3) ; 56.6 (C17) ; 56.4 (C14) ; 50.3 C(5’) ; 46.0 (C13) ; 42.0 (C4) ; 40.6 
(C12) ; 39.5 (C24) ; 36.2 (C20) ; 34.7 (C22) ; 34.4 (C3’) ; 32.1 (C1) ; 31.8 (C2) ; 29.1 
(C9) ; 28.4 (C8’) ; 28.2 C(2’) ; 28.1 (C25) ; 27.7 (C16) ; 23.9 (C23) ; 23.6 (C11) ; 22.9 
(C26 or C27) ; 22.6 (C26 or C27) ; 22.3 (C15) ; 18.9 (C21) ; 12.0 (C18) 
 
ESI ((+),soultion in CHCl3 dissolved in acetone + CH3COONa (10% in H2O)): 620.3 
(M+Na)+ 
 
9.3.3.2. Synthesis of cholcalciferol -azido levulinate ester 
 
HO
O
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O
N3
O
O
O
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71
C27H44O
[384.64]
10
C5H7N3O3
[157.13]
DCC, DMAP
CH2Cl2
73
C32H49N3O3
[523.75]  
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 In a dry flask under argon atmosphere, 384 mg (1.0 mmol, 1eq) of cholcalciferol (vitamin 
D3) was charged and then 15ml CH2Cl2 was added. The mass was cooled to 0 0C, 16 mg 
(0.1 mmol, 0.1eq) of DMAP was added followed by 228 mg (1.1 mmol, 1.1eq) of DCC. 
Finally, 176 mg (1.1 mmol, 1.1eq) of azido levulinic acid was charged. The reaction was 
brought to room temperature and was kept at room temperature overnight. The reaction 
was not completed even after 5 days (Hex/AcOEt 8:2), the mixture was filtered through 
celite bed.The solvent was evaporated off by rotovapor. The crude mass was purified by 
flash chromatography (CH2Cl2/AcOEt 9:1, silica gel- 60 times the crude mass) which 
yielded 156 mg of cholcalciferol -azido levulinate ester.( vitamin D3 -azido levulinate 
ester). (Yield= 29.8%). 
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Rf : 0.24 (Hexane/AcOEt 8:2) ; 0.28 (Hexane/éther 1:1) ; 0.77 (CH2Cl2/AcOEt 9:1) 
 
IR (film) : 3441bw; 3079w; 2949s; 2104s; 1808w; 1731s; 1645w; 1467m; 1440m; 
1415m; 1379s; 1277s; 1201s; 1094m; 1047m; 1010m; 909m; 835w; 735m; 649vw; 554vw 
 
1H-NMR (400 MHz, CDCl3, 300K, δ (ppm)) : 6.18 (d, 1H, 3J6-7= 11.21, CH(6)) ; 6,00 (d, 
1H, 3J7-6= 11.27, CH(7)) ; 5.04 (s, 1H, CH2(19E)) ; 4.95-4.91 (m, 1H, CH(3α)) ; 4.81 (s, 
1H, CH2(19Z)) ; 3.98 (s, 2H, CH2(5’)) ; 2.79 (d, 1H, 3J9-11= 12.29, CH2(9β)) ; 2.67-2.61 
(m, 4H, CH2(3’+2’)) ; 2.53 (d, 1H, 3J4-3= 0.03, CH2(4α)) ; 2.35-2.30 (m, 2H, 
CH2(1β+4β)) ; 2.18-2.15 (m, 1H, CH2(1α)) ; 1.96-1.77 (m, 5H, CH(14), CH2(2α + 12β + 
16β)) ; 1.75-1.68 (m, 1H, CH2(2β)) ; 1.65-1.62 (m, 2H, CH2(9α + 11α)) ; 1.52-1.44 (m, 
4H, CH(25), CH2(15 + 11β)) ; 1.33-1.21 (m, 7H, CH(17), CH2(12α + 16α + 22 + 23)) ; 
1.11-1.09 (m, 4H, CH2(23 + 24)) ; 0.99-0.95 (m, 1H, CH(20)) ; 0.90-0.88 (m, 3H, 
CH3(21)) ; 0.85-0.83 (m, 6H, CH3(26 + 27)) ; 0.51 (s, 3H, CH3(18)) 
 
13C-NMR (100 MHz, CDCl3, 300K, δ (ppm)) : 203.1 (C4’) ; 171.7 (C1’) ; 144.5 (C10) ; 
142.7 (C8) ; 134.2 (C5) ; 122.6 (C6) ; 117.5 (C7) ; 112.9 (C19) ; 72.4 (C3) ; 57.5 (C5’) ; 
56.6 (C17) ; 56.4 (C14) ; 46.0 (C13) ; 42.0 (C4) ; 40.6 (C12) ; 39.5 (C24) ; 36.2 (C20) ; 
36.1* (C22) ; 34.5 (C3’) ; 32.1 (C1) ; 31.8 (C2) ; 29.1 (C9) ; 28.2 (C2’) ; 28.1 (C25) ; 
27.7 (C16) ; 23.9 (C23) ; 23.6 (C11) ; 23.0 (C26 or C27) ; 22.6 (C26 or C27) ; 22.3 
(C15) ; 18.9 (C21) ; 12.0 (C18) 
(* peaks visible by DEPT) 
 
ESI ((+), acetone + CH3COONa (10% in H2O)): 546.4 (M+Na)+; 562.4 (M+O+Na)+ 
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 9.4. Synthesis of nucleoside-ALA derivatives 
9.4.1. Synthesis of adenosine-ALA derivative 
9.4.1.1. Synthesis of 5´- O-(Boc-ALA)-adenosine 
C20H28N6O8
[480.47]
C13H22N2O5
[286.32]
BocHN
O
O
N
O
N
NN
N
NH2
O
OHOH
HO
BocHN
O
O
N
NN
N
NH2
O
OHOH
O
C10H13N5O4
[267.24]
Lipase f rom
Candida
antarctica
(LCA)
12 74
75
 
267 mg (1.0 mmol, 1eq) of adenosine.was taken in a dry flask under argon atmosphere 
and was dissolved in 7 ml anhydrous distilled THF. 200 mg (10 units per mg of protein; 
1unit hydrolyses 1µmol or 0.001mmol of an ester; approximately, 2 mmol, 2eq) of lipase 
from Candida antarctica (LCA, Novozyme 435) enzyme (before use, dried by keeping at 
vacuum 10-2 mbar for 3-4 days) was added and then 860 mg (3.0 mmol, 3eq) of Boc-
ALA-oxime ester was added to the solution. The reaction was maintained at 600C for 
24h. (controlled by TLC eluent :ether: MeOH 8:2). The mass was filtered over celite bed, 
the filtered cake was washed with 3× 10ml THF. The THF was evaporated off by 
rotovapor .The residue was taken for flash chromatography. (silica gel- 80times of the 
residue mass; eluent from ether: MeOH 8:2). The main fractions were concentrated to 
give 117 mg of pure product 5´-O-(BOC- ALA) -adenosine was obtained as white solid. 
(Yield = 24.8 %). 
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 Batch: RV 284 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 8.29 (s, 1H, HC(2)); 8.18 (s, 1H, 
HC(8)); 6.83 (sbr, 1H, NH); 6.02 (d, 3J1´-2´ = 4.2 Hz, 1H, HC(1´)); 4.65 (t, 3J2´-1´ ≈4.2 Hz, 
3J2´-3´ ≈4.2 Hz, 1H, HC(2´)); 4.41 (dd, 3J5´a-4´ ≈ 3.3Hz, 3J5´a-5´b =12Hz, 1H, HC(5´a)); 4.38-
4.33 (m, 2H, HC(3´) and HC(5´b)); 4.30-4.27 (m, 1H, HC(4´)); 3.94 (s, 2H, H2C(55)); 
2.76 (t, 3J2-3 ≈ 6.0Hz, 2H, H2C(52)); 2.63 (3J3-2 ≈ 6.0Hz, 2H, H2C(53)); 1.40 (s, 9H, 
H3C(58a,58b,58c); and other peaks due to traces of ether and impuritiy. 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) = 206.6 (C54); 173.4 (C(51)); 157.4 
(56); 156.4 (C(4)); 153.2 (C(2)); 149.6 (C(6)); 140.0 (C(8)), 120.0 (C(5)); 89.7(C(1´)); 
82.7 (C(4´)); 74.8 (C(2´)); 70.9 (C(3´)); 64.4 (C(5´)); 50.4 (C(55);  34.5 (C(53)); 28.5 
(C(58a,58b,58c)); 28.1 (C(52)); and other peaks due to traces of ether and impuritiy. 
 
MS (APCI (-)): m/z relative intensity [M + Na]+ = 503.1; [M +H]+ = 481.1. 
 
9.4.2. Synthesis of thymidine-ALA derivative 
9.4.2.1. Synthesis of 3´, 5´- O-di (Boc-ALA)-thymidine 
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O
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O
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HO
C10H14N2O5
242.23 g/mol
C30H44N4O13
668.69 g/mol
5
165
238a
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In a dry two necked flask 0.5 g (2.06 mmol) of thymidine and 1.2 g (11.9 mmol) of 
triethyl amine was dissolved in 20 ml dioxane under nitrogen atmosphere. Then 2.4 g 
(10.4 mmol) of Boc-ALA 5, 2.15 g (10.4 mmol) of DCC and 0.02 g (0.16 mmol) of 
DMAP. The reaction was stirred at ambient temperature for 2h. The reaction mass was 
then filtered over celite and the solvent was evaporated. The mass was later extracted 
with 200 ml CH2Cl2, followed by extraction with saturated NaHCO3 solution. The 
organic phase is dried over MgSO4 and solvent evaporated. The 4.3 g crude was purified 
by column chromatography using 200 g silica gel with AcOEt. The pure final product 
was obtained with 98% yield. 
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Analysis in progress 
9.4.2.2. Synthesis of 3´, 5´- O-di (ALA)-thymidine 
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In a dry flask, 0.7 g (1.05 mmol) of 3´, 5´- O-di (Boc-ALA)-thymidine was dissolved in 
20 ml of CH2Cl2 . The solution is cooled to 0-5°C and 6.0 g (52.61 mmol) of TFA was 
added slowly. Then, the reaction was stirred for 30 minutes at ambient temperature. After 
evaporating TFA, the traces of TFA were removed by trituraation and co evaporation 
with ether. Finally dry product of 0.4 g 3´, 5´- O-di (ALA)-thymidine was obtained with 
82% yield. 
 
Analysis in progress 
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 9.5. Synthesis of ALA based peptides and ALA esters 
(non sugars) 
9.5.1. Synthesis of GABA- ALA(OMe) peptide 
9.5.1.1. Synthesis of Boc-GABA-PFP ester 
 
C9H17NO4
[203.23]
HO
F
F
F
F
F
DCC
C6HF5O
[184.06]
C15H16NO4F5
[369.28]
O
BocHN
O
F
F
F
F
F
OH
BocHN
O
6876 77
 
 
To a solution of 813 mg (4 mmol, 1eq) Boc-GABA (Boc-γ-aminobutyric acid) in 25 ml 
EtOAc at -100C, was added a solution of 740 mg (4 mmol, 1eq) pentafluoro phenol in 10 
ml EtOAc. The reaction mass was brought to ambient temperature and kept at that 
temperature for 3 h. The mixture was filtered over celite bed and the solvent was 
evaporated off. The residue on precipitation with ether afforded 1447 mg Boc-GABA-
PFP ester. (Yield = 98%) 
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 Batch : RV 61 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 4.68 (sbr, 1H, NH) ;3.24 (q, 3J4-NH ≈6.5 
Hz, 3J4-3 ≈6.5 Hz, 2H, H2C(4)); 2.71 (t, 3J2-3 = 7.4Hz, 2H, H2C(2)); 1.95 (quint, 3J3-2 ≈ 
7.1Hz, 3J3-4 ≈ 7.1Hz, 2H, H2C(3)); 1.44 (s, 9H, H3C(7a,7b,7c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 169.5 (C(1)) ; 156.4 (C(5)) ; 142.5, 
142.4, 142.4, 142.3, 140.0, 140.0, 139.9, 139.2, 138.5, 138.4, 136.7 and 136.5; 125.0 
(C11), (C12), (C13), (C14) ; 79.9 (C(6)) ; 39.9 (C(4)) ; 30.9 (C(2)) ; 28.7 (C(7a,7b,7c)) ; 
25.6 (C(3)).  
 
MS (APCI (-)): m/z relative intensity [M + Na]+ = 392.0 
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 9.5.1.2. Synthesis of Boc-GABA-ALA (OMe) peptide 
 
C15H16NO4F5
[369.28]
O
BocHN
O
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H2 / Pd
C6H9N3O3
[171.16]
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78
 
 
To a solution of 1447 mg (3.92 mmol, 1.5eq) Boc-GABA-PFP ester in 20 ml MeOH, was 
added 457 mg (2.67 mmol, 1eq) of  5-azido-4-oxo methyl pentanoate (5-azido methyl 
levulinate) in 10 ml MeOH. To this mixture was added 85 mg (0.08 mmol, 0.03eq) of 
10% Palladium over activated carbon. The mass was subjected to hydrogenation in 
ambient temperature with the pressure of 60psi H2 under mechanical agitation. Once the 
reaction was completed, (approximately 24hrs; TLC eluent: EtOAc/ Hexane 3:1) the H2 
pressure was released. The reaction mass was filtered over celite bed to get rid off 
palladium, the celite bed was washed with 3 × 10ml MeOH. The solvent in the filtrate 
was evaporated off by rotovapor and a yellow oily mass was obtained. This yellow crude 
mass was purified by flash chromatography. (eluent = 100% EtOAc). The pure fraction 
of 770 mg BOC-GABA-ALA (OMe) peptide was thus obtained. (Yield = 87.3%) 
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Batch: RV 67 
  
Rf: (100% EtOAc): 0.14 (KMnO4) 
 
1H-NMR (400 MHz, CDCl3 & CD3OD, 298 K): δH (ppm) = 6.80 (sbr, 1H, CONH); 4.92 
((sbr, 1H, NHBoc); 4.13 (d, 3J5-NH=5.0Hz, 2H, H2C(5)); 3.62 (s, 3H, H3C(11); 3.12 (sbr, 
2H, H2C(9); 2.72-2.68 (m, 2H, H2C(3)); 2.61-2.59 (m, 2H, H2C(2)); 2.24 (t, 3J7-8 = 7.4Hz, 
2H, H2C(7)); 1.76 (quint, 3J8-7 ≈ 7.0Hz, 3J8-9 ≈ 7.0Hz, 2H, H2C(8)); 1.40  (s, 9H, 
H3C(12a,12b,12c), other peaks due to EtOAc solvent. 
 
13C-NMR (100 MHz, CDCl3 & CD3OD, 298K) : δC (ppm) =  173.3 (C(1)) ; 156.7 (C(10) 
and C(6)) ; 79.8 (C(11)); 52.2 (C(11); 49.5 (C(5)); 40.1 (C(9)); 34.9 (C(3)); 33.5 (C(7)); 
28.7 (C(12a,12b,12c)); 27.9 (C(2)); 26.5 (C(8))  
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 353.1 
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 9.5.1.3. Synthesis of GABA-ALA (OMe) peptide 
 
CF3COOH H
N O
O
O
O
H3N
C12H19F3N2O6
[344.28]
H
N O
O
O
O
BocHN
C15H26N2O6
[330.37]
CF3COO
M+=231.27 ; CF3COO = 113.01
78 79
 
330 mg (1.0 mmol, 1eq) of BOC-GABA-ALA (OMe) peptide was dissolved in 10ml 
CH2Cl2 and cooled to -100C. To this solution, 14.8g (10ml, 129.0mmol, 129eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was co evaporated 2times with distilled ether, then triturated with dry ether 
and the ether solution was decanted. The trituration with ether and decanting top clear 
ether solution after centrifuge was repeated 2 times more. The settled solid product on 
drying yielded 330 mg of GABA-ALA (OMe) peptide (Yield=95.8%). 
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Batch: RV 70, RV87 
  
IR (KBr): 3428m, 3280m, 3079m, 2959m, 2925m, 2345vw, 2115vw, 1742vs, 1723vs, 
1688s, 1666vs, 1639vs, 1557m, 1480vw, 1431m,1407w, 1385w, 1366w, 1275vw, 1206vs, 
1179s, 1167m, 1139s, 1086w, 1018w, 978w, 879vw, 838m, 801m,724s, 656vw, 600vw, 
553vw, 518vw, 485vw, 467vw. 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 4.09 (s, 2H, H2C(5)); 3.64 (s, 3H, 
H3C(11); 3.01 (t, 3J9-8 ≈ 7.5Hz, 2H, H2C(9); 2.78-2.75 (m, 2H, H2C(3)); 2.60-2.57 (m, 2H, 
H2C(2)); 2.43 (t, 3J7-8 = 7.0Hz, 2H, H2C(7)); 1.95 (quint, 3J8-7 ≈ 7.0Hz, 3J8-9 ≈ 7.0Hz, 2H, 
H2C(8)). 
 
13C-NMR (100 MHz, CD3OD, 298K) : δC (ppm) =  206.3 (C(4)); 174.9 (C(1)); 173.3 
(C(6)); 162.9 (q,2JC-F ≈ 35.9, CF3COO¯ ); 118.1 (q,1JC-F ≈ 290.0, CF3COO¯ ); 52.2 
(C(11); 49.7 (C(5)); 40.2 (C(9)); 35.1 (C(3)); 33.3 (C(7)); 28.3 (C(2)); 24.3 (C(8))  
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 231.1 
 
CHN: C12H19F3N2O6   Calculated:  C 41.86   H 5.56   N 8.14;  
                                     Observed:    C 41.80   H 5.53   N 7.76 
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 9.5.2. Synthesis of Tyr- ALA peptide 
 
9.5.2.1. Synthesis of Boc-Tyr (OtBu)-PFP ester 
 
OH
BocHN
O
O
C18H27NO5
[337.41]
HO
F
F
F
F
F
DCC
C6HF5O
[184.06]
C24H26NO5F5
[503.46]
BocHN
O
O
O
F
F
F
F
F
80 68 81
 
To a solution of 1000 mg (2.96 mmol, 1eq) Boc-tyrosine (OtBu)  (Boc-TyrOtBu) in 25 ml 
EtOAc at -100C, was added a solution of 546 mg (2.96 mmol, 1eq) pentafluoro phenol in 
10 ml EtOAc. The reaction mass was brought to ambient temperature and kept at that 
temperature for 3 h. The mixture was filtered over celite bed and the solvent was 
evaporated off. The residue on precipitation with ether afforded 1471 mg Boc-Tyr(OtBu)-
PFP ester. (Yield = 98.6%) 
 
O
O
O
F
F
F
F
F
O
O
N
H4
1
23
5a
5b
5c
21
22
23
24
25
26 27a
27b
27c
11
12
13
14
 
Batch : RV 62 
 
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.14- 7.11 (m, 2H, Aromatic C(23) and 
C(24)); 6.97- 6.94 (m, 2H, Aromatic C(23´) and C(24´)); 5.00 (d, 3J2-NH =8.0Hz, 1H, NH); 
4.88 (d, 3J2-21 =6.0Hz, 1H, HC(2)); 3.25 (dd, 3J2-21a ≈ 6.0Hz, 3J21a-21b =14.0Hz,  2H, 
HC(21a)); 3.14 (dd, 3J2-21b ≈ 6.5Hz, 3J21a-21b =14.0Hz,  2H, HC(21b))); 1.43 and 1.34 (2× s, 
18H, H3C(5a,5b,5c) and H3C(27a,27b,27c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 168.8 (C(1)); 155.3 (C(3)); 142.7, 
142.6, 141.3, 140.1, 139.5, 138.8, 137.0 and 130.0 (C11), (C12), (C13), (C14), C(22) and 
C(25); 130.1,124.7 (C(23), C(23´), C(24) and C(24´));  80.9 and 78.9 (C(4) and C(26)); 54.8 
(C(2));  37.6 (C(21)) ; 29.2 and 28.6 (C(5a,5b,5c) and C(27a,27b,27c)).  
 
MS (ESI ): m/z relative intensity [M + Na]+ = 526.1 
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 9.5.2.2. Synthesis of Boc-Tyr(OtBu)-ALA (OMe) peptide 
 
ON3
O
O
H2 / Pd
C6H9N3O3
[171.16]
C24H36N2O7
[464.55]
OPFP
BocHN
O
O
BocHN
O
O
O
H
N
O
O
C24H26NO5F5
[503.46]
81 10 82
 
 
To a solution of 1471 mg (2.92 mmol, 1.5eq) Boc-Tyr(OtBu)-PFP ester in 20 ml MeOH, 
was added 338 mg (1.97 mmol, 1eq) of  5-azido-4-oxo methyl pentanoate (5-azido 
methyl levulinate) in10 ml MeOH. To this mixture was added 65 mg (0.061 mmol, 
0.03eq) of 10% Palladium over activated carbon. The mass was subjected to 
hydrogenation in ambient temperature with the pressure of 60psi H2 under mechanical 
agitation. Once the reaction was completed, (approximately 24hrs; TLC eluent: EtOAc/ 
Hexane 3:1) the H2 pressure was released. The reaction mass was filtered over celite bed 
to get rid off palladium, the celite bed was washed with 3 × 10ml MeOH. The solvent in 
the filtrate was evaporated off by rotovapor and a yellow oily mass was obtained. This 
yellow crude mass was purified by flash chromatography. (silica gel- 65 times the crude 
mass; eluent = 3:1 EtOAc: Hexane). The pure fraction of 823 mg Boc-Tyr(OtBu)-ALA 
(OMe) peptide was thus obtained. (Yield = 89.9%) 
O
O
O
O
N
H9
6
78
10a
10b
10c
71
72
73
74
75
76 7
7a
77b
77c
H
N O
O
O
4
1
2
35 11  
Batch: RV 68 
  
Rf: (3:1 EtOAc: Hexane): 0.37 (KMnO4) 
 
IR (KBr): 3354vs, 2986s, 2937m, 2921m, 2873vw, 2854vw, 1741vs, 1719vs, 1694vs, 
1650vs, 1610w, 1578vw, 1513vs, 1476vw, 1462w, 1437s, 1402m, 1390m, 1367vs, 
1334w,1312w, 1291w, 1250s, 1237s, 1205s, 1165vs, 1126w, 1105m, 1078m, 1017m, 
1050m, 968m, 941vw, 926w, 904m, 868vw, 840m, 804vw, 794vw, 779w, 755w, 725w, 
701vw, 657m, 638vw, 620m, 568m, 544w, 503vw, 478vw, 460vw. 
  
1H-NMR (400 MHz, CDCl3 & CD3OD, 298 K): δH (ppm) = 7.06 (d, 3J73-74 =8.3Hz, 2H, 
HC(74) and HC(74´)); 6.88 (d, 3J73-74 ≈ 8.3Hz, 2H, HC(73) and HC(73´)); 6.71 (sbr, 1H, 
CONH); 5.08 ((sbr, 1H, NHBoc); 4.36 (m, 1H, HC(7)); 4.15 (dd, 3J5a-NH ≈ 5.0Hz, 3J5a-5b 
=19.4Hz 1H, HC(5a)); 4.05 (dd, 3J5b-NH ≈ 5.0Hz, 3J5a-5b =19.4Hz 1H, HC(5b)); 3.64 (s, 
3H, H3C(11); 3.06 (dd, 3J71a-7 ≈ 6.5Hz, 3J71a-71b =14.0Hz 1H, HC(71a)); 2.97-2.95 (m, 1H, 
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 HC(71b)); 2.69-2.66 (m, 2H, H2C(3)); 2.61-2.59 (m, 2H, H2C(2)); 1.37 and 1.30 (2×s, 
18H, H3C(7a,7b,7c) and H3C(10a,10b,10c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) =  203.7 (C(4)); 173.1 (C(1)); 171.9 
(C(6)); 154.6 (C(8)); 131.8, 130.0, 124.7 (aromatic C(72), C(75), C(73), C(74), C(73´) and 
C(74´));  80.5 and 78.7 (C(9) and C(76)); 56.1 (C(7));  52.3 (C(11); 49.4 (C(5)); 38.2 
(C(71)); 34.8 (C(3)); 29.2, 28.6  (C(10a,10b,10c) and C(77a,77b,77c)); 27.9 (C(2). 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 487.1 
 
9.5.2.3. Synthesis of Tyr- ALA(OMe) peptide 
 
C17H21F3N2O7
[422.35]
CF3COOH
CF3COO
M+=309.34 ; CF3COO = 113.01
C24H36N2O7
[464.55]
BocHN
O
O
O
H
N
O
O
H3N
O
OH
O
H
N
O
O
82 83
 
465 mg (1.0 mmol, 1eq) of Boc-Tyr(OtBu)-ALA (OMe) peptide was dissolved in 10ml 
CH2Cl2 and cooled to -100C. To this solution, 14.8g (10ml, 129.0mmol, 129eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was co evaporated 2times with distilled ether, then triturated with dry ether 
and the ether solution was decanted. The trituration with ether and decanting top clear 
ether solution after centrifuge was repeated 2 times more. The settled solid product on 
drying yielded 392 mg of Tyr- ALA(OMe) peptide (Yield=92.8%). 
                                                     
O
OH
H3N
6
7
71
72
73
74
75
H
N O
O
O
4
1
2
35 11
CF3COO
 
Batch: RV71, RV 86 
  
1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) = 8.81 (d, 3JNH-5 ≈ 5.3Hz, 1H, CONH);  
8.16 (sbr, 3H, NH3+); 7.12-6.91 (m, 2H, HC(74) and HC(74´)); 6.72-6.60 (m, 2H, HC(73) 
and HC(73´)); 4.07 (d, 3J5-NH ≈ 5.3Hz, 2H, H2C(5));  4.03 (m, 1H, HC(7)); 3.57 (s, 3H, 
H3C(11); 3.02 (dd, 3J71a-7 ≈ 5.8Hz, 3J71a-71b =14.0Hz 1H, HC(71a)); 2.87 (dd, 3J71a-7 ≈ 
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 7.8Hz, 3J71a-71b =14.0Hz 1H, HC(71b)); 2.69-2.60 (m, 2H, H2C(3)); 2.59-2.48 (m, 2H, 
H2C(2)); 3.81, 3.60, 3.55-3.50, 3.17 peaks due to impurity. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) =  204.9 (C(4)); 172.8 (C(1)); 159.3-
155.0 (CF3COO¯ ); 130.9 - 124.9 (aromatic C(72), C(75), C(73), C(74), C(73´) and C(74´)); 
120.5-114.7 (CF3COO¯ ); 53.8 (C(7));  51.5 (C(11); 48.5 (C(5)); 36.5 (C(71)); 34.1 
(C(3)); 27.3 (C(2); 168.7, 51.4, 29.8-28.0 peaks due to impurity. 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯+ with OH/OD] + = 312.0 
 
9.5.3. Synthesis of ALA- ALA(OMe) peptide 
9.5.3.1. Synthesis of Boc-ALA-ALA (OMe) peptide 
 
ON3
O
O
H2 / Pd
C6H9N3O3
[171.16]
C16H26N2O7
[358.38]
C16H16NO5F5
[397.23]
OPFPBocHN
O
O
BocHN
O
O
O
H
N
O
O
7 10
84
 
To a solution of 1589 mg (4.0 mmol, 2.0eq) Boc-ALA-PFP ester in 40 ml AcOEt, was 
added 342 mg (2.0 mmol, 1eq) of  5-azido-4-oxo methyl pentanoate (5-azido methyl 
levulinate) in 10 ml MeOH. To this mixture was added 64 mg (0.06 mmol, 0.03eq) of 
10% Palladium over activated carbon. The mass was subjected to hydrogenation in 
ambient temperature with the pressure of 60psi H2 under mechanical agitation. Once the 
reaction was completed, (approximately 24hrs; TLC eluent: EtOAc/ Hexane 3:1) the H2 
pressure was released. The reaction mass was filtered over celite bed to get rid off 
palladium, the celite bed was washed with 3 × 10ml MeOH. The solvent in the filtrate 
was evaporated off by rotovapor and a yellow oily mass was obtained. This yellow crude 
mass was purified by flash chromatography. (gradient eluent = 100% CH2Cl2 to 95:5 
CH2Cl2 :MeOH ). The pure fraction of 62 mg BOC-ALA-ALA (OMe) peptide was thus 
obtained. (Yield = 17.3%) 
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HN
O
O
67
8
9
10
O
O
11
12
131132
133 O
H
N
O
O
12
3
45
11
 
 
Rf: (95:5 CH2Cl2 :MeOH): 0.25 (KMnO4) 
 
1H-NMR (400 MHz, CD3OD, 298 K): δH (ppm) = 4.16 (s, 2H, H2C(10)); 3.66 (s, 3H, 
H3C(11);3.35 and 3.02 (2× d, AB system, 2J =14.5Hz, 2H, H2C(5)); 2.89 (ddd, A of 
ABX2 system, 2J3a-3b=18.2Hz, 3J3a-2a=7.7Hz, 3J3a-2b=6.0Hz, 1H, HC(3a)); 2.77 (ddd, B of 
ABX2 system, 2J3b-3a=18.2Hz, 3J3b-2a=6.6Hz, 3J3b-2b=5.7Hz, 1H, HC(3b)); 2.66 (ddd, A of 
ABX2 system, 2J2a-2b=17.2Hz, 3J2a-3a=7.7Hz, 3J2a-3b=5.6Hz, 1H, HC(2a)); 2.59 (ddd, B of 
ABX2 system, 2J2b-2a=17.2Hz, 3J2b-3a=6.0Hz, 3J2b-3b=5.7Hz, 1H, HC(2b)); 2.51-2.34 (m, 
3H, H2C(8) and HC(7a)); 2.03-1.95 (m, 1H, HC(7b)); 1.44  (s, 9H, H3C(131,132,133). 
 
13C-NMR (100 MHz, CDCl3 & CD3OD, 298K) : δC (ppm) =  207.0 (C(4) and C(9)); 
177.3 (C(1)); 174.8 (C(6)); 158.4 (C(11); 80.6 (C(12)); 52.3 (C(11); 48.7 (C(10)); 46.6 
(C(5)); 35.4 (C(3)); 32.1 (C(7)); 30.4 (C(8));  28.7 (C(131,132,133));  28.6 (C(2)). 
 
9.5.4. Synthesis of 6-ketocholestanol ester of ALA (6KC-ALA) 
9.5.4.1. Synthesis of 6-ketocholestanol ester of Boc-ALA  
 
BOC-ALA
EDCI,DMAP
(CH2)3
H3C
CH3
HCH3
H
HH
H
O
OBocHN
O
O
C27H46O2
[402.65]
C37H61NO6
[615.88]
(CH2)3
H3C
CH3
HCH3
H
HH
H
O
HO
239 240
 
In a dry flask under argon atmosphere, 725 mg (1.8 mmol, 1.2eq) of 6-ketocholestanol 
was charged and then 20ml CH2Cl2 was added. The mass was cooled to 0 0C, then 185 
mg (1.5 mmol, 1eq) of DMAP was added followed by 316.3 mg (1.65 mmol, 1.1eq) of 
EDCI. Finally, 350 mg (1.5 mmol, 1eq) of BOC-ALA was charged. The reaction was 
brought to room temperature and was kept at room temperature overnight. The solvent 
was evaporated off by rotovapor. The crude mass was dissolved in 50ml AcOEt and 
extracted with 75 ml H2O.The organic phase is washed with 75 ml cold 1N citric acid 
solution, followed by 100ml saturated NaHCO3 solution and finally by 100ml saturated 
NaCl solution. The organic phase is dried over MgSO4 and the solvent was evaporated 
off by rotavapor. The remaining mass was purified by flash chromatography (1:1 EtOAc: 
Hexane) which yielded 620 mg of 6-ketocholestanol ester of Boc-ALA. (Yield= 67.1%) 
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H3C
CH3
HCH3
H
HH
H
O
OHN
O
O
1
2
3
4
5
6
7
10 8
9
11
12
13
14 15
16
17
20
21
19
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22
23
24
25
27
26
31
32
33
34
35
O
O
3637
38a
38b
38c
 
Batch: RV 157, RV 162 
  
Rf: (1:1 EtOAc: Hexane): 0.35 (KMnO4) 
 
IR (KBr): 3428m, 2951s, 2870m, 2851m, 1745s, 1731s, 1713vs, 1703vs, 1496s, 1470m, 
1443w, 1414w, 1382w, 1366s, 1302w,1282w, 1251w, 1226w, 1199m, 1169s, 1100w, 
1073w, 1005w, 994w, 957w, 925vw, 887vw, 856vw, 780vw, 745vw, 640vw, 520vw. 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.22 (sbr, 1H, NH); 4.6 (sbr,1H, 
HC(3)); 4.1 (s, 2H, H2C(35)); 2.69-2.66 (m, 2H, H2C(33); 2.60-2.53 (s, 2H, H2C(32); 2.27 
(dd, 3J5-4a=13.1Hz, 3J5-4b=4.4Hz, 1H, HC(5)); 2.22 (dd, 2J7a-7b=12.5Hz, 3J7a-8≈2.3Hz, 1H, 
HC(7a)); 2.01-1.98 (m, 1H, HC(7b)); 1.92 (t, 3J4-3, 3J4-5 ≈ 12.8Hz, 2H, H2C(4); 1.88-0.93 
(m, ≈36H); 0.87 (d, 3J21-20 =6.5Hz, 3H, H3C(21)); 0.81 (d, 3J26-25 =6.6Hz, 3H, H3C(26)); 
0.80 (d, 3J27-25 =6.6Hz, 3H, H3C(27)); 0.73 (s, 3H, H3C(19)); 0.62 (s, 3H, H3C(18)).  
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) =  210.5 (C(6)); 204.7 (C(34)); 172.2 
(C(31)); 156.0 (C(36));  80.0 C(37)); 73.7 (C(3));  50.6 (C(35); 34.7 (C(33)); 28.5 (C(32); 
28.3 (C(38a,38b,38c); 23.2, 23.0, 19.0, 13.3, 12.3 (C(27), C(26), C(21), C(19), C(18)). 
 
MS (ESI (+)): m/z relative intensity [2×M+ Na] + = 1252.8 
9.5.4.2. Synthesis of 6-ketocholestanol ester of ALA 
 
 
CH2Cl2
CF3COOH
(CH2)3
H3C
CH3
HCH3
H
HH
H
O
OH3N
O
O
C34H54 F3NO6
[629.79]
(CH2)3
H3C
CH3
HCH3
H
HH
H
O
OBocHN
O
O
C37H61NO6
[615.88]
CF3COO
M+=516.77 ; CF3COO = 113.01
240 241
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 500 mg (0.81 mmol, 1eq) of 6-ketocholestanol ester of Boc-ALA was dissolved in 20ml 
CH2Cl2 and cooled to -100C. To this solution, 9.2 g (6.2ml, 81.2mmol, 100eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was co evaporated 2times with distilled ether, then the solid on drying 
yielded 490 mg of 6-ketocholestanol ester of ALA which was a highly hygroscopic white 
solid. (Yield=95.9%). 
H3C
CH3
HCH3
H
HH
H
O
OH3N
O
O
CF3COO
1
2
3
4
5
6
7
10 8
9
11
12
13
14 15
16
17
20
21
19
18
22
23
24
25
27
26
31
32
33
34
35
 
Batch: RV 163 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) =  7.98 (sbr, 3H, NH); 4.6 (sbr,1H, 
HC(3)); 4.1 (s, 2H, H2C(35)); 2.77 (s, 2H, H2C(33); 2.59 (s, 2H, H2C(32); 2.27-2.24 (m, 
2H); 2.04-1.98  (m, 1H)); 1.95 (t, 3J4-3, 3J4-5 ≈ 12.8Hz, 2H, H2C(4); 1.83-0.96 (m, ≈27H); 
0.90 (d, 3J21-20 =6.3Hz, 3H, H3C(21)); 0.84 (d, 3J26-25 =6.5Hz, 3H, H3C(26)); 0.84 (d, 3J27-25 
=6.5Hz, 3H, H3C(27)); 0.73 (s, 3H, H3C(19)); 0.64 (s, 3H, H3C(18)).  
 
 13C-NMR (100 MHz, CDCl3,  298K) : δC (ppm) = 212.4 (C(6)); 202.4 (C(34)); 172.3 
(C(31)); 161.0 (q,2JC-F ≈ 35.0, CF3COO¯ ); 115.6 (q,1JC-F ≈ 291.0, CF3COO¯ ); 73.8 
(C(3));  47.7 (C(35); 34.4 (C(33)); 28.1 (C(32); 23.2, 23.0, 19.0, 13.3, 12.3 (C(27), C(26), 
C(21), C(19), C(18)). 
 
9.5.5. Synthesis of ALA substituted phloroglucinol 
9.5.5.1. Synthesis of tri Boc-ALA substituted phloroglucinol 
     
OHHO
OH
BocHN
O
O
NHBoc
O
O
OO
O NHBoc
O
O
C6H6O3
[126.11]
DCC, DPTS
C36H51N3O15
[765.80]
OHBocHN
O
O
C10H17NO5
[231.16]
85 5 86
 
In a dry flask under argon atmosphere, 380 mg (3.0 mmol, 1.0eq) of phloroglucinol was 
dissolved in 75ml EtOAc, followed by addition of 540 mg (1.8 mmol, 0.6eq, 0.2eq per -
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 OH) of DPTS and 20 ml CH2Cl2. Then, 2228 mg (10.8 mmol, 3.6eq, 1.2eq per –OH) of 
DCC was added and finally 2500 mg (10.8 mmol, 3.6eq, 1.2eq per –OH) of Boc-ALA 
was added. The reaction was kept at room temperature for 72h. The reaction mixture was 
filtered over celite bed and the solvent was evaporated off by rotovapor. The crude mass 
was purified by flash chromatography (100% ether; silica gel mass- 60 times the crude 
mass) which yielded 2.14 g of tri Boc-ALA substituted phloroglucinol. (Yield= 93.4%) 
O
O
NH
O
O
OO
O NH
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O
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O
O
O
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32
33
34
35
36
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38a
38b
38c
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52
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16
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58a
18b
58b
18c
58c
1
3
2
4
5
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Batch: RV 175, RV179 
  
Rf: (3:1 EtOAc: Hexane): 0.37 (KMnO4) 
 
IR (KBr): 3443w, 3360m, 3087vw, 3006w, 2977m, 2931w, 1768vs, 1745s, 1720vs, 
1702vs, 1603m, 1551m, 1521s, 1456m, 1407m, 1391m, 1367s, 1340w, 1283s, 1250s, 
1212m, 1146vs, 1091m, 1060m, 1017m, 993vw, 980vw, 968w, 915w, 896vw, 876w, 
779vw, 764vw, 752vw, 723vw, 724vw, 691vw, 666vw, 647vw, 567vw, 518vw, 509vw, 
464vw.  
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 6.76 (s, 3H, HC(2), HC(4) and HC(6)); 
5.33 (sbr, 3H, 3 × NH); 3.99 (d, 3J15-NH ≈ 5.0Hz, 3J35-NH ≈ 5.0Hz, 3J55-NH ≈ 5.0Hz,  6H, 
H2C(15), H2C(35)and H2C(55)); 2.81- 2.74 (m, 12H, H2C(12), H2C(13), H2C(32), H2C(33), 
H2C(52) and H2C(53)); 1.40 (s, 27H, H3C(18a,18b,18c), H3C(38a,38b,38c)  and 
H3C(58a,58b,58c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) =  204.3 (C(14), C(34), C(54)); 170.5 
(C(11), C(31), C(51))); 155.7 (C(16), C(36), C(56)); 151.0 (aromatic C(1), C(3), C(5)); 
112.9 (aromatic C(2), C(4), C(6)); 80.3 (C(17), C(37), C(57)); 50.2 (C(15), C(35), C(55)); 
34.1(C(13), C(33), C(53)); 28.3  (C(18a,18b,18c), C(38a,38b,38c)  and C(58a,58b,58c)); 27.8 
(C(12), C(32), C(52)); 
 
HR-MS [M+ Na] + = 788.3214 (Calculated =788.3218) 
 
9.5.5.2. Synthesis of tri ALA substituted phloroglucinol 
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M3+=468.47 ; CF3COO = 113.01
CF3COO
CF3COO
86
87
 
765.8 mg (1.0 mmol, 1eq) tri Boc-ALA substituted phloroglucinol was dissolved in 10ml 
CH2Cl2 and cooled to -100C. To this solution, 14.8g (10ml, 129.0mmol, 129eq) of 
trifluoroacetic acid was added dropwise by syringe. The reaction mass was maintained at 
0-50C for an hour. Once the deprotection of BOC was completed (controlled by the 
absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. 
The product was co evaporated 2times with distilled ether, then triturated with dry ether 
and the ether solution was decanted. The trituration with ether and decanting top clear 
ether solution after centrifuge was repeated 2 times more. The settled solid product on 
drying yielded 728 mg of tri ALA substituted phloroglucinol (Yield=90.1%). 
 
O
O
NH3
O
O
OO
O NH3
O
O
H3N 31
32
33
34
35
11
51
12
52
13
53
14
54
15
55
1
3
2
4
5
6
CF3COO
CF3COO
CF3COO  
Batch: RV 182 
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 1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 6.87 (s, 3H, HC(2), HC(4) and HC(6)); 
4.06 (s,   6H, H2C(15), H2C(35)and H2C(55)); 2.96- 2.88 (m, 12H, H2C(12), H2C(13), 
H2C(32), H2C(33), H2C(52) and H2C(53)). 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) =  203.9 (C(14), C(34), C(54)); 173.4 (C(11), 
C(31), C(51))); 163.0 (q,2JC-F ≈ 35.0, CF3COO¯ ); 151.2 (aromatic C(1), C(3), C(5));   
116.5 (q,1JC-F ≈ 291.0, CF3COO¯ ); 114.1 (aromatic C(2), C(4), C(6)); 47.3 (C(15), C(35), 
C(55)); 34.5(C(13), C(33), C(53)); 27.7 (C(12), C(32), C(52)).                                  
                              
9.5.6. Synthesis of ALA substituted glycerol 
9.5.6.1. Synthesis of tri-Boc-ALA substituted glycerol 
                
HO
OH
HO
O
O
O
BocHN
BocHN
NHBoc
O
O
OO
O
O
C3H8O3
[92.09]
DCC, DPTS
C33H53N3O15
[731.78]
OHBocHN
O
O
C10H17NO5
[231.16]
88 5 89
 
In a dry flask under argon atmosphere, 319 mg (3.46 mmol, 1.0eq) of glycerol was 
dissolved in 25ml CH2Cl2, followed by addition of 1250 mg (4.24 mmol, 1.2eq, 0.4eq per 
-OH) of DPTS. Then, the mixture was cooled to 00C, 2600 mg (12.5 mmol, 3.6eq, 1.2eq 
per –OH) of DCC was added and finally 2884 mg (12.5 mmol, 3.6eq, 1.2eq per –OH) of 
Boc-ALA was added. The reaction was kept at room temperature for 72h. The reaction 
mixture was filtered over celite bed and the solvent was evaporated off by rotovapor. The 
crude mass was purified by flash chromatography (100% EtOAc; silica gel mass- 70 
times the crude mass) which yielded 1850 mg of tri Boc-ALA substituted glycerol. 
(Yield= 73%).                              
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 O
O
O
HN
HN
NH
O
O
OO
O
O
31
32
33
34
35
36
37
38a
38b
38c
11
21
12 2
2
13
23
14 2
4
15
2516
26
17
27
18a
28a
18b
28b
18c
28c
1
3
2
O
O
O
O
O
O
 
Batch: RV 217. 
 
Rf: (3:1 EtOAc: Hexane): 0.37 (KMnO4) 
   
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.42, 5.36 (2× sbr, 3H, 3 × NH); 5.18 
(ddd, 3J1a-2≈4.0Hz, 3J3a-2≈4.0Hz, 3J1b-2≈6.0Hz, 3J3b-2≈6.0Hz,  ≈10.2Hz ,1H, HC(2)); 4.20 
(dd, 3J1a-2≈4.0Hz, 3J3a-2≈4.0Hz (vicinal), 3J1b-1a=12.0Hz, 3J3b-3a =12.0Hz (geminal));  4.11 
(dd, 3J1b-2≈6.0Hz, 3J3b-2≈6.0Hz (vicinal), 3J1b-1a=12.0Hz, 3J3b-3a =12.0Hz (geminal));  3.99 
(d, 3J15-NH ≈ 5.0Hz, 3J25-NH ≈ 5.0Hz, 3J35-NH ≈ 5.0Hz,  6H, H2C(15), H2C(25)and H2C(35)); 
2.70- 2.58 (m, 12H, H2C(12), H2C(13), H2C(22), H2C(23), H2C(32) and H2C(33)); 1.38 (s, 
27H, H3C(18a,18b,18c), H3C(28a,28b,28c)  and H3C(38a,38b,38c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) =  204.5 (C(14), C(24), C(34)); 172.0 
(C(11), C(21), C(31))); 155.6 (C(16), C(26), C(36)); 79.8 (C(17), C(27), C(37)); 69.2 (C(2)); 
62.3 (C(1) and C(3)); 50.2 (C(15), C(25), C(35)); 34.2(C(13), C(23), C(33)); 28.3  
(C(18a,18b,18c), C(28a,28b,28c)  and C(38a,38b,38c)); 27.5 (C(12), C(22), C(32)). 
 
MS (ESI (+)): m/z relative intensity [M+ Na] + = 754.3 
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 9.5.6.2. Synthesis of tri ALA substituted glycerol 
 
O
O
O
H3N
H3N
NH3
O
O
OO
O
O
[773.50]
O
O
O
BocHN
BocHN
NHBoc
O
O
OO
O
O
C33H53N3O15
[731.78]
C24H32F9N3O15
CF3COOH
CF3COO M3+=434.46 ; CF3COO = 113.01
CF3COO
CF3COO
89
90
 
732 mg (1.0 mmol, 1eq) tri Boc-ALA substituted glycerol was dissolved in 10ml CH2Cl2 
and cooled to -100C. To this solution, 14.8g (10ml, 129.0mmol, 129eq) of trifluoroacetic 
acid was added dropwise by syringe. The reaction mass was maintained at 0-50C for an 
hour. Once the deprotection of BOC was completed (controlled by the absence of BOC 
peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid was evaporated off. The product was 
co evaporated 2times with distilled ether, then triturated with dry ether and the ether 
solution was decanted. The trituration with ether and decanting top clear ether solution 
after centrifuge was repeated 2 times more. The settled solid product on drying yielded 
687 mg of tri ALA substituted glycerol (Yield=89%). 
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 O
O
O
H3N
H3N
NH3
O
O
OO
O
O
31
32
33
34
35
11
21
12 2
2
13
23
14 2
4
15
25
1
3
2
CF3COO
CF3COO
CF3COO  
Batch: RV 299 
  
1H-NMR (400 MHz, D2O, 298 K): δH (ppm) = 5.34- 5.29 (m, 1H, HC(2)); 4.35 (dd, 3J1a-
2≈4.0Hz, 3J3a-2≈4.0Hz (vicinal), 3J1b-1a=12.0Hz, 3J3b-3a =12.0Hz (geminal));  4.29 (dd, 3J1b-
2≈6.0Hz, 3J3b-2≈6.0Hz (vicinal), 3J1b-1a=12.0Hz, 3J3b-3a =12.0Hz (geminal));  4.13 (s, 6H, 
H2C(15), H2C(25)and H2C(35)); 2.95- 2.72 (m, 12H, H2C(12), H2C(13), H2C(22), H2C(23), 
H2C(32) and H2C(33)); 1.38 (s, 27H, H3C(18a,18b,18c), H3C(28a,28b,28c)  and 
H3C(38a,38b,38c) and other peaks due to solvent ether. 
 
13C-NMR (100 MHz, D2O, 298K) : δC (ppm) =  204.1, 204.0 (C(14), C(24), C(34)); 174.5, 
174.1 (C(11), C(21), C(31))); 163.2 (q,2JC-F ≈ 35.0, CF3COO¯ ); 116.7 (q,1JC-F ≈ 292.0, 
CF3COO¯ ); 70.3 (C(2)); 63.1 (C(1) and C(3)); 47.3 (C(15), C(25), C(35)); 34.5 (C(13), 
C(23), C(33)); 27.5 (C(12), C(22), C(32)); 
 
9.6. Synthesis of porphobilinogen based peptides 
9.6.1. Synthesis of precursors for porphobilinogen 
9.6.1.1. Synthesis of 5-azido-4,4-dimethoxy methyl pentanoate 
ON3
O
O
ON3
O
(H3CO)3CH
p-TsOH, MeOH
C8H15N3O4C6H9N3O3
[217.23][171.16]
O O
3 91
 
                   
In a dry flask fitted with a reflux condenser, under argon atmosphere, 7.5 g (43.82 mmol, 
1.0eq) of 5-azido methyl levulinate was dissolved in 60ml MeOH, followed by addition 
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 of 23.25 g (24ml, 219 mmol, 5eq) of trimethyl orthoformate drop wise and finally added 
0.33 g (1.75 mmol, 0.04eq) of p-toluene sulphonic acid monohydrate. Then, the mixture 
was heated to reflux and kept at reflux for 14h. The mass was later cooled; added 1.44 g 
NaHCO3, stirred for 15min, filtered over paper and the solvent was evaporated. The oily 
residue was purified by distilling the product using oil vacuum pump (650C at 0.07 
mbar).8.55 g of pure 5-azido-4,4-dimethoxy methyl pentanoate (5- azido-4,4-dimethoxy 
levulinate )was obtained. (Yield= 89%).      
ON3
O
O O
1
2
3
45 11
41 41'
 
Batch: Step02B #01, Step02B #02 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 3.62 (s, 3H, H3C(11); 3.21 (s, 2H, 
H2C(5)) ; 3.17 (s, 6H, H2C(41) and H2C(41´)) ;  2.28-2.00 (m, AA’ part of a system 
AA’BB’, 4H, H2C(3) and H2C(2)) . 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.6 (C(1)) ; 101.7 (C(4)); 52.0 (C(41) 
and C(41´)); 51.3 (C(11)) ; 48.7 (C(5)); 29.0 (C(3)) ; 28.0 (C(2)). 
9.6.1.2. Synthesis of 5-hydroxy -4-oxo methyl pentanoate 
OBr
O
O
OHO
O
O
1) HCCOH, DBU
2) Neutral alumina
C6H9BrO3 C6H10O4
[209.04] [146.14]
2 92
 
In a dry flask under argon atmosphere, 5.75 g (27.5 mmol, 1.0eq) of 5-bromo methyl 
levulinate was dissolved in 37ml benzene, followed by addition of 1.52 g (1.1ml, 
33mmol, 1.2eq) of formic acid drop wise. The mixture was cooled 100C and added 5.22 g 
(34.8mmol, 1.25eq) of DBU drop wise in 1h by using an addition funnel. Then, the 
mixture was brought to ambient temperature, maintained at that temperature for 1h. Later 
50 ml of water was added and extracted with 5×50 ml CH2Cl2. The combined organic 
layer was extracted with 140 ml 0.1N HCl and then washed with 150 ml water. The 
organic layer was dried over MgSO4 and the solvent was evaporated. The residue of 4.12 
g of 5.formyloxy methyl levulinate was taken for hydrolysis on a column prepared using 
240 g neutral alumina. The column was run using 98:2 CH2Cl2: MeOH solvent mixture 
and then using 1:1 CH2Cl2: MeOH solvent mixture. The solvent from pure fractions were 
evaporated and the residue was taken for distillation using ball tube glass oven 
(Kugelrohr), (100- 1200C at 0.07 mbar). 2.81 g of pure 5-hydroxy-4-oxo-methyl 
pentanoate (5-hydroxy-levulinate) was obtained. (Yield= 69.7%).                   
OHO
O
O
1
2
3
4
5
11
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 Batch: Step02 #01, Step02 #02 
 
Rf: (1:1 EtOAc: Hexane): 0.39 (KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 4.19 (s, 2H, H2C(5)) ; 3.56 (s, 3H, 
H3C(11);  2.64-2.56 (m, AA’ part of a system AA’BB’, 4H, H2C(3) and H2C(2)) . 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 208.8 (C(4)); 173.2 (C(1)); 68.5 
(C(5));  52.2 (C(11)); 33.1 (C(3)) ; 27.7 (C(2)). 
9.6.1.3. Synthesis of 4,5-bis-trimethylsilyloxy- methyl pent-3-enoate 
 
OHO
O
O
O
O
1) LiHMDS
2) TMS-Cl
3) MeI
C12H26O4Si2C6H10O4
[290.51][146.14]
O
Si
O
Si
92 93
 
In a dry flask under argon atmosphere, 30.3ml (30.3 mmol, 2.2 eq) of 1M LiHMDS 
solution in THF was taken and cooled to -780C, added by syringea solution of 2 g (13.68 
mmol, 1.0eq) of 5-hydroxy-4-oxo-methyl pentanoate dissolved in 30ml THF. This 
organge-yellow solution was stirred at -780C for 2 h, then added drop wise 3.3 g (3.85 ml, 
30.3mmol, 2.2eq) of trimethylchlorosilane. The reaction mixture was brought to ambient 
temperature, evaporated solvent. The residue was dissolved in 150 ml pentane, filtered 
over celite bed and evaporated solvent. The yellow oily residue was taken for distillation 
using ball tube glass oven (Kugelrohr), (130- 1400C at 0.02 mbar). 2.52 g of pure 4,5-bis-
trimethylsilyloxy- methyl pent-3-enoate was obtained. (Yield= 62.9%).      
O
O
O
Si
O
Si
12
3
4
5
11
61
62
63
71
72
73
 
Batch: Step03 #01,#02,#03,#04 and #05, 
 
Rf: (1:1 EtOAc: Hexane): 0.72 (KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 4.92 (tt, 3J=7.0Hz, 4J=1.0Hz, 1H, 
HC(3)) ;  3.92 ((d,  4J=1.0Hz, 2H, H2C(5)); 3.63 (s, 3H, H3C(11); 3.04 ((d, 3J=7.0Hz, 2H, 
H2C(2)); 0.16  and 0.10 (2×s, 18H, H3C (61, 62, 63, 71, 72 and 73). 
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 13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 172.9 (C(1)); 151.8 (C(4)); 100.7 
(C(3)); 64.2 (C(5));  51.9 (C(11)); 31.0 (C(2)); 1.0 and -0.20 (C (61, 62, 63, 71, 72 and 73). 
9.6.1.4. Synthesis of 4-azidomethyl-3-(2-hydroxy acetyl)-4-methoxy- dimethyl 
heptanedioate 
ON3
O
C8H15N3O4
[217.23]
O O
O
O
TiCl4
C12H26O4Si2 C13H21N3O7
[290.51] [331.3]
O
Si
O
Si
CH2Cl2
OO
HO N3
OO
O
O
H
93 91 94
 
In a dry flask under argon atmosphere, 2.3 g (7.92 mmol, 1.0eq) of 4,5-bis-
trimethylsilyloxy- methyl pent-3-enoate was dissolved in 16ml CH2Cl2 (basic alox 
treated) , cooled to -780C and added drop wise  of 2.07 g (9.53 mmol, 1.2eq) of  -azido-
4,4-dimethoxy methyl pentanoate  in 16ml CH2Cl2. To the mixture was then added 7.6 g 
(40.2mmol, 5eq) freshly distilled TiCl4. The mixture was maintained at -55 0C for 16h. 
Then, the mixture was brought to ambient temperature; 75 ml of 2N NaOH was added 
and extracted with 5×100 ml CHCl3. The combined organic layer was extracted with 300 
ml satd.NH4Cl solution, the organic layer was dried over MgSO4 and the solvent was 
evaporated. The residue was taken for column chromatography (silica gel -100 times the 
crude mass) using eluent gradient from 100% hexane to 1:1 hexane:EtOAc. Pure 
fractions afforded 1.16 g of 4-azidomethyl-3-(2-hydroxy acetyl)-4-methoxy- dimethyl 
heptanedioate. (Yield= 44.1%).    
1
2
3
4
5
11
6
7
71
OO
HO N3
OO
O
O
H
41´
3132 4
1
 
 
Batch: Step04 #08 to #13 and #16 to #19. 
 
Rf: (1:1 EtOAc: Hexane): 0.30 (KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 4.47 (dd,  3J =5.4Hz, 2J=19.1Hz, 1H, 
HC(32a)); 4.34 (dd,  3J =3.7Hz, 2J=19.1Hz, 1H, HC(32b)); 3.69 (s, 3H, H3C(71); 3.65 (s, 
3H, H3C(11); 3.52 and 3.35 (2×d, AB system, 2J=13.3Hz, 1H each, H2C(41´)); 3.31 (dd, 
3J3-2a =2.5Hz, 3J3 -2b =12.0Hz, 1H, HC(3)); 3.24 (s, 3H, H3C(41); 2.98 (dd, 3J2a-3 =12.0Hz, 
2J2a -2b =17.3Hz, 1H, HC(2a)); 2.45 (dd, 3J2b-3 =2.5Hz, 2J2b -2a =17.3Hz, 1H, HC(2b)); 2.37 
(ddd, 2J6a-6b ≈16.0Hz, 3J6 -5b ≈10.0Hz, 3J6 -5a ≈6.0Hz, 2H, HC (6a) and HC(6b)); 2.13 (ddd, 
2J5a-5b ≈15.5Hz, 3J5a -6b ≈9.6Hz, 3J5a -6a ≈6.0Hz, 1H, HC (5a)); 1.81(ddd, 2J5b-5a ≈15. 6Hz, 
3J5b -6a ≈9.7Hz, 3J5b -6b ≈6.0Hz, 1H, HC (5b)). 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 211.9 (C(31); 173.6 (C(7); 172.6 
(C(1)); 79.0 (C(4)); 71.1 (C(32)); 54.0 (C(41´)); 52.6(C(11));. 52.4(C(71)); 50.7(C(41));. 
47.7 (C(3)); 32.4 (C(2)); 27.6 (C(6)); 26.1(C(5)). 
9.6.1.5. Synthesis of 3-(2-azido-acetyl)-4-azidomethyl--4-methoxy- dimethyl 
heptanedioate 
 
PPh3, DIAD
C13H20N6O6
[356.3]
HN3
OO
N3 N3
OO
O
O
H
C13H21N3O7
[331.3]
OO
HO N3
OO
O
O
H
94 95
 
In a dry flask under argon atmosphere, 885 mg (3.37 mmol, 1.12 eq) was dissolved in 35 
ml benzene, cooled to 5-100C, added drop wise 680 mg (3.36 mmol, 1.11eq) of DIAD, 
added then drop wise 1000 mg (3.02 mmol, 1.0eq) of 4-azidomethyl-3-(2-hydroxy 
acetyl)-4-methoxy- dimethyl heptanedioate dissolved in 15ml benzene. Finally added 
drop wise 3ml (0.2 g, 6.88% w/v, 4.8 mmol, 1.6eq) of HN3 solution in benzene. (HN3 
generated by adding 1ml of 98%H2SO4 to 2.27 g NaN3 in 3 ml water). The mixture was 
maintained at 10 0C for 2h-3h. Then, the mixture was brought to ambient temperature and 
the solvent was evaporated. The residue was taken for column chromatography (silica gel 
- 50 times the crude mass) using eluent gradient from 95:5 CH2Cl2: EtOAc to 80:20 
CH2Cl2: EtOAc. Pure fractions afforded 1.0 g of 3-(2-azido-acetyl)-4-azidomethyl--4-
methoxy- dimethyl heptanedioate. (Yield= 93.0%).    
1
2
3
4
5
11
6
7
71
OO
N3 N3
OO
O
O
H
41
3132
 
Batch: Step05 #01 to #09. 
 
Rf: (8:2 CH2Cl2: EtOAc): 0.57 (KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 4.22 (d,  2J=18.3Hz, 1H, HC(32a)); 4.14 
(d,  2J=18.3Hz, 1H, HC(32b)); 3.68 (s, 3H, H3C(71); 3.65 (s, 3H, H3C(11); 3.55 and 3.36 
(2×d, AB system, 2J=13.2Hz, 1H each, H2C(41´)); 3.24 (dd, 3J3-2a =2.5Hz, 3J3 -2b =12.0Hz, 
1H, HC(3)); 3.23 (s, 3H, H3C(41); 2.98 (dd, 3J2a-3 =12.2Hz, 2J2a -2b =19.0Hz, 1H, HC(2a)); 
2.42 (dd, 3J2b-3 =2.5Hz, 2J2b -2a =17.3Hz, 1H, HC(2b)); 2.50-2.23 (m, 2H, H2C (6)); 2.14 
(ddd, 2J5a-5b ≈15.5Hz, 3J5a -6b ≈9.5Hz, 3J5a -6a ≈6.0Hz, 1H, HC (5a)); 1.79 (ddd, 2J5b-5a ≈15. 
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 6Hz, 3J5b -6a ≈9.7Hz, 3J5b -6b ≈6.0Hz, 1H, HC (5b)); 4.36, 1.29-1.25 (minor peaks due to 
impurity). 
 
13C-NMR (100 MHz, CDCl3, 298K): δC (ppm) == 206.2 (C(31); 173.2 (C(7); 172.4 
(C(1)); 79.0 (C(4)); 60.2 (C(32)); 53.4 (C(41´)); 52.3 (C(11)); 52.1(C(71)); 50.4 (C(41)); 
48.7 (C(3)); 32.4 (C(2)); 27.3 (C(6)); 25.6 (C(5)); 
208.5,173.7,79.5,68.9,52.3,50.2,28.6,28.1,27.7,22.5,14.6 (minor peaks due to traces of 
impuriy). 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 379.1 
9.6.2. Synthesis of porphobilinogen-Ala-peptide 
9.6.2.1. Synthesis of Boc-Ala -PFP ester 
 
C8H15NO4
[189.21]
HO
F
F
F
F
F
DCC
C6HF5O
[184.06]
C14H14NO4F5
[355.08]
OH
BocHN
O
BocHN
O
O
F
F
F
F
F
96 68 97
 
 
In a dry flask under argon atmosphere, 2.25 g (11.89 mmol, 1eq) of BOC-Ala was 
charged. This was dissolved in 50 ml dioxane and the mass was cooled to 0 0C. Then 2.2g 
(11.90 mmol, 1.0eq) of pentafluorophenol was added followed by 2.5 g (12.12 mmol, 
1.02eq) of DCC. The reaction was brought to room temperature and was kept at room 
temperature overnight. The reaction mass was then filtered over celite bed to get rid off 
DCU and the solvent was evaporated off by rotovapor. The thick yellow oily mass 
obtained was triturated with hexane to remove excess pentafluorphenol and the white 
solid obtained was filtered off. The white solid was dried which yielded 3.76g of BOC-
Ala-PFP ester. (Yield= 89.2%) 
O
O
F
F
F
F
F
N
H
1
2
3
4O
O
5
6a
6b 6c
11
12
13
14
 
Batch: Step06B Ala #01 to #04 . 
 
Rf: (8:2 Hexane: EtOAc): 0.53 (UV active; KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 5.01 (sbr, 1H, NH); 4.66 (m, 3J2 -3 
≈7Hz, 1H, HC(2)); 1.58 (d, 3J3-2=7.0 Hz, 3H, H3C(3)); 1.46 (s, 9H, H3C(6a, 6b, 6c). 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 170.1 (C(1); 155.3 (C(4)); 80.5 (C(5)); 
49.5 (C(2)); 28.6 (C(6a,6b,6c)); 18.6 (C(3)). 
9.6.2.2. Synthesis of porphobilinogen-Boc-Ala -peptide 
 
N
H
OO
OOH2 / Pd
C13H20N6O6
[356.3]
OO
N3 N3
OO
O
O
H
C14H14NO4F5
[355.08]
BocHN
O
OPFP
BocHN
O
H
N
C20H31N3O7
[425.47]
95 97 98
 
In a hydrogenation autoclave reactor, added 20ml MeOH followed by 60mg (0.0564 
mmol, 0.04 eq) of 10% palladium on activated charcoal. This mixture was 
prehydrogenated with hydrogen for 10 min, later added 1.1 g (3.09 mmol, 2.3eq) of 
BOC-Ala-PFP ester followed by a solution of 0.476 g (1.337 mmol, 1eq) 3-(2-azido-
acetyl)-4-azidomethyl--4-methoxy- dimethyl heptanedioate in 20ml MeOH. The mass 
was subjected to hydrogenation in ambient temperature with the pressure of 60psi H2 
under mechanical agitation. Once the reaction was completed, (approximately 24hrs; 
TLC eluent: hexane/AcOEt 1:1) the H2 pressure was released. The reaction mass was 
filtered over celite bed to get rid off palladium, the celite bed was washed with 3 × 25ml 
MeOH. The solvent in the filtrate was evaporated off by rotovapor and a yellow oily 
mass was obtained. This yellow crude mass was purified by flash chromatography (silica 
gel- 70 times the curude mass) using gradient eluent system. (from hexane/AcOEt 4:6 to 
100% AcOEt). The pure fraction of 332 mg porphobilinogen-Boc-Ala -peptide was thus 
obtained. (Yield = 58%) 
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Batch: Step06 Ala #01 to #05. 
 
Rf: (3:1 EtOAc: Hexane): 0.35 (UV 254, KMnO4 and violet Ehlrich) 
 
 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.95 (sbr, 1H, NH pyrrole); 7.06 ((sbr, 
1H, NH-H2C(51)); 6.43 (d,  3J2-NH =2.6Hz, 1H, HC(2)); 5.20 (d,  3JNH-53 =7.1Hz, 1H, NH-
HC(53)); 4.32-4.13 (m, 3H, H2C(51) and HC(53)); 3.67 (s, 3H, H3C(34) or H3C(43); 3.65 
(s, 3H, H3C(34) or H3C(43); 3.42 (s, 3H, H2C(41)); 2.74-2.70 (m, 2H, HC(31)); 2.54-2.50 
(m, 2H, HC(32)); 1.44-1.30 (m, 12H, H3C(56a, 56b, 56c) and H3C(53´)). 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.7 (C(33); 173.5 (C(42)); 173.2 
(C(52)); 155.4 (C(54)); 126.7 (C(5)); 121.1 (C(3)); 114.5 (C(2)); 111.4 (C(4)); 80.0 
(C(55)); 52.1 (C43)); 51.5 (C(34)); 50.2 (C(53)); 35.3 (C51)); 31.9 (C(32)); 29.8 (C(41)); 
28.2 (C(56a,56b and 56c)); 20.4 (C(31)); 18.5 (C(53´)).  
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 448.1 
9.6.2.3. Synthesis of porphobilinogen-Ala -peptide 
 
N
H
OO
OO
CF3COOH
H3N
O
H
N
N
H
OO
OO
BocHN
O
H
N
C20H31N3O7
[425.47]
CF3COO
C17H24F3N3O7
[439.38]
M+=326.36 ; CF3COO = 113.01
98 99
 
84 mg (0.19 mmol, 1eq) of porphobilinogen-Boc-Ala -peptide was dissolved in 5ml 
CH2Cl2 (Basic alox treated) and cooled to -100C. To this solution, 2.2g (1.5ml, 19.3mmol, 
100eq) of trifluoroacetic acid was added dropwise by syringe. The reaction mass was 
maintained at 5-100C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was dried by high vacuum oil pimp for 2-3 days and 
yielded 83 mg of porphobilinogen-Ala -peptide which was a highly hygroscopic and 
viscous semisolid. (Yield=98%). 
1
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Batch: Step 07 #04 to #09. 
 
 1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) = 10.47 ((sbr, 1H, NH pyrrole); 8.51 
((t, 3JNH-51 =5.0 Hz, 1H, NH-H2C(51)); 8.08 (sbr, 3H, NH3+)); 6.44 (d,  3J2-NH =2.6Hz, 1H, 
HC(2)); 4.22-4.19 (m, 2H, H2C(51)); 3.78-3.75 (m, 1H, HC(53)); 3.58 (s, 3H, H3C(34) or 
H3C(43); 3.57 (s, 3H, H3C(34) or H3C(43); 3.44 (d, 3J41a-41b =16.0 Hz, 1H, HC(41a); 3.40 
(d, 3J41b-41a =16.0 Hz, 1H, HC(41b);2.59-2.54 (m, 2H, HC(31)); 2.49-2.46 (m, 2H, HC(32)); 
1.31 (d, 3H, H3C(53´)). 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.2 (C(33); 172.2 (C(42)); 169.0 
(C(52)); 159.1(q,2JC-F = 36.2, CF3COO¯ );  125.4 (C(5)); 120.8 (C(3)); 115.9 (q,1JC-F ≈ 
291.9, CF3COO¯ ); 114.1 (C(2)); 111.5 (C(4)); 51.6 (C43)); 51.3 (C(34)); 48.2 (C(53)); 
34.4 (C51)); 34.3 (C(32)); 29.4 (C(41)); 20.3 (C(31)); 17.2 (C(53´)).  
 
MS (ESI (+)):m/z relative intensity [M-CF3COO¯] + = 326  
9.6.3. Synthesis of porphobilinogen-Phe-peptide 
9.6.3.1. Synthesis of Boc-Phe -PFP ester 
C14H19NO4
[265.30]
HO
F
F
F
F
F
DCC
C6HF5O
[184.06]
C20H18NO4F5
[431.35]
OH
BocHN
O
BocHN
O
O
F
F
F
F
F
100 68 101
 
In a dry flask under argon atmosphere, 1.33 g (5 mmol, 1eq) of BOC-Phe was charged. 
This was dissolved in 25 ml dioxane and the mass was cooled to 0 0C. Then 0.92g (5 
mmol, 1.0eq) of pentafluorophenol was added followed by 1.12 g (5.43 mmol, 1.08eq) of 
DCC. The reaction was brought to room temperature and was kept at room temperature 
overnight. The reaction mass was then filtered over celite bed to get rid off DCU and the 
solvent was evaporated off by rotovapor. The thick yellow oily mass obtained was 
triturated with hexane to remove excess pentafluorphenol and the white solid obtained 
was filtered off. The white solid was dried which yielded 1.85 g of BOC-Phe-PFP ester. 
(Yield= 85.8 %) 
O
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F
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F
F
N
H
1
2
3
4O
O
5
6a
6b 6c
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2
13
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31
33
32 34
 
Batch: Step06B Phe #01  
 
Rf: (8:2 Hexane: EtOAc): 0.7 (UV active; KMnO4) 
    
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 7.39-7.30 (m, 5H, aromatic); 5.00 (d, 
3JNH -2 =8Hz,  1H, NH); 4.94 (q, 3J2 -3 ≈7Hz, 3J2 -NH ≈7Hz 1H, HC(2)); 3.34 (dd, 3J3a-2=5.7 
Hz, 3J3a-3b=14.0 Hz, 1H, H2C(3a)); 3.23 (dd, 3J3b-2= 6.6 Hz, 3J3b-3a=14.0 Hz, 1H, 
H2C(3b)); 1.46 (s, 9H, H3C(6a, 6b, 6c). 
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13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 168.8 (C(1); 155.3 (C(4)); 142.8-137.0 
(C11, C12, C13, C14, C12´, C13´); 135.3 (C(C31); 129.7-127.8 (C32, C33, C34, C32´, C33´); 
81.0 (C(5));  54.8 (C(2)); 38.2 (C(3)); 28.6 (C(6a,6b,6c)). 
9.6.3.2. Synthesis of porphobilinogen-Boc-Phe -peptide 
 
C20H18NO4F5
[431.35]
BocHN
O
OPFP
N
H
OO
OO
H2 / Pd
C13H20N6O6
[356.3]
OO
N3
N3
OO
O
O
H
BocHN
O
H
N
C26H35N3O7
[501.57]
10195 102
 
In a hydrogenation autoclave reactor, added 40ml MeOH followed by 55 mg (0.0517 
mmol, 0.04 eq) of 10% palladium on activated charcoal. This mixture was 
prehydrogenated with hydrogen for 10 min, later added 1.21 g (2.8 mmol, 2.1eq) of 
BOC-Phe-PFP ester followed by a solution of 0.476 g (1.337 mmol, 1eq) 3-(2-azido-
acetyl)-4-azidomethyl--4-methoxy- dimethyl heptanedioate in 20ml MeOH. The mass 
was subjected to hydrogenation in ambient temperature with the pressure of 60psi H2 
under mechanical agitation. Once the reaction was completed, (approximately 24hrs; 
TLC eluent: hexane/AcOEt 1:1) the H2 pressure was released. The reaction mass was 
filtered over celite bed to get rid off palladium, the celite bed was washed with 3 × 25ml 
MeOH. The solvent in the filtrate was evaporated off by rotovapor and a yellow oily 
mass was obtained. This yellow crude mass was purified by flash chromatography (silica 
gel- 70 times the curude mass) using gradient eluent system. (from hexane/AcOEt 4:6 to 
100% AcOEt). The pure fraction of 425 mg porphobilinogen-Boc-Phe -peptide was thus 
obtained. (Yield = 63.4%)                                                               
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Batch: Step06 Phe #01  and #02. 
 
Rf: (3:1 EtOAc: Hexane): 0.46 (UV 254, KMnO4 and violet Ehlrich) 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.60 (sbr, 1H, NH pyrrole); 7.30-7.08 
(m, 5H, aromatic); 6.72 ((sbr, 1H, NH-H2C(51)); 6.45 (d,  3J2-NH =2.4Hz, 1H, HC(2)); 5.10 
(sbr, 1H, NH-HC(53)); 4.36-4.32 (m, 1H, HC(53)); 4.29 (dd, 4J =2.4Hz, 3J51-NH =5.6Hz, 
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 H2C(51)); 3.69 (s, 3H, H3C(34) or H3C(43); 3.64 (s, 3H, H3C(34) or H3C(43); 3.38 (s, 3H, 
H2C(41)); 3.06 (d,  3J53a-53 =6.6Hz, 2H, HC(53a)); 2.78-2.74 (m, 2H, HC(31)); 2.59-2.55 (m, 
2H, HC(32)); 1.40 (s, H, H3C(56a, 56b, 56c). 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 174.1 (C(33); 173.4 (C(42)); 172.4 
(C(52)); 155.7 (C(54)); 136.8 (C(53b)); 129.7-127.0 (aromatic); 127.2 (C(5)); 121.6 (C(3)); 
114.8 (C(2)); 111.8 (C(4)); 80.5 (C(55)); 56.2 (C(53));52.5 (C43)); 51.9 (C(34)); 39.1 
(C(53a)); 35.3 (C51) and (C(32)); 30.2 (C(41)); 28.6 (C(56a,56b and 56c)); 20.9 (C(31)). 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 524.2 
9.6.3.3. Synthesis of porphobilinogen-Phe -peptide 
N
H
OO
OO
H3N
O
H
NCF3COOH
CF3COO
C23H28F3N3O7
[515.48]
M+=402.46 ; CF3COO = 113.01
N
H
OO
OO
BocHN
O
H
N
C26H35N3O7
[501.57]
102 103
 
103 mg (0.20 mmol, 1eq) of Porphobilinogen-Boc-Phe -peptide was dissolved in 5ml 
CH2Cl2 (Basic alox treated) and cooled to -100C. To this solution, 2.3g (1.5ml, 20 mmol, 
100eq) of trifluoroacetic acid was added dropwise by syringe. The reaction mass was 
maintained at 5-100C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was dried by high vacuum oil pimp for 2-3 days and 
yielded 96 mg of Porphobilinogen-Ala -peptide which was a highly hygroscopic and 
viscous semisolid. (Yield=93%). 
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Batch: Step 07 Phe #05.  
  
1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) = 10.40 ((d, 3JNH-2 =2.0Hz,  1H, NH 
pyrrole); 8.58 ((t, 3JNH-51 =5.0 Hz, 1H, NH-H2C(51)); 8.08 (d, 3JNH-53 =3.4 Hz, 3H, NH3+)); 
7.30-7.18 (m, 5H, aromatic); 6.44 (d,  3J2-NH =2.6Hz, 1H, HC(2)); 4.17 (d, 3J51-NH =5.0 Hz,  
2H, H2C(51)); 3.96-3.95 (mbr, 1H, HC(53)); 3.58 (s, 3H, H3C(34) or H3C(43); 3.56 (s, 3H, 
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 H3C(34) or H3C(43); 3.38 (d, 3J41a-41b =16.0 Hz, 1H, HC(41a); 3.34 (d, 3J41b-41a =16.0 Hz, 
1H, HC(41b); 3.04 (dd, 3J53a-53 ≈6.0Hz, 2J53a-53a´ =14.0Hz ,1H, HC(53a)); 2.92 (dd, 3J53a-53 
≈6.0Hz, 2J53a-53a´ =14.0Hz ,1H, HC(53a´)) ; 2.58-2.52 (m, 2H, H2C(31)); 2.51-2.48 (m, 2H, 
H2C(32)); 1.52, 1.15-1.12 (minor peaks due to traces of impurity). 
 
13C-NMR (100 MHz, DMSO-d6, 298K) : δC (ppm) = 173.1 (C(33); 172.2 (C(42)); 167.6 
(C(52)); 158.4(q,2JC-F = 36.2, CF3COO¯ );  135.0 (C(53b)); 129.5 (C(53c) and (53c´)); 128.6 
(C(53d) and (53d´)); 127.2 (C(53e)); 125.1 (C(5)); 120.8 (C(3)); 115.8 (q,1JC-F ≈ 292, 
CF3COO¯ ); 114.1 (C(2)); 111.6 (C(4)); 53.5 (C(53)); 51.5 (C43)); 51.2 (C(34)); 37.1 
(C(53a)); 34.4 (C51)); 34.3 (C(32)); 29.4 (C(41)); 20.3 (C(31)). 
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + = 401.9   
 
9.6.4. Synthesis of porphobilinogen-Lys-peptide 
9.6.4.1. Synthesis of Boc-Boc-lys -PFP ester 
 
C16H30N2O6
[527.70]
HO
F
F
F
F
F
DCC
C22H29N2O6F5
[512.47]
ODCHA
BocHN
O
F
F
F
F
F
NHBoc
O
BocHN
O
NHBoc
,
2)
1) CH3COOH
C12H23N.
104 105
 
In a dry flask under argon atmosphere, 1.45 g (2.75 mmol, 1eq) of Boc-Boc-lys-DCHA 
salt was charged. This was dissolved in 40 ml EtOAc, the mass was cooled to 0 0C, added 
40 ml water and neutralised with 0.7 g (11.66 mmol, 4.25eq) acetic acid to obtain Boc-
Boc-lys-OH free acid. The organic layer was washed with 3×50 ml water and the organic 
layer concentrated to give 1.2 g Boc-Boc-lys-OH free acid. This was dissolved in 30 ml 
EtOAc and cooled to 0 0C.Then 0.49g (2.66 mmol, 1.0eq) of pentafluorophenol was 
added followed by 0.63 g (3.05 mmol, 1.1eq) of DCC. The reaction was brought to room 
temperature and was kept at room temperature overnight. The reaction mass was then 
filtered over celite bed to get rid off DCU and the solvent was evaporated off by 
rotovapor. 1.4 g of Boc-Boc-lys-PFP ester was obtained (Yield= 99%). This thick oily 
mass was taken directly for next step.  
9.6.4.2. Synthesis of porphobilinogen- Boc-Boc-lys -peptide 
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 C22H29N2O6F5
[512.47]
BocHN
O
NHBoc
OPFP
BocHN
O
NHBoc
N
H
OO
OO
H2 / Pd
C13H20N6O6
[356.3]
OO
N3 N3
OO
O
O
H H
N
C28H46N4O9
[582.68]
95 105 106
 
In a hydrogenation autoclave reactor, added 20ml MeOH followed by 50 mg (0.047 
mmol, 0.04 eq) of 10% palladium on activated charcoal. This mixture was 
prehydrogenated with hydrogen for 10 min, later added 1.4 g (2.73 mmol, 2.2eq) of Boc-
Boc-lys-PFP ester followed by a solution of 0.44 g (1.234 mmol, 1eq) 3-(2-azido-acetyl)-
4-azidomethyl--4-methoxy- dimethyl heptanedioate in 20ml MeOH. The mass was 
subjected to hydrogenation in ambient temperature with the pressure of 60psi H2 under 
mechanical agitation. Once the reaction was completed, (approximately 24hrs; TLC 
eluent: hexane/AcOEt 1:1) the H2 pressure was released. The reaction mass was filtered 
over celite bed to get rid off palladium, the celite bed was washed with 3 × 25ml MeOH. 
The solvent in the filtrate was evaporated off by rotovapor and a yellow oily mass was 
obtained. This yellow crude mass was purified by flash chromatography (silica gel- 70 
times the curude mass) using gradient eluent system. (from hexane/AcOEt 4:6 to 100% 
AcOEt). The pure fraction of 494 mg porphobilinogen- Boc-Boc-lys -peptide was thus 
obtained. (Yield = 68.7%) 
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Batch: Step06 lys #01 to #03. 
 
Rf: (3:1 EtOAc: Hexane): 0.36 (UV 254, KMnO4 and violet Ehlrich) 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.98 (sbr, 1H, NH pyrrole); 7.03 ((sbr, 
1H, NH-H2C(51)); 6.43 (d,  3J2-NH =2.5Hz, 1H, HC(2)); 5.28 (sbr, 1H, NH-HC(53)); 4.71 
(t, 3JNH-57 =6.0 Hz, 1H, NH-H2C(57)); 4.31 (d, 3J51-NH =5.7Hz, H2C(51)); 4.04-4.03 (mbr, 
1H, HC(53)); 3.66 (s, 3H, H3C(34) or H3C(43); 3.64 (s, 3H, H3C(34) or H3C(43); 3.42 (s, 
2H, H2C(41)); 3.06-3.03 (m, 3J57-NH =6.0 Hz, 2H, H2C(57)); 2.73-2.69 (m, 2H, H2C(31)); 
2.54-2.49 (m, 2H, H2C(32)); 1.92-1.89 (m,  1H, HC(54a)); 1.70-1.64 (m,  1H, 
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 HC(55a));1.44-1.26  (m,  21H, H3C(59a, 59b, 59c), H3C(53c, 53c´, 53c´´),  HC(55b) and H2C(56) 
); 1.18-1.05 (m,  1H, HC(54b)); 1.78-1.70 and 1.62- 1.50 peaks due to impurity. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.7 (C(33); 173.2 (C(42)); 171.1 
(C(52));156.1 (C(58)); 155.7 (C(53a)); 126.7 (C(5)); 121.1 (C(3)); 114.5 (C(2)); 111.4 
(C(4)); 80.0 (C(59)); 79.1 (C(53b)); 54.5 (C(53)); 52.1 (C43)); 51.5 (C(34)); 39.8 (C(57)); 
34.9 (C51) and (C(32)); 33.9 (C(54)); 29.8 (C(41)); 29.5 (C(56)); 28.4 (C(59a, 59b, 59c) , 
C(53c, 53c´, 53c´´)); 24.9 (C(55)); 20.5 (C(31)); 32.1, 25.6, 22.4 peaks due to impurity. 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 605.4; [M + K] + = 621.2 
  
9.6.4.3. Synthesis of porphobilinogen- lys -peptide 
 
BocHN
O
NHBoc
N
H
OO
OO
H
N
C28H46N4O9
[582.68]
CF3COOH
CF3COO
C25H39F3N4O9
[610.50]
M+=384.47 ; CF3COO = 113.01
H3N
O
NH3
N
H
OO
OO
H
N
CF3COO
106 107
 
70 mg (0.12 mmol, 1eq) of porphobilinogen- Boc-Boc-lys -peptide was dissolved in 7ml 
CH2Cl2 (Basic alox treated) and cooled to -100C. To this solution, 1.33 g (0.9ml, 11.9 
mmol, 100eq) of trifluoroacetic acid was added dropwise by syringe. The reaction mass 
was maintained at 5-100C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was dried by high vacuum oil pimp for 2-3 days and 
yielded 65 mg of porphobilinogen- lys -peptide which was a highly hygroscopic and 
viscous semisolid (Yield=90.8%). 
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Batch: Step 07 lys #02 to #06. 
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 1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) = 10.46 ((d, 3JNH-2 =2.3Hz, 1H, NH 
pyrrole); 8.62 ((t, 3JNH-51 =5.0 Hz, 1H, NH-H2C(51)); 8.08 (s, 3H, NH3+- HC(53)); 7.81 (s, 
3H, NH3+- H2C(57)); 6.44 (d,  3J2-NH =2.6 Hz, 1H, HC(2)); 4.21 (d, 3J51-NH =5.0 Hz,  2H, 
H2C(51)); 3.69 (mbr, 1H, HC(53)); 3.58 (s, 3H, H3C(34) or H3C(43); 3.56 (s, 3H, H3C(34) 
or H3C(43); 3.44 (d, 3J41a-41b =16.0 Hz, 1H, HC(41a); 3.34 (d, 3J41b-41a =16.0 Hz, 1H, 
HC(41b); 2.73 (m, 2H, H2C(57)); 2.58-2.53 (m, 2H, H2C(31)); 2.50-2.46 (m, 2H, H2C(32)); 
1.72-1.64 (m, 2H, H2C(54)); 1.53-1.46 (m, 2H, H2C(56)); 1.31-1.23 (m, 2H, H2C(55)); 
1.38 due to traces of “Boc” unprotected product.  
 
13C-NMR (100 MHz, DMSO-d6, 298K) : δC (ppm) = 173.2 (C(33); 172.3 (C(42)); 168.2 
(C(52)); 158.5 (q,2JC-F ≈ 35.0, CF3COO¯ ); 125.4 (C(5)); 120.8 (C(3)); 116.2 (q,1JC-F ≈ 
293, CF3COO¯ ); 114.2 (C(2)); 111.5 (C(4)); 52.1 (C(53)); 51.6 (C43)); 51.3 (C(34)); 38.6 
(C(57)); 34.4 (C51)); 34.3 (C(32)); 30.6 (C54)); 29.4 (C(41)); 26.4 (C56)); 21.3 (C55)); 20.3 
(C(31)); 79.8, 78.3, 28.3, 49.6, 34.2, 31.5 due to traces of “Boc” unprotected product.  
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + =383.2   
 
9.6.5. Synthesis of porphobilinogen-Asp-peptide 
9.6.5.1. Synthesis of Boc-Asp-(OtBu) -PFP ester 
 
C13H23NO6
[470.7]
HO
F
F
F
F
F
DCC
C19H22NO6F5
[455.37]
ODCHA
BocHN
O
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O
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F
F
F
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O
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O
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O
,2)
1) CH3COOH
C12H23N.
108 109
 
In a dry flask under argon atmosphere, 1.42 g (3.02 mmol, 1eq) of Boc-Asp-(OtBu)-
DCHA salt was charged. This was dissolved in 40 ml EtOAc, the mass was cooled to 0 
0C, added 40 ml water and neutralised with 1.5 g (24 mmol, 8eq) acetic acid to obtain 
Boc-Asp (OtBu)-OH free acid. The organic layer was washed with 3×50 ml water and the 
organic layer concentrated to give Boc-Asp (OtBu)-OH free acid. This was dissolved in 
20 ml EtOAc and cooled to 0 0C. Then 0.58g (3.15 mmol, 1.04eq) of pentafluorophenol 
was added followed by 0.68 g (3.29 mmol, 1.1eq) of DCC. The reaction was brought to 
room temperature and was kept at room temperature overnight. The reaction mass was 
then filtered over celite bed to get rid off DCU and the solvent was evaporated off by 
rotovapor. 1.36 g of Boc-Asp-(OtBu)-PFP ester was obtained (Yield= 99%). This thick 
oily mass was taken directly for next step.  
                                   
9.6.5.2. Synthesis of Boc-Asp-(OMe) -PFP ester 
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1) CH3COOH
110 111
 
In a dry flask under argon atmosphere, 0.65 g (2.63 mmol, 1eq) of Boc-Asp-(OtBu)-
DCHA salt was charged. This was dissolved in 20 ml EtOAc, the mass was cooled to 0 
0C, then 0.48g (2.63 mmol, 1.0eq) of pentafluorophenol in 10 ml EtOAc was added 
followed by 0.61 g (2.95 mmol, 1.1eq) of DCC. The reaction was brought to room 
temperature and was kept at room temperature overnight. The reaction mass was then 
filtered over celite bed to get rid off DCU and the solvent was evaporated off by 
rotovapor. 1.07 g of Boc-Asp-(OMe)-PFP ester was obtained (Yield= 98%). This thick 
oily mass was taken directly for next step.                                      
9.6.5.3. Synthesis of porphobilinogen- Boc-Asp-(OtBu) -peptide 
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H
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O
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In a hydrogenation autoclave reactor, added 30ml MeOH followed by 60 mg (0.05 mmol, 
0.04 eq) of 10% palladium on activated charcoal. This mixture was prehydrogenated with 
hydrogen for 10 min, later added 1.36 g (2.98 mmol, 2.2eq) of Boc-Asp-(OtBu) -PFP 
ester followed by a solution of 0.484 g (1.358 mmol, 1eq) 3-(2-azido-acetyl)-4-
azidomethyl--4-methoxy- dimethyl heptanedioate in 20ml MeOH. The mass was 
subjected to hydrogenation in ambient temperature with the pressure of 60psi H2 under 
mechanical agitation. Once the reaction was completed, (approximately 24hrs; TLC 
eluent: hexane/AcOEt 1:1) the H2 pressure was released. The reaction mass was filtered 
over celite bed to get rid off palladium, the celite bed was washed with 3 × 25ml MeOH. 
The solvent in the filtrate was evaporated off by rotovapor and a yellow oily mass was 
obtained. This yellow crude mass was purified by flash chromatography (silica gel- 70 
times the curude mass) using gradient eluent system. (from hexane/AcOEt 4:6 to 100% 
AcOEt). The pure fraction of 578 mg porphobilinogen- Boc-Asp-(OtBu) -peptide was 
thus obtained. (Yield = 80.9%) 
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Batch: Step06 Asp(OtBu)  #01 and #02. 
 
Rf: (3:1 EtOAc: Hexane): 0.35 (UV 254, KMnO4 and violet Ehlrich) 
 
 1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.75 (sbr, 1H, NH pyrrole); 7.08 ((dbr, 
3JNH-51 =9.0Hz,1H, NH-H2C(51)); 6.42 (d,  3J2-NH =2.3Hz, 1H, HC(2)); 5.56 (dbr, 3JNH-53 
=8.0Hz, 1H, NH-HC(53));  4.40 (dd, 3J 51a-NH =6.4Hz, 2J51a-51b =15.3Hz, HC(51a)); 4.27 
(dd, 3J 51b-NH =5.6Hz, 2J51a-51b =15.3Hz, HC(51b)); 4.42- 4.38  (mbr, 1H, HC(53)); 3.66 (s, 
3H, H3C(34) or H3C(43); 3.65 (s, 3H, H3C(34) or H3C(43); 3.46-3.41 (m, 2H, H2C(41)); 
2.91- 2.80 (m, 1H, HC(54a)); 2.74-2.71 (m, 2H, H2C(31)); 2.60 (dd, 3J54a- 53≈5.5Hz, 2J54a-54b 
=16.0Hz, 1H, HC(54b)); 2.55-2.51 (m, 2H, H2C(32)); 1.44-1.40  (m,  18H, H3C(57a, 57b, 
57c) and H3C(53c, 53c´, 53c´´)); other minor peaks due to impurities and solvent EtOAc. 
 
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.9 (C(33); 172.9 (C(42)); 172.0 
(C(52)); 171.3 (C(55));155.5 (C(53a)); 127.1 (C(5)); 121.2 (C(3)); 114.5 (C(2)); 111.3 
(C(4)); 81.9 (C(53b)); 80.5 (C(56)); 52.1 (C(34)); 51.6 (C43)); 50.8 (C(53)); 37.6 (C(54)); 
35.1 (C51); 35.0 (C(32)); 30.0 (C(41)); 28.3 and 28.1  (C(57a, 57b, 57c) and C(53c, 53c´, 
53c´´)); 20.6 (C(31)); other minor peaks due to solvent and impurity. 
9.6.5.4. Synthesis of porphobilinogen- Boc-Asp-(OMe) -peptide 
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In a hydrogenation autoclave reactor, added 30ml MeOH followed by 60 mg (0.05 mmol, 
0.04 eq) of 10% palladium on activated charcoal. This mixture was prehydrogenated with 
hydrogen for 10 min, later added 1.07 g (2.59 mmol, 2.2eq) of Boc-Asp-(OMe) -PFP 
ester followed by a solution of 0.44 g (1.234 mmol, 1eq) 3-(2-azido-acetyl)-4-
azidomethyl--4-methoxy- dimethyl heptanedioate in 20ml MeOH. The mass was 
subjected to hydrogenation in ambient temperature with the pressure of 60psi H2 under 
mechanical agitation. Once the reaction was completed, (approximately 24hrs; TLC 
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 eluent: hexane/AcOEt 1:1) the H2 pressure was released. The reaction mass was filtered 
over celite bed to get rid off palladium, the celite bed was washed with 3 × 25ml MeOH. 
The solvent in the filtrate was evaporated off by rotovapor and a yellow oily mass was 
obtained. This yellow crude mass was purified by flash chromatography (silica gel- 70 
times the curude mass) using gradient eluent system. (from hexane/AcOEt 4:6 to 100% 
AcOEt). The pure fraction of 468 mg porphobilinogen- Boc-Asp-(OMe) -peptide was 
thus obtained. (Yield = 78.4%) 
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Batch: Step06 Asp(OMe)  #01to #03. 
 
Rf: (3:1 EtOAc: Hexane): 0.35 (UV 254, KMnO4 and violet Ehlrich) 
  
1H-NMR (400 MHz, CDCl3, 298 K): δH (ppm) = 8.82 (sbr, 1H, NH pyrrole); 7.18 ((sbr, 
1H, NH-H2C(51)); 6.43 (d,  3J2-NH =2.5Hz, 1H, HC(2)); 5.63 (dbr, 3JNH-53 =8.7Hz, 1H, NH-
HC(53));  4.37 (dd, 3J 51a-NH =6.2Hz, 2J51a-51b =15.2Hz, HC(51a)); 4.29 (dd, 3J 51b-NH =5.6Hz, 
2J51a-51b =15.2Hz, HC(51b)); 4.48 (mbr, 1H, HC(53)); 3.66 (s, 3H, H3C(34) or H3C(43) or 
H3C(56); 3.65 (s, 3H, H3C(34) or H3C(43) or H3C(56); 3.62 (s, 3H, H3C(34) or H3C(43) or 
H3C(56); 3.42 (s, 2H, H2C(41)); 2.74-2.65 (m, 2H, H2C(31)); 2.54-2.51 (m, 2H, H2C(32)); 
1.90 (dd, 3J54a- 53≈3.5Hz, 2J54a-54b =12.5Hz ,1H, HC(54a)); 1.40  (s, 9H, H3C(53c, 53c´, 
53c´´)); 1.14- 1.06 (m, 1H,  HC(54b)); other minor peaks (3.01-2.94, 1.69-1.55, 1.35-1.26) 
due to impurities. 
  
13C-NMR (100 MHz, CDCl3, 298K) : δC (ppm) = 173.7 (C(33); 172.9 (C(42)); 172.1 
(C(52)); 171.5 (C(55)); 155.4 (C(53a)); 126.7 (C(5)); 121.1 (C(3)); 114.5 (C(2)); 111.4 
(C(4)); 80.4 (C(53b)); 52.0 (C(34) or (C43)); 51.9 (C(34) or (C43)); 51.5 (C(56));  50.7 
(C(53)); 34.9 (C51); 34.8 (C(32)); 33.8 (C(54)); 29.7 (C(41)); 28.2 (C(53c, 53c´, 53c´´)); 20.4 
(C(31)); other minor peaks (52.5;49.0;36.1;25.5;24.8) due to solvent and impurity. 
 
MS (ESI (+)): m/z relative intensity [M + Na] + = 506.2; [M + K] + = 522.1 
9.6.5.5. Synthesis of porphobilinogen-Asp (OMe)-peptide 
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108 mg (0.22 mmol, 1eq) of porphobilinogen- Boc-Asp-(OMe) -peptide was dissolved in 
5ml CH2Cl2 (Basic alox treated) and cooled to -100C. To this solution, 2.48 g (1.7ml, 21.7 
mmol, 98eq) of trifluoroacetic acid was added dropwise by syringe. The reaction mass 
was maintained at 5-100C for an hour. Once the deprotection of BOC was completed 
(controlled by the absence of BOC peak in 1H-NMR), CH2Cl2 and trifluoroacetic acid 
was evaporated off. The product was dried by high vacuum oil pimp for 2-3 days and 
yielded 102 mg of porphobilinogen- lys -peptide which was a highly hygroscopic and 
viscous semisolid. (Yield=92.6%) 
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Batch: Step 07Asp (OMe) #03 and #05. 
   
1H-NMR (400 MHz, DMSO-d6, 298 K): δH (ppm) = 10.45 ((d, 3JNH-2 =2.0Hz, 1H, NH 
pyrrole); 8.62 ((t, 3JNH-51 ≈5.0 Hz, 1H, NH-H2C(51)); 8.25 (s, 3H, NH3+- HC(53)); 6.44 (d,  
3J2-NH =2.6 Hz, 1H, HC(2)); 4.23 (dd, 3J51a-NH ≈5.0 Hz, 2J51a-51b ≈14.8 Hz 1H, HC(51a)); 
4.18 (dd, 3J51b-NH ≈5.0 Hz, 2J51b-51a ≈14.8 Hz 1H, HC(51b)); 4.06 (mbr, 1H, HC(53)); 3.64 
(s, 3H, H3C(56)); 3.58 (s, 3H, H3C(34) or H3C(43); 3.57 (s, 3H, H3C(34) or H3C(43); 3.41 
(s, 2H, H2C(41); 2.90 (dd, 3J54a-53 ≈4.3 Hz, 2J54a-54b ≈17.2 Hz 1H, HC(54a)); 2.78 (dd, 3J54b-
5
3 ≈8.3 Hz, 2J54b-54a ≈17.2 Hz 1H, HC(54b));  2.59-2.54 (m, 2H, H2C(31)); 2.50-2.46 (m, 
2H, H2C(32)); 2.09, 1.54, 1.24 and 1.11 peaks due to traces of impurity.  
 
13C-NMR (100 MHz, DMSO-d6, 298K) : δC (ppm) = 173.1 (C(33); 172.2 (C(42)); 169.6 
(C(52) or C(55)); 166.8 (C(52) or C(55)); 158.2 (q,2JC-F ≈ 34.0, CF3COO¯ ); 125.1 (C(5)); 
120.8 (C(3)); 116.2 (q,1JC-F ≈ 295, CF3COO¯ ); 114.1 (C(2)); 111.5 (C(4)); 52.1, 51.5, 
51.2 (C(34),(C43) and C(56));  48.9 (C(53)); 35.4 (C(54)); 34.4 (C51)); 34.3 (C(32)); 29.3 
(C(41)); 20.3 (C(31));  
 
MS (ESI (+)): m/z relative intensity [M-CF3COO¯] + =384.0   
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